{"paper_id": "9b71a937bc54eed0edc41cb938793004ea8bf8b8", "metadata": {"title": "Evidence for the Use of Intravenous Immunoglobulins-A Review of the Literature", "authors": [{"first": "Shaye", "middle": [], "last": "Kivity", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Uriel", "middle": [], "last": "Katz", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Natalie", "middle": [], "last": "Daniel", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Udi", "middle": [], "last": "Nussinovitch", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Neophytos", "middle": [], "last": "Papageorgiou", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yehuda", "middle": [], "last": "Shoenfeld", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [{"text": "Intravenous immunoglobulins (IVIg) were first introduced in the middle of the twentieth century for the treatment of primary immunodeficiencies. In 1981, Paul Imbach noticed an improvement of immune-mediated thrombocytopenia, in patients receiving IVIg for immunodeficiencies. This opened a new era for the treatment of autoimmune conditions with IVIg. Since then, IVIg has become an important treatment option in a wide spectrum of diseases, including autoimmune and acute inflammatory conditions, most of them off-label (not included in the US Food and Drug Administration recommendation). A panel of immunologists and internists with experience in IVIg therapy reviewed the medical literature for published data concerning treatment with IVIg. The quality of evidence was assessed, and a summary of the available relevant literature in each disease was given. To our knowledge, this is the first all-inclusive comprehensive review, developed to assist the clinician when considering the use of IVIg in autoimmune diseases, immune deficiencies, and other conditions.", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "Abstract Intravenous immunoglobulins (IVIg) were first introduced in the middle of the twentieth century for the treatment of primary immunodeficiencies. In 1981, Paul Imbach noticed an improvement of immune-mediated thrombocytopenia, in patients receiving IVIg for immunodeficiencies. This opened a new era for the treatment of autoimmune conditions with IVIg. Since then, IVIg has become an important treatment option in a wide spectrum of diseases, including autoimmune and acute inflammatory conditions, most of them off-label (not included in the US Food and Drug Administration recommendation). A panel of immunologists and internists with experience in IVIg therapy reviewed the medical literature for published data concerning treatment with IVIg. The quality of evidence was assessed, and a summary of the available relevant literature in each disease was given. To our knowledge, this is the first all-inclusive comprehensive review, developed to assist the clinician when considering the use of IVIg in autoimmune diseases, immune deficiencies, and other conditions. ", "cite_spans": [{"start": 163, "end": 167, "text": "Paul", "ref_id": null}], "ref_spans": [], "section": ""}, {"text": "Intravenous immunoglobulins (IVIg) are gamma globulins purified from the pooled plasma of thousands of donors, typically containing more than 95% of unmodified immunoglobulin G (IgG) and only trace amounts of IgA or IgM. Immune globulin products from human plasma were first used in 1952 to treat immune deficiencies. About 30 years later, Paul Imbach observed that patients with immune thrombocytopenia and agammaglobulinemia receiving immunoglobulins as immune replacement therapy recovered from their thrombocytopenia [1] . This was the first observation to suggest treatment of autoimmune diseases with IVIg. Later on, the ability to administer large quantities of immunoglobulin intravenously was gained owing to technological advances, among them the improvement in plasma fractionation. As a result, IVIg slowly became an important treatment option in a number of diseases beyond primary immune deficiencies, including autoimmune and acute inflammatory conditions, most of them off-label indications. These indications have crossed over into almost every medical specialty. The US Food and Drug Administration (FDA) has approved the use of IVIg for the following six conditions: primary immunodeficiencies, immune thrombocytopenic purpura (ITP), Kawasaki disease, hematopoietic stem cell transplantation, chronic B cell lymphocytic leukemia, and pediatric HIV. Many offlabel indications have emerged; some of these new indications for IVIg are based on solid clinical evidence; others are based on relatively few data or anecdotal reports (case series, case reports). This lack of firm evidence is due to the difficulty in performing appropriate clinical trials in diseases with low prevalence. There is a need for an evidence-based guidance for the use of IVIg to help improve patient care consistency. Another issue is the efficacy of different preparations of IVIg. The FDA has recommended the use of particular preparations of IVIg for each labeled indication in accordance to the specific preparation used to demonstrate a beneficial effect. Of course, there is selection bias since generally only a few preparations have been tested for a given disease. This is in recognition of the difficulty to reproduce the properties of an IVIg preparation, which may vary from one manufacturer to the other due to differences in the donor population, number of donors, period of donation, production methods, virus/bacteria inactivation methods, etc. IVIg properties may also vary from batch to batch made by the same manufacturer, complicating homogeneity even more.", "cite_spans": [{"start": 521, "end": 524, "text": "[1]", "ref_id": "BIBREF0"}], "ref_spans": [], "section": "Introduction"}, {"text": "Possible mechanisms of action of IVIg in autoimmune and inflammatory diseases are: intact Fc-dependent blockage of IgG (as in ITP), inhibition of membrane attack complexes (C5b-C9) and activated components C3b and C4b (as in Kawasaki's disease), and anti-idiotypes against autoantibodies (as in acquired hemophilia due to autoantibodies against factor VIII). IVIg also contains various cytokines and natural antibodies that may act against pathogens, altered molecules, cells, autoreactive B cell clones, and tumors.", "cite_spans": [], "ref_spans": [], "section": "Introduction"}, {"text": "IVIg therapy reviewed the medical literature indexed in PubMed using specific terms for each specific disease/ condition AND (\"IVIg\" OR \"IgIV\" OR \"Intravenous Immunoglobuli*\" OR \"gamma globuli*\"). There was no limitation on language, year of publication, or publication status. We used all clinical data ranging from multicentered randomized controlled trials (RCT) and meta-analysis to case reports. From each article, we extracted details of the study design, number of patients, type of intervention including the dose and IVIg preparation used (if mentioned), and response to treatment. The relevant data were summarized in a hierarchical manner according to the study design and number of participants. When evidence was based on higher level of evidence studies, such as RCTs, lower levels of evidence studies (such as case control studies) were disregarded. Specific diseases were classified in tables according to the specialty they belong to and are followed by a short summary of recommendations, including the level of evidence and the strength of recommendation, as assessed by known guidelines (Table 1 ) [2] . To our knowledge, this is the first comprehensive review which summarizes all up-to-date published data regarding the usage of IVIg in autoimmune diseases, immune deficiencies, and other indications.", "cite_spans": [{"start": 1118, "end": 1121, "text": "[2]", "ref_id": "BIBREF1"}], "ref_spans": [{"start": 1107, "end": 1115, "text": "(Table 1", "ref_id": null}], "section": "A panel of immunologists and internists with experience in"}, {"text": "The tables below summarize the clinical data gathered from studies dealing with IVIg treatment for different conditions. Each table is followed by our evidence-based recommendations for the usage of IVIg.", "cite_spans": [], "ref_spans": [], "section": "Results"}, {"text": "The following conditions refer to ( Table 2) .", "cite_spans": [], "ref_spans": [{"start": 36, "end": 44, "text": "Table 2)", "ref_id": "TABREF1"}], "section": "Results"}, {"text": "Level of evidence B Systemic lupus erythematosus (SLE) is a multisystemic disease with various manifestations. There is some evidence that IVIg, given in patients without an increased risk for thromboembolic events or renal failure, is a safe and beneficial adjunct therapy for SLE patients with systemic flare-ups who are resistant to or refuse conventional treatment (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "SLE-systemic flare-up"}, {"text": "Level of evidence C Lupus myocarditis is an uncommon but severe complication of SLE. There is no consensus on the specific treatment of SLE myocarditis. Most reports describe treatment with high-dose corticosteroids (CS), followed by either cyclophosphamide or azathioprine, in addition to conventional treatment for heart failure. There is little evidence that IVIg is effective when immunosuppressive therapy fails (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Lupus myocarditis"}, {"text": "Level of evidence B As with the treatment of ITP, IVIg seems to be useful in managing the bleeding complications of patients with lupus-associated thrombocytopenia (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "SLE and thrombocytopenia"}, {"text": "Level of evidence C Standard therapy for subacute cutaneous lupus erythematosus (SCLE) includes CS (topical, intralesional, systemic), antimalarials, and other immunosuppressive agents. IVIg may be considered in refractory cases, but more study should be done (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Subacute cutaneous lupus erythematosus"}, {"text": "Level of evidence C Kikuchi, also called histiocytic necrotizing lymphadenitis, is a rare benign disease. There is little evidence that treatment with IVIg is superior to other antiinflammatory treatments (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Subacute cutaneous lupus erythematosus"}, {"text": "Level of recommendation C Giving the fact that adult still disease responds to CS and biological and anti-tumor necrosis factor (TNF) treatment, there is low-level evidence that IVIg has an additional benefit for treatment of this disease (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Adult still disease"}, {"text": "Level of recommendation B Immunosuppression with CSs and cytotoxic agents should be used in systemic vasculitis before considering IVIg. There is however some evidence that IVIg might be useful and therefore in refractory cases it may be worth to try (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Systemic vasculitis (including GA and MPA)"}, {"text": "Level of evidence B CSS is a rare disease. The initial management of CSS consists of high doses of CS. For patients with severe disease or those who are unresponsive to CS, treatment with IVIg was warranted (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Churg-Strauss syndrome"}, {"text": "Level of evidence B Infection with hepatitis C virus (HCV) may be associated with a variety of autoimmune phenomena causing a therapeutic dilemma for treatment with interferon alpha (IFN alpha), which stimulates autoimmune symptoms, or with CS, which may lead to an increase of viral load. Treatment with IVIg may act synergistically with Table 1 Recommendation guidelines [2] Level of evidence A: more than one randomized controlled trial (RCT)/meta-analysis B: a single RCT or well-designed nonrandomized trial like prospective observational registries (case-controls, cohorts). C: expert consensus: this includes case reports and retrospective series; here, the expert decides based on his experience Strength of recommendation Class I: conditions for which there is evidence and/or general agreement that a given procedure/therapy is useful and effective Class II: conditions for which there is conflicting evidence and/or divergence of opinion about the usefulness/efficacy of performing the procedure/therapy Class IIa: weight of evidence/opinion is in favor of usefulness/efficacy Class IIb: usefulness/efficacy is less well established by evidence/opinion Class III: conditions for which there is evidence and/or general agreement that a procedure/therapy is not useful/effective and in some cases may be harmful (2) , acquired factor VIII inhibitors (2) , acquired von Willebrand disease (2) , pure red cell aplasia(3), pancytopenia (1), myelofibrosis (1), pneumonitis (2) , pleural effusion (1), pericarditis (2) , myocarditis (2) , CNS Improvement of SLE-related condition ", "cite_spans": [{"start": 373, "end": 376, "text": "[2]", "ref_id": "BIBREF1"}, {"start": 1321, "end": 1324, "text": "(2)", "ref_id": "BIBREF1"}, {"start": 1359, "end": 1362, "text": "(2)", "ref_id": "BIBREF1"}, {"start": 1397, "end": 1400, "text": "(2)", "ref_id": "BIBREF1"}, {"start": 1478, "end": 1481, "text": "(2)", "ref_id": "BIBREF1"}, {"start": 1519, "end": 1522, "text": "(2)", "ref_id": "BIBREF1"}, {"start": 1537, "end": 1540, "text": "(2)", "ref_id": "BIBREF1"}], "ref_spans": [{"start": 339, "end": 346, "text": "Table 1", "ref_id": null}], "section": "Hepatitis C virus with autoimmune features"}, {"text": "Level of evidence C Mixed connective tissue disease (MCTD) is an autoimmune condition which combines features of polymyositis, systemic lupus erythematosus, scleroderma, and dermatomyositis and is thus considered an overlap syndrome. There is scarce evidence that treatment with IVIg helps to improve skin manifestations in MCTD (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Mixed connective tissue disease"}, {"text": "Level of evidence B Systemic sclerosis is characterized by hardening and scarring of the skin and inner organs. There is some evidence that treatment with IVIg helps to improve skin and systemic symptoms (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Systemic sclerosis"}, {"text": "Level of evidence A There is evidence that IVIg is useful for the treatment of patients with severe chronic JRA; its treatment may help also reduce the need for CS and other immunosuppressive therapy (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Juvenile rheumatoid arthritis"}, {"text": "Level of evidence B There is hardly any convincing evidence that IVIg benefits patients with RA (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Rheumatoid arthritis"}, {"text": "Level of evidence C There is some evidence that patients with ataxic sensory neuropathy refractory to immunosuppressive therapy will benefit from IVIg (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Sj\u00f6gren's disease"}, {"text": "Level of evidence B In patients with DM and PM that are resistant or partially responsive to conventional therapies, IVIg was effective (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Myopathies (PM, DM, and IBM)"}, {"text": "Level of evidence A In IBM, IVIg showed marginal improvements in muscle strength which were nonsignificant and thus were not recommended (strength of recommendation III).", "cite_spans": [], "ref_spans": [], "section": "Myopathies (PM, DM, and IBM)"}, {"text": "Level of evidence C Behcet's disease is a multisystemic disorder presenting with recurrent oral and genital ulcers as well as ocular and central nervous system involvement. The severe cases may respond to systemic CSs, interferon, or anti-TNF therapy. There is some evidence to support IVIg treatment for refractory eye and skin involvement (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Behcet's disease"}, {"text": "The following conditions refer to (Table 3) .", "cite_spans": [], "ref_spans": [{"start": 34, "end": 43, "text": "(Table 3)", "ref_id": "TABREF6"}], "section": "Behcet's disease"}, {"text": "Level of evidence B There is weak evidence that IVIg is useful in the treatment of acquired hemophilia. IVIg may be tried in the case in which CS and cytotoxic agents fail or when facing an emergency situation as an additional therapy IVIg (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Acquired hemophilia"}, {"text": "Level of evidence A There is strong evidence that IVIg is of benefit in reducing the number and severity of infections in patients with acquired hypogammaglobulinemia in the context of hematological malignancy (strength of recom-mendation I). While this is true, both cost and the potential of adverse effects, most prominently acute renal failure and thromboembolic phenomena [3] [4] [5] , prevent a clear-cut recommendation for the use of IVIg in acquired hypogammaglobulinemia. With this in mind, IVIg may be recommended at the replacement dose of 400 mg/kg each 3 to 4 weeks in cases in which severe or recurrent infections have occurred.", "cite_spans": [{"start": 377, "end": 380, "text": "[3]", "ref_id": "BIBREF2"}, {"start": 381, "end": 384, "text": "[4]", "ref_id": "BIBREF3"}, {"start": 385, "end": 388, "text": "[5]", "ref_id": "BIBREF4"}], "ref_spans": [], "section": "Acquired hypogammaglobulinemia"}, {"text": "Level of evidence C Pure red cell aplasia may be immunemediated due to a background neoplasia, most frequently hematologic, or due to an immune disease or as an immune response triggered by drugs. It may also occur secondary to parvovirus B19 infection which may also lead to aplastic anemia. Treatment of the causative disease is the most important issue. Weak evidence supports the use of IVIg in pure red cell aplasia. IVIg may however be used in the case in which first-line therapy (i.e., CS and immunosuppressive drugs) fails to achieve a remission (strength of recommendation IIa). IVIg is first-line therapy in immunosuppressed hosts in which infection with parvovirus B19 results in pure red cell aplasia.", "cite_spans": [], "ref_spans": [], "section": "Pure red cell aplasia"}, {"text": "Level of evidence B and C According to Federici and colleagues [6] , 48% of the cases of acquired von Willebrand syndrome are associated with lymphoproliferative diseases, 15% with myeloproliferative disorders, and 21% with cardiovascular diseases. In another paper, Federici and colleagues [7] claim that 33% of the reported cases are associated with a monoclonal gammopathy of uncertain significance. Then, the detection and specific treatment of the underlying disease is as important as the immediate therapy of the coagulation disorder. In accordance to the scant existing evidence of IVIg therapy in this disorder, IVIg should be used in cases of standard therapy (desmopressin and factor VIII/von Willebrand factor concentrate) failure and in urgent situations as an addition to such therapy (strength of recommendation IIb). IVIg may also be used in the preparation for surgery.", "cite_spans": [{"start": 63, "end": 66, "text": "[6]", "ref_id": "BIBREF5"}, {"start": 291, "end": 294, "text": "[7]", "ref_id": "BIBREF6"}], "ref_spans": [], "section": "Acquired von Willebrand syndrome"}, {"text": "Level of evidence C While idiopathic aplastic anemia can be transient as in the case of parvovirus-B19-induced bone marrow depression, idiopathic aplastic anemia should first be treated with immunosuppressive drugs like CS or cyclosporine or with antithymocyte or antilymphocyte immunoglobulins as well as supportive blood components transfusions. Stem cell POEMS syndrome polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes transplantation is always the alternative in the case of failure of the aforementioned treatments. Due to the low level of evidence of IVIg for the treatment of idiopathic aplastic anemia, we cannot recommend its liberal use but it may be tried in the case of treatment failure, before stem cell transplantation is performed (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Aplastic anemia"}, {"text": "Level of evidence B Immunosuppression with CS and then cytotoxic agents should be used in autoimmune hemolytic anemia before considering IVIg. There is however some evidence that IVIg might be useful and therefore in refractory cases before considering splenectomy it may be worth a try (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Autoimmune hemolytic anemia"}, {"text": "Level of evidence C Although immune neutropenia may also be an adverse effect resulting from IVIg treatment as have been published elsewhere [8] , IVIg has been used to treat immune neutropenia. The evidence is weak and responses are not as good as those with CS and granulocyte colony-stimulating factor (strength of recommendation IIb).", "cite_spans": [{"start": 141, "end": 144, "text": "[8]", "ref_id": "BIBREF7"}], "ref_spans": [], "section": "Autoimmune neutropenia"}, {"text": "Level of evidence C Evans' syndrome is usually a therapyresistant condition that has been treated combining CS, IVIg, and immunosuppressive therapy. Although convincing evidence is lacking for the use of IVIg in view of the severity and the refractory nature of several cases of Evans' syndrome, IVIg may be considered among the treatment options generally together with CS with or without immunosuppressive therapy (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Evans' syndrome"}, {"text": "Level of evidence B The only study comparing IVIg against other treatment (CS), although nonrandomized, suggests that IVIg raises the platelet number and prevents intracranial bleeding in a significant percentage of treated patients. The level of evidence is low, but the alternatives for prenatal treatment of fetuses at risk are not better and the risks involved are huge (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Fetal/neonatal alloimmune thrombocytopenia"}, {"text": "Level of evidence A Strong evidence denies any benefit from the use of IVIg around stem cell/bone marrow transplantation, both from the infectious or from the graftversus-host disease point of views (strength of recommendation III).", "cite_spans": [], "ref_spans": [], "section": "Stem cell/bone marrow transplantation"}, {"text": "Level of evidence A There is clear evidence for the use of IVIg when facing newborn hemolysis as it reduces the need of plasmapheresis (PP) therapy (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Hemolytic disease of the newborn"}, {"text": "Level of evidence C There is no reliable evidence to recommend the use of IVIg to prevent or to treat hemolytic transfusion reactions (strength of evidence IIb).", "cite_spans": [], "ref_spans": [], "section": "Hemolytic transfusion reaction"}, {"text": "Level of evidence C Apart from two papers reporting two cases and another case, there is no evidence to recommend the use of IVIg either to prevent or to treat hemolytic transfusion reactions in sickle cell patients, specially taking into consideration the additional risk of thrombosis due to a change in the rheologic properties of the blood after IVIg infusion (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Hemolytic transfusion reaction in sickle cell disease"}, {"text": "Level of evidence B There is conflicting evidence that IVIg benefits patients with hemolytic uremic syndrome (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Hemolytic uremic syndrome"}, {"text": "Level of evidence B There is no evidence that IVIg benefits patients with thrombotic thrombocytopenic purpura (strength of recommendation III).", "cite_spans": [], "ref_spans": [], "section": "Thrombotic thrombocytopenic purpura"}, {"text": "Level of evidence C There is low-level evidence that IVIg is useful for this disease. On the other hand, thromboembolic phenomena, which are part of the heparin-induced thrombocytopenia clinical picture, might be enhanced by the rheologic blood changes after IVIg infusion. Therefore, IVIg should not be generally recommended for this disease (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Heparin-induced thrombocytopenia"}, {"text": "Level of evidence B Evidence comes only from one crossover randomized placebo-controlled trial which supports the use of IVIg in HIV-associated thrombocytopenia, especially when platelet count is very low or the risk of bleeding is high (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "HIV-associated thrombocytopenia"}, {"text": "Level of evidence A Since Imbach's observation [1] , acute ITP has been the prototype of IVIg-responsive immune disease. There is consistent evidence that IVIg is beneficial in children with ITP (strength of recommendation I). Notwithstanding this, CS therapy is still the first-line treatment for ITP, and single-dose anti-D immunoglobulin [9, 10] is a [8] good alternative for Rh-positive patients. IVIg should be considered when there is bleeding or when the bleeding risk is high or upon failure of other treatments. In adult acute ITP patients, there is no placebo-controlled RCT, but when compared with CS IVIg induces a faster response. Again, CS is the first-line treatment for adults but IVIg may be given in severe or refractory cases. There is weak evidence that IVIg can improve mother and fetal prognosis in pregnancy. IVIg may be used when a fast correction in platelet number is needed.", "cite_spans": [{"start": 47, "end": 50, "text": "[1]", "ref_id": "BIBREF0"}, {"start": 341, "end": 344, "text": "[9,", "ref_id": "BIBREF8"}, {"start": 345, "end": 348, "text": "10]", "ref_id": "BIBREF9"}, {"start": 354, "end": 357, "text": "[8]", "ref_id": "BIBREF7"}], "ref_spans": [], "section": "Acute immune thrombocytopenic purpura"}, {"text": "Level of evidence B By the merits of its own research, IVIg may be considered to treat ITP in the context of HIV. Although no hard evidence exists due to the fact that this particular group of patients has not been investigated as well as has non-HIV-related ITP, it will be hard to argue that the recommendation of the latter may not be extended to HIV-related ITP (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Immune thrombocytopenic purpura in HIV"}, {"text": "In chronic ITP, IVIg has so far not demonstrated a plausible benefit. Only prospective noncontrolled trials are available and we found only one evaluating maintenance IVIg for chronic ITP, in which the overwhelming majority of patients had a recrudescence of thrombocytopenia in spite of a good initial response to IVIg (level of evidence and strength of recommendation B-IIb). A small number of patients benefited and therefore IVIg might be tried in drug refractory cases of chronic ITP in which there is a contraindication for splenectomy.", "cite_spans": [], "ref_spans": [], "section": "Chronic immune thrombocytopenic purpura"}, {"text": "Level of evidence C Series of patients treated with fast response to IVIg suggest a benefit of IVIg treatment in posttransfusional purpura, although with low-level of evidence.", "cite_spans": [], "ref_spans": [], "section": "Posttransfusional purpura"}, {"text": "In the context of a patient with severe risk to bleeding or actual bleeding, IVIg can be used if the diagnosis of posttransfusional purpura is made (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Posttransfusional purpura"}, {"text": "Level of evidence C Hemophagocytic syndrome is a severe reaction leading to high mortality. Inconsistent and low-level evidence do not warrant a clear-cut recommendation of IVIg for this syndrome. However, due to the lack of effective and standardized treatment in an otherwise highly lethal disease, IVIg may be used along with other therapies like monoclonal antibodies, CS, cytotoxic drugs, and support measures (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Hemophagocytic syndrome"}, {"text": "Level of evidence C There are only anecdotal reports, both showing benefit and lack of benefit. There is no evidence that IVIg has a beneficial effect on polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "POEMS"}, {"text": "Level of evidence C There is no convincing evidence that IVIg has any beneficial effect in this disease (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Diffuse B cell posttransplant lymphoproliferative disorder"}, {"text": "The following conditions refer to (Table 4 ).", "cite_spans": [], "ref_spans": [{"start": 34, "end": 42, "text": "(Table 4", "ref_id": "TABREF7"}], "section": "Diffuse B cell posttransplant lymphoproliferative disorder"}, {"text": "Level of evidence B IVIg is not used for the treatment of CMV infection but may be helpful in treatment of hemophagocytic syndrome related to CMV and other viruses (see hematology section); there is some evidence for its effectiveness in preventing seroconversion in transplant patients who are immunosuppressed (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Cytomegalovirus"}, {"text": "Level of evidence B IVIg can reduce infections in children with perinatal HIV but has not been proven to reduce mortality (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Human immunodeficiency virus"}, {"text": "Level of evidence B No evidence for the effectiveness of IVIg in the treatment in malaria exists (strength recommendation III).", "cite_spans": [], "ref_spans": [], "section": "Malaria"}, {"text": "Level of evidence A Postpolio syndrome (PPS) typically affects survivors of poliovirus infection, 15-20 years after the original infection, with fatigue, muscular weakness, and pain. There are two RCTs demonstrating some inconsistent evidence for the effectiveness of IVIg treatment on quality of life, pain, and muscle strength in patients with PPS (strength of recommendation IIa). ", "cite_spans": [], "ref_spans": [], "section": "Postpolio syndrome"}, {"text": "Level of evidence A Sepsis is a life-threatening condition, resulting mainly from the patient's immune response to a severe infection. Significant but heterogenic reduction in mortality with IVIg treatment in septic patients was demonstrated in a meta-analysis of 14 RCTs. These results were not confirmed when only high-quality studies were analyzed (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Sepsis"}, {"text": "Level of evidence C Infection with West Nile virus can cause fatal encephalitis in immunosuppressed and elderly patients, in which case effective treatment is lacking. The effectiveness of IVIg in these situations is supported by a few case reports and may be considered (strength of recommendation IIa)", "cite_spans": [], "ref_spans": [], "section": "West Nile"}, {"text": "Level of evidence A Treatment with IVIg has not proven to reduce infectious-related mortality in postsurgical patients, but there is inconsistent evidence that IVIg reduces ICUrelated infections and hospital stay in these patients (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Infection prophylaxis-in intensive care units"}, {"text": "Level of evidence A There is conflicting evidence regarding the usefulness of IVIg treatment for these patients. It should be taken into consideration that patients treated with IVIg after bone marrow transplantation (BMT) may have a higher incidence of fatal hepatic veno-occlusive disease (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Infection prophylaxis-in immune-compromised patients"}, {"text": "Level of evidence B Necrotizing fasciitis is caused by deep-skin infection with bacteria, mainly group A streptococcus. The mainstay of nuclear factor treatment is prompt surgical exploration and antibiotic therapy. IVIg might have additional benefit to antibiotic therapy for treatment of patients who refuse surgery or are not surgical candidates. (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Necrotizing fasciitis"}, {"text": "Level of evidence B There is weak evidence that IVIg is useful in the treatment of recurrent otitis media (strength of recommendation IIb). Level of evidence B Some evidence that IVIg is effective in preventing perinatal transmission of varicella. IVIg may also be used for treatment adults with severe respiratory failure due to varicella pneumonia (level of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Recurrent otitis media"}, {"text": "The following conditions refer to (Table 5) .", "cite_spans": [], "ref_spans": [{"start": 34, "end": 43, "text": "(Table 5)", "ref_id": "TABREF10"}], "section": "Recurrent otitis media"}, {"text": "Level of evidence B Although the best level of evidence is not strong, the improvement shown for treated pregnancies is beyond the natural possibility of a subsequent spared pregnancy which has been estimated to be approximately 40% ( [11] #110). In view of this data and the difficulty for large RCTs, IVIg may be considered to prevent recurrent perinatal hemochromatosis (strength of recommendation IIa).", "cite_spans": [{"start": 235, "end": 239, "text": "[11]", "ref_id": "BIBREF10"}], "ref_spans": [], "section": "Perinatal hemochromatosis"}, {"text": "Level of evidence A There is evidence that IVIg improves the outcome of pregnancy in secondary recurrent miscarriage (in women that had a previous pregnancy that reached at least the second trimester (strength of recommendation IIb)). This has so far not been shown for primary recurrent miscarriage (strength of recommendation III).", "cite_spans": [], "ref_spans": [], "section": "Recurrent pregnancy loss excluding antiphospholipid syndrome"}, {"text": "Level of evidence A The evidence is against the use of IVIg in pregnancy of women affected by antiphospholipid syndrome (strength of recommendation III).", "cite_spans": [], "ref_spans": [], "section": "Recurrent pregnancy loss due to antiphospholipid syndrome"}, {"text": "Level of evidence B Evidence from a small RCT indicates that IVIg may reduce the rate of fetal infection after premature rupture of membranes (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Prevention of infection after premature rupture of membranes"}, {"text": "Level of evidence A The evidence is scarce but the only meta-analysis based on data from three RCTs found a benefit in the number of live births in women treated with IVIg. After in vitro fertilization (IVF) failure, IVIg along with IVF techniques may be weighted (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Failure of in vitro fertilization"}, {"text": "The following conditions refer to (Table 6) .", "cite_spans": [], "ref_spans": [{"start": 34, "end": 43, "text": "(Table 6)", "ref_id": "TABREF13"}], "section": "Failure of in vitro fertilization"}, {"text": "Level of evidence B A randomized double-blind study has demonstrated significant increase of ejection fraction (EF) and improved quality of life following IVIg administration, regardless of the congestive heart failure (CHF) cause. CHF is a proinflammatory state due to an increase of cytokines such as TNF-\u03b1 and interleukin (IL)-1. Some of the cytokines have been shown to induce myocardial dysfunction due to negative inotropic effect [12] . Another possible mechanism in CHF pathogenesis is mediated by anti-\u03b21 adrenergic receptor (strength of recommendation IIa).", "cite_spans": [{"start": 437, "end": 441, "text": "[12]", "ref_id": "BIBREF11"}], "ref_spans": [], "section": "Congestive heart failure"}, {"text": "Level of evidence B Dilated cardiomyopathy (DCM) is caused by various triggers or may be idiopathic. Immune abnormalities and autoantibodies may play a role in the pathogenesis. Nevertheless, no significant effect was noted following IVIg administration in recent-onset DCM compared to placebo [13] . A trial on 17 patients with idiopathic DCM showed significant improvement of EF and quality of life compared with placebo [14] . Therefore, IVIg treatment in DCM remains controversial, and it is possible that IVIg treatment is beneficial in specific subpopulation and when treatment is initiated at a certain time window (strength of recommendation IIb).", "cite_spans": [{"start": 294, "end": 298, "text": "[13]", "ref_id": "BIBREF12"}, {"start": 423, "end": 427, "text": "[14]", "ref_id": "BIBREF13"}], "ref_spans": [], "section": "Dilated cardiomyopathy"}, {"text": "Level of evidence C Peripartum cardiomyopathy (PPCM) is a rare disorder. It is believed that autoimmune mechanisms play a role in the pathogenesis. In a small nonrandomized retrospective trial, there was a significant improvement of EF following IVIg administration compared with conventional treatment. Although there is partial evidence of IVIg effectiveness in PPCM, its use should be considered due to the generally poor prognosis of PPCM patients who show no clinical improvement (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Peripartum cardiomyopathy"}, {"text": "Level of evidence B Treatment with CS or cytotoxic agents was found ineffective [15, 16] . In an RCT trial of 62 patients with new-onset DCM of which some had myocarditis [13] , there was no significant difference in EF improvement between IVIg and placebo group. Nevertheless, in a prospective nonrandomized trial, there was a significant improvement of fractional shortening compared to control. We conclude that further research is warranted regarding IVIg use in myocarditis due to inconclusive results (strength of recommendation IIb). Chronic idiopathic pericarditis (CIP) appears in up to 25% of acute pericarditis cases. It may be associated with viral infections and autoantibodies [21] . There is limited evidence on the role of IVIg as an alternative therapy for prolonged steroid or colchicine treatment in CIP (strength of recommendation IIa).", "cite_spans": [{"start": 80, "end": 84, "text": "[15,", "ref_id": "BIBREF14"}, {"start": 85, "end": 88, "text": "16]", "ref_id": "BIBREF15"}, {"start": 171, "end": 175, "text": "[13]", "ref_id": "BIBREF12"}, {"start": 691, "end": 695, "text": "[21]", "ref_id": null}], "ref_spans": [], "section": "Myocarditis"}, {"text": "Atherosclerosis is believed to be mediated also by humeral and cellular immune mechanisms. There are accumulating data that support a role of IVIg in prevention of atherosclerosis. Possible mechanisms include decrease of matrix metalloproteinase 9 secretion from mononuclear cells [22], increase of IL-10 [12] , and decrease of oxidized lowdensity lipoprotein uptake by macrophages [23] . Nevertheless, clinical trials are required in order to establish the relationship between IVIg use and atherosclerosis therapy.", "cite_spans": [{"start": 305, "end": 309, "text": "[12]", "ref_id": "BIBREF11"}, {"start": 382, "end": 386, "text": "[23]", "ref_id": null}], "ref_spans": [], "section": "Atherosclerosis"}, {"text": "Level of evidence A It is the leading cause of acquired heart disease in the USA. Kawasaki disease is an FDA-approved absolute indication for IVIg therapy. The frequency of CA aneurysm development and associated morbidity and mortality have been dramatically decreased as a result of IVIg therapy when given within 10 days following the onset of fever. A single dose of 2 g/kg of IVIg over 10 H is usually ", "cite_spans": [], "ref_spans": [], "section": "Kawasaki disease"}, {"text": "Level of evidence B Because there is no efficient treatment for established rheumatic carditis, several agents has been proposed in an attempt to change the natural history. IVIg has failed to change clinical outcome and disease progression and therefore is not recommended for treatment of acute rheumatic fever (strength of recommendation III).", "cite_spans": [], "ref_spans": [], "section": "Rheumatic fever"}, {"text": "Level of evidence C Neonatal lupus erythematosus is a rare disease that is associated with anti-Ro and anti-La autoantibodies [26] . A single case series of eight subjects had ", "cite_spans": [{"start": 126, "end": 130, "text": "[26]", "ref_id": null}], "ref_spans": [], "section": "Congenital heart block in neonatal lupus erythematosus"}, {"text": "Level of evidence C IVIg has anti-idiotypic properties, as well as human leukocyte antigen molecules that may neutralize high panel reactive antibodies in sensitized patients awaiting cardiac transplantation. There is some evidence for IVIg benefit in patients with left ventricular assist device who are awaiting cardiac transplantation (strength of recommendation IIa). Nevertheless, IVIg did not reduce sensitization in previously unsensitized patients who underwent Norwood procedure (strength of recommendation III).", "cite_spans": [], "ref_spans": [], "section": "Cardiac transplantation"}, {"text": "The following conditions refer to (Table 7) .", "cite_spans": [], "ref_spans": [{"start": 34, "end": 43, "text": "(Table 7)", "ref_id": "TABREF16"}], "section": "Cardiac transplantation"}, {"text": "Level of evidence C Linear IgA bullous disease may affect the eye (in 67% of patients) and may present as chronic cicatrizing conjunctivitis. Systemic disease may be treated with systemic CS and dapsone. In poorly responsive patients, IVIg treatment may be used, although its use should be further investigated (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Ophthalmic IgA bullous disease"}, {"text": "Level of evidence C Mucous membrane pemphigoid (MMP) may involve the eye. There is some evidence for the beneficial effect of IVIg in MMP that involves the eye. IVIg may provide more rapid control of symptoms and prevents remissions during long-term follow-up [28, 29] . This notion should be supported by larger randomized trials (strength of recommendation IIa).", "cite_spans": [{"start": 260, "end": 264, "text": "[28,", "ref_id": null}, {"start": 265, "end": 268, "text": "29]", "ref_id": null}], "ref_spans": [], "section": "Mucous membrane pemphigoid"}, {"text": "Level of evidence C There are some but limited data regarding the potential benefit of IVIg use in Behcet's disease. Further study is required. Nevertheless, IVIg should be carefully considered in patients resistant to conventional immunosuppressive therapy (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Ocular Behcet's disease"}, {"text": "Level of evidence A The natural history of optic neuritis in multiple sclerosis patients is not altered by IVIg transfusion, neither clinically nor radiologically. Therefore, IVIg is not recommended in that setting (strength of recommendation III).", "cite_spans": [], "ref_spans": [], "section": "Optic neuritis"}, {"text": "Level of evidence C There is anecdotal evidence for the possible beneficial role of IVIg in the treatment of inflammatory pseudotumor of orbit (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Inflammatory pseudotumor of orbit"}, {"text": "Level of evidence C Birdshot retinochoroiditis is a rare inflammatory disease (bilateral autoimmune posterior uveitis of idiopathic origin). Without immunosuppressive treatment, a progressive visual deterioration will occurs in 80% of patients [30] . There is supporting evidence for the use of IVIg, especially in patients unresponsive to other therapies (strength of recommendation IIa).", "cite_spans": [{"start": 244, "end": 248, "text": "[30]", "ref_id": null}], "ref_spans": [], "section": "Birdshot retinochoroiditis"}, {"text": "Level of evidence C It is caused by inflammatory process of unknown etiology, which is confined to the orbit. There are very limited data on the effect of IVIg in patients with orbital myositis. Such treatment might be considered in symptomatic patients, resistant to other therapies (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Orbital myositis"}, {"text": "Level of evidence C Most cases of refractory uveitis (RU) are associated with autoimmune mechanisms. There are some data supporting the use of IVIg in resistant RU, although more research is required in order to establish clinical guidelines (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Refractory uveitis"}, {"text": "Level of evidence B It seems that IVIg is as efficient as CS in the treatment of Graves' ophthalmopathy. Nevertheless, despite similar clinical response to treatment, IVIg was associated with fewer side effects and the study group showed more tolerance towards it. Therefore, we conclude that IVIg should be considered in CS intolerance (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Graves' ophthalmopathy"}, {"text": "Level of evidence C There is limited evidence for the benefit of IVIg in cancer-associated retinopathy. Nevertheless, since spontaneous recovery usually does not occur, IVIg may be used in progressive visual compromise in addition to CS or plasmapheresis (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Paraneoplastic visual loss"}, {"text": "The following conditions refer to (Table 8 ). ", "cite_spans": [], "ref_spans": [{"start": 34, "end": 42, "text": "(Table 8", "ref_id": "TABREF18"}], "section": "Paraneoplastic visual loss"}, {"text": "Level of evidence B A few case reports and a single RCT clearly indicate the efficacy of IVIg in the treatment of lupus nephritis. In all cases, patients had a beneficial response to IVIg and a significant improvement of renal function was noted. Therefore, IVIg is recommended as an alternative treatment in lupus nephritis or in cases that conventional immunosuppressive treatment fails (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Lupus nephritis"}, {"text": "Level of evidence C Although evidence for the use of IVIg in renal transplant rejection is limited to case reports and case series results showed that IVIg may be effective for treating acute or chronic renal transplant rejection. IVIg may improve renal function and reverse Ab-mediated rejection. IVIg may be considered among the treatment options generally together with immunosuppressive therapy (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Renal transplant rejection"}, {"text": "Level of evidence C There is weak evidence indicating significant benefit from the use of IVIg in antineutrophil cytoplasmic antibody (ANCA)-associated RPGN. Several case series and case reports showed that IVIg may improve renal function and therefore is recommended as a potential therapy for ANCA-associated RPGN (strength of recommendation I). ", "cite_spans": [], "ref_spans": [], "section": "ANCA-associated rapidly progressive glomerulonephritis (RPGN)"}, {"text": "Level of evidence C The use of IVIg in BK-virus-associated nephropathy in renal allograft recipient is limited only in a few case reports. Nevertheless, in these cases, IVIg showed significant efficacy and with concomitant reduction of immunosuppression it may be considered as one of the treatment options in this disease (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "BK-virus-associated nephropathy in renal allograft recipients"}, {"text": "Level of evidence B Results coming from a single-arm nonrandomized study and a prospective cohort study showed that IVIg may be effective in treating severe IgA nephropathy and therefore it may be considered as a possible treatment option. However, RCTs are needed to confirm this efficacy (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "IgA nephropathy"}, {"text": "The efficacy of IVIg in membranous nephropathy was studied in few retrospective trials and a case series. Results from these studies indicate that IVIg may be effective in induction of remission. Although there is no strong evidence, IVIg may be considered as an additional option in treatment of membranous nephropathy (strength of level of evidence C; recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Membranous nephropathy"}, {"text": "The following conditions refer to (Table 9 ). ", "cite_spans": [], "ref_spans": [{"start": 34, "end": 42, "text": "(Table 9", "ref_id": "TABREF20"}], "section": "Membranous nephropathy"}, {"text": "Level of evidence B There is some evidence that IVIg have steroid-sparing effect and may be effective as monotherapy and/or adjunctive therapy in patients with previously severe unresponsive pemphigus vulgaris (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Pemphigus vulgaris"}, {"text": "Level of evidence C Adjunctive to standard immunotherapy treatment with IVIg may cause improvement in clinical course and may have steroid-sparing effect in previously steroid-dependent patients with refractory pemphigus foliaceus (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Pemphigus foliaceus"}, {"text": "Level of evidence C In some severe cases of bullous pemphigoid, IVIg was found to be effective as monotherapy and adjunctive therapy as well; it had steroid-sparing effect and led to improvement of quality of life (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Bullous pemphigoid"}, {"text": "Level of evidence C There is some evidence that IVIg monotherapy may be at least as effective as standard immunosuppressive treatment and lead to quick therapy response and better quality of life (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Mucous membrane pemphigoid"}, {"text": "Level of evidence C The sparse data of positive effect of IVIg on severe cases of epidermolysis bullosa acquisita, linear IgA disease, and pemphigoid gestationis were published (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Epidermolysis bullosa acquisita, linear IgA disease, pemphigoid gestationis"}, {"text": "Summary In autoimmune blistering diseases, the treatment with IVIg may be effective and has to be implicated in cases with severe disease, resistant to conventional therapy or those who experienced severe complications of such therapy.", "cite_spans": [], "ref_spans": [], "section": "Epidermolysis bullosa acquisita, linear IgA disease, pemphigoid gestationis"}, {"text": "Level of evidence C The randomized studies have not been performed and the current knowledge about effectiveness of IVIg in SJS and TEN is based on results of multiple prospective noncontrolled studies, retrospective case series, and case reports. The data are limited and inconclusive (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Stevens-Johnson syndrome and toxic epidermal necrolysis"}, {"text": "Level of evidence B The current data based on single, randomized, controlled, and evaluator-blinded trial and number of prospective noncontrolled studies suggest that IVIg may be effective as monotherapy in pediatric patients and as adjunctive therapy in adults. However, in view of the low-cost effectiveness of IVIg, this treatment should be used in cases of severe disabling atopic dermatitis (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Atopic dermatitis"}, {"text": "Level of evidence C A number of case reports and case series describe the beneficial effect of IVIg in chronic idiopathic and autoimmune urticaria, but randomized controlled studies are still lacking. The use of IVIg has to be limited to severe unresponsive cases of chronic urticaria or in case of severe complications of conventional treatment (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Urticaria"}, {"text": "Level of evidence C Only three cases of severe resistant psoriasis with psoriatic arthritis responsive to treatment with high-dose immunoglobulin were reported. We conclude that there is now evidence of effectiveness of IVIg in psoriasis (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Psoriasis"}, {"text": "Level of evidence C IVIg was successfully used in few cases of previously unresponsive pyoderma gangrenosum, but its systematic use cannot be recommended (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Pyoderma gangrenosum"}, {"text": "Level of evidence C Several case reports and case series showed IVIg to be effective for nephrogenic fibrosing dermopathy, pretibial myxedema, and Arndt-Gottron scleromyxedema, but still well-controlled studies are lacking. We suppose that IVIg can be used in severe cases of these rare conditions, unresponsive to conventional treatment (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Miscellaneous dermatoses"}, {"text": "The following conditions refer to (Table 10 ). ", "cite_spans": [], "ref_spans": [{"start": 34, "end": 43, "text": "(Table 10", "ref_id": null}], "section": "Miscellaneous dermatoses"}, {"text": "Retrospective series report [299] No difference in length of stay, mechanical ventilation, severity of inflammatory response or incidence of sepsis, wound progression, time to healing, and mortality 16 TEN patients with initial rash involving 65\u00b129%, treated with IVIg vs. 16 patients with TEN initial rash involving 65\u00b127% not treated with IVIg IVIg (Gamimune\u00ae N, Bayer Inc., Toronto, CA) 0.2 to 0.7 g/kg per day according to discretion of attending physician on duty, as 5% or 10% solution according to availability, for 4\u00b11 day Retrospective [300] No difference of SCORAD index and in global evaluation of disease severity by patients at day 30 10 adult patients (mean age 28) with sever atopic dermatitis IVIg 1 g/kg per day (Sandoglobulin\u00ae, Sandoz, France) immediate or delayed by 1 month (meanwhile intensive therapy with emollients and topical CS (limited to class II 60 g/month)), for 2 days in 8-h infusion, as monotherapy RC evaluatorblinded trial [301] Atopic dermatitis Improvement in skin score (mEASI) was apparent in responders (4/6 patients) from 2 to 3 months and continued to improve over a 6-month period; after 7 months, there was a significant reduction of the overall mEASI; CD69-expressing T cells decreased to 60% from baseline; no change of TNF-a and IFN-g 6 adult patients with severe stable atopic dermatitis Flebogamma\u00ae 5% 2 g/kg per month given in 2-5 days for 6 months as adjunctive treatment, followed for 3 months", "cite_spans": [{"start": 28, "end": 33, "text": "[299]", "ref_id": "BIBREF262"}, {"start": 545, "end": 550, "text": "[300]", "ref_id": "BIBREF263"}, {"start": 958, "end": 963, "text": "[301]", "ref_id": "BIBREF264"}], "ref_spans": [], "section": "days after blisters onset"}, {"text": "Open, single center, prospective [302] 3/3 patients improved skin scores, allowing reduction of steroid dose 3 adult patients with severe atopic dermatitis and steroid-related side effects Alphaglobin\u00ae (Grifols, UK) or Sandoglobulin \u00ae (Novartis, UK) 2 g/kg per month in 3-5 days adjunctive to CS Case report [303] Clinic Rev Allerg Immunol (2010) 38:201-269 Case report [318] First patient had significant reduction in skin scores (36/60 to 11/60) for 1 year only; second had a dramatic sustained response with continued Tx (interval subsequently increased to 10 weeks) 2 patients with scleromyxedema and severe skin disease IVIg 0.4 g/kg per day for 5 days, monthly", "cite_spans": [{"start": 33, "end": 38, "text": "[302]", "ref_id": "BIBREF265"}, {"start": 308, "end": 313, "text": "[303]", "ref_id": "BIBREF266"}, {"start": 370, "end": 375, "text": "[318]", "ref_id": "BIBREF282"}], "ref_spans": [], "section": "days after blisters onset"}, {"text": "Case report [319] Improvement after the first treatment, continuous skin softening and reduction of induration, sustained response to treatment after 20 courses A 48-year-old female with long-standing scleromyxedema unresponsive to highdose CS and immunosuppressive (CP, melphalan) treatment IVIg 2 g/kg in 2 days (Intratect\u00ae; Biotest, Dreieich, Germany) every 4 weeks, adjunctive to PD 10 mg/day Case report [320] Progressive clinical improvement over several months allowing discontinuation of PD but rapid deterioration afterwards with lethal CVA despite reinstating PD and CP An 81-year-old female with scleromyxedema and IDDM IVIg (Gamimune N, 10%, Bayer) 1.5 g/ kg (dose reduced due to CHF) every 4 weeks and oral PD 30 mg/day Case report [321] A positive response after 2 cycles An 82-year-old female with a 12-year history of scleromyxedema unresponsive to various preceding therapies Venimmun\u00ae N (ZLB Behring, Germany) 0.5 g/kg for 5 days at 4-week intervals as monotherapy", "cite_spans": [{"start": 12, "end": 17, "text": "[319]", "ref_id": "BIBREF283"}, {"start": 409, "end": 414, "text": "[320]", "ref_id": "BIBREF284"}, {"start": 745, "end": 750, "text": "[321]", "ref_id": "BIBREF285"}], "ref_spans": [], "section": "days after blisters onset"}, {"text": "Case report [322] Marked clinical improvement, maintained with repeated IVIg infusions A 56-year-old woman with scleromyxedema IVIg (Sandoglobulin\u00ae) 2 g/kg over 5 days as monotherapy Case report [323] Complete clearance of skin lesions, sustained effect after 1 year without treatment Case report [324] Clinic Rev Allerg Immunol (2010) 38: Kaposi's sarcoma", "cite_spans": [{"start": 12, "end": 17, "text": "[322]", "ref_id": "BIBREF286"}, {"start": 195, "end": 200, "text": "[323]", "ref_id": "BIBREF287"}, {"start": 297, "end": 302, "text": "[324]", "ref_id": "BIBREF288"}], "ref_spans": [], "section": "days after blisters onset"}, {"text": "Level of evidence C A patient with polymyositis and Kaposi sarcoma had remission of both conditions on IVIg therapy (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "days after blisters onset"}, {"text": "Level of evidence C Stabilization of metastatic melanoma was shown in the small group of patients after addition of IVIg to standard therapy (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Metastatic melanoma"}, {"text": "Level of evidence CIVIg was shown to be effective in preventing severe recurrent chemotherapy-induced oral mucositis in two patients treated with methotrexate (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Chemotherapy-induced oral mucositis"}, {"text": "Level of evidence C Anecdotal case report describes complete remission of metastatic malignant thymoma after four cycles of IVIg given to myasthenic patient (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Thymus carcinoma"}, {"text": "Level of evidence C After thymectomy, two patients with Good syndrome were maintained with IVIg for developed immunodeficiency; one of them developed Kaposi sarcoma after 3 years (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Thymoma and immunodeficiency (Good syndrome)"}, {"text": "The following conditions refer to (Table 11) .", "cite_spans": [], "ref_spans": [{"start": 34, "end": 44, "text": "(Table 11)", "ref_id": "TABREF25"}], "section": "Thymoma and immunodeficiency (Good syndrome)"}, {"text": "Summary There are still no randomized controlled trials evaluating efficacy of IVIg and it cannot be recommended for treatment of epithelial or other solid malignancies.", "cite_spans": [], "ref_spans": [], "section": "Thymoma and immunodeficiency (Good syndrome)"}, {"text": "Level of evidence C There is some evidence that IVIg therapy can improve the Neuropathy Impairment Score in patients with diabetic demyelinating polyneuropathy (strength of recommendation IIa). A few case reports describe regression of symptoms of proximal diabetic neuropathy, diabetic amyotrophy, and cranial nerve neuropathy in different diabetic patients treated with IVIg (strength of recommendation IIa). We conclude that evidence for the use of IVIg in diabetic neuropathies is poor and its systematic use cannot be recommended. Disease Improvement in all but relapse in 1 patient, 2 weeks to 6 months for full response, most needing 6-8 weekly cycles 10 patients, 30-79 years old with scleromyxedema IVIg 2 g/kg per month given over 5 days;", "cite_spans": [], "ref_spans": [], "section": "Diabetes mellitus"}, {"text": "Octagam\u00ae (2 patients), Sandoglobulin\u00ae (3 patients), Gammagard \u00aeSD (1 patient), unknown (2patients); adjunctive to PD (2 patients) and thalidomide (1 patient) or as monotherapy (7 patients) Review of published case reports [325] Regrowth of eyelashes, eyebrows, and body and scalp hair after second dose, significant hair regrowth with 5-6 cm of scalp hair ", "cite_spans": [{"start": 222, "end": 227, "text": "[325]", "ref_id": "BIBREF289"}], "ref_spans": [], "section": "Diabetes mellitus"}, {"text": "Level of evidence B Therapeutic efforts including dietary therapy and immunomodulation with IVIg fail to improve prognosis in patients with X-linked adrenoleukodystrophy and BMT remains the only treatment that can reverse early neurological manifestations and adrenal impairment of ALD (strength of recommendation III).", "cite_spans": [], "ref_spans": [], "section": "X-linked adrenoleukodystrophy"}, {"text": "Level of evidence C No evidence supports the use of IVIg in Waterhouse-Friderichsen syndrome due to meningococcal sepsis (strength of recommendation III).", "cite_spans": [], "ref_spans": [], "section": "Waterhouse-Friderichsen syndrome"}, {"text": "Level of evidence C No evidence supports the use of IVIg in autoimmune polyendocrine syndrome type 2 (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Autoimmune polyendocrine syndrome"}, {"text": "The following conditions refer to (Table 12) .", "cite_spans": [], "ref_spans": [{"start": 34, "end": 44, "text": "(Table 12)", "ref_id": "TABREF1"}], "section": "Autoimmune polyendocrine syndrome"}, {"text": "Level of evidence C There is weak evidence coming out from several case reports that IVIg may be a useful treatment option either as a combination therapy with CS or in cases that steroid treatment fails (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Acute disseminated encephalomyelitis"}, {"text": "Level of evidence B Taking into consideration the limited evidence (one RCT) and the unfavorable effect of IVIg treatment, at this point, IVIg should not be used as treatment of adrenoleukodystrophy (strength of recommendation III).", "cite_spans": [], "ref_spans": [], "section": "Adrenoleukodystrophy"}, {"text": "Level of evidence C No benefit was observed from the use of IVIg in two case series. Considering the weak evidence and the negative outcome, IVIg is not recommended for the treatment of amyotrophic lateral sclerosis (strength of recommendation III).", "cite_spans": [], "ref_spans": [], "section": "Amyotrophic lateral sclerosis"}, {"text": "Level of evidence C The use of IVIg in autism is only limited to case series and the effect is questionable. IVIg is not recommended at the moment for the treatment of autism (strength of recommendation III).", "cite_spans": [], "ref_spans": [], "section": "Autism"}, {"text": "Level of evidence A Several RCTs evaluated the effectiveness of IVIg. The results of these studies are strongly pointing to the useful effect of IVIg in patients with chronic inflammatory demyelinating polyneuropathy. IVIg should be considered as an additional option in combination with other immunosuppressive agents (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Chronic inflammatory demyelinating polyneuropathy"}, {"text": "Level of evidence C In this rare syndrome, IVIg was reported in several case reports and a retrospective study proved that it induced significant response. Although there is no strong evidence, IVIg may be considered as an additional option in treatment of opsoclonus myoclonus (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Opsoclonus myoclonus"}, {"text": "Level of evidence B Results coming from one small RCT testing the effect of IVIg showed significant improvement in symptoms; therefore, IVIg is recommended as an additional option for treatment of PANDAS (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections PANDAS"}, {"text": "Level of evidence A Data from several RCTs and a metaanalysis showed significant differences between IVIg and placebo favoring the use of IVIg in relapsing-remitting multiple sclerosis (MS). On the other hand, a recent RCT including 127 patients with relapsing-remitting MS treated with IVIg or placebo showed no significant difference in the proportion of relapse-free patients among treated groups. Another recent RCT including 231 patients showed that IVIg can delay progression of disease in primary chronic progressive MS but no significant difference in progression was noted for secondary chronic progressive MS. To conclude, IVIg may be used as an alternative therapy in relapsingremitting MS and in primary chronic progressive MS when standard immunosuppression therapy fails (strength of recommendation IIb). ", "cite_spans": [], "ref_spans": [], "section": "Multiple sclerosis"}, {"text": "Level of evidence A There is strong evidence, several randomized controlled trials, and a meta-analysis that prove that IVIg is of benefit in improving the disability grade in patients with Guillain-Barr\u00e9 syndrome. No significant difference between IVIg and PP was found. IVIg should be considered as a treatment option in Guillain-Barr\u00e9 syndrome (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Guillain-Barr\u00e9"}, {"text": "Level of evidence A There is no reliable evidence to recommend the use of IVIg in paraproteinemic neuropathy. A restricted number of RCT's and a systematic review showed only modest benefit with IVIg in the short term (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Paraproteinemic neuropathy (IgM)"}, {"text": "Level of evidence B A single small RCT showed significant improvement in patients suffering from Lambert-Eaton myasthenic syndrome with the use of IVIg compared to placebo. Therefore, it is acceptable to consider the use of IVIg in this rare and severe neurological syndrome (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Lambert-Eaton myasthenic syndrome"}, {"text": "Level of evidence B Data from a small randomize control trial and several case reports showed that the use of IVIg led to significant improvement in patients with stiff-person syndrome and was superior to placebo. IVIg should be considered as a treatment option in this syndrome especially if the first-line treatment fails (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Stiff-person syndrome"}, {"text": "Level of evidence A Two RCTs investigated the efficacy of IVIg in patients with intractable childhood epilepsy compared with placebo. Results from these studies do not support benefit from the use of IVIg. Therefore, IVIg is not recommended for the treatment of intractable childhood epilepsy (strength of recommendation III).", "cite_spans": [], "ref_spans": [], "section": "Intractable childhood epilepsy"}, {"text": "Level of evidence C There is no reliable evidence (level of evidence C-III) to recommend the use of IVIg in the treatment of critical illness polyneuropathy (strength of recommendation III). ", "cite_spans": [], "ref_spans": [], "section": "Critical illness polyneuropathy"}, {"text": "Level of evidence A Several RCTs and a meta-analysis examined the efficacy of IVIg in patient with myasthenia gravis. Results are conflicting. A recent metaanalysis concluded that there is insufficient evidence to determine the efficacy of IVIg in myasthenia gravis. IVIg may be used as treatment for myasthenia gravis severe acute exacerbations (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Myasthenia gravis"}, {"text": "The following conditions refer to (Table 13 ).", "cite_spans": [], "ref_spans": [{"start": 34, "end": 43, "text": "(Table 13", "ref_id": "TABREF6"}], "section": "Myasthenia gravis"}, {"text": "Level of evidence B Retrospective analyses revealed that IVIg is beneficial in terms of reduction of acute and chronic infections and days of stay in the hospital. Intravenous route is preferred over intramuscular administration of immunoglobulin and the number and severity of complications are inversely correlated with the dose of IVIg (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "X-linked agammaglobulinemia"}, {"text": "Level of evidence C Despite relatively low evidence of effectiveness of IVIg, the majority of WAS patients are treated with IVIg, which appears to be effective in reduction of acute and chronic infections in these immunodeficient patients (strength of recommendation IIa).", "cite_spans": [], "ref_spans": [], "section": "Wiscott-Aldrich syndrome"}, {"text": "Level of evidence C There is weak evidence that IVIg is useful in the treatment of hyper-IgE syndrome. IVIg may be tried in cases in which recurrent live-threatening diseases cannot be controlled by antibiotic prophylaxis (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "Hyper-IgE syndrome (job syndrome)"}, {"text": "Level of evidence C There is scarce evidence that IVIg is useful in the treatment of IgG subclass deficiencies. Most of the experience reported is patients with IgG2 deficiency. In our opinion, when antibiotic treatment is not effective, IVIg would be a reasonable alternative (strength of recommendation IIb).", "cite_spans": [], "ref_spans": [], "section": "IgG subclass deficiencies"}, {"text": "Level of evidence B This is a heterogeneous group. Specific deficiency of antibodies after vaccination has been found to correlate with infection susceptibility. Most of the published experience regarding IVIg is in patients with deficiency of antibodies to capsular polysaccharide. IVIg has been reported to be beneficial in some cases. This is not surprising as antibodies to bacterial capsular polysaccharide are contained in IVIg [31] . The evidence for the use of IVIg in specific antibody deficiency is not strong but might be warranted when recurrent infection is present and it is possible to demonstrate low antibody responses to a relevant vaccine (strength of recommendation IIa).", "cite_spans": [{"start": 434, "end": 438, "text": "[31]", "ref_id": null}], "ref_spans": [], "section": "Specific antibody deficiency"}, {"text": "Level of evidence B The hyper-IgM syndrome (HIGM) is a rare hereditary immune deficiency, characterized by a low or nil level of IgG and IgA and a normal or increased level of IgM, predominately affecting boys. Its clinical manifestations are dominated by recurrent infection, notably of the digestive tube, the ears, nose, and throat and the lungs. IVIg may be considered to treat patients with HIGM and recurrent infections (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Hyper-immunoglobulin-G syndrome"}, {"text": "Level of evidence C Transient hypogammaglobulinemia of infancy is characterized by a prolongation and accentuation of the physiologic hypogammaglobulinemia normally occurring during the first 3 to 6 months of life and recovers spontaneously between 18 and 36 months of age. Infants with transient hyogammaglobulinemia of infancy (THI) may remain asymptomatic or develop recurrent sinopulmonary infections, but severe or lifethreatening infections are rare. In general, supportive and antimicrobial therapies are sufficient management for the treatment of specific infections in patients with THI. In cases in which infections are severe or refractory to conventional therapy, IVIg is sometimes considered although literature reports are lacking (strength of recommendation I).", "cite_spans": [], "ref_spans": [], "section": "Transient hypogammaglobulinemia of infancy"}, {"text": "Level of evidence B SCID is a severe form of heritable immunodeficiency in which both \"arms\" of the adaptive immune system are defected. These babies, if untreated, usually die within 1 year due to severe recurrent infections. Treatment with BMT is successful, and IVIg is used as an adjuvant for this therapy (strength of recommendation I). ", "cite_spans": [], "ref_spans": [], "section": "Severe combined immunodeficiency"}, {"text": "Many different genetic diseases will ultimately result in primary phagocytic defect: cyclic neutropenia, severe congenital neutropenia, Shwachman-Diamond syndrome, leu-kocyte adhesion deficiency, Rac2 deficiency, interferon-\u03b3 and IL-12 defects, chronic granulomatous disease, myeloperoxidase deficiency, Chediak-Higashi syndrome, and neutrophil-specific granule deficiency [34] . An extensive PubMed-based search revealed little if any information regarding the efficacy of IVIg in the above entities.", "cite_spans": [{"start": 373, "end": 377, "text": "[34]", "ref_id": null}], "ref_spans": [], "section": "Primary phagocytic defect"}, {"text": "IgA deficiency may be associated with preventable anaphylaxis or anaphylactoid reaction following IVIg transfusion [35] . This adverse reaction is encountered in patients with selective IgA deficiency and high titer of anti-IgA antibodies. In those patients, anaphylaxis can be avoided by the use of IgA-depleted IVIg preparation [36] .", "cite_spans": [{"start": 115, "end": 119, "text": "[35]", "ref_id": null}, {"start": 330, "end": 334, "text": "[36]", "ref_id": null}], "ref_spans": [], "section": "IgA deficiency"}, {"text": "This article summarizes most of the studies dealing with IVIg administration that were publicized until recently. We have included an array of clinical conditions, some in which the use of IVIg is expected according to their pathogenesis, such as primary immunodeficiencies and rheumatic diseases, and others somewhat less obvious indications including cardiac and oncologic diseases. In some diseases, the usage of IVIg was found to be highly recommended (with a level of evidence A and strength of recommendation I): Kawasaki disease, acquired hypogammaglobulinemia, juvenile rheumatoid arthritis, hemolytic disease of the newborn, acute immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and Guillain-Barr\u00e9 syndrome. For many other diseases, treatment with IVIg was found effective as well, but this was less well established, either due to a lack of well-designed studies or due to conflicting evidence among them. In some diseases, there is a strong recommendation against using IVIg (with a level of evidence A and strength of recommendation III): stem cell/bone marrow transplantation, inclusion body myositis, recurrent pregnancy loss due to antiphospholipid syndrome, optic neuritis, and intractable childhood epilepsy. Nevertheless, the effectiveness of IVIg in such a large span of diseases fortifies the accumulating evidence that many pathological conditions are autoimmune mediated. ", "cite_spans": [], "ref_spans": [], "section": "Discussion"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "High-dose intravenous gamma globulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood", "authors": [{"first": "P", "middle": [], "last": "Imbach", "suffix": ""}, {"first": "S", "middle": [], "last": "Barandun", "suffix": ""}, {"first": "C", "middle": [], "last": "Baumgartner", "suffix": ""}, {"first": "A", "middle": [], "last": "Hirt", "suffix": ""}, {"first": "F", "middle": [], "last": "Hofer", "suffix": ""}, {"first": "H", "middle": ["P"], "last": "Wagner", "suffix": ""}], "year": 1981, "venue": "Helv Paediatr Acta", "volume": "36", "issn": "", "pages": "81--86", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "ACC/ AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation", "authors": [{"first": "S", "middle": ["A"], "last": "Hunt", "suffix": ""}, {"first": "D", "middle": ["W"], "last": "Baker", "suffix": ""}, {"first": "M", "middle": ["H"], "last": "Chin", "suffix": ""}, {"first": "M", "middle": ["P"], "last": "Cinquegrani", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Feldman", "suffix": ""}, {"first": "G", "middle": ["S"], "last": "Francis", "suffix": ""}, {"first": "T", "middle": ["G"], "last": "Ganiats", "suffix": ""}, {"first": "S", "middle": [], "last": "Goldstein", "suffix": ""}, {"first": "G", "middle": [], "last": "Gregoratos", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Jessup", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Noble", "suffix": ""}, {"first": "M", "middle": [], "last": "Packer", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Silver", "suffix": ""}, {"first": "L", "middle": ["W"], "last": "Stevenson", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Gibbons", "suffix": ""}, {"first": "E", "middle": ["M"], "last": "Antman", "suffix": ""}, {"first": "J", "middle": ["S"], "last": "Alpert", "suffix": ""}, {"first": "D", "middle": ["P"], "last": "Faxon", "suffix": ""}, {"first": "V", "middle": [], "last": "Fuster", "suffix": ""}, {"first": "G", "middle": [], "last": "Gregoratos", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Jacobs", "suffix": ""}, {"first": "L", "middle": ["F"], "last": "Hiratzka", "suffix": ""}, {"first": "R", "middle": ["O"], "last": "Russell", "suffix": ""}, {"first": "S", "middle": ["C"], "last": "Smith", "suffix": ""}], "year": 2001, "venue": "Heart Failure Society of America. Circulation", "volume": "104", "issn": "", "pages": "2996--3007", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "Review: intravenous immunoglobulin therapy and thromboembolic complications", "authors": [{"first": "U", "middle": [], "last": "Katz", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shoenfeld", "suffix": ""}], "year": 2005, "venue": "Lupus", "volume": "14", "issn": "", "pages": "802--808", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "Intravenous immunoglobulin: adverse effects and safe administration", "authors": [{"first": "H", "middle": [], "last": "Orbach", "suffix": ""}, {"first": "U", "middle": [], "last": "Katz", "suffix": ""}, {"first": "Y", "middle": [], "last": "Sherer", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shoenfeld", "suffix": ""}], "year": 2005, "venue": "Clin Rev Allergy Immunol", "volume": "29", "issn": "", "pages": "173--184", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Intravenous immunoglobulin and the kidney-a two-edged sword", "authors": [{"first": "H", "middle": [], "last": "Orbach", "suffix": ""}, {"first": "M", "middle": [], "last": "Tishler", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shoenfeld", "suffix": ""}], "year": 2004, "venue": "Semin Arthritis Rheum", "volume": "34", "issn": "", "pages": "593--601", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Acquired von Willebrand syndrome: data from an international registry", "authors": [{"first": "A", "middle": ["B"], "last": "Federici", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Rand", "suffix": ""}, {"first": "P", "middle": [], "last": "Bucciarelli", "suffix": ""}, {"first": "U", "middle": [], "last": "Budde", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Van Genderen", "suffix": ""}, {"first": "H", "middle": [], "last": "Mohri", "suffix": ""}, {"first": "D", "middle": [], "last": "Meyer", "suffix": ""}, {"first": "F", "middle": [], "last": "Rodeghiero", "suffix": ""}, {"first": "J", "middle": ["E"], "last": "Sadler", "suffix": ""}], "year": 2000, "venue": "Thromb Haemost", "volume": "84", "issn": "", "pages": "345--349", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches", "authors": [{"first": "A", "middle": ["B"], "last": "Federici", "suffix": ""}, {"first": "F", "middle": [], "last": "Stabile", "suffix": ""}, {"first": "G", "middle": [], "last": "Castaman", "suffix": ""}, {"first": "M", "middle": ["T"], "last": "Canciani", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Mannucci", "suffix": ""}], "year": 1998, "venue": "Blood", "volume": "92", "issn": "", "pages": "2707--2711", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "Transient neutropenia induced by intravenous immune globulin", "authors": [{"first": "E", "middle": [], "last": "Ben-Chetrit", "suffix": ""}, {"first": "C", "middle": [], "last": "Putterman", "suffix": ""}], "year": 1992, "venue": "N Engl J Med", "volume": "326", "issn": "", "pages": "270--271", "other_ids": {}}, "BIBREF8": {"ref_id": "b8", "title": "Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura", "authors": [{"first": "M", "middle": ["S"], "last": "El Alfy", "suffix": ""}, {"first": "G", "middle": ["M"], "last": "Mokhtar", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "El-Laboudy", "suffix": ""}, {"first": "A", "middle": ["S"], "last": "Khalifa", "suffix": ""}], "year": 2006, "venue": "Acta Haematol", "volume": "115", "issn": "", "pages": "46--52", "other_ids": {}}, "BIBREF9": {"ref_id": "b9", "title": "Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children", "authors": [{"first": "M", "middle": ["D"], "last": "Tarantino", "suffix": ""}, {"first": "G", "middle": [], "last": "Young", "suffix": ""}, {"first": "S", "middle": ["J"], "last": "Bertolone", "suffix": ""}, {"first": "K", "middle": ["A"], "last": "Kalinyak", "suffix": ""}, {"first": "F", "middle": ["E"], "last": "Shafer", "suffix": ""}, {"first": "R", "middle": [], "last": "Kulkarni", "suffix": ""}, {"first": "L", "middle": ["C"], "last": "Weber", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Davis", "suffix": ""}, {"first": "H", "middle": [], "last": "Lynn", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Nugent", "suffix": ""}], "year": 2006, "venue": "J Pediatr", "volume": "148", "issn": "", "pages": "489--494", "other_ids": {}}, "BIBREF10": {"ref_id": "b10", "title": "New hope for treatment of neonatal haemochromatosis", "authors": [{"first": "P", "middle": [], "last": "Gissen", "suffix": ""}, {"first": "D", "middle": [], "last": "Kelly", "suffix": ""}], "year": 2004, "venue": "Lancet", "volume": "364", "issn": "9446", "pages": "1644--1645", "other_ids": {}}, "BIBREF11": {"ref_id": "b11", "title": "Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment", "authors": [{"first": "P", "middle": [], "last": "Aukrust", "suffix": ""}, {"first": "L", "middle": [], "last": "Gullestad", "suffix": ""}, {"first": "K", "middle": ["T"], "last": "Lappegard", "suffix": ""}, {"first": "T", "middle": [], "last": "Ueland", "suffix": ""}, {"first": "H", "middle": [], "last": "Aass", "suffix": ""}, {"first": "L", "middle": [], "last": "Wikeby", "suffix": ""}, {"first": "S", "middle": [], "last": "Simonsen", "suffix": ""}, {"first": "S", "middle": ["S"], "last": "Froland", "suffix": ""}, {"first": "T", "middle": ["E"], "last": "Mollnes", "suffix": ""}], "year": 2001, "venue": "Circulation", "volume": "104", "issn": "", "pages": "1494--1500", "other_ids": {}}, "BIBREF12": {"ref_id": "b12", "title": "Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy", "authors": [{"first": "D", "middle": ["M"], "last": "Mcnamara", "suffix": ""}, {"first": "R", "middle": [], "last": "Holubkov", "suffix": ""}, {"first": "R", "middle": ["C"], "last": "Starling", "suffix": ""}, {"first": "G", "middle": ["W"], "last": "Dec", "suffix": ""}, {"first": "E", "middle": [], "last": "Loh", "suffix": ""}, {"first": "G", "middle": [], "last": "Torre-Amione", "suffix": ""}, {"first": "A", "middle": [], "last": "Gass", "suffix": ""}, {"first": "K", "middle": [], "last": "Janosko", "suffix": ""}, {"first": "T", "middle": [], "last": "Tokarczyk", "suffix": ""}, {"first": "P", "middle": [], "last": "Kessler", "suffix": ""}, {"first": "D", "middle": ["L"], "last": "Mann", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Feldman", "suffix": ""}], "year": 2001, "venue": "Circulation", "volume": "103", "issn": "", "pages": "2254--2259", "other_ids": {}}, "BIBREF13": {"ref_id": "b13", "title": "Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure", "authors": [{"first": "L", "middle": [], "last": "Gullestad", "suffix": ""}, {"first": "H", "middle": [], "last": "Aass", "suffix": ""}, {"first": "J", "middle": ["G"], "last": "Fjeld", "suffix": ""}, {"first": "L", "middle": [], "last": "Wikeby", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Andreassen", "suffix": ""}, {"first": "H", "middle": [], "last": "Ihlen", "suffix": ""}, {"first": "S", "middle": [], "last": "Simonsen", "suffix": ""}, {"first": "J", "middle": [], "last": "Kjekshus", "suffix": ""}, {"first": "S", "middle": [], "last": "Nitter-Hauge", "suffix": ""}, {"first": "T", "middle": [], "last": "Ueland", "suffix": ""}, {"first": "Lien", "middle": ["E"], "last": "Froland", "suffix": ""}, {"first": "S", "middle": ["S"], "last": "Aukrust", "suffix": ""}, {"first": "P", "middle": [], "last": "", "suffix": ""}], "year": 2001, "venue": "Circulation", "volume": "103", "issn": "", "pages": "220--225", "other_ids": {}}, "BIBREF14": {"ref_id": "b14", "title": "Successful highdose intravenous immunoglobulin therapy for a patient with fulminant myocarditis", "authors": [{"first": "S", "middle": [], "last": "Kato", "suffix": ""}, {"first": "S", "middle": [], "last": "Morimoto", "suffix": ""}, {"first": "S", "middle": [], "last": "Hiramitsu", "suffix": ""}, {"first": "A", "middle": [], "last": "Uemura", "suffix": ""}, {"first": "M", "middle": [], "last": "Ohtsuki", "suffix": ""}, {"first": "Y", "middle": [], "last": "Kato", "suffix": ""}, {"first": "K", "middle": [], "last": "Miyagishima", "suffix": ""}, {"first": "N", "middle": [], "last": "Mori", "suffix": ""}, {"first": "H", "middle": [], "last": "Hishida", "suffix": ""}], "year": 2007, "venue": "Heart Vessels", "volume": "22", "issn": "", "pages": "48--51", "other_ids": {}}, "BIBREF15": {"ref_id": "b15", "title": "The current status of immune modulating therapy for", "authors": [{"first": "G", "middle": ["A"], "last": "Stouffer", "suffix": ""}, {"first": "R", "middle": ["G"], "last": "Sheahan", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Lenihan", "suffix": ""}, {"first": "P", "middle": [], "last": "Patel", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Lenihan", "suffix": ""}], "year": 2003, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF16": {"ref_id": "b16", "title": "Intravenous immunoglobulins for adult Still's disease and pregnancy", "authors": [{"first": "E", "middle": [], "last": "Liozon", "suffix": ""}, {"first": "K", "middle": [], "last": "Ly", "suffix": ""}, {"first": "Y", "middle": [], "last": "Aubard", "suffix": ""}, {"first": "E", "middle": [], "last": "Vidal", "suffix": ""}], "year": 1999, "venue": "Rheumatology (Oxford)", "volume": "38", "issn": "", "pages": "1024--1025", "other_ids": {}}, "BIBREF17": {"ref_id": "b17", "title": "Intravenous immunoglobulin for ANCAassociated systemic vasculitis with persistent disease activity", "authors": [{"first": "D", "middle": ["R"], "last": "Jayne", "suffix": ""}, {"first": "H", "middle": [], "last": "Chapel", "suffix": ""}, {"first": "D", "middle": [], "last": "Adu", "suffix": ""}, {"first": "S", "middle": [], "last": "Misbah", "suffix": ""}, {"first": "D", "middle": [], "last": "O&apos;donoghue", "suffix": ""}, {"first": "D", "middle": [], "last": "Scott", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Lockwood", "suffix": ""}], "year": 2000, "venue": "QJM", "volume": "93", "issn": "", "pages": "433--439", "other_ids": {}}, "BIBREF18": {"ref_id": "b18", "title": "Pooled intravenous immunoglobulin in the management of systemic vasculitis", "authors": [{"first": "D", "middle": ["R"], "last": "Jayne", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Lockwood", "suffix": ""}], "year": 1993, "venue": "Adv Exp Med Biol", "volume": "336", "issn": "", "pages": "469--472", "other_ids": {}}, "BIBREF19": {"ref_id": "b19", "title": "Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin", "authors": [{"first": "C", "middle": [], "last": "Richter", "suffix": ""}, {"first": "A", "middle": [], "last": "Schnabel", "suffix": ""}, {"first": "E", "middle": [], "last": "Csernok", "suffix": ""}, {"first": "De", "middle": [], "last": "Groot", "suffix": ""}, {"first": "K", "middle": [], "last": "Reinhold-Keller", "suffix": ""}, {"first": "E", "middle": [], "last": "Gross", "suffix": ""}, {"first": "W", "middle": ["L"], "last": "", "suffix": ""}], "year": 1995, "venue": "Clin Exp Immunol", "volume": "101", "issn": "", "pages": "2--7", "other_ids": {}}, "BIBREF20": {"ref_id": "b20", "title": "Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin", "authors": [{"first": "Y", "middle": [], "last": "Levy", "suffix": ""}, {"first": "Y", "middle": [], "last": "Sherer", "suffix": ""}, {"first": "J", "middle": [], "last": "George", "suffix": ""}, {"first": "P", "middle": [], "last": "Langevitz", "suffix": ""}, {"first": "A", "middle": [], "last": "Ahmed", "suffix": ""}, {"first": "Y", "middle": [], "last": "Bar-Dayan", "suffix": ""}, {"first": "F", "middle": [], "last": "Fabbrizzi", "suffix": ""}, {"first": "J", "middle": [], "last": "Terryberry", "suffix": ""}, {"first": "J", "middle": [], "last": "Peter", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shoenfeld", "suffix": ""}], "year": 1999, "venue": "Int Arch Allergy Immunol", "volume": "119", "issn": "", "pages": "231--238", "other_ids": {}}, "BIBREF21": {"ref_id": "b21", "title": "Intravenous immunoglobulin as sole therapy for systemic vasculitis", "authors": [{"first": "D", "middle": ["R"], "last": "Jayne", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Lockwood", "suffix": ""}], "year": 1996, "venue": "Br J Rheumatol", "volume": "35", "issn": "", "pages": "1150--1153", "other_ids": {}}, "BIBREF22": {"ref_id": "b22", "title": "Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan", "authors": [{"first": "E", "middle": [], "last": "Muso", "suffix": ""}, {"first": "T", "middle": [], "last": "Ito-Ihara", "suffix": ""}, {"first": "T", "middle": [], "last": "Ono", "suffix": ""}, {"first": "E", "middle": [], "last": "Imai", "suffix": ""}, {"first": "K", "middle": [], "last": "Yamagata", "suffix": ""}, {"first": "A", "middle": [], "last": "Akamatsu", "suffix": ""}, {"first": "K", "middle": [], "last": "Suzuki", "suffix": ""}], "year": 2004, "venue": "Jpn J Infect Dis", "volume": "57", "issn": "", "pages": "17--18", "other_ids": {}}, "BIBREF23": {"ref_id": "b23", "title": "Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome", "authors": [{"first": "M", "middle": ["G"], "last": "Danieli", "suffix": ""}, {"first": "M", "middle": [], "last": "Cappelli", "suffix": ""}, {"first": "G", "middle": [], "last": "Malcangi", "suffix": ""}, {"first": "F", "middle": [], "last": "Logullo", "suffix": ""}, {"first": "A", "middle": [], "last": "Salvi", "suffix": ""}, {"first": "G", "middle": [], "last": "Danieli", "suffix": ""}], "year": 2004, "venue": "Ann Rheum Dis", "volume": "63", "issn": "", "pages": "1649--1654", "other_ids": {}}, "BIBREF24": {"ref_id": "b24", "title": "Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin", "authors": [{"first": "N", "middle": [], "last": "Tsurikisawa", "suffix": ""}, {"first": "M", "middle": [], "last": "Taniguchi", "suffix": ""}, {"first": "H", "middle": [], "last": "Saito", "suffix": ""}, {"first": "H", "middle": [], "last": "Himeno", "suffix": ""}, {"first": "A", "middle": [], "last": "Ishibashi", "suffix": ""}, {"first": "S", "middle": [], "last": "Suzuki", "suffix": ""}, {"first": "K", "middle": [], "last": "Akiyama", "suffix": ""}], "year": 2004, "venue": "Ann Allergy Asthma Immunol", "volume": "92", "issn": "", "pages": "80--87", "other_ids": {}}, "BIBREF25": {"ref_id": "b25", "title": "Efficacy of intravenous immunoglobulin therapy in a case of autoimmunemediated chronic active hepatitis", "authors": [{"first": "F", "middle": [], "last": "Carmassi", "suffix": ""}, {"first": "M", "middle": [], "last": "Morale", "suffix": ""}, {"first": "R", "middle": [], "last": "Puccetti", "suffix": ""}, {"first": "F", "middle": [], "last": "Pistelli", "suffix": ""}, {"first": "R", "middle": [], "last": "Palla", "suffix": ""}, {"first": "G", "middle": [], "last": "Bevilacqua", "suffix": ""}, {"first": "P", "middle": [], "last": "Viacava", "suffix": ""}, {"first": "A", "middle": [], "last": "Antonelli", "suffix": ""}, {"first": "G", "middle": [], "last": "Mariani", "suffix": ""}], "year": 1992, "venue": "Clin Exp Rheumatol", "volume": "10", "issn": "", "pages": "13--17", "other_ids": {}}, "BIBREF26": {"ref_id": "b26", "title": "Intravenous immunoglobulin plus interferon-alpha in autoimmune hepatitis C", "authors": [{"first": "M", "middle": [], "last": "Malaguarnera", "suffix": ""}, {"first": "N", "middle": [], "last": "Guccione", "suffix": ""}, {"first": "S", "middle": [], "last": "Musumeci", "suffix": ""}, {"first": "A", "middle": [], "last": "Brogna", "suffix": ""}, {"first": "M", "middle": [], "last": "Motta", "suffix": ""}, {"first": "Di", "middle": [], "last": "Fazio", "suffix": ""}, {"first": "I", "middle": [], "last": "", "suffix": ""}], "year": 2004, "venue": "BioDrugs", "volume": "18", "issn": "", "pages": "63--70", "other_ids": {}}, "BIBREF27": {"ref_id": "b27", "title": "High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Sch\u00f6nlein purpura", "authors": [{"first": "G", "middle": [], "last": "Rostoker", "suffix": ""}, {"first": "D", "middle": [], "last": "Desvaux-Belghiti", "suffix": ""}, {"first": "Y", "middle": [], "last": "Pilatte", "suffix": ""}, {"first": "M", "middle": [], "last": "Petit-Phar", "suffix": ""}, {"first": "C", "middle": [], "last": "Philippon", "suffix": ""}, {"first": "L", "middle": [], "last": "Deforges", "suffix": ""}, {"first": "H", "middle": [], "last": "Terzidis", "suffix": ""}, {"first": "L", "middle": [], "last": "Intrator", "suffix": ""}, {"first": "C", "middle": [], "last": "Andre", "suffix": ""}, {"first": "S", "middle": [], "last": "Adnot", "suffix": ""}, {"first": "P", "middle": [], "last": "Bonin", "suffix": ""}, {"first": "P", "middle": [], "last": "Bierling", "suffix": ""}, {"first": "P", "middle": [], "last": "Remy", "suffix": ""}, {"first": "G", "middle": [], "last": "Lagrue", "suffix": ""}, {"first": "P", "middle": [], "last": "Lang", "suffix": ""}, {"first": "B", "middle": [], "last": "Weil", "suffix": ""}], "year": 1994, "venue": "Ann Intern Med", "volume": "120", "issn": "", "pages": "476--484", "other_ids": {}}, "BIBREF28": {"ref_id": "b28", "title": "Intravenous immunoglobulin therapy for severe digestive manifestations of Henoch-Sch\u00f6nlein purpura", "authors": [{"first": "T", "middle": [], "last": "Lamireau", "suffix": ""}, {"first": "L", "middle": [], "last": "Rebouissoux", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Hehunstre", "suffix": ""}], "year": 2001, "venue": "Acta Paediatr", "volume": "90", "issn": "", "pages": "1081--1082", "other_ids": {}}, "BIBREF29": {"ref_id": "b29", "title": "Successful treatment of adult-onset Henoch-Sch\u00f6nlein purpura nephritis with high-dose immunoglobulins", "authors": [{"first": "A", "middle": [], "last": "Kusuda", "suffix": ""}, {"first": "K", "middle": [], "last": "Migita", "suffix": ""}, {"first": "M", "middle": [], "last": "Tsuboi", "suffix": ""}, {"first": "M", "middle": [], "last": "Degawa", "suffix": ""}, {"first": "N", "middle": [], "last": "Matsuoka", "suffix": ""}, {"first": "M", "middle": [], "last": "Tominaga", "suffix": ""}, {"first": "A", "middle": [], "last": "Kawakami", "suffix": ""}, {"first": "Y", "middle": [], "last": "Kawabe", "suffix": ""}, {"first": "T", "middle": [], "last": "Taguchi", "suffix": ""}, {"first": "K", "middle": [], "last": "Eguchi", "suffix": ""}], "year": 1999, "venue": "Intern Med", "volume": "38", "issn": "", "pages": "376--379", "other_ids": {}}, "BIBREF30": {"ref_id": "b30", "title": "Henoch-Sch\u00f6nlein nephritis. Adverse effect of treatment with intravenous immunoglobulin", "authors": [{"first": "I", "middle": ["R"], "last": "Villarreal", "suffix": ""}, {"first": "O", "middle": [], "last": "Ortega", "suffix": ""}, {"first": "A", "middle": [], "last": "Vigil", "suffix": ""}, {"first": "P", "middle": [], "last": "Gallar", "suffix": ""}, {"first": "A", "middle": [], "last": "Oliet", "suffix": ""}, {"first": "A", "middle": [], "last": "Garcia-Rubiales", "suffix": ""}, {"first": "E", "middle": [], "last": "Jimenez", "suffix": ""}], "year": 1999, "venue": "Nephrol Dial Transplant", "volume": "14", "issn": "", "pages": "795--797", "other_ids": {}}, "BIBREF31": {"ref_id": "b31", "title": "Intravenous immunoglobulin in Henoch-Sch\u00f6nlein purpura", "authors": [{"first": "M", "middle": ["A"], "last": "Hamidou", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Pottier", "suffix": ""}, {"first": "B", "middle": [], "last": "Dupas", "suffix": ""}], "year": 1996, "venue": "Ann Intern Med", "volume": "125", "issn": "", "pages": "1013--1014", "other_ids": {}}, "BIBREF32": {"ref_id": "b32", "title": "Fasciitis in mixed connective tissue disease successfully treated with highdose intravenous immunoglobulin", "authors": [{"first": "M", "middle": [], "last": "Matsuda", "suffix": ""}, {"first": "J", "middle": [], "last": "Miki", "suffix": ""}, {"first": "K", "middle": [], "last": "Oguchi", "suffix": ""}, {"first": "K", "middle": [], "last": "Tabata", "suffix": ""}, {"first": "S", "middle": [], "last": "Ikeda", "suffix": ""}], "year": 2003, "venue": "Intern Med", "volume": "42", "issn": "", "pages": "910--911", "other_ids": {}}, "BIBREF33": {"ref_id": "b33", "title": "Efficacy of pulsed intravenous immunoglobulin therapy in mixed connective tissue disease", "authors": [{"first": "A", "middle": [], "last": "Ulmer", "suffix": ""}, {"first": "I", "middle": [], "last": "Kotter", "suffix": ""}, {"first": "A", "middle": [], "last": "Pfaff", "suffix": ""}, {"first": "G", "middle": [], "last": "Fierlbeck", "suffix": ""}], "year": 2002, "venue": "J Am Acad Dermatol", "volume": "46", "issn": "", "pages": "123--127", "other_ids": {}}, "BIBREF34": {"ref_id": "b34", "title": "Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study", "authors": [{"first": "Y", "middle": [], "last": "Levy", "suffix": ""}, {"first": "H", "middle": [], "last": "Amital", "suffix": ""}, {"first": "P", "middle": [], "last": "Langevitz", "suffix": ""}, {"first": "F", "middle": [], "last": "Nacci", "suffix": ""}, {"first": "A", "middle": [], "last": "Righi", "suffix": ""}, {"first": "L", "middle": [], "last": "Conforti", "suffix": ""}, {"first": "S", "middle": [], "last": "Generini", "suffix": ""}, {"first": "Matucci", "middle": [], "last": "Cerinic", "suffix": ""}, {"first": "M", "middle": [], "last": "Shoenfeld", "suffix": ""}, {"first": "Y", "middle": [], "last": "", "suffix": ""}], "year": 2004, "venue": "Arthritis Rheum", "volume": "50", "issn": "", "pages": "1005--1007", "other_ids": {}}, "BIBREF35": {"ref_id": "b35", "title": "High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma", "authors": [{"first": "H", "middle": [], "last": "Ihn", "suffix": ""}, {"first": "Y", "middle": [], "last": "Mimura", "suffix": ""}, {"first": "N", "middle": [], "last": "Yazawa", "suffix": ""}, {"first": "M", "middle": [], "last": "Jinnin", "suffix": ""}, {"first": "Y", "middle": [], "last": "Asano", "suffix": ""}, {"first": "K", "middle": [], "last": "Yamane", "suffix": ""}, {"first": "K", "middle": [], "last": "Tamaki", "suffix": ""}], "year": 2007, "venue": "Br J Dermatol", "volume": "156", "issn": "", "pages": "1058--1060", "other_ids": {}}, "BIBREF36": {"ref_id": "b36", "title": "Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study", "authors": [{"first": "F", "middle": [], "last": "Nacci", "suffix": ""}, {"first": "A", "middle": [], "last": "Righi", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Conforti", "suffix": ""}, {"first": "I", "middle": [], "last": "Miniati", "suffix": ""}, {"first": "G", "middle": [], "last": "Fiori", "suffix": ""}, {"first": "D", "middle": [], "last": "Martinovic", "suffix": ""}, {"first": "D", "middle": [], "last": "Melchiorre", "suffix": ""}, {"first": "T", "middle": [], "last": "Sapir", "suffix": ""}, {"first": "M", "middle": [], "last": "Blank", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shoenfeld", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Pignone", "suffix": ""}, {"first": "M", "middle": ["M"], "last": "Cerinic", "suffix": ""}], "year": 2007, "venue": "Ann Rheum Dis", "volume": "66", "issn": "", "pages": "977--979", "other_ids": {}}, "BIBREF37": {"ref_id": "b37", "title": "Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin-a preliminary report", "authors": [{"first": "Y", "middle": [], "last": "Levy", "suffix": ""}, {"first": "Y", "middle": [], "last": "Sherer", "suffix": ""}, {"first": "P", "middle": [], "last": "Langevitz", "suffix": ""}, {"first": "M", "middle": [], "last": "Lorber", "suffix": ""}, {"first": "P", "middle": [], "last": "Rotman", "suffix": ""}, {"first": "F", "middle": [], "last": "Fabrizzi", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shoenfeld", "suffix": ""}], "year": 2000, "venue": "Clin Rheumatol", "volume": "19", "issn": "", "pages": "207--211", "other_ids": {}}, "BIBREF38": {"ref_id": "b38", "title": "Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group", "authors": [{"first": "E", "middle": ["H"], "last": "Giannini", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Lovell", "suffix": ""}, {"first": "E", "middle": ["D"], "last": "Silverman", "suffix": ""}, {"first": "R", "middle": ["P"], "last": "Sundel", "suffix": ""}, {"first": "B", "middle": ["L"], "last": "Tague", "suffix": ""}, {"first": "Ruperto", "middle": ["N"], "last": "", "suffix": ""}], "year": 1996, "venue": "J Rheumatol", "volume": "23", "issn": "", "pages": "919--924", "other_ids": {}}, "BIBREF39": {"ref_id": "b39", "title": "Therapeutical and immunological effects of methylprednisolone pulse therapy in comparison with intravenous immunoglobulin. Treatment in patients with juvenile chronic arthritis", "authors": [{"first": "J", "middle": [], "last": "Oppermann", "suffix": ""}, {"first": "D", "middle": [], "last": "Mobius", "suffix": ""}], "year": 1994, "venue": "Acta Univ Carol Med (Praha)", "volume": "40", "issn": "", "pages": "117--121", "other_ids": {}}, "BIBREF40": {"ref_id": "b40", "title": "Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a follow-up study", "authors": [{"first": "Y", "middle": [], "last": "Uziel", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "Laxer", "suffix": ""}, {"first": "R", "middle": [], "last": "Schneider", "suffix": ""}, {"first": "E", "middle": ["D"], "last": "Silverman", "suffix": ""}], "year": 1996, "venue": "J Rheumatol", "volume": "23", "issn": "", "pages": "910--918", "other_ids": {}}, "BIBREF41": {"ref_id": "b41", "title": "High dose immunoglobulin therapy in severe juvenile chronic arthritis: long-term follow-up in 16 patients", "authors": [{"first": "A", "middle": ["M"], "last": "Prieur", "suffix": ""}, {"first": "A", "middle": [], "last": "Adleff", "suffix": ""}, {"first": "M", "middle": [], "last": "Debre", "suffix": ""}, {"first": "P", "middle": [], "last": "Boulate", "suffix": ""}, {"first": "C", "middle": [], "last": "Griscelli", "suffix": ""}], "year": 1990, "venue": "Clin Exp Rheumatol", "volume": "8", "issn": "", "pages": "603--608", "other_ids": {}}, "BIBREF42": {"ref_id": "b42", "title": "Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis", "authors": [{"first": "K", "middle": ["S"], "last": "Kanik", "suffix": ""}, {"first": "C", "middle": ["H"], "last": "Yarboro", "suffix": ""}, {"first": "Y", "middle": [], "last": "Naparstek", "suffix": ""}, {"first": "P", "middle": ["H"], "last": "Plotz", "suffix": ""}, {"first": "R", "middle": ["L"], "last": "Wilder", "suffix": ""}], "year": 1996, "venue": "Arthritis Rheum", "volume": "39", "issn": "", "pages": "1027--1029", "other_ids": {}}, "BIBREF43": {"ref_id": "b43", "title": "Immunomodulating therapy of rheumatoid arthritis by high-dose intravenous immunoglobulin", "authors": [{"first": "H", "middle": [], "last": "Becker", "suffix": ""}, {"first": "G", "middle": [], "last": "Mitropoulou", "suffix": ""}, {"first": "K", "middle": [], "last": "Helmke", "suffix": ""}], "year": 1989, "venue": "Klin Wochenschr", "volume": "67", "issn": "", "pages": "286--290", "other_ids": {}}, "BIBREF44": {"ref_id": "b44", "title": "High dose intravenous immunoglobulin (IVIg) in severe refractory rheumatoid arthritis: no evidence for efficacy", "authors": [{"first": "W", "middle": ["P"], "last": "Maksymowych", "suffix": ""}, {"first": "A", "middle": [], "last": "Avina-Zubieta", "suffix": ""}, {"first": "M", "middle": [], "last": "Luong", "suffix": ""}, {"first": "A", "middle": ["S"], "last": "Russell", "suffix": ""}], "year": 1996, "venue": "Clin Exp Rheumatol", "volume": "14", "issn": "", "pages": "657--660", "other_ids": {}}, "BIBREF45": {"ref_id": "b45", "title": "Successful treatment of 'malignant rheumatoid arthritis' in Japan with pooled intravenous immunoglobulin", "authors": [{"first": "H", "middle": [], "last": "Maeda", "suffix": ""}, {"first": "O", "middle": [], "last": "Furonaka", "suffix": ""}, {"first": "K", "middle": [], "last": "Matsushima", "suffix": ""}, {"first": "Y", "middle": [], "last": "Awaya", "suffix": ""}, {"first": "M", "middle": [], "last": "Kuwabara", "suffix": ""}], "year": 2001, "venue": "Rheumatology (Oxford)", "volume": "40", "issn": "", "pages": "955--956", "other_ids": {}}, "BIBREF46": {"ref_id": "b46", "title": "Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sj\u00f6gren's syndrome. IV immunoglobulin", "authors": [{"first": "Y", "middle": [], "last": "Takahashi", "suffix": ""}, {"first": "T", "middle": [], "last": "Takata", "suffix": ""}, {"first": "M", "middle": [], "last": "Hoshino", "suffix": ""}, {"first": "M", "middle": [], "last": "Sakurai", "suffix": ""}, {"first": "I", "middle": [], "last": "Kanazawa", "suffix": ""}], "year": 2003, "venue": "Neurology", "volume": "60", "issn": "", "pages": "503--505", "other_ids": {}}, "BIBREF47": {"ref_id": "b47", "title": "Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sj\u00f6gren's syndrome", "authors": [{"first": "M", "middle": [], "last": "Kizawa", "suffix": ""}, {"first": "K", "middle": [], "last": "Mori", "suffix": ""}, {"first": "M", "middle": [], "last": "Iijima", "suffix": ""}, {"first": "H", "middle": [], "last": "Koike", "suffix": ""}, {"first": "N", "middle": [], "last": "Hattori", "suffix": ""}], "year": 2006, "venue": "J Neurol Neurosurg Psychiatry", "volume": "77", "issn": "", "pages": "967--969", "other_ids": {}}, "BIBREF48": {"ref_id": "b48", "title": "Intravenous immunoglobulin therapy in sensory neuropathy associated with Sj\u00f6gren's syndrome", "authors": [{"first": "J", "middle": ["A"], "last": "Molina", "suffix": ""}, {"first": "J", "middle": [], "last": "Benito-Leon", "suffix": ""}, {"first": "F", "middle": [], "last": "Bermejo", "suffix": ""}, {"first": "F", "middle": ["J"], "last": "Jimenez-Jimenez", "suffix": ""}, {"first": "J", "middle": [], "last": "Olivan", "suffix": ""}], "year": 1996, "venue": "J Neurol Neurosurg Psychiatry", "volume": "60", "issn": "", "pages": "", "other_ids": {}}, "BIBREF49": {"ref_id": "b49", "title": "A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis", "authors": [{"first": "M", "middle": ["C"], "last": "Dalakas", "suffix": ""}, {"first": "I", "middle": [], "last": "Illa", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Dambrosia", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Soueidan", "suffix": ""}, {"first": "D", "middle": ["P"], "last": "Stein", "suffix": ""}, {"first": "C", "middle": [], "last": "Otero", "suffix": ""}, {"first": "S", "middle": ["T"], "last": "Dinsmore", "suffix": ""}, {"first": "S", "middle": [], "last": "Mccrosky", "suffix": ""}], "year": 1993, "venue": "N Engl J Med", "volume": "329", "issn": "", "pages": "", "other_ids": {}}, "BIBREF50": {"ref_id": "b50", "title": "Intravenous immunoglobulin treatment in autoimmune diseases", "authors": [{"first": "M", "middle": ["G"], "last": "Danieli", "suffix": ""}, {"first": "L", "middle": [], "last": "Calcabrini", "suffix": ""}, {"first": "A", "middle": [], "last": "Marchetti", "suffix": ""}, {"first": "V", "middle": [], "last": "Calabrese", "suffix": ""}, {"first": "L", "middle": [], "last": "Pettinari", "suffix": ""}, {"first": "C", "middle": [], "last": "Massaccesi", "suffix": ""}, {"first": "A", "middle": [], "last": "Gabrielli", "suffix": ""}, {"first": "G", "middle": [], "last": "Danieli", "suffix": ""}], "year": 2007, "venue": "Recenti Prog Med", "volume": "98", "issn": "", "pages": "322--326", "other_ids": {}}, "BIBREF51": {"ref_id": "b51", "title": "Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis", "authors": [{"first": "E", "middle": [], "last": "Saito", "suffix": ""}, {"first": "T", "middle": [], "last": "Koike", "suffix": ""}, {"first": "H", "middle": [], "last": "Hashimoto", "suffix": ""}, {"first": "N", "middle": [], "last": "Miyasaka", "suffix": ""}, {"first": "Y", "middle": [], "last": "Ikeda", "suffix": ""}, {"first": "M", "middle": [], "last": "Hara", "suffix": ""}, {"first": "H", "middle": [], "last": "Yamada", "suffix": ""}, {"first": "T", "middle": [], "last": "Yoshida", "suffix": ""}, {"first": "M", "middle": [], "last": "Harigai", "suffix": ""}, {"first": "Y", "middle": [], "last": "Ichikawa", "suffix": ""}], "year": 2008, "venue": "Mod Rheumatol", "volume": "18", "issn": "", "pages": "34--44", "other_ids": {}}, "BIBREF52": {"ref_id": "b52", "title": "A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM", "authors": [{"first": "M", "middle": ["C"], "last": "Dalakas", "suffix": ""}, {"first": "B", "middle": [], "last": "Koffman", "suffix": ""}, {"first": "M", "middle": [], "last": "Fujii", "suffix": ""}, {"first": "S", "middle": [], "last": "Spector", "suffix": ""}, {"first": "K", "middle": [], "last": "Sivakumar", "suffix": ""}, {"first": "E", "middle": [], "last": "Cupler", "suffix": ""}], "year": 2001, "venue": "Neurology", "volume": "56", "issn": "", "pages": "323--327", "other_ids": {}}, "BIBREF53": {"ref_id": "b53", "title": "High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study", "authors": [{"first": "M", "middle": ["C"], "last": "Walter", "suffix": ""}, {"first": "H", "middle": [], "last": "Lochmuller", "suffix": ""}, {"first": "M", "middle": [], "last": "Toepfer", "suffix": ""}, {"first": "B", "middle": [], "last": "Schlotter", "suffix": ""}, {"first": "P", "middle": [], "last": "Reilich", "suffix": ""}, {"first": "M", "middle": [], "last": "Schroder", "suffix": ""}, {"first": "W", "middle": [], "last": "Muller-Felber", "suffix": ""}, {"first": "D", "middle": [], "last": "Pongratz", "suffix": ""}], "year": 2000, "venue": "J Neurol", "volume": "247", "issn": "", "pages": "22--28", "other_ids": {}}, "BIBREF54": {"ref_id": "b54", "title": "Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study", "authors": [{"first": "M", "middle": ["C"], "last": "Dalakas", "suffix": ""}, {"first": "B", "middle": [], "last": "Sonies", "suffix": ""}, {"first": "J", "middle": [], "last": "Dambrosia", "suffix": ""}, {"first": "E", "middle": [], "last": "Sekul", "suffix": ""}, {"first": "E", "middle": [], "last": "Cupler", "suffix": ""}, {"first": "K", "middle": [], "last": "Sivakumar", "suffix": ""}], "year": 1997, "venue": "Neurology", "volume": "48", "issn": "", "pages": "712--716", "other_ids": {}}, "BIBREF55": {"ref_id": "b55", "title": "Intravenous immunoglobulin therapy for resistant ocular Behcet's disease", "authors": [{"first": "N", "middle": [], "last": "Seider", "suffix": ""}, {"first": "I", "middle": [], "last": "Beiran", "suffix": ""}, {"first": "J", "middle": [], "last": "Scharf", "suffix": ""}, {"first": "B", "middle": [], "last": "Miller", "suffix": ""}], "year": 2001, "venue": "Br J Ophthalmol", "volume": "85", "issn": "", "pages": "1287--1288", "other_ids": {}}, "BIBREF56": {"ref_id": "b56", "title": "Behcet's syndrome treated with highdose intravenous IgG and low-dose aspirin", "authors": [{"first": "E", "middle": [], "last": "Rewald", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Jaksic", "suffix": ""}], "year": 1990, "venue": "J R Soc Med", "volume": "83", "issn": "", "pages": "652--653", "other_ids": {}}, "BIBREF57": {"ref_id": "b57", "title": "A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gamma globulin", "authors": [{"first": "R", "middle": ["S"], "last": "Schwartz", "suffix": ""}, {"first": "D", "middle": ["A"], "last": "Gabriel", "suffix": ""}, {"first": "L", "middle": ["M"], "last": "Aledort", "suffix": ""}, {"first": "D", "middle": [], "last": "Green", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Kessler", "suffix": ""}], "year": 1995, "venue": "Blood", "volume": "86", "issn": "", "pages": "797--804", "other_ids": {}}, "BIBREF58": {"ref_id": "b58", "title": "Low response to high-dose intravenous immunoglobulin in the treatment of acquired factor VIII inhibitor", "authors": [{"first": "L", "middle": [], "last": "Crenier", "suffix": ""}, {"first": "J", "middle": [], "last": "Ducobu", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Des Grottes", "suffix": ""}, {"first": "J", "middle": [], "last": "Cerny", "suffix": ""}, {"first": "C", "middle": [], "last": "Delaunoit", "suffix": ""}, {"first": "P", "middle": [], "last": "Capel", "suffix": ""}], "year": 1996, "venue": "Br J Haematol", "volume": "95", "issn": "", "pages": "750--753", "other_ids": {}}, "BIBREF59": {"ref_id": "b59", "title": "Intravenous immunoglobulin therapy for acquired coagulation inhibitors: a critical review", "authors": [{"first": "K", "middle": [], "last": "Yamamoto", "suffix": ""}, {"first": "J", "middle": [], "last": "Takamatsu", "suffix": ""}, {"first": "H", "middle": [], "last": "Saito", "suffix": ""}], "year": 2007, "venue": "Int J Hematol", "volume": "85", "issn": "", "pages": "287--293", "other_ids": {}}, "BIBREF60": {"ref_id": "b60", "title": "Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review", "authors": [{"first": "A", "middle": ["C"], "last": "Dykes", "suffix": ""}, {"first": "I", "middle": ["D"], "last": "Walker", "suffix": ""}, {"first": "G", "middle": ["D"], "last": "Lowe", "suffix": ""}, {"first": "R", "middle": ["C"], "last": "Tait", "suffix": ""}], "year": 2001, "venue": "Haemophilia", "volume": "7", "issn": "", "pages": "160--163", "other_ids": {}}, "BIBREF61": {"ref_id": "b61", "title": "Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study", "authors": [{"first": "S", "middle": [], "last": "Molica", "suffix": ""}, {"first": "P", "middle": [], "last": "Musto", "suffix": ""}, {"first": "F", "middle": [], "last": "Chiurazzi", "suffix": ""}, {"first": "G", "middle": [], "last": "Specchia", "suffix": ""}, {"first": "M", "middle": [], "last": "Brugiatelli", "suffix": ""}, {"first": "L", "middle": [], "last": "Cicoira", "suffix": ""}, {"first": "D", "middle": [], "last": "Levato", "suffix": ""}, {"first": "F", "middle": [], "last": "Nobile", "suffix": ""}, {"first": "M", "middle": [], "last": "Carotenuto", "suffix": ""}, {"first": "V", "middle": [], "last": "Liso", "suffix": ""}, {"first": "B", "middle": [], "last": "Rotoli", "suffix": ""}], "year": 1996, "venue": "Haematologica", "volume": "81", "issn": "", "pages": "121--126", "other_ids": {}}, "BIBREF62": {"ref_id": "b62", "title": "Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors", "authors": [{"first": "H", "middle": [], "last": "Griffiths", "suffix": ""}, {"first": "V", "middle": [], "last": "Brennan", "suffix": ""}, {"first": "J", "middle": [], "last": "Lea", "suffix": ""}, {"first": "C", "middle": [], "last": "Bunch", "suffix": ""}, {"first": "M", "middle": [], "last": "Lee", "suffix": ""}, {"first": "H", "middle": [], "last": "Chapel", "suffix": ""}], "year": 1989, "venue": "Blood", "volume": "73", "issn": "", "pages": "366--368", "other_ids": {}}, "BIBREF63": {"ref_id": "b63", "title": "Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia", "authors": [{"first": "B", "middle": ["J"], "last": "Boughton", "suffix": ""}, {"first": "N", "middle": [], "last": "Jackson", "suffix": ""}, {"first": "S", "middle": [], "last": "Lim", "suffix": ""}, {"first": "N", "middle": [], "last": "Smith", "suffix": ""}], "year": 1995, "venue": "Clin Lab Haematol", "volume": "17", "issn": "", "pages": "75--80", "other_ids": {}}, "BIBREF64": {"ref_id": "b64", "title": "Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma", "authors": [{"first": "H", "middle": ["M"], "last": "Chapel", "suffix": ""}, {"first": "M", "middle": [], "last": "Lee", "suffix": ""}, {"first": "R", "middle": [], "last": "Hargreaves", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Pamphilon", "suffix": ""}, {"first": "A", "middle": ["G"], "last": "Prentice", "suffix": ""}], "year": 1994, "venue": "Lancet", "volume": "343", "issn": "", "pages": "1059--1063", "other_ids": {}}, "BIBREF65": {"ref_id": "b65", "title": "Immunoglobulin prophylaxis during intensive treatment of acute lymphoblastic leukemia in children", "authors": [{"first": "A", "middle": [], "last": "Gimesi", "suffix": ""}, {"first": "M", "middle": [], "last": "Eibl", "suffix": ""}, {"first": "R", "middle": [], "last": "Koos", "suffix": ""}, {"first": "P", "middle": [], "last": "Somlo", "suffix": ""}, {"first": "E", "middle": [], "last": "Magyarossy", "suffix": ""}, {"first": "G", "middle": [], "last": "Kardos", "suffix": ""}, {"first": "E", "middle": [], "last": "Fazekas", "suffix": ""}, {"first": "M", "middle": [], "last": "Schmidt", "suffix": ""}, {"first": "J", "middle": [], "last": "Borsi", "suffix": ""}, {"first": "D", "middle": [], "last": "Schuler", "suffix": ""}], "year": 1992, "venue": "Acta Paediatr Hung", "volume": "32", "issn": "", "pages": "115--125", "other_ids": {}}, "BIBREF66": {"ref_id": "b66", "title": "Treatment of fever and neutropenia with antibiotics versus antibiotics plus intravenous gamma globulin in childhood leukemia", "authors": [], "year": 1989, "venue": "Eur J Pediatr", "volume": "148", "issn": "", "pages": "401--402", "other_ids": {}}, "BIBREF67": {"ref_id": "b67", "title": "Immunoglobulin replacement in chronic lymphocytic leukaemia", "authors": [{"first": "C", "middle": [], "last": "Bunch", "suffix": ""}], "year": 1988, "venue": "Nouv Rev Fr Hematol", "volume": "30", "issn": "", "pages": "419--422", "other_ids": {}}, "BIBREF68": {"ref_id": "b68", "title": "Prophylaxis against infections with intravenous immunoglobulins in multiple myeloma", "authors": [{"first": "P", "middle": [], "last": "Musto", "suffix": ""}, {"first": "M", "middle": [], "last": "Brugiatelli", "suffix": ""}, {"first": "M", "middle": [], "last": "Carotenuto", "suffix": ""}], "year": 1995, "venue": "Br J Haematol", "volume": "89", "issn": "", "pages": "945--946", "other_ids": {}}, "BIBREF69": {"ref_id": "b69", "title": "Hypogammaglobulinaemia in low grade B cell tumours; significance and therapy", "authors": [{"first": "H", "middle": [], "last": "Chapel", "suffix": ""}, {"first": "H", "middle": [], "last": "Griffiths", "suffix": ""}, {"first": "V", "middle": [], "last": "Brennan", "suffix": ""}, {"first": "C", "middle": [], "last": "Bunch", "suffix": ""}, {"first": "J", "middle": [], "last": "Lea", "suffix": ""}, {"first": "M", "middle": [], "last": "Lee", "suffix": ""}], "year": 1991, "venue": "Immunol Invest", "volume": "20", "issn": "", "pages": "187--191", "other_ids": {}}, "BIBREF70": {"ref_id": "b70", "title": "Pure red cell aplasia: treatment with intravenous immunoglobulin concentrate", "authors": [{"first": "O", "middle": ["F"], "last": "Ballester", "suffix": ""}, {"first": "H", "middle": ["I"], "last": "Saba", "suffix": ""}, {"first": "L", "middle": ["C"], "last": "Moscinski", "suffix": ""}, {"first": "R", "middle": [], "last": "Nelson", "suffix": ""}, {"first": "P", "middle": [], "last": "Foulis", "suffix": ""}], "year": 1992, "venue": "Semin Hematol", "volume": "29", "issn": "", "pages": "106--108", "other_ids": {}}, "BIBREF71": {"ref_id": "b71", "title": "Treatment of pure red cell aplasia by high dose intravenous immunoglobulins", "authors": [{"first": "J", "middle": ["P"], "last": "Clauvel", "suffix": ""}, {"first": "W", "middle": [], "last": "Vainchenker", "suffix": ""}, {"first": "A", "middle": [], "last": "Herrera", "suffix": ""}, {"first": "K", "middle": [], "last": "Dellagi", "suffix": ""}, {"first": "G", "middle": [], "last": "Vinci", "suffix": ""}, {"first": "A", "middle": [], "last": "Tabilio", "suffix": ""}, {"first": "C", "middle": [], "last": "Lacombe", "suffix": ""}], "year": 1983, "venue": "Br J Haematol", "volume": "55", "issn": "", "pages": "380--382", "other_ids": {}}, "BIBREF72": {"ref_id": "b72", "title": "Dose-by-dose virological and hematological responses to intravenous immunoglobulin in an immunocompromised patient with persistent parvovirus B19 infection", "authors": [{"first": "J", "middle": ["W"], "last": "Tang", "suffix": ""}, {"first": "J", "middle": ["S"], "last": "Lau", "suffix": ""}, {"first": "S", "middle": ["Y"], "last": "Wong", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Cheung", "suffix": ""}, {"first": "C", "middle": ["H"], "last": "Chan", "suffix": ""}, {"first": "K", "middle": ["F"], "last": "Wong", "suffix": ""}, {"first": "A", "middle": [], "last": "Wong", "suffix": ""}, {"first": "P", "middle": ["K"], "last": "Chan", "suffix": ""}], "year": 2007, "venue": "J Med Virol", "volume": "79", "issn": "", "pages": "1401--1405", "other_ids": {}}, "BIBREF73": {"ref_id": "b73", "title": "Pure red cell aplasia due to parvovirus B19 infection after liver transplantation: a case report and review of the literature", "authors": [{"first": "T", "middle": ["B"], "last": "Liang", "suffix": ""}, {"first": "D", "middle": ["L"], "last": "Li", "suffix": ""}, {"first": "J", "middle": [], "last": "Yu", "suffix": ""}, {"first": "X", "middle": ["L"], "last": "Bai", "suffix": ""}, {"first": "L", "middle": [], "last": "Liang", "suffix": ""}, {"first": "S", "middle": ["G"], "last": "Xu", "suffix": ""}, {"first": "W", "middle": ["L"], "last": "Wang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shen", "suffix": ""}, {"first": "M", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "S", "middle": ["S"], "last": "Zheng", "suffix": ""}], "year": 2007, "venue": "World J Gastroenterol", "volume": "13", "issn": "", "pages": "2007--2010", "other_ids": {}}, "BIBREF74": {"ref_id": "b74", "title": "Acute renal failure in a pediatric kidney allograft recipient treated with intravenous immunoglobulin for parvovirus B19 induced pure red cell aplasia", "authors": [{"first": "M", "middle": ["M"], "last": "Subtirelu", "suffix": ""}, {"first": "J", "middle": ["T"], "last": "Flynn", "suffix": ""}, {"first": "R", "middle": ["S"], "last": "Schechner", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Pullman", "suffix": ""}, {"first": "D", "middle": [], "last": "Feuerstein", "suffix": ""}, {"first": "Del", "middle": [], "last": "Rio", "suffix": ""}, {"first": "M", "middle": [], "last": "", "suffix": ""}], "year": 2005, "venue": "Pediatr Transplant", "volume": "9", "issn": "", "pages": "801--804", "other_ids": {}}, "BIBREF75": {"ref_id": "b75", "title": "Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma", "authors": [{"first": "K", "middle": ["W"], "last": "Song", "suffix": ""}, {"first": "P", "middle": [], "last": "Mollee", "suffix": ""}, {"first": "B", "middle": [], "last": "Patterson", "suffix": ""}, {"first": "W", "middle": [], "last": "Brien", "suffix": ""}, {"first": "M", "middle": [], "last": "Crump", "suffix": ""}], "year": 2002, "venue": "Br J Haematol", "volume": "119", "issn": "", "pages": "125--127", "other_ids": {}}, "BIBREF76": {"ref_id": "b76", "title": "Relapsing pure red cell aplasia associated with B-cell chronic lymphocytic leukemia successfully treated by intravenous immunoglobulin concentrate", "authors": [{"first": "R", "middle": [], "last": "Castelli", "suffix": ""}, {"first": "A", "middle": [], "last": "Vismara", "suffix": ""}, {"first": "G", "middle": [], "last": "Pavia", "suffix": ""}, {"first": "R", "middle": [], "last": "Dagani", "suffix": ""}, {"first": "T", "middle": [], "last": "Porro", "suffix": ""}], "year": 2002, "venue": "Ann Ital Med Int", "volume": "17", "issn": "", "pages": "47--50", "other_ids": {}}, "BIBREF77": {"ref_id": "b77", "title": "A case of persistent anemia in a renal transplant recipient: association with parvovirus B19 infection", "authors": [{"first": "S", "middle": ["H"], "last": "Choi", "suffix": ""}, {"first": "S", "middle": ["P"], "last": "Chang", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Won", "suffix": ""}, {"first": "J", "middle": ["S"], "last": "Lee", "suffix": ""}, {"first": "H", "middle": ["S"], "last": "Chi", "suffix": ""}, {"first": "W", "middle": ["S"], "last": "Yang", "suffix": ""}, {"first": "S", "middle": ["K"], "last": "Park", "suffix": ""}], "year": 2002, "venue": "Scand J Infect Dis", "volume": "34", "issn": "", "pages": "71--75", "other_ids": {}}, "BIBREF78": {"ref_id": "b78", "title": "Fulminant parvovirus infection following erythropoietin treatment in a patient with acquired immunodeficiency syndrome", "authors": [{"first": "J", "middle": [], "last": "Borkowski", "suffix": ""}, {"first": "M", "middle": [], "last": "Amrikachi", "suffix": ""}, {"first": "S", "middle": ["D"], "last": "Hudnall", "suffix": ""}], "year": 2000, "venue": "Arch Pathol Lab Med", "volume": "124", "issn": "", "pages": "441--445", "other_ids": {}}, "BIBREF79": {"ref_id": "b79", "title": "Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin-a report of eight patients", "authors": [{"first": "P", "middle": ["R"], "last": "Koduri", "suffix": ""}, {"first": "R", "middle": [], "last": "Kumapley", "suffix": ""}, {"first": "J", "middle": [], "last": "Valladares", "suffix": ""}, {"first": "C", "middle": [], "last": "Teter", "suffix": ""}], "year": 1999, "venue": "Am J Hematol", "volume": "61", "issn": "", "pages": "16--20", "other_ids": {}}, "BIBREF80": {"ref_id": "b80", "title": "Successful treatment of persistent erythroid aplasia caused by parvovirus B19 infection in a patient with common variable immunodeficiency with lowdose immunoglobulin", "authors": [{"first": "T", "middle": [], "last": "Chuhjo", "suffix": ""}, {"first": "S", "middle": [], "last": "Nakao", "suffix": ""}, {"first": "T", "middle": [], "last": "Matsuda", "suffix": ""}], "year": 1999, "venue": "Am J Hematol", "volume": "60", "issn": "", "pages": "222--224", "other_ids": {}}, "BIBREF81": {"ref_id": "b81", "title": "Red cell aplasia caused by parvovirus B19 in AIDS: use of i.v. immunoglobulin", "authors": [{"first": "P", "middle": ["R"], "last": "Koduri", "suffix": ""}, {"first": "R", "middle": [], "last": "Kumapley", "suffix": ""}, {"first": "N", "middle": ["D"], "last": "Khokha", "suffix": ""}, {"first": "A", "middle": ["R"], "last": "Patel", "suffix": ""}], "year": 1997, "venue": "Ann Hematol", "volume": "75", "issn": "", "pages": "67--68", "other_ids": {}}, "BIBREF82": {"ref_id": "b82", "title": "Parvovirus B19 in HIV infection: a treatable cause of anemia", "authors": [{"first": "A", "middle": [], "last": "Fuller", "suffix": ""}, {"first": "L", "middle": [], "last": "Moaven", "suffix": ""}, {"first": "D", "middle": [], "last": "Spelman", "suffix": ""}, {"first": "W", "middle": ["J"], "last": "Spicer", "suffix": ""}, {"first": "H", "middle": [], "last": "Wraight", "suffix": ""}, {"first": "D", "middle": [], "last": "Curtis", "suffix": ""}, {"first": "J", "middle": [], "last": "Leydon", "suffix": ""}, {"first": "J", "middle": [], "last": "Doultree", "suffix": ""}, {"first": "S", "middle": [], "last": "Locarnini", "suffix": ""}], "year": 1996, "venue": "", "volume": "28", "issn": "", "pages": "277--280", "other_ids": {}}, "BIBREF83": {"ref_id": "b83", "title": "Management of persistent B19 parvovirus infection in AIDS", "authors": [{"first": "B", "middle": [], "last": "Ramratnam", "suffix": ""}, {"first": "A", "middle": [], "last": "Gollerkeri", "suffix": ""}, {"first": "F", "middle": ["J"], "last": "Schiffman", "suffix": ""}, {"first": "P", "middle": [], "last": "Rintels", "suffix": ""}, {"first": "T", "middle": ["P"], "last": "Flanigan", "suffix": ""}], "year": 1995, "venue": "Br J Haematol", "volume": "91", "issn": "", "pages": "90--92", "other_ids": {}}, "BIBREF84": {"ref_id": "b84", "title": "Chronic idiopathic pure red cell aplasia: successful treatment during pregnancy and durable response to intravenous immunoglobulin", "authors": [{"first": "M", "middle": ["J"], "last": "Mant", "suffix": ""}], "year": 1994, "venue": "J Intern Med", "volume": "236", "issn": "", "pages": "593--595", "other_ids": {}}, "BIBREF85": {"ref_id": "b85", "title": "Pure red cell aplasia associated with systemic lupus erythematosus: remission after a single course of intravenous immunoglobulin", "authors": [{"first": "Y", "middle": [], "last": "Ilan", "suffix": ""}, {"first": "Y", "middle": [], "last": "Naparstek", "suffix": ""}], "year": 1993, "venue": "Acta Haematol", "volume": "89", "issn": "", "pages": "152--154", "other_ids": {}}, "BIBREF86": {"ref_id": "b86", "title": "Parvovirus B19-induced red cell aplasia treated with plasmapheresis and immunoglobulin", "authors": [{"first": "J", "middle": ["K"], "last": "Ramage", "suffix": ""}, {"first": "A", "middle": [], "last": "Hale", "suffix": ""}, {"first": "E", "middle": [], "last": "Gane", "suffix": ""}, {"first": "B", "middle": [], "last": "Cohen", "suffix": ""}, {"first": "M", "middle": [], "last": "Boyle", "suffix": ""}, {"first": "G", "middle": [], "last": "Mufti", "suffix": ""}, {"first": "R", "middle": [], "last": "Williams", "suffix": ""}], "year": 1994, "venue": "Lancet", "volume": "343", "issn": "", "pages": "667--668", "other_ids": {}}, "BIBREF87": {"ref_id": "b87", "title": "Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin", "authors": [{"first": "W", "middle": ["A"], "last": "Mcguire", "suffix": ""}, {"first": "H", "middle": ["H"], "last": "Yang", "suffix": ""}, {"first": "E", "middle": [], "last": "Bruno", "suffix": ""}, {"first": "J", "middle": [], "last": "Brandt", "suffix": ""}, {"first": "R", "middle": [], "last": "Briddell", "suffix": ""}, {"first": "T", "middle": ["D"], "last": "Coates", "suffix": ""}, {"first": "R", "middle": [], "last": "Hoffman", "suffix": ""}], "year": 1987, "venue": "N Engl J Med", "volume": "317", "issn": "", "pages": "1004--1008", "other_ids": {}}, "BIBREF88": {"ref_id": "b88", "title": "Persistent parvovirus B19 infection and pure red cell aplasia in Waldenstrom's macroglobulinemia: successful treatment with high-dose intravenous immunoglobulin", "authors": [{"first": "M", "middle": [], "last": "Karmochkine", "suffix": ""}, {"first": "E", "middle": [], "last": "Oksenhendler", "suffix": ""}, {"first": "M", "middle": [], "last": "Leruez-Ville", "suffix": ""}, {"first": "A", "middle": [], "last": "Jaccard", "suffix": ""}, {"first": "F", "middle": [], "last": "Morinet", "suffix": ""}, {"first": "S", "middle": [], "last": "Herson", "suffix": ""}], "year": 1995, "venue": "Am J Hematol", "volume": "50", "issn": "", "pages": "227--228", "other_ids": {}}, "BIBREF89": {"ref_id": "b89", "title": "Clinical significance of inhibitors in acquired von Willebrand syndrome", "authors": [{"first": "H", "middle": [], "last": "Mohri", "suffix": ""}, {"first": "S", "middle": [], "last": "Motomura", "suffix": ""}, {"first": "H", "middle": [], "last": "Kanamori", "suffix": ""}, {"first": "M", "middle": [], "last": "Matsuzaki", "suffix": ""}, {"first": "S", "middle": [], "last": "Watanabe", "suffix": ""}, {"first": "A", "middle": [], "last": "Maruta", "suffix": ""}, {"first": "F", "middle": [], "last": "Kodama", "suffix": ""}, {"first": "T", "middle": [], "last": "Okubo", "suffix": ""}], "year": 1998, "venue": "Blood", "volume": "91", "issn": "", "pages": "3623--3629", "other_ids": {}}, "BIBREF90": {"ref_id": "b90", "title": "Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus", "authors": [{"first": "J", "middle": ["F"], "last": "Viallard", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Pellegrin", "suffix": ""}, {"first": "C", "middle": [], "last": "Vergnes", "suffix": ""}, {"first": "A", "middle": [], "last": "Borel-Derlon", "suffix": ""}, {"first": "G", "middle": [], "last": "Clofent-Sanchez", "suffix": ""}, {"first": "A", "middle": ["T"], "last": "Nurden", "suffix": ""}, {"first": "B", "middle": [], "last": "Leng", "suffix": ""}, {"first": "P", "middle": [], "last": "Nurden", "suffix": ""}], "year": 1999, "venue": "Br J Haematol", "volume": "105", "issn": "", "pages": "532--537", "other_ids": {}}, "BIBREF91": {"ref_id": "b91", "title": "Intravenous immunoglobulin in the treatment of aplastic anemia", "authors": [{"first": "P", "middle": ["D"], "last": "Sadowitz", "suffix": ""}, {"first": "R", "middle": ["L"], "last": "Dubowy", "suffix": ""}], "year": 1990, "venue": "Am J Pediatr Hematol Oncol", "volume": "12", "issn": "", "pages": "198--200", "other_ids": {}}, "BIBREF92": {"ref_id": "b92", "title": "Transient aplastic anemia caused by parvovirus B19 infection in a heart transplant recipient", "authors": [{"first": "G", "middle": ["A"], "last": "Bergen", "suffix": ""}, {"first": "P", "middle": ["E"], "last": "Sakalosky", "suffix": ""}, {"first": "J", "middle": ["T"], "last": "Sinnott", "suffix": ""}], "year": 1996, "venue": "J Heart Lung Transplant", "volume": "15", "issn": "", "pages": "843--845", "other_ids": {}}, "BIBREF93": {"ref_id": "b93", "title": "Treatment of hematologic disorders other than immune thrombocytopenic purpura with intravenous immunoglobulin (IVIg)-report of seven cases and review of the literature", "authors": [{"first": "Y", "middle": [], "last": "Sherer", "suffix": ""}, {"first": "Y", "middle": [], "last": "Levy", "suffix": ""}, {"first": "F", "middle": [], "last": "Fabbrizzi", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shoenfeld", "suffix": ""}], "year": 2000, "venue": "Eur J Intern Med", "volume": "11", "issn": "", "pages": "85--88", "other_ids": {}}, "BIBREF94": {"ref_id": "b94", "title": "Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients", "authors": [{"first": "G", "middle": [], "last": "Flores", "suffix": ""}, {"first": "C", "middle": [], "last": "Cunningham-Rundles", "suffix": ""}, {"first": "A", "middle": ["C"], "last": "Newland", "suffix": ""}, {"first": "J", "middle": ["B"], "last": "Bussel", "suffix": ""}], "year": 1993, "venue": "Am J Hematol", "volume": "44", "issn": "", "pages": "237--242", "other_ids": {}}, "BIBREF95": {"ref_id": "b95", "title": "Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases", "authors": [{"first": "J", "middle": [], "last": "Bux", "suffix": ""}, {"first": "G", "middle": [], "last": "Behrens", "suffix": ""}, {"first": "G", "middle": [], "last": "Jaeger", "suffix": ""}, {"first": "K", "middle": [], "last": "Welte", "suffix": ""}], "year": 1998, "venue": "Blood", "volume": "91", "issn": "", "pages": "181--186", "other_ids": {}}, "BIBREF96": {"ref_id": "b96", "title": "Use of intravenous gamma globulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia", "authors": [{"first": "M", "middle": ["W"], "last": "Hilgartner", "suffix": ""}, {"first": "J", "middle": [], "last": "Bussel", "suffix": ""}], "year": 1987, "venue": "Am J Med", "volume": "83", "issn": "", "pages": "25--29", "other_ids": {}}, "BIBREF97": {"ref_id": "b97", "title": "Evans syndrome: results of a national survey", "authors": [{"first": "P", "middle": [], "last": "Mathew", "suffix": ""}, {"first": "G", "middle": [], "last": "Chen", "suffix": ""}, {"first": "W", "middle": [], "last": "Wang", "suffix": ""}], "year": 1997, "venue": "J Pediatr Hematol Oncol", "volume": "19", "issn": "", "pages": "433--437", "other_ids": {}}, "BIBREF98": {"ref_id": "b98", "title": "Evans syndrome. Results of a pilot study utilizing a multiagent treatment protocol", "authors": [{"first": "A", "middle": [], "last": "Scaradavou", "suffix": ""}, {"first": "J", "middle": [], "last": "Bussel", "suffix": ""}], "year": 1995, "venue": "J Pediatr Hematol Oncol", "volume": "17", "issn": "", "pages": "290--295", "other_ids": {}}, "BIBREF99": {"ref_id": "b99", "title": "Intravenous gamma globulin for thrombocytopenia in children with Evans syndrome", "authors": [{"first": "R", "middle": [], "last": "Nuss", "suffix": ""}, {"first": "W", "middle": [], "last": "Wang", "suffix": ""}], "year": 1987, "venue": "Am J Pediatr Hematol Oncol", "volume": "9", "issn": "", "pages": "164--167", "other_ids": {}}, "BIBREF100": {"ref_id": "b100", "title": "Induction of remission with intravenous immunoglobulin and cyclophosphamide in steroid-resistant Evans' syndrome associated with dermatomyositis", "authors": [{"first": "D", "middle": ["K"], "last": "Chang", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Yoo", "suffix": ""}, {"first": "T", "middle": ["H"], "last": "Kim", "suffix": ""}, {"first": "J", "middle": ["B"], "last": "Jun", "suffix": ""}, {"first": "I", "middle": ["H"], "last": "Lee", "suffix": ""}, {"first": "S", "middle": ["C"], "last": "Bae", "suffix": ""}, {"first": "I", "middle": ["S"], "last": "Kim", "suffix": ""}, {"first": "S", "middle": ["Y"], "last": "Kim", "suffix": ""}], "year": 2001, "venue": "Clin Rheumatol", "volume": "20", "issn": "", "pages": "63--66", "other_ids": {}}, "BIBREF101": {"ref_id": "b101", "title": "Fetomaternal alloimmune thrombocytopenia: antenatal therapy with IvIgG and steroids-more questions than answers. European Working Group on FMAIT", "authors": [{"first": "C", "middle": [], "last": "Kaplan", "suffix": ""}, {"first": "M", "middle": ["F"], "last": "Murphy", "suffix": ""}, {"first": "H", "middle": [], "last": "Kroll", "suffix": ""}, {"first": "A", "middle": ["H"], "last": "Waters", "suffix": ""}], "year": 1998, "venue": "Br J Haematol", "volume": "100", "issn": "", "pages": "62--65", "other_ids": {}}, "BIBREF102": {"ref_id": "b102", "title": "Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebocontrolled, multicenter trial", "authors": [{"first": "C", "middle": [], "last": "Cordonnier", "suffix": ""}, {"first": "S", "middle": [], "last": "Chevret", "suffix": ""}, {"first": "M", "middle": [], "last": "Legrand", "suffix": ""}, {"first": "H", "middle": [], "last": "Rafi", "suffix": ""}, {"first": "N", "middle": [], "last": "Dhedin", "suffix": ""}, {"first": "B", "middle": [], "last": "Lehmann", "suffix": ""}, {"first": "F", "middle": [], "last": "Bassompierre", "suffix": ""}, {"first": "E", "middle": [], "last": "Gluckman", "suffix": ""}], "year": 2003, "venue": "Ann Intern Med", "volume": "139", "issn": "", "pages": "8--18", "other_ids": {}}, "BIBREF103": {"ref_id": "b103", "title": "A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT)", "authors": [{"first": "P", "middle": [], "last": "Zikos", "suffix": ""}, {"first": "M", "middle": ["T"], "last": "Van Lint", "suffix": ""}, {"first": "T", "middle": [], "last": "Lamparelli", "suffix": ""}, {"first": "F", "middle": [], "last": "Gualandi", "suffix": ""}, {"first": "D", "middle": [], "last": "Occhini", "suffix": ""}, {"first": "N", "middle": [], "last": "Mordini", "suffix": ""}, {"first": "G", "middle": [], "last": "Berisso", "suffix": ""}, {"first": "S", "middle": [], "last": "Bregante", "suffix": ""}, {"first": "A", "middle": [], "last": "Bacigalupo", "suffix": ""}], "year": 1998, "venue": "Haematologica", "volume": "83", "issn": "", "pages": "132--137", "other_ids": {}}, "BIBREF104": {"ref_id": "b104", "title": "A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery", "authors": [{"first": "K", "middle": ["M"], "last": "Sullivan", "suffix": ""}, {"first": "J", "middle": [], "last": "Storek", "suffix": ""}, {"first": "K", "middle": ["J"], "last": "Kopecky", "suffix": ""}, {"first": "J", "middle": [], "last": "Jocom", "suffix": ""}, {"first": "G", "middle": [], "last": "Longton", "suffix": ""}, {"first": "M", "middle": [], "last": "Flowers", "suffix": ""}, {"first": "M", "middle": [], "last": "Siadak", "suffix": ""}, {"first": "J", "middle": [], "last": "Nims", "suffix": ""}, {"first": "R", "middle": ["P"], "last": "Witherspoon", "suffix": ""}, {"first": "C", "middle": [], "last": "Anasetti", "suffix": ""}, {"first": "F", "middle": ["R"], "last": "Appelbaum", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Bowden", "suffix": ""}, {"first": "C", "middle": ["D"], "last": "Buckner", "suffix": ""}, {"first": "S", "middle": ["W"], "last": "Crawford", "suffix": ""}, {"first": "H", "middle": ["J"], "last": "Deeg", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Hansen", "suffix": ""}, {"first": "G", "middle": ["B"], "last": "Mcdonald", "suffix": ""}, {"first": "J", "middle": ["E"], "last": "Sanders", "suffix": ""}, {"first": "R", "middle": [], "last": "Storb", "suffix": ""}], "year": 1996, "venue": "Biol Blood Marrow Transplant", "volume": "2", "issn": "", "pages": "44--53", "other_ids": {}}, "BIBREF105": {"ref_id": "b105", "title": "Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients", "authors": [{"first": "D", "middle": ["J"], "last": "Winston", "suffix": ""}, {"first": "W", "middle": ["G"], "last": "Ho", "suffix": ""}, {"first": "K", "middle": [], "last": "Bartoni", "suffix": ""}, {"first": "R", "middle": ["E"], "last": "Champlin", "suffix": ""}], "year": 1993, "venue": "Bone Marrow Transplant", "volume": "12", "issn": "", "pages": "283--288", "other_ids": {}}, "BIBREF106": {"ref_id": "b106", "title": "A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation", "authors": [{"first": "D", "middle": ["J"], "last": "Winston", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Antin", "suffix": ""}, {"first": "S", "middle": ["N"], "last": "Wolff", "suffix": ""}, {"first": "B", "middle": ["E"], "last": "Bierer", "suffix": ""}, {"first": "T", "middle": [], "last": "Small", "suffix": ""}, {"first": "K", "middle": ["B"], "last": "Miller", "suffix": ""}, {"first": "C", "middle": [], "last": "Linker", "suffix": ""}, {"first": "H", "middle": [], "last": "Kaizer", "suffix": ""}, {"first": "H", "middle": ["M"], "last": "Lazarus", "suffix": ""}, {"first": "F", "middle": ["B"], "last": "Petersen", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Cowan", "suffix": ""}, {"first": "W", "middle": ["G"], "last": "Ho", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Wingard", "suffix": ""}, {"first": "G", "middle": ["J"], "last": "Schiller", "suffix": ""}, {"first": "M", "middle": ["C"], "last": "Territo", "suffix": ""}, {"first": "J", "middle": [], "last": "Jiao", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Petrarca", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Tonetta", "suffix": ""}], "year": 2001, "venue": "Bone Marrow Transplant", "volume": "28", "issn": "", "pages": "187--196", "other_ids": {}}, "BIBREF107": {"ref_id": "b107", "title": "High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group", "authors": [{"first": "S", "middle": ["N"], "last": "Wolff", "suffix": ""}, {"first": "J", "middle": ["W"], "last": "Fay", "suffix": ""}, {"first": "R", "middle": ["H"], "last": "Herzig", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Greer", "suffix": ""}, {"first": "S", "middle": [], "last": "Dummer", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Brown", "suffix": ""}, {"first": "R", "middle": ["H"], "last": "Collins", "suffix": ""}, {"first": "D", "middle": ["A"], "last": "Stevens", "suffix": ""}, {"first": "G", "middle": ["P"], "last": "Herzig", "suffix": ""}], "year": 1993, "venue": "Ann Intern Med", "volume": "118", "issn": "", "pages": "937--942", "other_ids": {}}, "BIBREF108": {"ref_id": "b108", "title": "Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation", "authors": [{"first": "K", "middle": ["M"], "last": "Sullivan", "suffix": ""}, {"first": "K", "middle": ["J"], "last": "Kopecky", "suffix": ""}, {"first": "J", "middle": [], "last": "Jocom", "suffix": ""}, {"first": "L", "middle": [], "last": "Fisher", "suffix": ""}, {"first": "C", "middle": ["D"], "last": "Buckner", "suffix": ""}, {"first": "J", "middle": ["D"], "last": "Meyers", "suffix": ""}, {"first": "G", "middle": ["W"], "last": "Counts", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Bowden", "suffix": ""}, {"first": "F", "middle": ["B"], "last": "Peterson", "suffix": ""}, {"first": "R", "middle": ["P"], "last": "Witherspoon", "suffix": ""}], "year": 1990, "venue": "N Engl J Med", "volume": "323", "issn": "", "pages": "705--712", "other_ids": {}}, "BIBREF109": {"ref_id": "b109", "title": "Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates", "authors": [{"first": "G", "middle": ["S"], "last": "Alcock", "suffix": ""}, {"first": "H", "middle": [], "last": "Liley", "suffix": ""}], "year": 2002, "venue": "Cochrane Database Syst Rev", "volume": "3", "issn": "", "pages": "", "other_ids": {}}, "BIBREF110": {"ref_id": "b110", "title": "Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn", "authors": [{"first": "R", "middle": [], "last": "Gottstein", "suffix": ""}, {"first": "R", "middle": ["W"], "last": "Cooke", "suffix": ""}], "year": 2003, "venue": "Arch Dis Child Fetal Neonatal Ed", "volume": "88", "issn": "", "pages": "6--10", "other_ids": {}}, "BIBREF111": {"ref_id": "b111", "title": "High-dose intravenous immunoglobulin in non-ABO transfusion incompatibility", "authors": [{"first": "A", "middle": ["I"], "last": "Kohan", "suffix": ""}, {"first": "R", "middle": ["C"], "last": "Niborski", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Rey", "suffix": ""}, {"first": "G", "middle": [], "last": "Amerise", "suffix": ""}, {"first": "M", "middle": ["I"], "last": "Vazquez", "suffix": ""}, {"first": "N", "middle": [], "last": "Zani", "suffix": ""}, {"first": "R", "middle": [], "last": "Calahonra", "suffix": ""}, {"first": "A", "middle": [], "last": "Binaghi", "suffix": ""}, {"first": "J", "middle": [], "last": "Sanchez Avalos", "suffix": ""}], "year": 1994, "venue": "Vox Sang", "volume": "67", "issn": "", "pages": "195--198", "other_ids": {}}, "BIBREF112": {"ref_id": "b112", "title": "Haemolytic transfusion reaction-successful attenuation with methylprednisolone and high dose immunoglobulin", "authors": [{"first": "B", "middle": ["E"], "last": "Woodcock", "suffix": ""}, {"first": "S", "middle": [], "last": "Walker", "suffix": ""}, {"first": "K", "middle": [], "last": "Adams", "suffix": ""}], "year": 1993, "venue": "Clin Lab Haematol", "volume": "15", "issn": "", "pages": "59--61", "other_ids": {}}, "BIBREF113": {"ref_id": "b113", "title": "Hyperhemolytic transfusion reaction in sickle cell disease", "authors": [{"first": "N", "middle": [], "last": "Win", "suffix": ""}, {"first": "H", "middle": [], "last": "Doughty", "suffix": ""}, {"first": "P", "middle": [], "last": "Telfer", "suffix": ""}, {"first": "B", "middle": ["J"], "last": "Wild", "suffix": ""}, {"first": "T", "middle": ["C"], "last": "Pearson", "suffix": ""}], "year": 2001, "venue": "Transfusion", "volume": "41", "issn": "", "pages": "323--328", "other_ids": {}}, "BIBREF114": {"ref_id": "b114", "title": "Use of intravenous immunoglobulin and intravenous methylprednisolone in hyperhaemolysis syndrome in sickle cell disease", "authors": [{"first": "N", "middle": [], "last": "Win", "suffix": ""}, {"first": "T", "middle": [], "last": "Yeghen", "suffix": ""}, {"first": "M", "middle": [], "last": "Needs", "suffix": ""}, {"first": "F", "middle": ["E"], "last": "Chen", "suffix": ""}, {"first": "I", "middle": [], "last": "Okpala", "suffix": ""}], "year": 2004, "venue": "Hematology", "volume": "9", "issn": "", "pages": "433--436", "other_ids": {}}, "BIBREF115": {"ref_id": "b115", "title": "Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction", "authors": [{"first": "J", "middle": ["O"], "last": "Cullis", "suffix": ""}, {"first": "N", "middle": [], "last": "Win", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Dudley", "suffix": ""}, {"first": "T", "middle": [], "last": "Kaye", "suffix": ""}], "year": 1995, "venue": "Vox Sang", "volume": "69", "issn": "", "pages": "355--357", "other_ids": {}}, "BIBREF116": {"ref_id": "b116", "title": "The use of intravenous gamma globulin in the treatment of typical hemolytic uremic syndrome", "authors": [{"first": "W", "middle": ["L"], "last": "Robson", "suffix": ""}, {"first": "G", "middle": ["H"], "last": "Fick", "suffix": ""}, {"first": "T", "middle": [], "last": "Jadavji", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Leung", "suffix": ""}], "year": 1991, "venue": "Pediatr Nephrol", "volume": "5", "issn": "", "pages": "289--292", "other_ids": {}}, "BIBREF117": {"ref_id": "b117", "title": "High-dose intravenous gamma globulin infusions in hemolytic-uremic syndrome: a preliminary report", "authors": [{"first": "K", "middle": ["J"], "last": "Sheth", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Gill", "suffix": ""}, {"first": "H", "middle": ["E"], "last": "Leichter", "suffix": ""}], "year": 1990, "venue": "Am J Dis Child", "volume": "144", "issn": "", "pages": "268--270", "other_ids": {}}, "BIBREF118": {"ref_id": "b118", "title": "Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Italian Cooperative Group for TTP", "authors": [{"first": "R", "middle": [], "last": "Centurioni", "suffix": ""}, {"first": "E", "middle": [], "last": "Bobbio-Pallavicini", "suffix": ""}, {"first": "C", "middle": [], "last": "Porta", "suffix": ""}, {"first": "F", "middle": [], "last": "Rodeghiero", "suffix": ""}, {"first": "L", "middle": [], "last": "Gugliotta", "suffix": ""}, {"first": "A", "middle": [], "last": "Billio", "suffix": ""}, {"first": "F", "middle": [], "last": "Tacconi", "suffix": ""}, {"first": "E", "middle": [], "last": "Ascari", "suffix": ""}], "year": 1995, "venue": "Haematologica", "volume": "80", "issn": "", "pages": "325--331", "other_ids": {}}, "BIBREF119": {"ref_id": "b119", "title": "Efficacy of intravenous immunoglobulin in the treatment of thrombotic thrombocytopaenic purpura. A study of 44 cases", "authors": [{"first": "J", "middle": [], "last": "Dervenoulas", "suffix": ""}, {"first": "P", "middle": [], "last": "Tsirigotis", "suffix": ""}, {"first": "G", "middle": [], "last": "Bollas", "suffix": ""}, {"first": "A", "middle": ["A"], "last": "Koumarianou", "suffix": ""}, {"first": "V", "middle": [], "last": "Pappa", "suffix": ""}, {"first": "G", "middle": [], "last": "Mantzios", "suffix": ""}, {"first": "N", "middle": [], "last": "Xiros", "suffix": ""}, {"first": "T", "middle": [], "last": "Economopoulos", "suffix": ""}, {"first": "E", "middle": [], "last": "Papageorgiou", "suffix": ""}, {"first": "M", "middle": [], "last": "Pappa", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Raptis", "suffix": ""}], "year": 2001, "venue": "Acta Haematol", "volume": "105", "issn": "", "pages": "204--208", "other_ids": {}}, "BIBREF120": {"ref_id": "b120", "title": "High-dose intravenous gamma-globulins for heparininduced thrombocytopenia: a prompt response", "authors": [{"first": "A", "middle": [], "last": "Winder", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shoenfeld", "suffix": ""}, {"first": "R", "middle": [], "last": "Hochman", "suffix": ""}, {"first": "Keren", "middle": ["G"], "last": "Levy", "suffix": ""}, {"first": "Y", "middle": [], "last": "Eldor", "suffix": ""}, {"first": "A", "middle": [], "last": "", "suffix": ""}], "year": 1998, "venue": "J Clin Immunol", "volume": "18", "issn": "", "pages": "330--334", "other_ids": {}}, "BIBREF121": {"ref_id": "b121", "title": "The therapy of the heparin-induced thrombosis-thrombocytopenia syndrome with immunoglobulins", "authors": [{"first": "A", "middle": [], "last": "Prull", "suffix": ""}, {"first": "R", "middle": [], "last": "Nechwatal", "suffix": ""}, {"first": "H", "middle": [], "last": "Riedel", "suffix": ""}, {"first": "W", "middle": [], "last": "Maurer", "suffix": ""}], "year": 1992, "venue": "Dtsch Med Wochenschr", "volume": "117", "issn": "", "pages": "1838--1842", "other_ids": {}}, "BIBREF122": {"ref_id": "b122", "title": "An evaluation of intravenous immunoglobulin in the treatment of human immunodeficiency virus-associated thrombocytopenia", "authors": [{"first": "L", "middle": [], "last": "Jahnke", "suffix": ""}, {"first": "S", "middle": [], "last": "Applebaum", "suffix": ""}, {"first": "L", "middle": ["A"], "last": "Sherman", "suffix": ""}, {"first": "P", "middle": ["A"], "last": "Greenberger", "suffix": ""}, {"first": "D", "middle": [], "last": "Green", "suffix": ""}], "year": 1994, "venue": "Transfusion", "volume": "34", "issn": "", "pages": "759--764", "other_ids": {}}, "BIBREF123": {"ref_id": "b123", "title": "Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial", "authors": [{"first": "B", "middle": [], "last": "Godeau", "suffix": ""}, {"first": "S", "middle": [], "last": "Chevret", "suffix": ""}, {"first": "B", "middle": [], "last": "Varet", "suffix": ""}, {"first": "F", "middle": [], "last": "Lefrere", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Zini", "suffix": ""}, {"first": "F", "middle": [], "last": "Bassompierre", "suffix": ""}, {"first": "S", "middle": [], "last": "Cheze", "suffix": ""}, {"first": "E", "middle": [], "last": "Legouffe", "suffix": ""}, {"first": "C", "middle": [], "last": "Hulin", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Grange", "suffix": ""}, {"first": "O", "middle": [], "last": "Fain", "suffix": ""}, {"first": "P", "middle": [], "last": "Bierling", "suffix": ""}], "year": 2002, "venue": "Lancet", "volume": "359", "issn": "", "pages": "23--29", "other_ids": {}}, "BIBREF124": {"ref_id": "b124", "title": "The comparison of gamma globulin to steroids in treating adult immune thrombocytopenia. An interim analysis", "authors": [{"first": "P", "middle": [], "last": "Jacobs", "suffix": ""}, {"first": "L", "middle": [], "last": "Wood", "suffix": ""}], "year": 1989, "venue": "Blut", "volume": "59", "issn": "", "pages": "92--95", "other_ids": {}}, "BIBREF125": {"ref_id": "b125", "title": "A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura", "authors": [{"first": "V", "middle": ["S"], "last": "Blanchette", "suffix": ""}, {"first": "B", "middle": [], "last": "Luke", "suffix": ""}, {"first": "M", "middle": [], "last": "Andrew", "suffix": ""}, {"first": "S", "middle": [], "last": "Sommerville-Nielsen", "suffix": ""}, {"first": "D", "middle": [], "last": "Barnard", "suffix": ""}, {"first": "B", "middle": [], "last": "De Veber", "suffix": ""}, {"first": "M", "middle": [], "last": "Gent", "suffix": ""}], "year": 1993, "venue": "J Pediatr", "volume": "123", "issn": "", "pages": "989--995", "other_ids": {}}, "BIBREF126": {"ref_id": "b126", "title": "Clinical course of children with immune thrombocytopenic purpura treated with intravenous immunoglobulin G or megadose methylprednisolone or observed without therapy", "authors": [{"first": "F", "middle": [], "last": "Duru", "suffix": ""}, {"first": "T", "middle": [], "last": "Fisgin", "suffix": ""}, {"first": "N", "middle": [], "last": "Yarali", "suffix": ""}, {"first": "A", "middle": [], "last": "Kara", "suffix": ""}], "year": 2002, "venue": "Pediatr Hematol Oncol", "volume": "19", "issn": "", "pages": "219--225", "other_ids": {}}, "BIBREF127": {"ref_id": "b127", "title": "Intravenous immunoglobulin in the treatment of human immunodeficiency virus-related thrombocytopenia", "authors": [{"first": "M", "middle": ["U"], "last": "Rarick", "suffix": ""}, {"first": "T", "middle": [], "last": "Montgomery", "suffix": ""}, {"first": "S", "middle": [], "last": "Groshen", "suffix": ""}, {"first": "J", "middle": [], "last": "Sullivan-Halley", "suffix": ""}, {"first": "D", "middle": [], "last": "Jamin", "suffix": ""}, {"first": "A", "middle": [], "last": "Mazumder", "suffix": ""}, {"first": "P", "middle": ["S"], "last": "Gill", "suffix": ""}, {"first": "C", "middle": [], "last": "Loureiro", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Levine", "suffix": ""}], "year": 1991, "venue": "Am J Hematol", "volume": "38", "issn": "", "pages": "261--266", "other_ids": {}}, "BIBREF128": {"ref_id": "b128", "title": "Usefulness of a low-dose intravenous immunoglobulin regimen for the treatment of thrombocytopenia associated with AIDS", "authors": [{"first": "A", "middle": [], "last": "Majluf-Cruz", "suffix": ""}, {"first": "G", "middle": [], "last": "Luna-Castanos", "suffix": ""}, {"first": "S", "middle": [], "last": "Huitron", "suffix": ""}, {"first": "L", "middle": [], "last": "Nieto-Cisneros", "suffix": ""}], "year": 1998, "venue": "Am J Hematol", "volume": "59", "issn": "", "pages": "127--132", "other_ids": {}}, "BIBREF129": {"ref_id": "b129", "title": "Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP", "authors": [{"first": "M", "middle": [], "last": "Colovic", "suffix": ""}, {"first": "M", "middle": [], "last": "Dimitrijevic", "suffix": ""}, {"first": "C", "middle": [], "last": "Sonnenburg", "suffix": ""}, {"first": "N", "middle": [], "last": "Suvajdzic", "suffix": ""}, {"first": "M", "middle": [], "last": "Donfrid", "suffix": ""}, {"first": "A", "middle": [], "last": "Bogdanovic", "suffix": ""}], "year": 2003, "venue": "Hematol J", "volume": "4", "issn": "", "pages": "358--362", "other_ids": {}}, "BIBREF130": {"ref_id": "b130", "title": "Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin", "authors": [{"first": "B", "middle": [], "last": "Godeau", "suffix": ""}, {"first": "S", "middle": [], "last": "Lesage", "suffix": ""}, {"first": "M", "middle": [], "last": "Divine", "suffix": ""}, {"first": "V", "middle": [], "last": "Wirquin", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Farcet", "suffix": ""}, {"first": "P", "middle": [], "last": "Bierling", "suffix": ""}], "year": 1993, "venue": "Blood", "volume": "82", "issn": "", "pages": "1415--1421", "other_ids": {}}, "BIBREF131": {"ref_id": "b131", "title": "High-dose intravenous immunoglobulin for posttransfusion purpura", "authors": [{"first": "C", "middle": [], "last": "Mueller-Eckhardt", "suffix": ""}, {"first": "E", "middle": [], "last": "Kuenzlen", "suffix": ""}, {"first": "D", "middle": [], "last": "Thilo-Korner", "suffix": ""}, {"first": "H", "middle": [], "last": "Pralle", "suffix": ""}], "year": 1983, "venue": "N Engl J Med", "volume": "308", "issn": "", "pages": "", "other_ids": {}}, "BIBREF132": {"ref_id": "b132", "title": "High-dose intravenous immunoglobulin for post-transfusion purpura", "authors": [{"first": "T", "middle": [], "last": "Becker", "suffix": ""}, {"first": "S", "middle": [], "last": "Panzer", "suffix": ""}, {"first": "D", "middle": [], "last": "Maas", "suffix": ""}, {"first": "V", "middle": [], "last": "Kiefel", "suffix": ""}, {"first": "R", "middle": [], "last": "Sprenger", "suffix": ""}, {"first": "M", "middle": [], "last": "Kirschbaum", "suffix": ""}, {"first": "C", "middle": [], "last": "Mueller-Eckhardt", "suffix": ""}], "year": 1985, "venue": "Br J Haematol", "volume": "61", "issn": "", "pages": "149--155", "other_ids": {}}, "BIBREF133": {"ref_id": "b133", "title": "Post-transfusion purpura following open heart surgery: management by high dose intravenous immunoglobulin infusion", "authors": [{"first": "W", "middle": ["S"], "last": "Walker", "suffix": ""}, {"first": "P", "middle": ["L"], "last": "Yap", "suffix": ""}, {"first": "D", "middle": ["C"], "last": "Kilpatrick", "suffix": ""}, {"first": "F", "middle": ["E"], "last": "Boulton", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Crawford", "suffix": ""}, {"first": "C", "middle": ["T"], "last": "Sang", "suffix": ""}], "year": 1988, "venue": "Ann Hematol", "volume": "57", "issn": "", "pages": "323--325", "other_ids": {}}, "BIBREF134": {"ref_id": "b134", "title": "High-dose immunoglobulin therapy in renal transplant recipients with hemophagocytic histiocytic syndrome", "authors": [{"first": "G", "middle": [], "last": "Asci", "suffix": ""}, {"first": "H", "middle": [], "last": "Toz", "suffix": ""}, {"first": "M", "middle": [], "last": "Ozkahya", "suffix": ""}, {"first": "S", "middle": [], "last": "Cagirgan", "suffix": ""}, {"first": "S", "middle": [], "last": "Duman", "suffix": ""}, {"first": "S", "middle": [], "last": "Sezis", "suffix": ""}, {"first": "Ok", "middle": ["E"], "last": "", "suffix": ""}], "year": 2006, "venue": "J Nephrol", "volume": "19", "issn": "", "pages": "322--326", "other_ids": {}}, "BIBREF135": {"ref_id": "b135", "title": "Hemophagocytic syndrome: a review of 18 pediatric cases", "authors": [{"first": "C", "middle": ["J"], "last": "Chen", "suffix": ""}, {"first": "Y", "middle": ["C"], "last": "Huang", "suffix": ""}, {"first": "T", "middle": ["H"], "last": "Jaing", "suffix": ""}, {"first": "I", "middle": ["J"], "last": "Hung", "suffix": ""}, {"first": "C", "middle": ["P"], "last": "Yang", "suffix": ""}, {"first": "L", "middle": ["Y"], "last": "Chang", "suffix": ""}, {"first": "T", "middle": ["Y"], "last": "Lin", "suffix": ""}], "year": 2004, "venue": "J Microbiol Immunol Infect", "volume": "37", "issn": "", "pages": "157--163", "other_ids": {}}, "BIBREF136": {"ref_id": "b136", "title": "Immunomodulation treatment for childhood virus-associated haemophagocytic lymphohistiocytosis", "authors": [{"first": "R", "middle": ["L"], "last": "Chen", "suffix": ""}, {"first": "K", "middle": ["H"], "last": "Lin", "suffix": ""}, {"first": "D", "middle": ["T"], "last": "Lin", "suffix": ""}, {"first": "I", "middle": ["J"], "last": "Su", "suffix": ""}, {"first": "L", "middle": ["M"], "last": "Huang", "suffix": ""}, {"first": "P", "middle": ["I"], "last": "Lee", "suffix": ""}, {"first": "K", "middle": ["H"], "last": "Hseih", "suffix": ""}, {"first": "K", "middle": ["S"], "last": "Lin", "suffix": ""}, {"first": "C", "middle": ["Y"], "last": "Lee", "suffix": ""}], "year": 1995, "venue": "Br J Haematol", "volume": "89", "issn": "", "pages": "282--290", "other_ids": {}}, "BIBREF137": {"ref_id": "b137", "title": "Infection associated hemophagocytic syndrome: a report of 50 children", "authors": [{"first": "V", "middle": [], "last": "Ningsanond", "suffix": ""}], "year": 2000, "venue": "J Med Assoc Thai", "volume": "83", "issn": "", "pages": "1141--1149", "other_ids": {}}, "BIBREF138": {"ref_id": "b138", "title": "Intravenously administered immune globulin for the treatment of infection-associated hemophagocytic syndrome", "authors": [{"first": "B", "middle": [], "last": "Freeman", "suffix": ""}, {"first": "M", "middle": ["H"], "last": "Rathore", "suffix": ""}, {"first": "Salman", "middle": ["E"], "last": "Joyce", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Pitel", "suffix": ""}, {"first": "P", "middle": [], "last": "", "suffix": ""}], "year": 1993, "venue": "J Pediatr", "volume": "123", "issn": "", "pages": "479--481", "other_ids": {}}, "BIBREF139": {"ref_id": "b139", "title": "Successful treatment of cytomegalovirus-associated hemophagocytic syndrome by intravenous immunoglobulins", "authors": [{"first": "A", "middle": [], "last": "Hot", "suffix": ""}, {"first": "M", "middle": ["H"], "last": "Madoux", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Viard", "suffix": ""}, {"first": "B", "middle": [], "last": "Coppere", "suffix": ""}, {"first": "J", "middle": [], "last": "Ninet", "suffix": ""}], "year": 2008, "venue": "Am J Hematol", "volume": "83", "issn": "", "pages": "159--162", "other_ids": {}}, "BIBREF140": {"ref_id": "b140", "title": "Rapidly deteriorating polyneuropathy associated with osteosclerotic myeloma responsive to intravenous immunoglobulin and radiotherapy", "authors": [{"first": "J", "middle": [], "last": "Benito-Leon", "suffix": ""}, {"first": "F", "middle": [], "last": "Lopez-Rios", "suffix": ""}, {"first": "F", "middle": ["J"], "last": "Rodriguez-Martin", "suffix": ""}, {"first": "S", "middle": [], "last": "Madero", "suffix": ""}, {"first": "J", "middle": [], "last": "Ruiz", "suffix": ""}], "year": 1998, "venue": "J Neurol Sci", "volume": "158", "issn": "", "pages": "113--117", "other_ids": {}}, "BIBREF141": {"ref_id": "b141", "title": "Poor response to intravenous immunoglobulin therapy in patients with Castleman's disease and the POEMS syndrome", "authors": [{"first": "C", "middle": ["C"], "last": "Huang", "suffix": ""}, {"first": "C", "middle": ["C"], "last": "Chu", "suffix": ""}], "year": 1996, "venue": "J Neurol", "volume": "243", "issn": "", "pages": "726--727", "other_ids": {}}, "BIBREF142": {"ref_id": "b142", "title": "Intravenous immunoglobulin therapy in POEMS syndrome: a case report", "authors": [{"first": "Y", "middle": ["J"], "last": "Chang", "suffix": ""}, {"first": "C", "middle": ["C"], "last": "Huang", "suffix": ""}, {"first": "C", "middle": ["C"], "last": "Chu", "suffix": ""}], "year": 1996, "venue": "Zhonghua Yi Xue Za Zhi (Taipei)", "volume": "58", "issn": "", "pages": "366--369", "other_ids": {}}, "BIBREF143": {"ref_id": "b143", "title": "Successful treatment of post-transplant lymphoproliferative disorder with interferon-alpha and intravenous immunoglobulin", "authors": [{"first": "M", "middle": [], "last": "Cantarovich", "suffix": ""}, {"first": "J", "middle": ["S"], "last": "Barkun", "suffix": ""}, {"first": "R", "middle": ["D"], "last": "Forbes", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Kosiuk", "suffix": ""}, {"first": "J", "middle": ["I"], "last": "Tchervenkov", "suffix": ""}], "year": 1998, "venue": "Clin Transplant", "volume": "12", "issn": "", "pages": "109--115", "other_ids": {}}, "BIBREF144": {"ref_id": "b144", "title": "Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients", "authors": [{"first": "F", "middle": [], "last": "Leroy", "suffix": ""}, {"first": "A", "middle": [], "last": "Sechet", "suffix": ""}, {"first": "R", "middle": [], "last": "Abou Ayache", "suffix": ""}, {"first": "A", "middle": [], "last": "Thierry", "suffix": ""}, {"first": "S", "middle": [], "last": "Belmouaz", "suffix": ""}, {"first": "E", "middle": [], "last": "Desport", "suffix": ""}, {"first": "M", "middle": [], "last": "Bauwens", "suffix": ""}, {"first": "F", "middle": [], "last": "Bridoux", "suffix": ""}, {"first": "G", "middle": [], "last": "Touchard", "suffix": ""}], "year": 2006, "venue": "Transplant Proc", "volume": "38", "issn": "", "pages": "2324--2326", "other_ids": {}}, "BIBREF145": {"ref_id": "b145", "title": "The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group (1991) Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection", "authors": [], "year": null, "venue": "N Engl J Med", "volume": "325", "issn": "", "pages": "73--80", "other_ids": {}}, "BIBREF146": {"ref_id": "b146", "title": "Intravenous immunoglobulin in symptomatic and asymptomatic children with perinatal HIV infection", "authors": [{"first": "L", "middle": [], "last": "Olopoenia", "suffix": ""}, {"first": "M", "middle": [], "last": "Young", "suffix": ""}, {"first": "D", "middle": [], "last": "White", "suffix": ""}, {"first": "S", "middle": [], "last": "Barnes", "suffix": ""}, {"first": "F", "middle": [], "last": "Rahbar", "suffix": ""}, {"first": "A", "middle": [], "last": "Fomufod", "suffix": ""}], "year": 1997, "venue": "J Natl Med Assoc", "volume": "89", "issn": "", "pages": "543--547", "other_ids": {}}, "BIBREF147": {"ref_id": "b147", "title": "Plasmodium falciparum: diversity of isolates from Malawi in their cytoadherence to melanoma cells and monocytes in vitro", "authors": [{"first": "J", "middle": ["D"], "last": "Goldring", "suffix": ""}, {"first": "M", "middle": ["E"], "last": "Molyneux", "suffix": ""}, {"first": "T", "middle": [], "last": "Taylor", "suffix": ""}, {"first": "J", "middle": [], "last": "Wirima", "suffix": ""}, {"first": "M", "middle": [], "last": "Hommel", "suffix": ""}], "year": 1992, "venue": "Br J Haematol", "volume": "81", "issn": "", "pages": "413--418", "other_ids": {}}, "BIBREF148": {"ref_id": "b148", "title": "Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria", "authors": [{"first": "A", "middle": [], "last": "Sabchareon", "suffix": ""}, {"first": "T", "middle": [], "last": "Burnouf", "suffix": ""}, {"first": "D", "middle": [], "last": "Ouattara", "suffix": ""}, {"first": "P", "middle": [], "last": "Attanath", "suffix": ""}, {"first": "H", "middle": [], "last": "Bouharoun-Tayoun", "suffix": ""}, {"first": "P", "middle": [], "last": "Chantavanich", "suffix": ""}, {"first": "C", "middle": [], "last": "Foucault", "suffix": ""}, {"first": "T", "middle": [], "last": "Chongsuphajaisiddhi", "suffix": ""}, {"first": "P", "middle": [], "last": "Druilhe", "suffix": ""}], "year": 1991, "venue": "Am J Trop Med Hyg", "volume": "45", "issn": "", "pages": "297--308", "other_ids": {}}, "BIBREF149": {"ref_id": "b149", "title": "Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial", "authors": [{"first": "H", "middle": [], "last": "Gonzalez", "suffix": ""}, {"first": "K", "middle": ["S"], "last": "Sunnerhagen", "suffix": ""}, {"first": "I", "middle": [], "last": "Sjoberg", "suffix": ""}, {"first": "G", "middle": [], "last": "Kaponides", "suffix": ""}, {"first": "T", "middle": [], "last": "Olsson", "suffix": ""}, {"first": "K", "middle": [], "last": "Borg", "suffix": ""}], "year": 2006, "venue": "Lancet Neurol", "volume": "5", "issn": "", "pages": "493--500", "other_ids": {}}, "BIBREF150": {"ref_id": "b150", "title": "Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blinded randomized controlled pilot study", "authors": [{"first": "E", "middle": [], "last": "Farbu", "suffix": ""}, {"first": "T", "middle": [], "last": "Rekand", "suffix": ""}, {"first": "E", "middle": [], "last": "Vik-Mo", "suffix": ""}, {"first": "H", "middle": [], "last": "Lygren", "suffix": ""}, {"first": "N", "middle": ["E"], "last": "Gilhus", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Aarli", "suffix": ""}], "year": 2007, "venue": "Eur J Neurol", "volume": "14", "issn": "", "pages": "60--65", "other_ids": {}}, "BIBREF151": {"ref_id": "b151", "title": "Effect of intravenous immunoglobulin in patients with post-polio syndrome-an uncontrolled pilot study", "authors": [{"first": "G", "middle": [], "last": "Kaponides", "suffix": ""}, {"first": "H", "middle": [], "last": "Gonzalez", "suffix": ""}, {"first": "T", "middle": [], "last": "Olsson", "suffix": ""}, {"first": "K", "middle": [], "last": "Borg", "suffix": ""}], "year": 2006, "venue": "J Rehabil Med", "volume": "38", "issn": "", "pages": "138--140", "other_ids": {}}, "BIBREF152": {"ref_id": "b152", "title": "Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis", "authors": [{"first": "K", "middle": ["B"], "last": "Laupland", "suffix": ""}, {"first": "A", "middle": ["W"], "last": "Kirkpatrick", "suffix": ""}, {"first": "A", "middle": [], "last": "Delaney", "suffix": ""}], "year": 2007, "venue": "Crit Care Med", "volume": "35", "issn": "", "pages": "2686--2692", "other_ids": {}}, "BIBREF153": {"ref_id": "b153", "title": "Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis", "authors": [{"first": "A", "middle": [], "last": "Hamdan", "suffix": ""}, {"first": "P", "middle": [], "last": "Green", "suffix": ""}, {"first": "E", "middle": [], "last": "Mendelson", "suffix": ""}, {"first": "M", "middle": ["R"], "last": "Kramer", "suffix": ""}, {"first": "S", "middle": [], "last": "Pitlik", "suffix": ""}, {"first": "M", "middle": [], "last": "Weinberger", "suffix": ""}], "year": 2002, "venue": "Transpl Infect Dis", "volume": "4", "issn": "", "pages": "160--162", "other_ids": {}}, "BIBREF154": {"ref_id": "b154", "title": "Treatment of West Nile virus encephalitis with intravenous immunoglobulin", "authors": [{"first": "Z", "middle": [], "last": "Shimoni", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Niven", "suffix": ""}, {"first": "S", "middle": [], "last": "Pitlick", "suffix": ""}, {"first": "S", "middle": [], "last": "Bulvik", "suffix": ""}], "year": 2001, "venue": "Emerg Infect Dis", "volume": "7", "issn": "", "pages": "", "other_ids": {}}, "BIBREF155": {"ref_id": "b155", "title": "Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection", "authors": [], "year": 1992, "venue": "The Intravenous Immunoglobulin Collaborative Study Group", "volume": "327", "issn": "", "pages": "234--240", "other_ids": {}}, "BIBREF156": {"ref_id": "b156", "title": "Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. A randomized, placebo-controlled study", "authors": [{"first": "W", "middle": [], "last": "Glinz", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Grob", "suffix": ""}, {"first": "U", "middle": ["E"], "last": "Nydegger", "suffix": ""}, {"first": "T", "middle": [], "last": "Ricklin", "suffix": ""}, {"first": "F", "middle": [], "last": "Stamm", "suffix": ""}, {"first": "D", "middle": [], "last": "Stoffel", "suffix": ""}, {"first": "A", "middle": [], "last": "Lasance", "suffix": ""}], "year": 1985, "venue": "Intensive Care Med", "volume": "11", "issn": "", "pages": "288--294", "other_ids": {}}, "BIBREF157": {"ref_id": "b157", "title": "Prophylactic intravenous immunoglobulin replacement in high-risk burn patients", "authors": [{"first": "A", "middle": ["M"], "last": "Munster", "suffix": ""}, {"first": "K", "middle": ["T"], "last": "Moran", "suffix": ""}, {"first": "J", "middle": [], "last": "Thupari", "suffix": ""}, {"first": "M", "middle": [], "last": "Allo", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Winchurch", "suffix": ""}], "year": 1987, "venue": "J Burn Care Rehabil", "volume": "8", "issn": "", "pages": "376--380", "other_ids": {}}, "BIBREF158": {"ref_id": "b158", "title": "Safety and efficacy of intravenous immunoglobulin prophylaxis in pediatric head trauma patients: a double-blind controlled trial", "authors": [{"first": "A", "middle": ["M"], "last": "Gooding", "suffix": ""}, {"first": "J", "middle": ["F"], "last": "Bastian", "suffix": ""}, {"first": "B", "middle": ["M"], "last": "Peterson", "suffix": ""}, {"first": "N", "middle": ["W"], "last": "Wilson", "suffix": ""}], "year": 1993, "venue": "J Crit Care", "volume": "8", "issn": "", "pages": "212--216", "other_ids": {}}, "BIBREF159": {"ref_id": "b159", "title": "Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins", "authors": [{"first": "E", "middle": ["E"], "last": "Douzinas", "suffix": ""}, {"first": "M", "middle": ["T"], "last": "Pitaridis", "suffix": ""}, {"first": "G", "middle": [], "last": "Louris", "suffix": ""}, {"first": "I", "middle": [], "last": "Andrianakis", "suffix": ""}, {"first": "K", "middle": [], "last": "Katsouyanni", "suffix": ""}, {"first": "D", "middle": [], "last": "Karmpaliotis", "suffix": ""}, {"first": "J", "middle": [], "last": "Economidou", "suffix": ""}, {"first": "D", "middle": [], "last": "Syfras", "suffix": ""}, {"first": "C", "middle": [], "last": "Roussos", "suffix": ""}], "year": 2000, "venue": "Crit Care Med", "volume": "28", "issn": "", "pages": "8--15", "other_ids": {}}, "BIBREF160": {"ref_id": "b160", "title": "Reduced incidence of postoperative infection after intravenous administration of an immunoglobulin A-and immunoglobulin Menriched preparation in anergic patients undergoing cardiac surgery", "authors": [{"first": "H", "middle": ["G"], "last": "Kress", "suffix": ""}, {"first": "C", "middle": [], "last": "Scheidewig", "suffix": ""}, {"first": "H", "middle": [], "last": "Schmidt", "suffix": ""}, {"first": "R", "middle": [], "last": "Silber", "suffix": ""}], "year": 1999, "venue": "Crit Care Med", "volume": "27", "issn": "", "pages": "1281--1287", "other_ids": {}}, "BIBREF161": {"ref_id": "b161", "title": "Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes", "authors": [{"first": "H", "middle": [], "last": "Chapel", "suffix": ""}, {"first": "M", "middle": [], "last": "Dicato", "suffix": ""}, {"first": "H", "middle": [], "last": "Gamm", "suffix": ""}, {"first": "V", "middle": [], "last": "Brennan", "suffix": ""}, {"first": "F", "middle": [], "last": "Ries", "suffix": ""}, {"first": "C", "middle": [], "last": "Bunch", "suffix": ""}, {"first": "M", "middle": [], "last": "Lee", "suffix": ""}], "year": 1994, "venue": "Br J Haematol", "volume": "88", "issn": "", "pages": "209--212", "other_ids": {}}, "BIBREF162": {"ref_id": "b162", "title": "Clinical experience with 20 cases of group A streptococcus necrotizing fasciitis and myonecrosis: 1995 to 1997", "authors": [{"first": "C", "middle": ["T"], "last": "Haywood", "suffix": ""}, {"first": "A", "middle": [], "last": "Mcgeer", "suffix": ""}, {"first": "D", "middle": ["E"], "last": "Low", "suffix": ""}], "year": 1999, "venue": "Plast Reconstr Surg", "volume": "103", "issn": "", "pages": "1567--1573", "other_ids": {}}, "BIBREF163": {"ref_id": "b163", "title": "Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach", "authors": [{"first": "A", "middle": [], "last": "Norrby-Teglund", "suffix": ""}, {"first": "M", "middle": ["P"], "last": "Muller", "suffix": ""}, {"first": "A", "middle": [], "last": "Mcgeer", "suffix": ""}, {"first": "B", "middle": ["S"], "last": "Gan", "suffix": ""}, {"first": "V", "middle": [], "last": "Guru", "suffix": ""}, {"first": "J", "middle": [], "last": "Bohnen", "suffix": ""}, {"first": "P", "middle": [], "last": "Thulin", "suffix": ""}, {"first": "D", "middle": ["E"], "last": "Low", "suffix": ""}], "year": 2005, "venue": "Scand J Infect Dis", "volume": "37", "issn": "", "pages": "166--172", "other_ids": {}}, "BIBREF164": {"ref_id": "b164", "title": "High-dose immunoglobulin-life-saving in invasive group A streptococcal infection", "authors": [{"first": "B", "middle": [], "last": "Arnholm", "suffix": ""}, {"first": "A", "middle": [], "last": "Lundqvist", "suffix": ""}, {"first": "A", "middle": [], "last": "Stromberg", "suffix": ""}], "year": 2004, "venue": "Lakartidningen", "volume": "101", "issn": "", "pages": "2642--2644", "other_ids": {}}, "BIBREF165": {"ref_id": "b165", "title": "Group A streptococcal bacteraemia and necrotizing fasciitis in a renal transplant patient: a case for intravenous immunoglobulin therapy", "authors": [{"first": "A", "middle": [], "last": "Korzets", "suffix": ""}, {"first": "Y", "middle": [], "last": "Ori", "suffix": ""}, {"first": "D", "middle": [], "last": "Zevin", "suffix": ""}, {"first": "M", "middle": [], "last": "Weinberger", "suffix": ""}, {"first": "J", "middle": [], "last": "Kesslin", "suffix": ""}, {"first": "D", "middle": [], "last": "Seror", "suffix": ""}, {"first": "A", "middle": [], "last": "Kuperman", "suffix": ""}, {"first": "U", "middle": [], "last": "Gafter", "suffix": ""}], "year": 2002, "venue": "Nephrol Dial Transplant", "volume": "17", "issn": "", "pages": "150--152", "other_ids": {}}, "BIBREF166": {"ref_id": "b166", "title": "The effect of intravenous immunoglobulin treatment in recurrent acute otitis media", "authors": [{"first": "O", "middle": [], "last": "Kalm", "suffix": ""}, {"first": "K", "middle": [], "last": "Prellner", "suffix": ""}, {"first": "P", "middle": [], "last": "Christensen", "suffix": ""}], "year": 1986, "venue": "Int J Pediatr Otorhinolaryngol", "volume": "11", "issn": "", "pages": "237--246", "other_ids": {}}, "BIBREF167": {"ref_id": "b167", "title": "Effect of intravenous gamma globulin therapy in IgG2 deficient and IgG2 sufficient children with recurrent infections and poor response to immunization with Haemophilus influenzae type b capsular polysaccharide antigen", "authors": [{"first": "H", "middle": ["J"], "last": "Silk", "suffix": ""}, {"first": "D", "middle": [], "last": "Ambrosino", "suffix": ""}, {"first": "R", "middle": ["S"], "last": "Geha", "suffix": ""}], "year": 1990, "venue": "Ann Allergy", "volume": "64", "issn": "", "pages": "21--25", "other_ids": {}}, "BIBREF168": {"ref_id": "b168", "title": "Prophylaxis of intravenous immunoglobulin and acyclovir in perinatal varicella", "authors": [{"first": "Y", "middle": ["C"], "last": "Huang", "suffix": ""}, {"first": "T", "middle": ["Y"], "last": "Lin", "suffix": ""}, {"first": "Y", "middle": ["J"], "last": "Lin", "suffix": ""}, {"first": "R", "middle": ["I"], "last": "Lien", "suffix": ""}, {"first": "Y", "middle": ["H"], "last": "Chou", "suffix": ""}], "year": 2001, "venue": "Eur J Pediatr", "volume": "160", "issn": "", "pages": "91--94", "other_ids": {}}, "BIBREF169": {"ref_id": "b169", "title": "Experience of intravenous immunoglobulin and acyclovir in neonates at risk for severe varicella infection-report of five cases", "authors": [{"first": "S", "middle": ["J"], "last": "Lin", "suffix": ""}, {"first": "T", "middle": ["Y"], "last": "Lin", "suffix": ""}, {"first": "C", "middle": ["H"], "last": "Chiu", "suffix": ""}, {"first": "Y", "middle": ["C"], "last": "Huang", "suffix": ""}], "year": 1995, "venue": "Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi", "volume": "36", "issn": "", "pages": "53--57", "other_ids": {}}, "BIBREF170": {"ref_id": "b170", "title": "Two cases of severe adult varicella pneumonia", "authors": [{"first": "M", "middle": [], "last": "Saitou", "suffix": ""}, {"first": "K", "middle": [], "last": "Niitsuma", "suffix": ""}, {"first": "R", "middle": [], "last": "Kasukawa", "suffix": ""}], "year": 1998, "venue": "Nihon Kokyuki Gakkai Zasshi", "volume": "36", "issn": "", "pages": "251--255", "other_ids": {}}, "BIBREF171": {"ref_id": "b171", "title": "Varicella pneumonia in a healthy adult presenting with severe respiratory failure", "authors": [{"first": "T", "middle": [], "last": "Shirai", "suffix": ""}, {"first": "K", "middle": [], "last": "Sano", "suffix": ""}, {"first": "S", "middle": [], "last": "Matsuyama", "suffix": ""}, {"first": "Y", "middle": [], "last": "Honjo", "suffix": ""}, {"first": "M", "middle": [], "last": "Takashima", "suffix": ""}, {"first": "Y", "middle": [], "last": "Sasada", "suffix": ""}, {"first": "S", "middle": [], "last": "Takayanagi", "suffix": ""}, {"first": "K", "middle": [], "last": "Nagamatsu", "suffix": ""}, {"first": "M", "middle": [], "last": "Nawano", "suffix": ""}, {"first": "M", "middle": [], "last": "Fushimi", "suffix": ""}, {"first": "S", "middle": [], "last": "Imokawa", "suffix": ""}, {"first": "A", "middle": [], "last": "Sato", "suffix": ""}], "year": 1996, "venue": "Intern Med", "volume": "35", "issn": "", "pages": "315--318", "other_ids": {}}, "BIBREF172": {"ref_id": "b172", "title": "Intravenous immunoglobulin in adult varicella pneumonia complicated by acute respiratory distress syndrome", "authors": [{"first": "O", "middle": [], "last": "Tokat", "suffix": ""}, {"first": "N", "middle": [], "last": "Kelebek", "suffix": ""}, {"first": "G", "middle": [], "last": "Turker", "suffix": ""}, {"first": "S", "middle": ["F"], "last": "Kahveci", "suffix": ""}, {"first": "B", "middle": [], "last": "Ozcan", "suffix": ""}], "year": 2001, "venue": "J Int Med Res", "volume": "29", "issn": "", "pages": "252--255", "other_ids": {}}, "BIBREF173": {"ref_id": "b173", "title": "Varicella pneumonia complicated by acute respiratory distress syndrome in an adult", "authors": [{"first": "D", "middle": ["W"], "last": "Chou", "suffix": ""}, {"first": "C", "middle": ["H"], "last": "Lee", "suffix": ""}, {"first": "C", "middle": ["W"], "last": "Chen", "suffix": ""}, {"first": "H", "middle": ["Y"], "last": "Chang", "suffix": ""}, {"first": "T", "middle": ["R"], "last": "Hsiue", "suffix": ""}], "year": 1999, "venue": "J Formos Med Assoc", "volume": "98", "issn": "", "pages": "778--782", "other_ids": {}}, "BIBREF174": {"ref_id": "b174", "title": "Intravenous gamma globulin therapy for thrombocytopenic purpura associated with active varicella infection", "authors": [{"first": "T", "middle": [], "last": "Hara", "suffix": ""}, {"first": "Y", "middle": [], "last": "Mizuno", "suffix": ""}, {"first": "H", "middle": [], "last": "Igarashi", "suffix": ""}, {"first": "K", "middle": [], "last": "Ueda", "suffix": ""}], "year": 1987, "venue": "Eur J Pediatr", "volume": "146", "issn": "", "pages": "531--532", "other_ids": {}}, "BIBREF175": {"ref_id": "b175", "title": "An adult patient with varicella preceded by acute thrombocytopenia", "authors": [{"first": "K", "middle": [], "last": "Kaneda", "suffix": ""}, {"first": "K", "middle": [], "last": "Kojima", "suffix": ""}, {"first": "K", "middle": [], "last": "Shinagawa", "suffix": ""}, {"first": "F", "middle": [], "last": "Ishimaru", "suffix": ""}, {"first": "K", "middle": [], "last": "Ikeda", "suffix": ""}, {"first": "K", "middle": [], "last": "Niiya", "suffix": ""}, {"first": "M", "middle": [], "last": "Harada", "suffix": ""}], "year": 2001, "venue": "Rinsho Ketsueki", "volume": "42", "issn": "", "pages": "1142--1144", "other_ids": {}}, "BIBREF176": {"ref_id": "b176", "title": "High-dose immunoglobulin during pregnancy for recurrent neonatal haemochromatosis", "authors": [{"first": "P", "middle": ["F"], "last": "Whitington", "suffix": ""}, {"first": "J", "middle": ["U"], "last": "Hibbard", "suffix": ""}], "year": 2004, "venue": "Lancet", "volume": "364", "issn": "", "pages": "1690--1698", "other_ids": {}}, "BIBREF177": {"ref_id": "b177", "title": "Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review", "authors": [{"first": "B", "middle": [], "last": "Hutton", "suffix": ""}, {"first": "R", "middle": [], "last": "Sharma", "suffix": ""}, {"first": "D", "middle": [], "last": "Fergusson", "suffix": ""}, {"first": "A", "middle": [], "last": "Tinmouth", "suffix": ""}, {"first": "P", "middle": [], "last": "Hebert", "suffix": ""}, {"first": "J", "middle": [], "last": "Jamieson", "suffix": ""}, {"first": "M", "middle": [], "last": "Walker", "suffix": ""}], "year": 2007, "venue": "BJOG", "volume": "114", "issn": "", "pages": "134--142", "other_ids": {}}, "BIBREF178": {"ref_id": "b178", "title": "Immunotherapy for recurrent miscarriage", "authors": [{"first": "T", "middle": ["F"], "last": "Porter", "suffix": ""}, {"first": "Y", "middle": [], "last": "Lacoursiere", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Scott", "suffix": ""}], "year": 2006, "venue": "Cochrane Database Syst Rev", "volume": "4", "issn": "", "pages": "", "other_ids": {}}, "BIBREF179": {"ref_id": "b179", "title": "Intravenous immunoglobulin (IVIG) and recurrent spontaneous pregnancy loss", "authors": [], "year": 2006, "venue": "The Practice Committee of the American Society for Reproductive Medicine", "volume": "86", "issn": "", "pages": "226--227", "other_ids": {}}, "BIBREF180": {"ref_id": "b180", "title": "A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage", "authors": [{"first": "O", "middle": ["B"], "last": "Christiansen", "suffix": ""}, {"first": "B", "middle": [], "last": "Pedersen", "suffix": ""}, {"first": "A", "middle": [], "last": "Rosgaard", "suffix": ""}, {"first": "M", "middle": [], "last": "Husth", "suffix": ""}], "year": 2002, "venue": "Hum Reprod", "volume": "17", "issn": "", "pages": "809--816", "other_ids": {}}, "BIBREF181": {"ref_id": "b181", "title": "Critical analysis of intravenous immunoglobulin therapy for recurrent miscarriage", "authors": [{"first": "S", "middle": [], "last": "Daya", "suffix": ""}, {"first": "J", "middle": [], "last": "Gunby", "suffix": ""}, {"first": "F", "middle": [], "last": "Porter", "suffix": ""}, {"first": "J", "middle": [], "last": "Scott", "suffix": ""}, {"first": "D", "middle": ["A"], "last": "Clark", "suffix": ""}], "year": 1999, "venue": "Hum Reprod Update", "volume": "5", "issn": "", "pages": "475--482", "other_ids": {}}, "BIBREF182": {"ref_id": "b182", "title": "Short-term therapy for recurrent abortion using intravenous immunoglobulins: results of a double-blind placebo-controlled Italian study", "authors": [{"first": "A", "middle": [], "last": "Perino", "suffix": ""}, {"first": "A", "middle": [], "last": "Vassiliadis", "suffix": ""}, {"first": "A", "middle": [], "last": "Vucetich", "suffix": ""}, {"first": "N", "middle": [], "last": "Colacurci", "suffix": ""}, {"first": "G", "middle": [], "last": "Menato", "suffix": ""}, {"first": "M", "middle": [], "last": "Cignitti", "suffix": ""}, {"first": "A", "middle": ["E"], "last": "Semprini", "suffix": ""}], "year": 1997, "venue": "Hum Reprod", "volume": "12", "issn": "", "pages": "2388--2392", "other_ids": {}}, "BIBREF183": {"ref_id": "b183", "title": "Intravenous immunoglobulin for treatment of recurrent pregnancy loss", "authors": [{"first": "C", "middle": ["B"], "last": "Coulam", "suffix": ""}, {"first": "L", "middle": [], "last": "Krysa", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Stern", "suffix": ""}, {"first": "M", "middle": [], "last": "Bustillo", "suffix": ""}], "year": 1995, "venue": "Am J Reprod Immunol", "volume": "34", "issn": "", "pages": "333--337", "other_ids": {}}, "BIBREF184": {"ref_id": "b184", "title": "Placebocontrolled trial of treatment of unexplained secondary recurrent spontaneous abortions and recurrent late spontaneous abortions with i", "authors": [{"first": "O", "middle": ["B"], "last": "Christiansen", "suffix": ""}, {"first": "O", "middle": [], "last": "Mathiesen", "suffix": ""}, {"first": "M", "middle": [], "last": "Husth", "suffix": ""}, {"first": "K", "middle": ["L"], "last": "Rasmussen", "suffix": ""}, {"first": "H", "middle": ["J"], "last": "Ingerslev", "suffix": ""}, {"first": "J", "middle": ["G"], "last": "Lauritsen", "suffix": ""}, {"first": "N", "middle": [], "last": "Grunnet", "suffix": ""}], "year": 1995, "venue": "v. immunoglobulin. Hum Reprod", "volume": "10", "issn": "", "pages": "2690--2695", "other_ids": {}}, "BIBREF185": {"ref_id": "b185", "title": "Intravenous immunoglobulin in the prevention of recurrent miscarriage", "authors": [{"first": "The", "middle": [], "last": "German", "suffix": ""}, {"first": "Rsa/Ivig", "middle": [], "last": "Group", "suffix": ""}], "year": 1994, "venue": "Br J Obstet Gynaecol", "volume": "101", "issn": "", "pages": "1072--1077", "other_ids": {}}, "BIBREF186": {"ref_id": "b186", "title": "Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant", "authors": [{"first": "M", "middle": [], "last": "Empson", "suffix": ""}, {"first": "M", "middle": [], "last": "Lassere", "suffix": ""}, {"first": "J", "middle": [], "last": "Craig", "suffix": ""}, {"first": "J", "middle": [], "last": "Scott", "suffix": ""}], "year": 2005, "venue": "Cochrane Database Syst Rev", "volume": "2", "issn": "", "pages": "", "other_ids": {}}, "BIBREF187": {"ref_id": "b187", "title": "Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies", "authors": [{"first": "G", "middle": [], "last": "Triolo", "suffix": ""}, {"first": "A", "middle": [], "last": "Ferrante", "suffix": ""}, {"first": "F", "middle": [], "last": "Ciccia", "suffix": ""}, {"first": "A", "middle": [], "last": "Accardo-Palumbo", "suffix": ""}, {"first": "A", "middle": [], "last": "Perino", "suffix": ""}, {"first": "A", "middle": [], "last": "Castelli", "suffix": ""}, {"first": "A", "middle": [], "last": "Giarratano", "suffix": ""}, {"first": "G", "middle": [], "last": "Licata", "suffix": ""}], "year": 2003, "venue": "Arthritis Rheum", "volume": "48", "issn": "", "pages": "728--731", "other_ids": {}}, "BIBREF188": {"ref_id": "b188", "title": "A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group", "authors": [{"first": "D", "middle": ["W"], "last": "Branch", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Peaceman", "suffix": ""}, {"first": "M", "middle": [], "last": "Druzin", "suffix": ""}, {"first": "R", "middle": ["K"], "last": "Silver", "suffix": ""}, {"first": "Y", "middle": [], "last": "El-Sayed", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "Silver", "suffix": ""}, {"first": "M", "middle": ["S"], "last": "Esplin", "suffix": ""}, {"first": "J", "middle": [], "last": "Spinnato", "suffix": ""}, {"first": "J", "middle": [], "last": "Harger", "suffix": ""}], "year": 2000, "venue": "Am J Obstet Gynecol", "volume": "182", "issn": "", "pages": "122--127", "other_ids": {}}, "BIBREF189": {"ref_id": "b189", "title": "Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin", "authors": [{"first": "E", "middle": [], "last": "Vaquero", "suffix": ""}, {"first": "N", "middle": [], "last": "Lazzarin", "suffix": ""}, {"first": "H", "middle": [], "last": "Valensise", "suffix": ""}, {"first": "S", "middle": [], "last": "Menghini", "suffix": ""}, {"first": "Di", "middle": [], "last": "Pierro", "suffix": ""}, {"first": "G", "middle": [], "last": "Cesa", "suffix": ""}, {"first": "F", "middle": [], "last": "Romanini", "suffix": ""}, {"first": "C", "middle": [], "last": "", "suffix": ""}], "year": 2001, "venue": "Am J Reprod Immunol", "volume": "45", "issn": "", "pages": "174--179", "other_ids": {}}, "BIBREF190": {"ref_id": "b190", "title": "Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy", "authors": [{"first": "A", "middle": ["L"], "last": "Clark", "suffix": ""}, {"first": "D", "middle": ["W"], "last": "Branch", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "Silver", "suffix": ""}, {"first": "E", "middle": ["N"], "last": "Harris", "suffix": ""}, {"first": "S", "middle": [], "last": "Pierangeli", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Spinnato", "suffix": ""}], "year": 1999, "venue": "Obstet Gynecol", "volume": "93", "issn": "", "pages": "437--441", "other_ids": {}}, "BIBREF191": {"ref_id": "b191", "title": "The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization", "authors": [{"first": "G", "middle": [], "last": "Sher", "suffix": ""}, {"first": "W", "middle": [], "last": "Matzner", "suffix": ""}, {"first": "M", "middle": [], "last": "Feinman", "suffix": ""}, {"first": "G", "middle": [], "last": "Maassarani", "suffix": ""}, {"first": "C", "middle": [], "last": "Zouves", "suffix": ""}, {"first": "P", "middle": [], "last": "Chong", "suffix": ""}, {"first": "W", "middle": [], "last": "Ching", "suffix": ""}], "year": 1998, "venue": "Am J Reprod Immunol", "volume": "40", "issn": "", "pages": "74--82", "other_ids": {}}, "BIBREF192": {"ref_id": "b192", "title": "Recurrent first trimester spontaneous abortion associated with antiphospholipid antibodies: a pilot study of treatment with intravenous immunoglobulin", "authors": [{"first": "K", "middle": [], "last": "Marzusch", "suffix": ""}, {"first": "J", "middle": [], "last": "Dietl", "suffix": ""}, {"first": "R", "middle": [], "last": "Klein", "suffix": ""}, {"first": "D", "middle": [], "last": "Hornung", "suffix": ""}, {"first": "A", "middle": [], "last": "Neuer", "suffix": ""}, {"first": "P", "middle": ["A"], "last": "Berg", "suffix": ""}], "year": 1996, "venue": "Acta Obstet Gynecol Scand", "volume": "75", "issn": "", "pages": "922--926", "other_ids": {}}, "BIBREF193": {"ref_id": "b193", "title": "Normal fetal growth in women with antiphospholipid syndrome treated with high-dose intravenous immunoglobulin (IVIG)", "authors": [{"first": "H", "middle": [], "last": "Valensise", "suffix": ""}, {"first": "E", "middle": [], "last": "Vaquero", "suffix": ""}, {"first": "De", "middle": [], "last": "Carolis", "suffix": ""}, {"first": "C", "middle": [], "last": "Stipa", "suffix": ""}, {"first": "E", "middle": [], "last": "Perricone", "suffix": ""}, {"first": "R", "middle": [], "last": "Arduini", "suffix": ""}, {"first": "D", "middle": [], "last": "Romanini", "suffix": ""}, {"first": "C", "middle": [], "last": "", "suffix": ""}], "year": 1995, "venue": "Prenat Diagn", "volume": "15", "issn": "", "pages": "509--517", "other_ids": {}}, "BIBREF194": {"ref_id": "b194", "title": "The effect of antenatal intravenous immunoglobulin on ascending intrauterine infection after preterm premature rupture of the membranes: a pilot study", "authors": [{"first": "M", "middle": [], "last": "Hockel", "suffix": ""}, {"first": "A", "middle": [], "last": "Queisser-Luft", "suffix": ""}, {"first": "T", "middle": [], "last": "Beck", "suffix": ""}, {"first": "R", "middle": [], "last": "Zielberg", "suffix": ""}, {"first": "H", "middle": [], "last": "Stopfkuchen", "suffix": ""}, {"first": "R", "middle": [], "last": "Lissner", "suffix": ""}], "year": 1992, "venue": "J Perinat Med", "volume": "20", "issn": "", "pages": "101--110", "other_ids": {}}, "BIBREF195": {"ref_id": "b195", "title": "Is intravenous immunoglobulins (IVIG) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo transfer (IVF)", "authors": [{"first": "D", "middle": ["A"], "last": "Clark", "suffix": ""}, {"first": "C", "middle": ["B"], "last": "Coulam", "suffix": ""}, {"first": "R", "middle": ["B"], "last": "Stricker", "suffix": ""}], "year": 2006, "venue": "J Assist Reprod Genet", "volume": "23", "issn": "", "pages": "1--13", "other_ids": {}}, "BIBREF196": {"ref_id": "b196", "title": "Treatment of repeated unexplained in vitro fertilization failure with intravenous immunoglobulin: a randomized, placebo-controlled Canadian trial", "authors": [{"first": "M", "middle": ["D"], "last": "Stephenson", "suffix": ""}, {"first": "M", "middle": ["R"], "last": "Fluker", "suffix": ""}], "year": 2000, "venue": "Fertil Steril", "volume": "74", "issn": "", "pages": "1108--1113", "other_ids": {}}, "BIBREF197": {"ref_id": "b197", "title": "Intravenous immune globulin in the therapy of peripartum cardiomyopathy", "authors": [{"first": "B", "middle": [], "last": "Bozkurt", "suffix": ""}, {"first": "F", "middle": ["S"], "last": "Villaneuva", "suffix": ""}, {"first": "R", "middle": [], "last": "Holubkov", "suffix": ""}, {"first": "T", "middle": [], "last": "Tokarczyk", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Alvarez", "suffix": ""}, {"first": "G", "middle": ["A"], "last": "Macgowan", "suffix": ""}, {"first": "S", "middle": [], "last": "Murali", "suffix": ""}, {"first": "W", "middle": ["D"], "last": "Rosenblum", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Feldman", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "Mcnamara", "suffix": ""}], "year": 1999, "venue": "J Am Coll Cardiol", "volume": "34", "issn": "", "pages": "177--180", "other_ids": {}}, "BIBREF198": {"ref_id": "b198", "title": "Treatment of acute inflammatory cardiomyopathy with intravenous immunoglobulin ameliorates left ventricular function associated with suppression of inflammatory cytokines and decreased oxidative stress", "authors": [{"first": "C", "middle": [], "last": "Kishimoto", "suffix": ""}, {"first": "K", "middle": [], "last": "Shioji", "suffix": ""}, {"first": "M", "middle": [], "last": "Kinoshita", "suffix": ""}, {"first": "T", "middle": [], "last": "Iwase", "suffix": ""}, {"first": "S", "middle": [], "last": "Tamaki", "suffix": ""}, {"first": "M", "middle": [], "last": "Fujii", "suffix": ""}, {"first": "A", "middle": [], "last": "Murashige", "suffix": ""}, {"first": "H", "middle": [], "last": "Maruhashi", "suffix": ""}, {"first": "S", "middle": [], "last": "Takeda", "suffix": ""}, {"first": "H", "middle": [], "last": "Nonogi", "suffix": ""}, {"first": "T", "middle": [], "last": "Hashimoto", "suffix": ""}], "year": 2003, "venue": "Int J Cardiol", "volume": "91", "issn": "", "pages": "173--178", "other_ids": {}}, "BIBREF199": {"ref_id": "b199", "title": "Gamma-globulin treatment of acute myocarditis in the pediatric population", "authors": [{"first": "N", "middle": ["A"], "last": "Drucker", "suffix": ""}, {"first": "S", "middle": ["D"], "last": "Colan", "suffix": ""}, {"first": "A", "middle": ["B"], "last": "Lewis", "suffix": ""}, {"first": "A", "middle": ["S"], "last": "Beiser", "suffix": ""}, {"first": "D", "middle": ["L"], "last": "Wessel", "suffix": ""}, {"first": "M", "middle": [], "last": "Takahashi", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Baker", "suffix": ""}, {"first": "A", "middle": ["R"], "last": "Perez-Atayde", "suffix": ""}, {"first": "J", "middle": ["W"], "last": "Newburger", "suffix": ""}], "year": 1994, "venue": "Circulation", "volume": "89", "issn": "", "pages": "252--257", "other_ids": {}}, "BIBREF200": {"ref_id": "b200", "title": "The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment", "authors": [{"first": "K", "middle": [], "last": "Durongpisitkul", "suffix": ""}, {"first": "V", "middle": ["J"], "last": "Gururaj", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Park", "suffix": ""}, {"first": "Cf ;", "middle": [], "last": "Martin", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "Oates-Whitehead", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Baumer", "suffix": ""}, {"first": "L", "middle": [], "last": "Haines", "suffix": ""}, {"first": "S", "middle": [], "last": "Love", "suffix": ""}, {"first": "I", "middle": ["K"], "last": "Maconochie", "suffix": ""}, {"first": "A", "middle": [], "last": "Gupta", "suffix": ""}, {"first": "K", "middle": [], "last": "Roman", "suffix": ""}, {"first": "J", "middle": ["S"], "last": "Dua", "suffix": ""}, {"first": "I", "middle": [], "last": "Flynn", "suffix": ""}], "year": 1995, "venue": "Cochrane Database Syst Rev", "volume": "96", "issn": "", "pages": "", "other_ids": {}}, "BIBREF201": {"ref_id": "b201", "title": "The treatment of Kawasaki syndrome with intravenous gamma globulin", "authors": [{"first": "J", "middle": ["W"], "last": "Newburger", "suffix": ""}, {"first": "M", "middle": [], "last": "Takahashi", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Burns", "suffix": ""}, {"first": "A", "middle": ["S"], "last": "Beiser", "suffix": ""}, {"first": "K", "middle": ["J"], "last": "Chung", "suffix": ""}, {"first": "C", "middle": ["E"], "last": "Duffy", "suffix": ""}, {"first": "M", "middle": ["P"], "last": "Glode", "suffix": ""}, {"first": "W", "middle": ["H"], "last": "Mason", "suffix": ""}, {"first": "V", "middle": [], "last": "Reddy", "suffix": ""}, {"first": "S", "middle": ["P"], "last": "Sanders", "suffix": ""}], "year": 1986, "venue": "N Engl J Med", "volume": "315", "issn": "", "pages": "341--347", "other_ids": {}}, "BIBREF202": {"ref_id": "b202", "title": "Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin", "authors": [{"first": "P", "middle": [], "last": "Khowsathit", "suffix": ""}, {"first": "C", "middle": [], "last": "Hong-Hgam", "suffix": ""}, {"first": "A", "middle": [], "last": "Khositseth", "suffix": ""}, {"first": "S", "middle": [], "last": "Wanitkun", "suffix": ""}], "year": 2002, "venue": "J Med Assoc Thai", "volume": "85", "issn": "4", "pages": "1121--1126", "other_ids": {}}, "BIBREF203": {"ref_id": "b203", "title": "Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin", "authors": [{"first": "M", "middle": ["H"], "last": "Tsai", "suffix": ""}, {"first": "Y", "middle": ["C"], "last": "Huang", "suffix": ""}, {"first": "M", "middle": ["H"], "last": "Yen", "suffix": ""}, {"first": "C", "middle": ["C"], "last": "Li", "suffix": ""}, {"first": "C", "middle": ["H"], "last": "Chiu", "suffix": ""}, {"first": "P", "middle": ["Y"], "last": "Lin", "suffix": ""}, {"first": "T", "middle": ["Y"], "last": "Lin", "suffix": ""}, {"first": "L", "middle": ["Y"], "last": "Chang", "suffix": ""}], "year": 2006, "venue": "J Pediatr", "volume": "148", "issn": "", "pages": "38--43", "other_ids": {}}, "BIBREF204": {"ref_id": "b204", "title": "Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study", "authors": [{"first": "L", "middle": ["J"], "last": "Qin", "suffix": ""}, {"first": "H", "middle": ["W"], "last": "Wang", "suffix": ""}, {"first": "X", "middle": ["F"], "last": "Hu", "suffix": ""}, {"first": "Q", "middle": ["J"], "last": "Liu", "suffix": ""}, {"first": "H", "middle": [], "last": "Shi", "suffix": ""}, {"first": "Y", "middle": ["X"], "last": "Wei", "suffix": ""}, {"first": "Q", "middle": ["J"], "last": "Chen", "suffix": ""}, {"first": "P", "middle": ["X"], "last": "Cheng", "suffix": ""}], "year": 2006, "venue": "Zhonghua Er Ke Za Zhi", "volume": "44", "issn": "", "pages": "891--895", "other_ids": {}}, "BIBREF205": {"ref_id": "b205", "title": "A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease", "authors": [{"first": "K", "middle": [], "last": "Sakata", "suffix": ""}, {"first": "K", "middle": [], "last": "Hamaoka", "suffix": ""}, {"first": "S", "middle": [], "last": "Ozawa", "suffix": ""}, {"first": "A", "middle": [], "last": "Niboshi", "suffix": ""}, {"first": "T", "middle": [], "last": "Yoshihara", "suffix": ""}, {"first": "T", "middle": [], "last": "Nishiki", "suffix": ""}, {"first": "Y", "middle": [], "last": "Nakagawa", "suffix": ""}, {"first": "K", "middle": [], "last": "Kazuta", "suffix": ""}, {"first": "Y", "middle": [], "last": "Morimoto", "suffix": ""}, {"first": "Y", "middle": [], "last": "Kamiya", "suffix": ""}, {"first": "T", "middle": [], "last": "Yamamoto", "suffix": ""}, {"first": "Y", "middle": [], "last": "Horii", "suffix": ""}, {"first": "S", "middle": [], "last": "Kido", "suffix": ""}], "year": 2007, "venue": "Eur J Pediatr", "volume": "166", "issn": "", "pages": "565--571", "other_ids": {}}, "BIBREF206": {"ref_id": "b206", "title": "A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome", "authors": [{"first": "J", "middle": ["W"], "last": "Newburger", "suffix": ""}, {"first": "M", "middle": [], "last": "Takahashi", "suffix": ""}, {"first": "A", "middle": ["S"], "last": "Beiser", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Burns", "suffix": ""}, {"first": "J", "middle": [], "last": "Bastian", "suffix": ""}, {"first": "K", "middle": ["J"], "last": "Chung", "suffix": ""}, {"first": "S", "middle": ["D"], "last": "Colan", "suffix": ""}, {"first": "C", "middle": ["E"], "last": "Duffy", "suffix": ""}, {"first": "D", "middle": ["R"], "last": "Fulton", "suffix": ""}, {"first": "M", "middle": ["P"], "last": "Glode", "suffix": ""}], "year": 1991, "venue": "N Engl J Med", "volume": "324", "issn": "", "pages": "1633--1639", "other_ids": {}}, "BIBREF207": {"ref_id": "b207", "title": "Intravenous immunoglobulin in acute rheumatic fever: a randomized controlled trial", "authors": [{"first": "L", "middle": ["M"], "last": "Voss", "suffix": ""}, {"first": "N", "middle": ["J"], "last": "Wilson", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Neutze", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "Whitlock", "suffix": ""}, {"first": "R", "middle": ["V"], "last": "Ameratunga", "suffix": ""}, {"first": "L", "middle": ["M"], "last": "Cairns", "suffix": ""}, {"first": "D", "middle": ["R"], "last": "Lennon", "suffix": ""}], "year": 2001, "venue": "Circulation", "volume": "103", "issn": "", "pages": "401--406", "other_ids": {}}, "BIBREF208": {"ref_id": "b208", "title": "Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients", "authors": [{"first": "R", "middle": [], "last": "John", "suffix": ""}, {"first": "K", "middle": [], "last": "Lietz", "suffix": ""}, {"first": "E", "middle": [], "last": "Burke", "suffix": ""}, {"first": "J", "middle": [], "last": "Ankersmit", "suffix": ""}, {"first": "D", "middle": [], "last": "Mancini", "suffix": ""}, {"first": "N", "middle": [], "last": "Suciu-Foca", "suffix": ""}, {"first": "N", "middle": [], "last": "Edwards", "suffix": ""}, {"first": "E", "middle": [], "last": "Rose", "suffix": ""}, {"first": "M", "middle": [], "last": "Oz", "suffix": ""}, {"first": "S", "middle": [], "last": "Itescu", "suffix": ""}], "year": 1999, "venue": "Circulation", "volume": "100", "issn": "", "pages": "229--235", "other_ids": {}}, "BIBREF209": {"ref_id": "b209", "title": "Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients", "authors": [{"first": "S", "middle": ["G"], "last": "Drakos", "suffix": ""}, {"first": "A", "middle": ["G"], "last": "Kfoury", "suffix": ""}, {"first": "J", "middle": ["W"], "last": "Long", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Stringham", "suffix": ""}, {"first": "T", "middle": ["C"], "last": "Fuller", "suffix": ""}, {"first": "K", "middle": ["E"], "last": "Nelson", "suffix": ""}, {"first": "B", "middle": ["K"], "last": "Campbell", "suffix": ""}, {"first": "E", "middle": ["M"], "last": "Gilbert", "suffix": ""}, {"first": "D", "middle": ["G"], "last": "Renlund", "suffix": ""}], "year": 2006, "venue": "Ann Thorac Surg", "volume": "82", "issn": "", "pages": "889--893", "other_ids": {}}, "BIBREF210": {"ref_id": "b210", "title": "Failure of prophylactic intravenous immunoglobulin to prevent sensitization to cryopreserved allograft tissue used in congenital cardiac surgery", "authors": [{"first": "S", "middle": ["R"], "last": "Meyer", "suffix": ""}, {"first": "D", "middle": ["B"], "last": "Ross", "suffix": ""}, {"first": "K", "middle": [], "last": "Forbes", "suffix": ""}, {"first": "L", "middle": ["E"], "last": "Hawkins", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Halpin", "suffix": ""}, {"first": "S", "middle": ["N"], "last": "Nahirniak", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Rutledge", "suffix": ""}, {"first": "I", "middle": ["M"], "last": "Rebeyka", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Campbell", "suffix": ""}], "year": 2007, "venue": "J Thorac Cardiovasc Surg", "volume": "133", "issn": "", "pages": "1517--1523", "other_ids": {}}, "BIBREF211": {"ref_id": "b211", "title": "Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy", "authors": [{"first": "E", "middle": [], "last": "Letko", "suffix": ""}, {"first": "K", "middle": [], "last": "Bhol", "suffix": ""}, {"first": "C", "middle": ["S"], "last": "Foster", "suffix": ""}, {"first": "A", "middle": ["R"], "last": "Ahmed", "suffix": ""}], "year": 2000, "venue": "Ophthalmology", "volume": "107", "issn": "", "pages": "1524--1528", "other_ids": {}}, "BIBREF212": {"ref_id": "b212", "title": "A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis", "authors": [{"first": "J", "middle": ["H"], "last": "Noseworthy", "suffix": ""}, {"first": "P", "middle": ["C"], "last": "O&apos;brien", "suffix": ""}, {"first": "T", "middle": ["M"], "last": "Petterson", "suffix": ""}, {"first": "J", "middle": [], "last": "Weis", "suffix": ""}, {"first": "L", "middle": [], "last": "Stevens", "suffix": ""}, {"first": "W", "middle": ["K"], "last": "Peterson", "suffix": ""}, {"first": "D", "middle": [], "last": "Sneve", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Cross", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Leavitt", "suffix": ""}, {"first": "R", "middle": ["G"], "last": "Auger", "suffix": ""}, {"first": "B", "middle": ["G"], "last": "Weinshenker", "suffix": ""}, {"first": "D", "middle": ["W"], "last": "Dodick", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "Wingerchuk", "suffix": ""}, {"first": "M", "middle": [], "last": "Rodriguez", "suffix": ""}], "year": 2001, "venue": "", "volume": "56", "issn": "", "pages": "1514--1522", "other_ids": {}}, "BIBREF213": {"ref_id": "b213", "title": "A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis", "authors": [{"first": "H", "middle": ["G"], "last": "Roed", "suffix": ""}, {"first": "A", "middle": [], "last": "Langkilde", "suffix": ""}, {"first": "F", "middle": [], "last": "Sellebjerg", "suffix": ""}, {"first": "M", "middle": [], "last": "Lauritzen", "suffix": ""}, {"first": "P", "middle": [], "last": "Bang", "suffix": ""}, {"first": "A", "middle": [], "last": "Morup", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Frederiksen", "suffix": ""}], "year": 2005, "venue": "Neurology", "volume": "64", "issn": "", "pages": "804--810", "other_ids": {}}, "BIBREF214": {"ref_id": "b214", "title": "Successful intravenous immunoglobulin therapy for resistant inflammatory pseudotumor of the orbit", "authors": [{"first": "Z", "middle": [], "last": "Symon", "suffix": ""}, {"first": "N", "middle": [], "last": "Schneebaum", "suffix": ""}, {"first": "A", "middle": [], "last": "Eyal", "suffix": ""}, {"first": "S", "middle": [], "last": "Tal", "suffix": ""}, {"first": "N", "middle": [], "last": "Rozen", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shoenfeld", "suffix": ""}], "year": 2005, "venue": "Thyroid", "volume": "15", "issn": "", "pages": "398--399", "other_ids": {}}, "BIBREF215": {"ref_id": "b215", "title": "Efficacy of intravenous immunoglobulin in the treatment of Birdshot retinochoroiditis", "authors": [{"first": "N", "middle": [], "last": "Cassoux", "suffix": ""}, {"first": "L", "middle": [], "last": "Goichot-Bonnat", "suffix": ""}, {"first": "M", "middle": [], "last": "Karmochkine", "suffix": ""}, {"first": "F", "middle": [], "last": "Georges", "suffix": ""}, {"first": "N", "middle": [], "last": "Kullmann", "suffix": ""}, {"first": "P", "middle": [], "last": "Lehoang", "suffix": ""}, {"first": "M", "middle": [], "last": "Kazatchkine", "suffix": ""}], "year": 2002, "venue": "J Fr Ophtalmol", "volume": "25", "issn": "", "pages": "23--30", "other_ids": {}}, "BIBREF216": {"ref_id": "b216", "title": "Successful treatment of orbital myositis with intravenous immunoglobulins", "authors": [{"first": "S", "middle": [], "last": "Shambal", "suffix": ""}, {"first": "A", "middle": [], "last": "Lindner", "suffix": ""}, {"first": "S", "middle": [], "last": "Zierz", "suffix": ""}], "year": 1998, "venue": "Muscle Nerve", "volume": "21", "issn": "", "pages": "1359--1360", "other_ids": {}}, "BIBREF217": {"ref_id": "b217", "title": "The treatment of refractory uveitis with intravenous immunoglobulin", "authors": [{"first": "J", "middle": ["T"], "last": "Rosenbaum", "suffix": ""}, {"first": "R", "middle": ["K"], "last": "George", "suffix": ""}, {"first": "C", "middle": [], "last": "Gordon", "suffix": ""}], "year": 1999, "venue": "Am J Ophthalmol", "volume": "127", "issn": "", "pages": "545--549", "other_ids": {}}, "BIBREF218": {"ref_id": "b218", "title": "Efficacy of intravenous immunoglobulin treatment in refractory uveitis", "authors": [{"first": "S", "middle": [], "last": "Onal", "suffix": ""}, {"first": "C", "middle": ["S"], "last": "Foster", "suffix": ""}, {"first": "A", "middle": ["R"], "last": "Ahmed", "suffix": ""}], "year": 2006, "venue": "Ocul Immunol Inflamm", "volume": "14", "issn": "", "pages": "367--374", "other_ids": {}}, "BIBREF219": {"ref_id": "b219", "title": "Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy", "authors": [{"first": "L", "middle": [], "last": "Baschieri", "suffix": ""}, {"first": "A", "middle": [], "last": "Antonelli", "suffix": ""}, {"first": "S", "middle": [], "last": "Nardi", "suffix": ""}, {"first": "B", "middle": [], "last": "Alberti", "suffix": ""}, {"first": "A", "middle": [], "last": "Lepri", "suffix": ""}, {"first": "R", "middle": [], "last": "Canapicchi", "suffix": ""}, {"first": "P", "middle": [], "last": "Fallahi", "suffix": ""}], "year": 1997, "venue": "Thyroid", "volume": "7", "issn": "", "pages": "579--585", "other_ids": {}}, "BIBREF220": {"ref_id": "b220", "title": "Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy", "authors": [{"first": "G", "middle": [], "last": "Kahaly", "suffix": ""}, {"first": "S", "middle": [], "last": "Pitz", "suffix": ""}, {"first": "W", "middle": [], "last": "Muller-Forell", "suffix": ""}, {"first": "G", "middle": [], "last": "Hommel", "suffix": ""}], "year": 1996, "venue": "Clin Exp Immunol", "volume": "106", "issn": "", "pages": "197--202", "other_ids": {}}, "BIBREF221": {"ref_id": "b221", "title": "Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases", "authors": [{"first": "J", "middle": [], "last": "Guy", "suffix": ""}, {"first": "N", "middle": [], "last": "Aptsiauri", "suffix": ""}], "year": 1999, "venue": "Arch Ophthalmol", "volume": "117", "issn": "", "pages": "471--477", "other_ids": {}}, "BIBREF222": {"ref_id": "b222", "title": "Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin", "authors": [{"first": "C", "middle": [], "last": "Subhadra", "suffix": ""}, {"first": "A", "middle": ["Z"], "last": "Dudek", "suffix": ""}, {"first": "P", "middle": ["P"], "last": "Rath", "suffix": ""}, {"first": "M", "middle": ["S"], "last": "Lee", "suffix": ""}], "year": 2008, "venue": "J Neuroophthalmol", "volume": "28", "issn": "", "pages": "23--26", "other_ids": {}}, "BIBREF223": {"ref_id": "b223", "title": "A case-bycase protocol of membranous nephropathy treatment with endovenous infusion of high doses of human immunoglobulins", "authors": [{"first": "F", "middle": [], "last": "Floccari", "suffix": ""}, {"first": "V", "middle": [], "last": "Cosentini", "suffix": ""}, {"first": "M", "middle": [], "last": "Giacobbe", "suffix": ""}, {"first": "G", "middle": [], "last": "Coppolino", "suffix": ""}, {"first": "S", "middle": [], "last": "Campo", "suffix": ""}, {"first": "D", "middle": [], "last": "Bolignano", "suffix": ""}, {"first": "D", "middle": [], "last": "Tripodo", "suffix": ""}, {"first": "L", "middle": [], "last": "Nostro", "suffix": ""}, {"first": "M", "middle": [], "last": "Buemi", "suffix": ""}], "year": 2008, "venue": "Nephron Clin Pract", "volume": "108", "issn": "", "pages": "113--120", "other_ids": {}}, "BIBREF224": {"ref_id": "b224", "title": "Intravenous immunoglobulin therapy of membranous nephropathy: efficacy and safety", "authors": [{"first": "R", "middle": [], "last": "Palla", "suffix": ""}, {"first": "C", "middle": [], "last": "Cirami", "suffix": ""}, {"first": "V", "middle": [], "last": "Panichi", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Bianchi", "suffix": ""}, {"first": "M", "middle": [], "last": "Parrini", "suffix": ""}, {"first": "G", "middle": [], "last": "Grazi", "suffix": ""}], "year": 1991, "venue": "Clin Nephrol", "volume": "35", "issn": "", "pages": "98--104", "other_ids": {}}, "BIBREF225": {"ref_id": "b225", "title": "The short-and long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy. Kanazawa Study Group for Renal Diseases and Hypertension", "authors": [{"first": "H", "middle": [], "last": "Yokoyama", "suffix": ""}, {"first": "S", "middle": [], "last": "Goshima", "suffix": ""}, {"first": "T", "middle": [], "last": "Wada", "suffix": ""}, {"first": "M", "middle": [], "last": "Takaeda", "suffix": ""}, {"first": "K", "middle": [], "last": "Furuichi", "suffix": ""}, {"first": "K", "middle": [], "last": "Kobayashi", "suffix": ""}, {"first": "H", "middle": [], "last": "Kida", "suffix": ""}], "year": 1999, "venue": "Nephrol Dial Transplant", "volume": "14", "issn": "", "pages": "2379--2386", "other_ids": {}}, "BIBREF226": {"ref_id": "b226", "title": "High-dose intravenous immunoglobulin pulse therapy in patients with progressive immunoglobulin A nephropathy: a long-term follow-up", "authors": [{"first": "F", "middle": ["M"], "last": "Rasche", "suffix": ""}, {"first": "F", "middle": [], "last": "Keller", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Lepper", "suffix": ""}, {"first": "C", "middle": [], "last": "Aymanns", "suffix": ""}, {"first": "W", "middle": [], "last": "Karges", "suffix": ""}, {"first": "L", "middle": ["C"], "last": "Sailer", "suffix": ""}, {"first": "L", "middle": [], "last": "Muller", "suffix": ""}, {"first": "D", "middle": [], "last": "Czock", "suffix": ""}], "year": 2006, "venue": "Clin Exp Immunol", "volume": "146", "issn": "", "pages": "47--53", "other_ids": {}}, "BIBREF227": {"ref_id": "b227", "title": "Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients", "authors": [{"first": "A", "middle": [], "last": "Sener", "suffix": ""}, {"first": "A", "middle": ["A"], "last": "House", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Jevnikar", "suffix": ""}, {"first": "N", "middle": [], "last": "Boudville", "suffix": ""}, {"first": "V", "middle": ["C"], "last": "Mcalister", "suffix": ""}, {"first": "N", "middle": [], "last": "Muirhead", "suffix": ""}, {"first": "F", "middle": [], "last": "Rehman", "suffix": ""}, {"first": "P", "middle": ["P"], "last": "Luke", "suffix": ""}], "year": 2006, "venue": "Transplantation", "volume": "81", "issn": "", "pages": "117--120", "other_ids": {}}, "BIBREF228": {"ref_id": "b228", "title": "Intravenous immunoglobulin as rescue therapy for BK virus nephropathy", "authors": [{"first": "A", "middle": ["P"], "last": "Sharma", "suffix": ""}, {"first": "M", "middle": [], "last": "Moussa", "suffix": ""}, {"first": "S", "middle": [], "last": "Casier", "suffix": ""}, {"first": "F", "middle": [], "last": "Rehman", "suffix": ""}, {"first": "G", "middle": [], "last": "Filler", "suffix": ""}, {"first": "J", "middle": [], "last": "Grimmer", "suffix": ""}], "year": 2008, "venue": "Pediatr Transplant", "volume": "13", "issn": "", "pages": "123--129", "other_ids": {}}, "BIBREF229": {"ref_id": "b229", "title": "Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCAassociated rapidly progressive glomerulonephritis", "authors": [{"first": "T", "middle": [], "last": "Ito-Ihara", "suffix": ""}, {"first": "T", "middle": [], "last": "Ono", "suffix": ""}, {"first": "F", "middle": [], "last": "Nogaki", "suffix": ""}, {"first": "K", "middle": [], "last": "Suyama", "suffix": ""}, {"first": "M", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "S", "middle": [], "last": "Yonemoto", "suffix": ""}, {"first": "A", "middle": [], "last": "Fukatsu", "suffix": ""}, {"first": "T", "middle": [], "last": "Kita", "suffix": ""}, {"first": "K", "middle": [], "last": "Suzuki", "suffix": ""}, {"first": "E", "middle": [], "last": "Muso", "suffix": ""}], "year": 2006, "venue": "Nephron Clin Pract", "volume": "102", "issn": "", "pages": "35--42", "other_ids": {}}, "BIBREF230": {"ref_id": "b230", "title": "Successful use of high dose intravenous immunoglobulin in rapidly progressive crescentic glomerulonephritis with vasculitis", "authors": [{"first": "A", "middle": [], "last": "Basok", "suffix": ""}, {"first": "A", "middle": [], "last": "Shnaider", "suffix": ""}, {"first": "D", "middle": [], "last": "Tovbin", "suffix": ""}, {"first": "B", "middle": [], "last": "Rogachev", "suffix": ""}], "year": 2001, "venue": "Isr Med Assoc J", "volume": "3", "issn": "", "pages": "453--454", "other_ids": {}}, "BIBREF231": {"ref_id": "b231", "title": "Treatment of antineutrophil cytoplasmic autoantibodypositive systemic vasculitis and glomerulonephritis with pooled intravenous gamma globulin", "authors": [{"first": "P", "middle": [], "last": "Tuso", "suffix": ""}, {"first": "A", "middle": [], "last": "Moudgil", "suffix": ""}, {"first": "J", "middle": [], "last": "Hay", "suffix": ""}, {"first": "D", "middle": [], "last": "Goodman", "suffix": ""}, {"first": "E", "middle": [], "last": "Kamil", "suffix": ""}, {"first": "R", "middle": [], "last": "Koyyana", "suffix": ""}, {"first": "S", "middle": ["C"], "last": "Jordan", "suffix": ""}], "year": 1992, "venue": "Am J Kidney Dis", "volume": "20", "issn": "", "pages": "504--508", "other_ids": {}}, "BIBREF232": {"ref_id": "b232", "title": "Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients", "authors": [{"first": "H", "middle": [], "last": "Billing", "suffix": ""}, {"first": "S", "middle": [], "last": "Rieger", "suffix": ""}, {"first": "J", "middle": [], "last": "Ovens", "suffix": ""}, {"first": "C", "middle": [], "last": "Susal", "suffix": ""}, {"first": "A", "middle": [], "last": "Melk", "suffix": ""}, {"first": "R", "middle": [], "last": "Waldherr", "suffix": ""}, {"first": "G", "middle": [], "last": "Opelz", "suffix": ""}, {"first": "B", "middle": [], "last": "Tonshoff", "suffix": ""}], "year": 2008, "venue": "Transplantation", "volume": "86", "issn": "", "pages": "1214--1221", "other_ids": {}}, "BIBREF233": {"ref_id": "b233", "title": "Early diagnosis and successful treatment of acute antibodymediated rejection of a renal transplant", "authors": [{"first": "Y", "middle": ["W"], "last": "Yang", "suffix": ""}, {"first": "W", "middle": ["C"], "last": "Lin", "suffix": ""}, {"first": "M", "middle": ["S"], "last": "Wu", "suffix": ""}, {"first": "P", "middle": ["H"], "last": "Lee", "suffix": ""}, {"first": "M", "middle": ["K"], "last": "Tsai", "suffix": ""}], "year": 2008, "venue": "Exp Clin Transplant", "volume": "6", "issn": "", "pages": "211--214", "other_ids": {}}, "BIBREF234": {"ref_id": "b234", "title": "Plasmapheresis, intravenous cytomegalovirus-specific immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal transplant recipient: a case report", "authors": [{"first": "S", "middle": [], "last": "Furth", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Neu", "suffix": ""}, {"first": "J", "middle": [], "last": "Hart", "suffix": ""}, {"first": "A", "middle": [], "last": "Zachary", "suffix": ""}, {"first": "P", "middle": [], "last": "Colombani", "suffix": ""}, {"first": "B", "middle": ["A"], "last": "Fivush", "suffix": ""}], "year": 1999, "venue": "Pediatr Transplant", "volume": "3", "issn": "", "pages": "146--149", "other_ids": {}}, "BIBREF235": {"ref_id": "b235", "title": "Posttransplant therapy using high-dose human immunoglobulin (intravenous gamma globulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action", "authors": [{"first": "S", "middle": ["C"], "last": "Jordan", "suffix": ""}, {"first": "A", "middle": ["W"], "last": "Quartel", "suffix": ""}, {"first": "L", "middle": ["S"], "last": "Czer", "suffix": ""}, {"first": "D", "middle": [], "last": "Admon", "suffix": ""}, {"first": "G", "middle": [], "last": "Chen", "suffix": ""}, {"first": "M", "middle": ["C"], "last": "Fishbein", "suffix": ""}, {"first": "J", "middle": [], "last": "Schwieger", "suffix": ""}, {"first": "R", "middle": ["W"], "last": "Steiner", "suffix": ""}, {"first": "C", "middle": [], "last": "Davis", "suffix": ""}, {"first": "D", "middle": ["B"], "last": "Tyan", "suffix": ""}], "year": 1998, "venue": "Transplantation", "volume": "66", "issn": "", "pages": "800--805", "other_ids": {}}, "BIBREF236": {"ref_id": "b236", "title": "Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis", "authors": [{"first": "J", "middle": ["N"], "last": "Boletis", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Ioannidis", "suffix": ""}, {"first": "K", "middle": ["A"], "last": "Boki", "suffix": ""}, {"first": "H", "middle": ["M"], "last": "Moutsopoulos", "suffix": ""}], "year": 1999, "venue": "Lancet", "volume": "354", "issn": "", "pages": "569--570", "other_ids": {}}, "BIBREF237": {"ref_id": "b237", "title": "Intravenous immunoglobulin treatment of lupus nephritis", "authors": [{"first": "Y", "middle": [], "last": "Levy", "suffix": ""}, {"first": "Y", "middle": [], "last": "Sherer", "suffix": ""}, {"first": "J", "middle": [], "last": "George", "suffix": ""}, {"first": "J", "middle": [], "last": "Rovensky", "suffix": ""}, {"first": "J", "middle": [], "last": "Lukac", "suffix": ""}, {"first": "L", "middle": [], "last": "Rauova", "suffix": ""}, {"first": "P", "middle": [], "last": "Poprac", "suffix": ""}, {"first": "P", "middle": [], "last": "Langevitz", "suffix": ""}, {"first": "F", "middle": [], "last": "Fabbrizzi", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shoenfeld", "suffix": ""}], "year": 2000, "venue": "Semin Arthritis Rheum", "volume": "29", "issn": "", "pages": "321--327", "other_ids": {}}, "BIBREF238": {"ref_id": "b238", "title": "Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis", "authors": [{"first": "M", "middle": [], "last": "Meissner", "suffix": ""}, {"first": "Y", "middle": [], "last": "Sherer", "suffix": ""}, {"first": "Y", "middle": [], "last": "Levy", "suffix": ""}, {"first": "H", "middle": [], "last": "Chwalinska-Sadowska", "suffix": ""}, {"first": "P", "middle": [], "last": "Langevitz", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shoenfeld", "suffix": ""}], "year": 2000, "venue": "Rheumatol Int", "volume": "19", "issn": "", "pages": "199--201", "other_ids": {}}, "BIBREF239": {"ref_id": "b239", "title": "Successful treatment of rapidly progressive lupus nephritis associated with anti-MPO antibodies by intravenous immunoglobulins", "authors": [{"first": "H", "middle": [], "last": "Arahata", "suffix": ""}, {"first": "K", "middle": [], "last": "Migita", "suffix": ""}, {"first": "H", "middle": [], "last": "Izumoto", "suffix": ""}, {"first": "T", "middle": [], "last": "Miyashita", "suffix": ""}, {"first": "H", "middle": [], "last": "Munakata", "suffix": ""}, {"first": "H", "middle": [], "last": "Nakamura", "suffix": ""}, {"first": "M", "middle": [], "last": "Tominaga", "suffix": ""}, {"first": "T", "middle": [], "last": "Origuchi", "suffix": ""}, {"first": "Y", "middle": [], "last": "Kawabe", "suffix": ""}, {"first": "A", "middle": [], "last": "Hida", "suffix": ""}, {"first": "T", "middle": [], "last": "Taguchi", "suffix": ""}, {"first": "K", "middle": [], "last": "Eguchi", "suffix": ""}], "year": 1999, "venue": "Clin Rheumatol", "volume": "18", "issn": "", "pages": "77--81", "other_ids": {}}, "BIBREF240": {"ref_id": "b240", "title": "Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment", "authors": [], "year": 2001, "venue": "J Am Acad Dermatol", "volume": "45", "issn": "", "pages": "679--690", "other_ids": {}}, "BIBREF241": {"ref_id": "b241", "title": "The role of IVIG treatment in severe pemphigus vulgaris", "authors": [{"first": "S", "middle": [], "last": "Baum", "suffix": ""}, {"first": "A", "middle": [], "last": "Scope", "suffix": ""}, {"first": "A", "middle": [], "last": "Barzilai", "suffix": ""}], "year": 2006, "venue": "J Eur Acad Dermatol Venereol", "volume": "20", "issn": "", "pages": "548--552", "other_ids": {}}, "BIBREF242": {"ref_id": "b242", "title": "Treatment of pemphigus with intravenous immunoglobulin", "authors": [{"first": "J", "middle": ["C"], "last": "Bystryn", "suffix": ""}, {"first": "D", "middle": [], "last": "Jiao", "suffix": ""}, {"first": "S", "middle": [], "last": "Natow", "suffix": ""}], "year": 2002, "venue": "J Am Acad Dermatol", "volume": "47", "issn": "", "pages": "358--363", "other_ids": {}}, "BIBREF243": {"ref_id": "b243", "title": "Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris", "authors": [{"first": "N", "middle": [], "last": "Sami", "suffix": ""}, {"first": "A", "middle": [], "last": "Qureshi", "suffix": ""}, {"first": "E", "middle": [], "last": "Ruocco", "suffix": ""}], "year": 2002, "venue": "Arch Dermatol", "volume": "138", "issn": "", "pages": "1158--1162", "other_ids": {}}, "BIBREF244": {"ref_id": "b244", "title": "Effectiveness of intravenous immunoglobulin therapy for skin disease other than Toxic Epidermal Necrolysis: a retrospective review of Mayo Clinic experience", "authors": [{"first": "D", "middle": ["A"], "last": "Wetter", "suffix": ""}, {"first": "M", "middle": ["D"], "last": "Davis", "suffix": ""}, {"first": "J", "middle": [], "last": "Yiannias", "suffix": ""}], "year": 2005, "venue": "Mayo Clinic Proc", "volume": "80", "issn": "", "pages": "41--47", "other_ids": {}}, "BIBREF245": {"ref_id": "b245", "title": "Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional treatment", "authors": [{"first": "Razzaque", "middle": [], "last": "Ahmed", "suffix": ""}, {"first": "A", "middle": [], "last": "Sami", "suffix": ""}, {"first": "N", "middle": [], "last": "", "suffix": ""}], "year": 2002, "venue": "J Am Acad Dermatol", "volume": "46", "issn": "", "pages": "42--49", "other_ids": {}}, "BIBREF246": {"ref_id": "b246", "title": "Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus", "authors": [{"first": "N", "middle": [], "last": "Sami", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Bhol", "suffix": ""}], "year": 2002, "venue": "Razzaque Ahmed A", "volume": "105", "issn": "", "pages": "192--198", "other_ids": {}}, "BIBREF247": {"ref_id": "b247", "title": "Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus", "authors": [{"first": "N", "middle": [], "last": "Sami", "suffix": ""}, {"first": "A", "middle": [], "last": "Qureshi", "suffix": ""}], "year": 2002, "venue": "Razzaque Ahmed A", "volume": "12", "issn": "", "pages": "174--178", "other_ids": {}}, "BIBREF248": {"ref_id": "b248", "title": "Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment", "authors": [], "year": 2001, "venue": "J Am Acad Dermatol", "volume": "45", "issn": "", "pages": "825--835", "other_ids": {}}, "BIBREF249": {"ref_id": "b249", "title": "Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data", "authors": [{"first": "L", "middle": [], "last": "Engineer", "suffix": ""}, {"first": "Razzaque", "middle": [], "last": "Ahmed", "suffix": ""}, {"first": "A", "middle": [], "last": "", "suffix": ""}], "year": 2001, "venue": "J Am Acad Dermatol", "volume": "44", "issn": "", "pages": "83--88", "other_ids": {}}, "BIBREF250": {"ref_id": "b250", "title": "Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titers to human alpha6 integrin", "authors": [{"first": "N", "middle": [], "last": "Sami", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Bhol", "suffix": ""}], "year": 2002, "venue": "Razzaque Ahmed A", "volume": "129", "issn": "", "pages": "533--540", "other_ids": {}}, "BIBREF251": {"ref_id": "b251", "title": "A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulin and cyclosporin", "authors": [{"first": "S", "middle": [], "last": "Hern", "suffix": ""}, {"first": "K", "middle": [], "last": "Harman", "suffix": ""}, {"first": "B", "middle": ["S"], "last": "Bhogal", "suffix": ""}], "year": 1998, "venue": "Clin Exp Dermatol", "volume": "23", "issn": "", "pages": "185--188", "other_ids": {}}, "BIBREF252": {"ref_id": "b252", "title": "Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study", "authors": [{"first": "C", "middle": [], "last": "Prins", "suffix": ""}, {"first": "C", "middle": [], "last": "Vittorio", "suffix": ""}, {"first": "R", "middle": ["S"], "last": "Padilla", "suffix": ""}], "year": 2003, "venue": "Dermatology", "volume": "207", "issn": "", "pages": "96--99", "other_ids": {}}, "BIBREF253": {"ref_id": "b253", "title": "Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome", "authors": [{"first": "M", "middle": ["V"], "last": "Morici", "suffix": ""}, {"first": "G", "middle": [], "last": "Wesley", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Shetty", "suffix": ""}], "year": 2000, "venue": "J Rheumatol", "volume": "27", "issn": "", "pages": "2494--2497", "other_ids": {}}, "BIBREF254": {"ref_id": "b254", "title": "Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis", "authors": [{"first": "N", "middle": [], "last": "Al-Mutairi", "suffix": ""}, {"first": "J", "middle": [], "last": "Arun", "suffix": ""}, {"first": "N", "middle": ["E"], "last": "Osama", "suffix": ""}], "year": 2004, "venue": "Int J Dermatol", "volume": "43", "issn": "", "pages": "847--851", "other_ids": {}}, "BIBREF255": {"ref_id": "b255", "title": "High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis", "authors": [{"first": "E", "middle": [], "last": "Campione", "suffix": ""}, {"first": "G", "middle": ["C"], "last": "Marulli", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Carrozzo", "suffix": ""}], "year": 2003, "venue": "Acta Derm Venereol", "volume": "83", "issn": "", "pages": "430--432", "other_ids": {}}, "BIBREF256": {"ref_id": "b256", "title": "Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression", "authors": [{"first": "N", "middle": [], "last": "Bachot", "suffix": ""}, {"first": "J", "middle": [], "last": "Revuz", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Roujeau", "suffix": ""}], "year": 2003, "venue": "Arch Dermatol", "volume": "139", "issn": "", "pages": "33--36", "other_ids": {}}, "BIBREF257": {"ref_id": "b257", "title": "Treatment of toxic epidermal necrolysis. Experience with 9 patients with consideration of intravenous immunoglobulin", "authors": [{"first": "P", "middle": [], "last": "Spornraft-Ragaller", "suffix": ""}, {"first": "H", "middle": [], "last": "Theilen", "suffix": ""}, {"first": "G", "middle": ["S"], "last": "Gottschlich", "suffix": ""}, {"first": "M", "middle": [], "last": "Ragaller", "suffix": ""}], "year": 2006, "venue": "Hautarzt", "volume": "57", "issn": "", "pages": "185--194", "other_ids": {}}, "BIBREF258": {"ref_id": "b258", "title": "Intravenous immunoglobulin for treatment of toxic epidermal necrolysis", "authors": [{"first": "M", "middle": [], "last": "Nasser", "suffix": ""}, {"first": "O", "middle": [], "last": "Bitterman-Deutsch", "suffix": ""}, {"first": "F", "middle": [], "last": "Nassar", "suffix": ""}], "year": 2005, "venue": "Am J Med Sci", "volume": "329", "issn": "", "pages": "95--98", "other_ids": {}}, "BIBREF259": {"ref_id": "b259", "title": "Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature", "authors": [{"first": "D", "middle": [], "last": "Metry", "suffix": ""}, {"first": "P", "middle": [], "last": "Jung", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Levy", "suffix": ""}], "year": 2003, "venue": "Pediatrics", "volume": "112", "issn": "", "pages": "1430--1436", "other_ids": {}}, "BIBREF260": {"ref_id": "b260", "title": "Treatment of toxic epidermal necrolysis with high dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases", "authors": [{"first": "C", "middle": [], "last": "Prins", "suffix": ""}, {"first": "F", "middle": ["A"], "last": "Kerdel", "suffix": ""}, {"first": "R", "middle": ["S"], "last": "Padilla", "suffix": ""}], "year": 2003, "venue": "Arch Dermatol", "volume": "139", "issn": "", "pages": "26--32", "other_ids": {}}, "BIBREF261": {"ref_id": "b261", "title": "Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami Experience", "authors": [{"first": "J", "middle": ["T"], "last": "Trent", "suffix": ""}, {"first": "R", "middle": ["S"], "last": "Kirsner", "suffix": ""}, {"first": "P", "middle": [], "last": "Romanelli", "suffix": ""}, {"first": "F", "middle": ["A"], "last": "Kerdel", "suffix": ""}], "year": 2003, "venue": "Arch Dermatol", "volume": "139", "issn": "", "pages": "39--43", "other_ids": {}}, "BIBREF262": {"ref_id": "b262", "title": "Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children", "authors": [{"first": "P", "middle": [], "last": "Tristani-Firouzi", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Petersen", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Saffle", "suffix": ""}], "year": 2002, "venue": "J Am Acad Dermatol", "volume": "47", "issn": "", "pages": "548--552", "other_ids": {}}, "BIBREF263": {"ref_id": "b263", "title": "Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis", "authors": [{"first": "R", "middle": [], "last": "Shortt", "suffix": ""}, {"first": "M", "middle": [], "last": "Gomez", "suffix": ""}, {"first": "N", "middle": [], "last": "Mittman", "suffix": ""}, {"first": "R", "middle": [], "last": "Cartotto", "suffix": ""}], "year": 2004, "venue": "J Burn Care Rehabil", "volume": "25", "issn": "", "pages": "246--255", "other_ids": {}}, "BIBREF264": {"ref_id": "b264", "title": "A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis", "authors": [{"first": "C", "middle": [], "last": "Paul", "suffix": ""}, {"first": "M", "middle": [], "last": "Lahfa", "suffix": ""}, {"first": "H", "middle": [], "last": "Bachelez", "suffix": ""}], "year": 2002, "venue": "Br J Dermatol", "volume": "147", "issn": "", "pages": "518--522", "other_ids": {}}, "BIBREF265": {"ref_id": "b265", "title": "Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts", "authors": [{"first": "S", "middle": [], "last": "Jolles", "suffix": ""}, {"first": "C", "middle": [], "last": "Sewell", "suffix": ""}, {"first": "D", "middle": [], "last": "Webster", "suffix": ""}], "year": 2003, "venue": "Acta Derm Venereol", "volume": "83", "issn": "", "pages": "433--437", "other_ids": {}}, "BIBREF266": {"ref_id": "b266", "title": "The treatment of atopic dermatitis with adjunctive high dose intravenous immunoglobulin: a report of three patients and review of the literature", "authors": [{"first": "S", "middle": [], "last": "Jolles", "suffix": ""}, {"first": "J", "middle": [], "last": "Hughes", "suffix": ""}, {"first": "Rustin", "middle": ["M"], "last": "", "suffix": ""}], "year": 2000, "venue": "Br J Dermatol", "volume": "142", "issn": "", "pages": "551--554", "other_ids": {}}, "BIBREF267": {"ref_id": "b267", "title": "High dose immunoglobulin in atopic dermatitis and hyper-IgE syndrome", "authors": [{"first": "M", "middle": [], "last": "Wakim", "suffix": ""}, {"first": "M", "middle": [], "last": "Alazard", "suffix": ""}, {"first": "A", "middle": [], "last": "Yajima", "suffix": ""}], "year": 1998, "venue": "Ann Allergy Asthma Immunol", "volume": "81", "issn": "", "pages": "153--158", "other_ids": {}}, "BIBREF268": {"ref_id": "b268", "title": "A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis", "authors": [{"first": "S", "middle": [], "last": "Jolles", "suffix": ""}], "year": 2002, "venue": "Clin Exp Dermatol", "volume": "27", "issn": "", "pages": "3--7", "other_ids": {}}, "BIBREF269": {"ref_id": "b269", "title": "Intravenous immunoglobulin un autoimmune chronic urticaria", "authors": [{"first": "B", "middle": ["F"], "last": "O&apos;donnell", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "Barr", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Black", "suffix": ""}], "year": 1998, "venue": "Br J Dermatol", "volume": "138", "issn": "", "pages": "101--106", "other_ids": {}}, "BIBREF270": {"ref_id": "b270", "title": "The effectiveness of low dose intravenous immunoglobulin in chronic urticaria", "authors": [{"first": "M", "middle": [], "last": "Kroiss", "suffix": ""}, {"first": "T", "middle": [], "last": "Vogt", "suffix": ""}, {"first": "M", "middle": [], "last": "Landthaler", "suffix": ""}], "year": 2000, "venue": "Acta Derm Venereol", "volume": "80", "issn": "", "pages": "", "other_ids": {}}, "BIBREF271": {"ref_id": "b271", "title": "Effect of highdose intravenous immunoglobulin delayed pressure urticaria", "authors": [{"first": "G", "middle": [], "last": "Dawn", "suffix": ""}, {"first": "M", "middle": [], "last": "Urcelay", "suffix": ""}, {"first": "A", "middle": [], "last": "Ah-Weng", "suffix": ""}], "year": 2003, "venue": "Br J Dermatol", "volume": "149", "issn": "", "pages": "836--840", "other_ids": {}}, "BIBREF272": {"ref_id": "b272", "title": "Solar urticaria: one case treated by intravenous immunoglobulin", "authors": [{"first": "I", "middle": [], "last": "Puech-Plottova", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Michel", "suffix": ""}, {"first": "B", "middle": [], "last": "Rouchouse", "suffix": ""}], "year": 2000, "venue": "Ann Dermatol Venereol", "volume": "127", "issn": "", "pages": "831--835", "other_ids": {}}, "BIBREF273": {"ref_id": "b273", "title": "Treatment of solar urticaria by intravenous immunoglobulins and PUVA therapy", "authors": [{"first": "S", "middle": [], "last": "Darras", "suffix": ""}, {"first": "M", "middle": [], "last": "S\u00e9grad", "suffix": ""}, {"first": "L", "middle": [], "last": "Mortier", "suffix": ""}], "year": 2004, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF275": {"ref_id": "b275", "title": "Intravenous immunoglobulin therapy suppresses manifestations of the angioedema with hypereosinophilia syndrome", "authors": [{"first": "F", "middle": ["M"], "last": "Orson", "suffix": ""}], "year": 2003, "venue": "Am J Med Sci", "volume": "326", "issn": "", "pages": "94--97", "other_ids": {}}, "BIBREF276": {"ref_id": "b276", "title": "Psoriasis: response to high-dose intravenous immunoglobulin in three patients", "authors": [{"first": "V", "middle": [], "last": "Gurmin", "suffix": ""}, {"first": "R", "middle": [], "last": "Mediwake", "suffix": ""}, {"first": "M", "middle": [], "last": "Fernando", "suffix": ""}], "year": 2002, "venue": "Br J Dermatol", "volume": "147", "issn": "", "pages": "554--557", "other_ids": {}}, "BIBREF277": {"ref_id": "b277", "title": "Treatment of pyoderma gangrenosum with intravenous immunoglobulin", "authors": [{"first": "D", "middle": ["L"], "last": "Cummins", "suffix": ""}, {"first": "G", "middle": ["J"], "last": "Anhalt", "suffix": ""}, {"first": "T", "middle": [], "last": "Monahan", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Meyerle", "suffix": ""}], "year": 2007, "venue": "Br J Dermatol", "volume": "157", "issn": "", "pages": "1235--1239", "other_ids": {}}, "BIBREF278": {"ref_id": "b278", "title": "Pyoderma gangrenosum treated with high-dose intravenous immunoglobulins: two cases and review of literature", "authors": [{"first": "N", "middle": [], "last": "Meyer", "suffix": ""}, {"first": "V", "middle": [], "last": "Ferraro", "suffix": ""}, {"first": "M", "middle": ["H"], "last": "Mignard", "suffix": ""}], "year": 2006, "venue": "Clin Drug Investig", "volume": "26", "issn": "", "pages": "541--546", "other_ids": {}}, "BIBREF279": {"ref_id": "b279", "title": "Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin", "authors": [{"first": "H", "middle": ["J"], "last": "Chung", "suffix": ""}, {"first": "K", "middle": ["Y"], "last": "Chung", "suffix": ""}], "year": 2004, "venue": "Br J Dermatol", "volume": "150", "issn": "", "pages": "596--597", "other_ids": {}}, "BIBREF280": {"ref_id": "b280", "title": "Pretibial myxedema and high-dose intravenous immunoglobulin treatment", "authors": [{"first": "A", "middle": [], "last": "Antonelli", "suffix": ""}, {"first": "A", "middle": [], "last": "Navarranne", "suffix": ""}, {"first": "R", "middle": [], "last": "Palla", "suffix": ""}], "year": 1994, "venue": "Thyroid", "volume": "4", "issn": "", "pages": "399--408", "other_ids": {}}, "BIBREF281": {"ref_id": "b281", "title": "Scleromyxedema. A case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG)", "authors": [{"first": "M", "middle": [], "last": "Blum", "suffix": ""}, {"first": "F", "middle": ["M"], "last": "Wigley", "suffix": ""}, {"first": "L", "middle": ["K"], "last": "Hummers", "suffix": ""}], "year": 2008, "venue": "Medicine", "volume": "87", "issn": "", "pages": "10--20", "other_ids": {}}, "BIBREF282": {"ref_id": "b282", "title": "Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin", "authors": [{"first": "A", "middle": [], "last": "Kulczycki", "suffix": ""}, {"first": "M", "middle": [], "last": "Nelson", "suffix": ""}, {"first": "A", "middle": [], "last": "Eisen", "suffix": ""}, {"first": "M", "middle": [], "last": "Heffernan", "suffix": ""}], "year": 2003, "venue": "Br J Dermatol", "volume": "149", "issn": "", "pages": "1276--1281", "other_ids": {}}, "BIBREF283": {"ref_id": "b283", "title": "Scleromyxedema: response to highdose intravenous immunoglobulin (hdIVIg)", "authors": [{"first": "R", "middle": ["K"], "last": "Lister", "suffix": ""}, {"first": "S", "middle": [], "last": "Jolles", "suffix": ""}, {"first": "S", "middle": [], "last": "Whittaker", "suffix": ""}, {"first": "C", "middle": [], "last": "Black", "suffix": ""}, {"first": "I", "middle": [], "last": "Forgacs", "suffix": ""}, {"first": "M", "middle": [], "last": "Cramp", "suffix": ""}, {"first": "M", "middle": [], "last": "Potter", "suffix": ""}, {"first": "M", "middle": ["H"], "last": "Rustin", "suffix": ""}], "year": 2000, "venue": "J Am Acad Dermatol", "volume": "43", "issn": "", "pages": "403--408", "other_ids": {}}, "BIBREF284": {"ref_id": "b284", "title": "Arndt-Gottron scleromyxedema: successful therapy with intravenous immunoglobulins", "authors": [{"first": "P", "middle": [], "last": "Gholam", "suffix": ""}, {"first": "M", "middle": [], "last": "Hartmann", "suffix": ""}, {"first": "A", "middle": [], "last": "Enk", "suffix": ""}], "year": 2007, "venue": "Br J Dermatol", "volume": "157", "issn": "", "pages": "1058--1060", "other_ids": {}}, "BIBREF285": {"ref_id": "b285", "title": "Combination oral prednisone and intravenous immunoglobulin in the treatment of scleromyxedema", "authors": [{"first": "C", "middle": [], "last": "Majeski", "suffix": ""}, {"first": "M", "middle": [], "last": "Taher", "suffix": ""}, {"first": "P", "middle": [], "last": "Grewal", "suffix": ""}], "year": 2005, "venue": "J Cutan Med Surg", "volume": "9", "issn": "", "pages": "99--104", "other_ids": {}}, "BIBREF286": {"ref_id": "b286", "title": "Successful therapy of scleromyxedema Arndt-Gottron with low-dose intravenous immunoglobulin", "authors": [{"first": "A", "middle": [], "last": "K\u00f6rber", "suffix": ""}, {"first": "T", "middle": [], "last": "Franckson", "suffix": ""}, {"first": "S", "middle": [], "last": "Grabbe", "suffix": ""}, {"first": "J", "middle": [], "last": "Dissemond", "suffix": ""}], "year": 2007, "venue": "Eur Acad Dermatol Venereol", "volume": "21", "issn": "", "pages": "553--554", "other_ids": {}}, "BIBREF287": {"ref_id": "b287", "title": "Marked improvement in scleromyxedema with high-dose immunoglobulin", "authors": [{"first": "S", "middle": [], "last": "Topf", "suffix": ""}, {"first": "M", "middle": [], "last": "Simon", "suffix": ""}, {"first": "H", "middle": [], "last": "Schell", "suffix": ""}, {"first": "M", "middle": [], "last": "L\u00fcftl", "suffix": ""}], "year": 2007, "venue": "Hautarzt", "volume": "58", "issn": "", "pages": "525--528", "other_ids": {}}, "BIBREF288": {"ref_id": "b288", "title": "Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulins", "authors": [{"first": "A", "middle": [], "last": "Wojas-Pelc", "suffix": ""}, {"first": "M", "middle": [], "last": "B\u0142aszczyk", "suffix": ""}, {"first": "M", "middle": [], "last": "Glinska", "suffix": ""}, {"first": "S", "middle": [], "last": "Jab\u0142onska", "suffix": ""}], "year": 2005, "venue": "Eur Acad Dermatol Venereol", "volume": "19", "issn": "", "pages": "462--465", "other_ids": {}}, "BIBREF289": {"ref_id": "b289", "title": "Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema", "authors": [{"first": "S", "middle": [], "last": "Jolles", "suffix": ""}, {"first": "J", "middle": [], "last": "Hughes", "suffix": ""}], "year": 2006, "venue": "Int Immunopharmacol", "volume": "6", "issn": "", "pages": "579--591", "other_ids": {}}, "BIBREF290": {"ref_id": "b290", "title": "Effect of IVIG on the hair regrowth in a common variable immune deficiency patient with alopecia universalis", "authors": [{"first": "S", "middle": [], "last": "Boonyaleepun", "suffix": ""}, {"first": "C", "middle": [], "last": "Boonyaleepun", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Schlactus", "suffix": ""}], "year": 1999, "venue": "Asian Pac J Allergy Immunol", "volume": "17", "issn": "", "pages": "59--62", "other_ids": {}}, "BIBREF291": {"ref_id": "b291", "title": "Regression of Kaposi's sarcoma after intravenous immunoglobulin treatment for polymyositis", "authors": [{"first": "Y", "middle": [], "last": "Carmeli", "suffix": ""}, {"first": "D", "middle": [], "last": "Mevorach", "suffix": ""}, {"first": "N", "middle": [], "last": "Kaminski", "suffix": ""}, {"first": "E", "middle": [], "last": "Raz", "suffix": ""}], "year": 1994, "venue": "Cancer", "volume": "73", "issn": "", "pages": "2859--2891", "other_ids": {}}, "BIBREF292": {"ref_id": "b292", "title": "Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma", "authors": [{"first": "J", "middle": [], "last": "Schachter", "suffix": ""}, {"first": "U", "middle": [], "last": "Katz", "suffix": ""}, {"first": "A", "middle": [], "last": "Mahrer", "suffix": ""}], "year": 2007, "venue": "Ann N Y Acad Sci", "volume": "1110", "issn": "", "pages": "305--314", "other_ids": {}}, "BIBREF293": {"ref_id": "b293", "title": "Intravenous immunoglobulin as prophylaxis of chemotherapy-induced oral mucositis", "authors": [{"first": "P", "middle": [], "last": "Plevova", "suffix": ""}, {"first": "B", "middle": [], "last": "Blazek", "suffix": ""}], "year": 1997, "venue": "J Natl Cancer Inst", "volume": "89", "issn": "", "pages": "326--327", "other_ids": {}}, "BIBREF294": {"ref_id": "b294", "title": "Total remission of thymus carcinoma after treatment with intravenous immunoglobulin", "authors": [{"first": "M", "middle": [], "last": "Murie-Fernandez", "suffix": ""}, {"first": "A", "middle": [], "last": "Gurpide", "suffix": ""}, {"first": "S", "middle": [], "last": "De La Cruz", "suffix": ""}, {"first": "P", "middle": [], "last": "De Castro", "suffix": ""}], "year": 2006, "venue": "Clin Transl Oncol", "volume": "8", "issn": "", "pages": "697--699", "other_ids": {}}, "BIBREF295": {"ref_id": "b295", "title": "Thymoma and immunodeficiency (Good syndrome): a report of 2 unusual cases and review of the literature", "authors": [{"first": "S", "middle": [], "last": "Agarwal", "suffix": ""}, {"first": "C", "middle": [], "last": "Cunningham-Rundles", "suffix": ""}], "year": 2007, "venue": "Ann Allergy Asthma Immunol", "volume": "98", "issn": "", "pages": "185--190", "other_ids": {}}, "BIBREF296": {"ref_id": "b296", "title": "Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy", "authors": [{"first": "K", "middle": ["R"], "last": "Sharma", "suffix": ""}, {"first": "J", "middle": [], "last": "Cross", "suffix": ""}, {"first": "D", "middle": ["R"], "last": "Ayyar", "suffix": ""}], "year": 2002, "venue": "Arch Neurol", "volume": "59", "issn": "", "pages": "751--757", "other_ids": {}}, "BIBREF297": {"ref_id": "b297", "title": "Intravenous immunoglobulin therapy markedly ameliorates muscle weakness and severe pain in proximal diabetic neuropathy", "authors": [{"first": "Y", "middle": [], "last": "Kawagashira", "suffix": ""}, {"first": "H", "middle": [], "last": "Watanabe", "suffix": ""}, {"first": "Y", "middle": [], "last": "Oki", "suffix": ""}], "year": 2007, "venue": "J Neurol Neurosurg Psychiatry", "volume": "78", "issn": "", "pages": "899--901", "other_ids": {}}, "BIBREF298": {"ref_id": "b298", "title": "Simultaneous multiple cranial nerve neuropathies and intravenous immunoglobulin treatment in diabetes mellitus", "authors": [{"first": "D", "middle": [], "last": "Uluduz", "suffix": ""}, {"first": "M", "middle": [], "last": "Bozluolcay", "suffix": ""}, {"first": "B", "middle": [], "last": "Ince", "suffix": ""}, {"first": "M", "middle": [], "last": "Kiziltan", "suffix": ""}], "year": 2005, "venue": "Neurol India", "volume": "54", "issn": "", "pages": "308--309", "other_ids": {}}, "BIBREF299": {"ref_id": "b299", "title": "A case of diabetic amyotrophy with severe atrophy and weakness of shoulder girdle muscles showing good response to intravenous immune globulin", "authors": [{"first": "Y", "middle": [], "last": "Wada", "suffix": ""}, {"first": "C", "middle": [], "last": "Yanagihara", "suffix": ""}, {"first": "Y", "middle": [], "last": "Nishimura", "suffix": ""}, {"first": "N", "middle": [], "last": "Oka", "suffix": ""}], "year": 2007, "venue": "Diabetes Res Clin Pract", "volume": "75", "issn": "", "pages": "107--110", "other_ids": {}}, "BIBREF300": {"ref_id": "b300", "title": "Antibodymediated rejection of a pancreas allograft", "authors": [{"first": "M", "middle": [], "last": "Melcher", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Olson", "suffix": ""}, {"first": "L", "middle": ["A"], "last": "Baxter-Lowe", "suffix": ""}], "year": 2006, "venue": "Am J Transplant", "volume": "6", "issn": "", "pages": "423--428", "other_ids": {}}, "BIBREF301": {"ref_id": "b301", "title": "Multifocal motor neuropath, type 1 diabetes and asymptomatic Hashimoto's thyroiditis: an unusual association", "authors": [{"first": "R", "middle": [], "last": "Reisin", "suffix": ""}, {"first": "C", "middle": [], "last": "Zurr\u00fa", "suffix": ""}, {"first": "C", "middle": [], "last": "Buso", "suffix": ""}], "year": 2005, "venue": "Neuromuscul Disord", "volume": "15", "issn": "", "pages": "358--360", "other_ids": {}}, "BIBREF302": {"ref_id": "b302", "title": "Multifocal motor neuropathy and asymptomatic Hashimoto's thyroiditis: first report of association", "authors": [{"first": "A", "middle": [], "last": "Toscano", "suffix": ""}, {"first": "C", "middle": [], "last": "Rodolico", "suffix": ""}, {"first": "S", "middle": [], "last": "Benvenga", "suffix": ""}], "year": 2002, "venue": "Neuromuscul Disord", "volume": "12", "issn": "", "pages": "566--568", "other_ids": {}}, "BIBREF303": {"ref_id": "b303", "title": "Thyrotoxic autoimmune encephalopathy in a female patient: only partial response to typical immunosuppressant treatment and remission after thyroidectomy", "authors": [{"first": "N", "middle": [], "last": "Yuceyar", "suffix": ""}, {"first": "M", "middle": [], "last": "Karadeniz", "suffix": ""}, {"first": "M", "middle": [], "last": "Erdogan", "suffix": ""}], "year": 2007, "venue": "Clin Neurol Neurosurg", "volume": "109", "issn": "", "pages": "458--462", "other_ids": {}}, "BIBREF304": {"ref_id": "b304", "title": "High dose immunoglobulin IV treatment in adrenoleukodystrophy", "authors": [{"first": "M", "middle": [], "last": "Cappa", "suffix": ""}, {"first": "E", "middle": [], "last": "Bertini", "suffix": ""}, {"first": "Del", "middle": [], "last": "Balzo", "suffix": ""}, {"first": "P", "middle": [], "last": "", "suffix": ""}], "year": 1994, "venue": "J Neurol Neurosurg Psychiatry", "volume": "57", "issn": "", "pages": "69--70", "other_ids": {}}, "BIBREF305": {"ref_id": "b305", "title": "Discussion on: high dose immunoglobulin IV treatment in adrenoleukodystrophy", "authors": [{"first": "W", "middle": [], "last": "Kohler", "suffix": ""}], "year": 1994, "venue": "J Neurol Neurosurg Psychiatry", "volume": "57", "issn": "", "pages": "", "other_ids": {}}, "BIBREF306": {"ref_id": "b306", "title": "Waterhouse-Friderichsen syndrome and bilateral renal cortical necrosis in meningococcal sepsis", "authors": [{"first": "M", "middle": [], "last": "Agraharkar", "suffix": ""}, {"first": "M", "middle": [], "last": "Fahlen", "suffix": ""}, {"first": "M", "middle": [], "last": "Siddiqui", "suffix": ""}], "year": 2000, "venue": "Am J Kidney Disease", "volume": "36", "issn": "", "pages": "396--400", "other_ids": {}}, "BIBREF307": {"ref_id": "b307", "title": "Autoimmune polyendocrine syndrome. Treatment with intravenous immunoglobulins", "authors": [{"first": "A", "middle": [], "last": "Antonelli", "suffix": ""}, {"first": "C", "middle": [], "last": "Gambuzza", "suffix": ""}, {"first": "B", "middle": [], "last": "Alberti", "suffix": ""}], "year": 1992, "venue": "Clin Ther", "volume": "141", "issn": "", "pages": "43--48", "other_ids": {}}, "BIBREF308": {"ref_id": "b308", "title": "Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome", "authors": [{"first": "W", "middle": ["G"], "last": "Leen", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Weemaes", "suffix": ""}, {"first": "M", "middle": ["M"], "last": "Verbeek", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Willemsen", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Rotteveel", "suffix": ""}], "year": 2008, "venue": "Pediatr Neurol", "volume": "39", "issn": "", "pages": "213--217", "other_ids": {}}, "BIBREF309": {"ref_id": "b309", "title": "Treatment of idiopathic opsoclonus-myoclonus syndrome with intravenous immunoglobulin", "authors": [{"first": "A", "middle": [], "last": "Unal", "suffix": ""}, {"first": "M", "middle": ["M"], "last": "Sumer", "suffix": ""}, {"first": "H", "middle": ["T"], "last": "Atasoy", "suffix": ""}, {"first": "N", "middle": [], "last": "Atasoy", "suffix": ""}], "year": 2004, "venue": "Neurol India", "volume": "52", "issn": "", "pages": "520--521", "other_ids": {}}, "BIBREF310": {"ref_id": "b310", "title": "Parainfectious opsoclonus-myoclonus syndrome: high dose intravenous immunoglobulins are effective", "authors": [{"first": "K", "middle": [], "last": "Glatz", "suffix": ""}, {"first": "H", "middle": ["M"], "last": "Meinck", "suffix": ""}, {"first": "B", "middle": [], "last": "Wildemann", "suffix": ""}], "year": 2003, "venue": "J Neurol Neurosurg Psychiatry", "volume": "74", "issn": "", "pages": "279--280", "other_ids": {}}, "BIBREF311": {"ref_id": "b311", "title": "Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: cerebellar atrophy, multiphasic relapses, and response to IVIG", "authors": [{"first": "M", "middle": ["R"], "last": "Pranzatelli", "suffix": ""}, {"first": "E", "middle": ["D"], "last": "Tate", "suffix": ""}, {"first": "M", "middle": [], "last": "Kinsbourne", "suffix": ""}, {"first": "V", "middle": ["S"], "last": "Caviness", "suffix": ""}, {"first": "B", "middle": [], "last": "Mishra", "suffix": ""}], "year": 2002, "venue": "Mov Disord", "volume": "17", "issn": "", "pages": "1387--1390", "other_ids": {}}, "BIBREF312": {"ref_id": "b312", "title": "Treatment with intravenously administered immunoglobulins of the neuroblastoma-associated opsoclonus-myoclonus", "authors": [{"first": "C", "middle": [], "last": "Borgna-Pignatti", "suffix": ""}, {"first": "R", "middle": [], "last": "Balter", "suffix": ""}, {"first": "P", "middle": [], "last": "Marradi", "suffix": ""}, {"first": "V", "middle": [], "last": "Colamaria", "suffix": ""}], "year": 1996, "venue": "J Pediatr", "volume": "129", "issn": "", "pages": "179--180", "other_ids": {}}, "BIBREF313": {"ref_id": "b313", "title": "Treatment of opsoclonus-myoclonus with high-dose intravenous immunoglobulin", "authors": [{"first": "M", "middle": [], "last": "Pless", "suffix": ""}, {"first": "M", "middle": [], "last": "Ronthal", "suffix": ""}], "year": 1996, "venue": "Neurology", "volume": "46", "issn": "", "pages": "583--584", "other_ids": {}}, "BIBREF314": {"ref_id": "b314", "title": "Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G", "authors": [{"first": "M", "middle": ["J"], "last": "Petruzzi", "suffix": ""}, {"first": "P", "middle": ["A"], "last": "De Alarcon", "suffix": ""}], "year": 1995, "venue": "J Pediatr", "volume": "127", "issn": "", "pages": "328--329", "other_ids": {}}, "BIBREF315": {"ref_id": "b315", "title": "High-dose i.v. human immunoglobulin in a case with infantile opsoclonus polymyoclonia syndrome", "authors": [{"first": "H", "middle": [], "last": "Sugie", "suffix": ""}, {"first": "Y", "middle": [], "last": "Sugie", "suffix": ""}, {"first": "H", "middle": [], "last": "Akimoto", "suffix": ""}, {"first": "K", "middle": [], "last": "Endo", "suffix": ""}, {"first": "M", "middle": [], "last": "Shirai", "suffix": ""}, {"first": "M", "middle": [], "last": "Ito", "suffix": ""}], "year": 1992, "venue": "Acta Paediatr", "volume": "81", "issn": "", "pages": "371--372", "other_ids": {}}, "BIBREF316": {"ref_id": "b316", "title": "Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonusmyoclonus", "authors": [{"first": "L", "middle": [], "last": "Bataller", "suffix": ""}, {"first": "F", "middle": [], "last": "Graus", "suffix": ""}, {"first": "A", "middle": [], "last": "Saiz", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Vilchez", "suffix": ""}], "year": 2001, "venue": "Brain", "volume": "124", "issn": "", "pages": "437--443", "other_ids": {}}, "BIBREF317": {"ref_id": "b317", "title": "Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood", "authors": [{"first": "S", "middle": ["J"], "last": "Perlmutter", "suffix": ""}, {"first": "S", "middle": ["F"], "last": "Leitman", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Garvey", "suffix": ""}, {"first": "S", "middle": [], "last": "Hamburger", "suffix": ""}, {"first": "E", "middle": [], "last": "Feldman", "suffix": ""}, {"first": "H", "middle": ["L"], "last": "Leonard", "suffix": ""}, {"first": "S", "middle": ["E"], "last": "Swedo", "suffix": ""}], "year": 1999, "venue": "Lancet", "volume": "354", "issn": "", "pages": "1153--1158", "other_ids": {}}, "BIBREF318": {"ref_id": "b318", "title": "Intravenous immunoglobulin in relapsingremitting multiple sclerosis: a dose-finding trial", "authors": [{"first": "F", "middle": [], "last": "Fazekas", "suffix": ""}, {"first": "F", "middle": ["D"], "last": "Lublin", "suffix": ""}, {"first": "D", "middle": [], "last": "Li", "suffix": ""}, {"first": "M", "middle": ["S"], "last": "Freedman", "suffix": ""}, {"first": "H", "middle": ["P"], "last": "Hartung", "suffix": ""}, {"first": "P", "middle": [], "last": "Rieckmann", "suffix": ""}, {"first": "P", "middle": ["S"], "last": "Sorensen", "suffix": ""}, {"first": "M", "middle": [], "last": "Maas-Enriquez", "suffix": ""}, {"first": "B", "middle": [], "last": "Sommerauer", "suffix": ""}, {"first": "K", "middle": [], "last": "Hanna", "suffix": ""}], "year": 2008, "venue": "Neurology", "volume": "71", "issn": "", "pages": "265--271", "other_ids": {}}, "BIBREF319": {"ref_id": "b319", "title": "Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study", "authors": [{"first": "D", "middle": [], "last": "Pohlau", "suffix": ""}, {"first": "H", "middle": [], "last": "Przuntek", "suffix": ""}, {"first": "M", "middle": [], "last": "Sailer", "suffix": ""}, {"first": "F", "middle": [], "last": "Bethke", "suffix": ""}, {"first": "J", "middle": [], "last": "Koehler", "suffix": ""}, {"first": "N", "middle": [], "last": "Konig", "suffix": ""}, {"first": "C", "middle": [], "last": "Heesen", "suffix": ""}, {"first": "P", "middle": [], "last": "Spath", "suffix": ""}, {"first": "I", "middle": [], "last": "Andresen", "suffix": ""}], "year": 2007, "venue": "Mult Scler", "volume": "13", "issn": "", "pages": "1107--1117", "other_ids": {}}, "BIBREF320": {"ref_id": "b320", "title": "No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis", "authors": [{"first": "H", "middle": ["F"], "last": "Petereit", "suffix": ""}, {"first": "D", "middle": [], "last": "Reske", "suffix": ""}, {"first": "R", "middle": [], "last": "Pukrop", "suffix": ""}, {"first": "M", "middle": [], "last": "Maas-Enriquez", "suffix": ""}, {"first": "G", "middle": [], "last": "Japp", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Jongen", "suffix": ""}, {"first": "H", "middle": ["W"], "last": "Kolmel", "suffix": ""}, {"first": "S", "middle": [], "last": "Merkelbach", "suffix": ""}, {"first": "H", "middle": ["P"], "last": "Hartung", "suffix": ""}, {"first": "W", "middle": ["D"], "last": "Heiss", "suffix": ""}], "year": 2006, "venue": "Mult Scler", "volume": "12", "issn": "", "pages": "66--71", "other_ids": {}}, "BIBREF321": {"ref_id": "b321", "title": "Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis-results of a retrospective multicenter observational study over five years", "authors": [{"first": "J", "middle": [], "last": "Haas", "suffix": ""}, {"first": "M", "middle": [], "last": "Maas-Enriquez", "suffix": ""}, {"first": "H", "middle": ["P"], "last": "Hartung", "suffix": ""}], "year": 2005, "venue": "Mult Scler", "volume": "11", "issn": "", "pages": "562--567", "other_ids": {}}, "BIBREF322": {"ref_id": "b322", "title": "Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial", "authors": [{"first": "O", "middle": ["R"], "last": "Hommes", "suffix": ""}, {"first": "P", "middle": ["S"], "last": "Sorensen", "suffix": ""}, {"first": "F", "middle": [], "last": "Fazekas", "suffix": ""}, {"first": "M", "middle": ["M"], "last": "Enriquez", "suffix": ""}, {"first": "H", "middle": ["W"], "last": "Koelmel", "suffix": ""}, {"first": "O", "middle": [], "last": "Fernandez", "suffix": ""}, {"first": "C", "middle": [], "last": "Pozzilli", "suffix": ""}, {"first": "O&apos;", "middle": [], "last": "Connor", "suffix": ""}, {"first": "P", "middle": [], "last": "", "suffix": ""}], "year": 2004, "venue": "Lancet", "volume": "364", "issn": "", "pages": "1149--1156", "other_ids": {}}, "BIBREF323": {"ref_id": "b323", "title": "Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis", "authors": [{"first": "P", "middle": ["S"], "last": "Sorensen", "suffix": ""}, {"first": "F", "middle": [], "last": "Fazekas", "suffix": ""}, {"first": "M", "middle": [], "last": "Lee", "suffix": ""}], "year": 2002, "venue": "Eur J Neurol", "volume": "9", "issn": "", "pages": "557--563", "other_ids": {}}, "BIBREF324": {"ref_id": "b324", "title": "Intravenous immunoglobulins in therapy of intermittent multiple sclerosis. An update", "authors": [{"first": "F", "middle": [], "last": "Fazekas", "suffix": ""}, {"first": "S", "middle": [], "last": "Strasser-Fuchs", "suffix": ""}, {"first": "H", "middle": ["P"], "last": "Hartung", "suffix": ""}], "year": 1998, "venue": "Nervenarzt", "volume": "69", "issn": "", "pages": "361--365", "other_ids": {}}, "BIBREF325": {"ref_id": "b325", "title": "Sarova-Pinhas I (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses", "authors": [{"first": "A", "middle": [], "last": "Achiron", "suffix": ""}, {"first": "U", "middle": [], "last": "Gabbay", "suffix": ""}, {"first": "R", "middle": [], "last": "Gilad", "suffix": ""}, {"first": "S", "middle": [], "last": "Hassin-Baer", "suffix": ""}, {"first": "Y", "middle": [], "last": "Barak", "suffix": ""}, {"first": "M", "middle": [], "last": "Gornish", "suffix": ""}, {"first": "A", "middle": [], "last": "Elizur", "suffix": ""}, {"first": "Y", "middle": [], "last": "Goldhammer", "suffix": ""}], "year": null, "venue": "Neurology", "volume": "50", "issn": "", "pages": "398--402", "other_ids": {}}, "BIBREF326": {"ref_id": "b326", "title": "A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results", "authors": [{"first": "P", "middle": ["S"], "last": "Sorensen", "suffix": ""}, {"first": "B", "middle": [], "last": "Wanscher", "suffix": ""}, {"first": "K", "middle": [], "last": "Schreiber", "suffix": ""}, {"first": "M", "middle": [], "last": "Blinkenberg", "suffix": ""}, {"first": "C", "middle": ["V"], "last": "Jensen", "suffix": ""}, {"first": "M", "middle": [], "last": "Ravnborg", "suffix": ""}], "year": 1997, "venue": "Mult Scler", "volume": "3", "issn": "", "pages": "145--148", "other_ids": {}}, "BIBREF327": {"ref_id": "b327", "title": "Immunotherapy for Guillain-Barr\u00e9 syndrome: a systematic review", "authors": [{"first": "R", "middle": ["A"], "last": "Hughes", "suffix": ""}, {"first": "A", "middle": ["V"], "last": "Swan", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Raphael", "suffix": ""}, {"first": "D", "middle": [], "last": "Annane", "suffix": ""}, {"first": "R", "middle": [], "last": "Van Koningsveld", "suffix": ""}, {"first": "P", "middle": ["A"], "last": "Van Doorn", "suffix": ""}], "year": 2007, "venue": "Brain", "volume": "130", "issn": "", "pages": "2245--2257", "other_ids": {}}, "BIBREF328": {"ref_id": "b328", "title": "High-dose immunoglobulin therapy for Guillain-Barr\u00e9 syndrome in Japanese children", "authors": [{"first": "J", "middle": [], "last": "Yata", "suffix": ""}, {"first": "K", "middle": [], "last": "Nihei", "suffix": ""}, {"first": "T", "middle": [], "last": "Ohya", "suffix": ""}, {"first": "Y", "middle": [], "last": "Hirano", "suffix": ""}, {"first": "M", "middle": [], "last": "Momoi", "suffix": ""}, {"first": "K", "middle": [], "last": "Maekawa", "suffix": ""}, {"first": "Y", "middle": [], "last": "Sakakihara", "suffix": ""}], "year": 2003, "venue": "Pediatr Int", "volume": "45", "issn": "", "pages": "543--549", "other_ids": {}}, "BIBREF329": {"ref_id": "b329", "title": "Intravenous immune globulins in patients with Guillain-Barr\u00e9 syndrome and contraindications to plasma exchange: 3 days versus 6 days", "authors": [{"first": "J", "middle": ["C"], "last": "Raphael", "suffix": ""}, {"first": "S", "middle": [], "last": "Chevret", "suffix": ""}, {"first": "M", "middle": [], "last": "Harboun", "suffix": ""}, {"first": "Jars-Guincestre", "middle": [], "last": "Mc", "suffix": ""}], "year": 2001, "venue": "J Neurol Neurosurg Psychiatry", "volume": "71", "issn": "", "pages": "235--238", "other_ids": {}}, "BIBREF330": {"ref_id": "b330", "title": "Intravenous immunoglobulin therapy for Guillain-Barr\u00e9 syndrome with IgG anti-GM1 antibody", "authors": [{"first": "S", "middle": [], "last": "Kuwabara", "suffix": ""}, {"first": "M", "middle": [], "last": "Mori", "suffix": ""}, {"first": "K", "middle": [], "last": "Ogawara", "suffix": ""}, {"first": "T", "middle": [], "last": "Hattori", "suffix": ""}, {"first": "S", "middle": [], "last": "Oda", "suffix": ""}, {"first": "M", "middle": [], "last": "Koga", "suffix": ""}, {"first": "Yuki", "middle": ["N"], "last": "", "suffix": ""}], "year": 2001, "venue": "Muscle Nerve", "volume": "24", "issn": "", "pages": "54--58", "other_ids": {}}, "BIBREF331": {"ref_id": "b331", "title": "Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome", "authors": [], "year": 1997, "venue": "Lancet", "volume": "349", "issn": "", "pages": "225--230", "other_ids": {}}, "BIBREF332": {"ref_id": "b332", "title": "Intravenous immune globulin in the Guillain-Barr\u00e9 syndrome", "authors": [{"first": "F", "middle": ["G"], "last": "Van Der Meche", "suffix": ""}], "year": 1994, "venue": "Clin Exp Immunol", "volume": "97", "issn": "1", "pages": "43--47", "other_ids": {}}, "BIBREF333": {"ref_id": "b333", "title": "Immunotherapy for IgM antimyelin-associated glycoprotein paraprotein-associated peripheral neuropathies", "authors": [{"first": "M", "middle": ["P"], "last": "Lunn", "suffix": ""}, {"first": "E", "middle": [], "last": "Nobile-Orazio", "suffix": ""}], "year": 2006, "venue": "Cochrane Database Syst Rev", "volume": "2", "issn": "", "pages": "", "other_ids": {}}, "BIBREF334": {"ref_id": "b334", "title": "A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy", "authors": [{"first": "G", "middle": [], "last": "Comi", "suffix": ""}, {"first": "L", "middle": [], "last": "Roveri", "suffix": ""}, {"first": "A", "middle": [], "last": "Swan", "suffix": ""}, {"first": "H", "middle": [], "last": "Willison", "suffix": ""}, {"first": "M", "middle": [], "last": "Bojar", "suffix": ""}, {"first": "I", "middle": [], "last": "Illa", "suffix": ""}, {"first": "C", "middle": [], "last": "Karageorgiou", "suffix": ""}, {"first": "E", "middle": [], "last": "Nobile-Orazio", "suffix": ""}, {"first": "P", "middle": [], "last": "Van Den Bergh", "suffix": ""}, {"first": "T", "middle": [], "last": "Swan", "suffix": ""}, {"first": "R", "middle": [], "last": "Hughes", "suffix": ""}, {"first": "Aubry", "middle": ["J"], "last": "Baumann", "suffix": ""}, {"first": "N", "middle": [], "last": "Hadden", "suffix": ""}, {"first": "R", "middle": [], "last": "Lunn", "suffix": ""}, {"first": "M", "middle": [], "last": "Knapp", "suffix": ""}, {"first": "M", "middle": [], "last": "Leger", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Bouche", "suffix": ""}, {"first": "P", "middle": [], "last": "Mazanec", "suffix": ""}, {"first": "R", "middle": [], "last": "Meucci", "suffix": ""}, {"first": "N", "middle": [], "last": "Van Der Meche", "suffix": ""}, {"first": "F", "middle": [], "last": "Toyka", "suffix": ""}, {"first": "K", "middle": [], "last": "", "suffix": ""}], "year": 2002, "venue": "J Neurol", "volume": "249", "issn": "", "pages": "1370--1377", "other_ids": {}}, "BIBREF335": {"ref_id": "b335", "title": "A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy", "authors": [{"first": "M", "middle": ["C"], "last": "Dalakas", "suffix": ""}, {"first": "R", "middle": ["H"], "last": "Quarles", "suffix": ""}, {"first": "R", "middle": ["G"], "last": "Farrer", "suffix": ""}, {"first": "J", "middle": [], "last": "Dambrosia", "suffix": ""}, {"first": "S", "middle": [], "last": "Soueidan", "suffix": ""}, {"first": "D", "middle": ["P"], "last": "Stein", "suffix": ""}, {"first": "E", "middle": [], "last": "Cupler", "suffix": ""}, {"first": "E", "middle": ["A"], "last": "Sekul", "suffix": ""}, {"first": "C", "middle": [], "last": "Otero", "suffix": ""}], "year": 1996, "venue": "Ann Neurol", "volume": "40", "issn": "", "pages": "792--795", "other_ids": {}}, "BIBREF336": {"ref_id": "b336", "title": "Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis", "authors": [{"first": "N", "middle": [], "last": "Meucci", "suffix": ""}, {"first": "E", "middle": [], "last": "Nobile-Orazio", "suffix": ""}, {"first": "G", "middle": [], "last": "Scarlato", "suffix": ""}], "year": 1996, "venue": "J Neurol", "volume": "243", "issn": "", "pages": "117--120", "other_ids": {}}, "BIBREF337": {"ref_id": "b337", "title": "Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy", "authors": [{"first": "M", "middle": ["C"], "last": "Dalakas", "suffix": ""}, {"first": "D", "middle": ["P"], "last": "Stein", "suffix": ""}, {"first": "C", "middle": [], "last": "Otero", "suffix": ""}, {"first": "E", "middle": [], "last": "Sekul", "suffix": ""}, {"first": "E", "middle": ["J"], "last": "Cupler", "suffix": ""}, {"first": "S", "middle": [], "last": "Mccrosky", "suffix": ""}], "year": 1994, "venue": "Arch Neurol", "volume": "51", "issn": "", "pages": "861--864", "other_ids": {}}, "BIBREF338": {"ref_id": "b338", "title": "Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome", "authors": [{"first": "P", "middle": ["G"], "last": "Bain", "suffix": ""}, {"first": "M", "middle": [], "last": "Motomura", "suffix": ""}, {"first": "J", "middle": [], "last": "Newsom-Davis", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Misbah", "suffix": ""}, {"first": "H", "middle": ["M"], "last": "Chapel", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Lee", "suffix": ""}, {"first": "A", "middle": [], "last": "Vincent", "suffix": ""}, {"first": "B", "middle": [], "last": "Lang", "suffix": ""}], "year": 1996, "venue": "Neurology", "volume": "47", "issn": "", "pages": "678--683", "other_ids": {}}, "BIBREF339": {"ref_id": "b339", "title": "Treatment of stiff-man syndrome with intravenous immune globulin", "authors": [{"first": "E", "middle": ["W"], "last": "Karlson", "suffix": ""}, {"first": "L", "middle": [], "last": "Sudarsky", "suffix": ""}, {"first": "E", "middle": [], "last": "Ruderman", "suffix": ""}, {"first": "S", "middle": [], "last": "Pierson", "suffix": ""}, {"first": "M", "middle": [], "last": "Scott", "suffix": ""}, {"first": "S", "middle": ["M"], "last": "Helfgott", "suffix": ""}], "year": 1994, "venue": "Arthritis Rheum", "volume": "37", "issn": "", "pages": "915--918", "other_ids": {}}, "BIBREF340": {"ref_id": "b340", "title": "Treatment of stiffman syndrome with intravenous immunoglobulin", "authors": [{"first": "A", "middle": ["A"], "last": "Amato", "suffix": ""}, {"first": "E", "middle": ["W"], "last": "Cornman", "suffix": ""}, {"first": "J", "middle": ["T"], "last": "Kissel", "suffix": ""}], "year": 1994, "venue": "Neurology", "volume": "44", "issn": "", "pages": "1652--1654", "other_ids": {}}, "BIBREF341": {"ref_id": "b341", "title": "Long-term remission of refractory stiff-man syndrome after treatment with intravenous immunoglobulin", "authors": [{"first": "H", "middle": [], "last": "Khanlou", "suffix": ""}, {"first": "G", "middle": [], "last": "Eiger", "suffix": ""}], "year": 1999, "venue": "Mayo Clin Proc", "volume": "74", "issn": "", "pages": "1231--1232", "other_ids": {}}, "BIBREF342": {"ref_id": "b342", "title": "High-dose intravenous immune globulin for stiff-person syndrome", "authors": [{"first": "M", "middle": ["C"], "last": "Dalakas", "suffix": ""}, {"first": "M", "middle": [], "last": "Fujii", "suffix": ""}, {"first": "M", "middle": [], "last": "Li", "suffix": ""}, {"first": "B", "middle": [], "last": "Lutfi", "suffix": ""}, {"first": "J", "middle": [], "last": "Kyhos", "suffix": ""}, {"first": "B", "middle": [], "last": "Mcelroy", "suffix": ""}], "year": 2001, "venue": "N Engl J Med", "volume": "345", "issn": "", "pages": "1870--1876", "other_ids": {}}, "BIBREF343": {"ref_id": "b343", "title": "High dose immunoglobulin IV treatment in adrenoleukodystrophy", "authors": [{"first": "M", "middle": [], "last": "Cappa", "suffix": ""}, {"first": "E", "middle": [], "last": "Bertini", "suffix": ""}, {"first": "P", "middle": [], "last": "Del Balzo", "suffix": ""}, {"first": "P", "middle": [], "last": "Cambiaso", "suffix": ""}, {"first": "Di", "middle": [], "last": "Biase", "suffix": ""}, {"first": "A", "middle": [], "last": "Salvati", "suffix": ""}, {"first": "S", "middle": [], "last": "", "suffix": ""}], "year": 1994, "venue": "J Neurol Neurosurg Psychiatry", "volume": "57", "issn": "", "pages": "", "other_ids": {}}, "BIBREF344": {"ref_id": "b344", "title": "Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double-blind/ dose finding clinical study", "authors": [{"first": "K", "middle": [], "last": "Van Rijckevorsel-Harmant", "suffix": ""}, {"first": "M", "middle": [], "last": "Delire", "suffix": ""}, {"first": "W", "middle": [], "last": "Schmitz-Moorman", "suffix": ""}, {"first": "H", "middle": ["G"], "last": "Wieser", "suffix": ""}], "year": 1994, "venue": "Int J Clin Lab Res", "volume": "24", "issn": "", "pages": "162--166", "other_ids": {}}, "BIBREF345": {"ref_id": "b345", "title": "Intravenous immunoglobulin: a single-blind trial in children with Lennox-Gastaut syndrome", "authors": [{"first": "N", "middle": [], "last": "Illum", "suffix": ""}, {"first": "K", "middle": [], "last": "Taudorf", "suffix": ""}, {"first": "C", "middle": [], "last": "Heilmann", "suffix": ""}, {"first": "T", "middle": [], "last": "Smith", "suffix": ""}, {"first": "K", "middle": [], "last": "Wulff", "suffix": ""}, {"first": "B", "middle": [], "last": "Mansa", "suffix": ""}, {"first": "P", "middle": [], "last": "Platz", "suffix": ""}], "year": 1990, "venue": "Neuropediatrics", "volume": "21", "issn": "", "pages": "87--90", "other_ids": {}}, "BIBREF346": {"ref_id": "b346", "title": "Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gramnegative sepsis", "authors": [{"first": "M", "middle": [], "last": "Mohr", "suffix": ""}, {"first": "L", "middle": [], "last": "Englisch", "suffix": ""}, {"first": "A", "middle": [], "last": "Roth", "suffix": ""}, {"first": "H", "middle": [], "last": "Burchardi", "suffix": ""}, {"first": "S", "middle": [], "last": "Zielmann", "suffix": ""}], "year": 1997, "venue": "Intensive Care Med", "volume": "23", "issn": "", "pages": "1144--1149", "other_ids": {}}, "BIBREF347": {"ref_id": "b347", "title": "Failure of high dose intravenous immunoglobulins to alter the clinical course of critical illness polyneuropathy", "authors": [{"first": "E", "middle": ["F"], "last": "Wijdicks", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Fulgham", "suffix": ""}], "year": 1994, "venue": "Muscle Nerve", "volume": "17", "issn": "", "pages": "1494--1495", "other_ids": {}}, "BIBREF348": {"ref_id": "b348", "title": "Experience with immunomodulatory treatments in Rasmussen's encephalitis", "authors": [{"first": "T", "middle": [], "last": "Granata", "suffix": ""}, {"first": "L", "middle": [], "last": "Fusco", "suffix": ""}, {"first": "G", "middle": [], "last": "Gobbi", "suffix": ""}, {"first": "E", "middle": [], "last": "Freri", "suffix": ""}, {"first": "F", "middle": [], "last": "Ragona", "suffix": ""}, {"first": "G", "middle": [], "last": "Broggi", "suffix": ""}, {"first": "R", "middle": [], "last": "Mantegazza", "suffix": ""}, {"first": "L", "middle": [], "last": "Giordano", "suffix": ""}, {"first": "F", "middle": [], "last": "Villani", "suffix": ""}, {"first": "G", "middle": [], "last": "Capovilla", "suffix": ""}, {"first": "F", "middle": [], "last": "Vigevano", "suffix": ""}, {"first": "B", "middle": ["D"], "last": "Bernardina", "suffix": ""}, {"first": "R", "middle": [], "last": "Spreafico", "suffix": ""}, {"first": "C", "middle": [], "last": "Antozzi", "suffix": ""}], "year": 2003, "venue": "", "volume": "61", "issn": "", "pages": "1807--1810", "other_ids": {}}, "BIBREF349": {"ref_id": "b349", "title": "Positive response to immunomodulatory therapy in an adult patient with Rasmussen's encephalitis", "authors": [{"first": "F", "middle": [], "last": "Villani", "suffix": ""}, {"first": "R", "middle": [], "last": "Spreafico", "suffix": ""}, {"first": "L", "middle": [], "last": "Farina", "suffix": ""}, {"first": "A", "middle": ["R"], "last": "Giovagnoli", "suffix": ""}, {"first": "P", "middle": [], "last": "Bernasconi", "suffix": ""}, {"first": "T", "middle": [], "last": "Granata", "suffix": ""}, {"first": "G", "middle": [], "last": "Avanzini", "suffix": ""}], "year": 2001, "venue": "Neurology", "volume": "56", "issn": "", "pages": "248--250", "other_ids": {}}, "BIBREF350": {"ref_id": "b350", "title": "Improvement in adult-onset Rasmussen's encephalitis with long-term immunomodulatory therapy", "authors": [{"first": "J", "middle": ["P"], "last": "Leach", "suffix": ""}, {"first": "D", "middle": ["W"], "last": "Chadwick", "suffix": ""}, {"first": "J", "middle": ["B"], "last": "Miles", "suffix": ""}, {"first": "I", "middle": ["K"], "last": "Hart", "suffix": ""}], "year": 1999, "venue": "Neurology", "volume": "52", "issn": "", "pages": "738--742", "other_ids": {}}, "BIBREF351": {"ref_id": "b351", "title": "Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients", "authors": [{"first": "Y", "middle": ["M"], "last": "Hart", "suffix": ""}, {"first": "M", "middle": [], "last": "Cortez", "suffix": ""}, {"first": "F", "middle": [], "last": "Andermann", "suffix": ""}, {"first": "P", "middle": [], "last": "Hwang", "suffix": ""}, {"first": "D", "middle": ["R"], "last": "Fish", "suffix": ""}, {"first": "O", "middle": [], "last": "Dulac", "suffix": ""}, {"first": "K", "middle": [], "last": "Silver", "suffix": ""}, {"first": "N", "middle": [], "last": "Fejerman", "suffix": ""}, {"first": "H", "middle": [], "last": "Cross", "suffix": ""}, {"first": "A", "middle": [], "last": "Sherwin", "suffix": ""}], "year": 1994, "venue": "Neurology", "volume": "44", "issn": "", "pages": "1030--1036", "other_ids": {}}, "BIBREF352": {"ref_id": "b352", "title": "Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebocontrolled trial", "authors": [{"first": "R", "middle": ["A"], "last": "Hughes", "suffix": ""}, {"first": "P", "middle": [], "last": "Donofrio", "suffix": ""}, {"first": "V", "middle": [], "last": "Bril", "suffix": ""}, {"first": "M", "middle": ["C"], "last": "Dalakas", "suffix": ""}, {"first": "C", "middle": [], "last": "Deng", "suffix": ""}, {"first": "K", "middle": [], "last": "Hanna", "suffix": ""}, {"first": "H", "middle": ["P"], "last": "Hartung", "suffix": ""}, {"first": "N", "middle": [], "last": "Latov", "suffix": ""}, {"first": "I", "middle": ["S"], "last": "Merkies", "suffix": ""}, {"first": "P", "middle": ["A"], "last": "Van Doorn", "suffix": ""}], "year": 2008, "venue": "Lancet Neurol", "volume": "7", "issn": "", "pages": "136--144", "other_ids": {}}, "BIBREF353": {"ref_id": "b353", "title": "Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy", "authors": [{"first": "R", "middle": [], "last": "Hughes", "suffix": ""}, {"first": "S", "middle": [], "last": "Bensa", "suffix": ""}, {"first": "H", "middle": [], "last": "Willison", "suffix": ""}, {"first": "P", "middle": [], "last": "Van Den Bergh", "suffix": ""}, {"first": "G", "middle": [], "last": "Comi", "suffix": ""}, {"first": "I", "middle": [], "last": "Illa", "suffix": ""}, {"first": "E", "middle": [], "last": "Nobile-Orazio", "suffix": ""}, {"first": "P", "middle": [], "last": "Van Doorn", "suffix": ""}, {"first": "M", "middle": [], "last": "Dalakas", "suffix": ""}, {"first": "M", "middle": [], "last": "Bojar", "suffix": ""}, {"first": "A", "middle": [], "last": "Swan", "suffix": ""}], "year": 2001, "venue": "Ann Neurol", "volume": "50", "issn": "", "pages": "195--201", "other_ids": {}}, "BIBREF354": {"ref_id": "b354", "title": "Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy", "authors": [{"first": "J", "middle": ["R"], "last": "Mendell", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Barohn", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Freimer", "suffix": ""}, {"first": "J", "middle": ["T"], "last": "Kissel", "suffix": ""}, {"first": "W", "middle": [], "last": "King", "suffix": ""}, {"first": "H", "middle": ["N"], "last": "Nagaraja", "suffix": ""}, {"first": "R", "middle": [], "last": "Rice", "suffix": ""}, {"first": "W", "middle": ["W"], "last": "Campbell", "suffix": ""}, {"first": "P", "middle": ["D"], "last": "Donofrio", "suffix": ""}, {"first": "C", "middle": ["E"], "last": "Jackson", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Lewis", "suffix": ""}, {"first": "M", "middle": [], "last": "Shy", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "Simpson", "suffix": ""}, {"first": "G", "middle": ["J"], "last": "Parry", "suffix": ""}, {"first": "M", "middle": ["H"], "last": "Rivner", "suffix": ""}, {"first": "C", "middle": ["A"], "last": "Thornton", "suffix": ""}, {"first": "M", "middle": ["B"], "last": "Bromberg", "suffix": ""}, {"first": "R", "middle": [], "last": "Tandan", "suffix": ""}, {"first": "Y", "middle": [], "last": "Harati", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Giuliani", "suffix": ""}], "year": 2001, "venue": "Neurology", "volume": "56", "issn": "", "pages": "445--449", "other_ids": {}}, "BIBREF355": {"ref_id": "b355", "title": "Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study", "authors": [{"first": "A", "middle": ["F"], "last": "Hahn", "suffix": ""}, {"first": "C", "middle": ["F"], "last": "Bolton", "suffix": ""}, {"first": "D", "middle": [], "last": "Zochodne", "suffix": ""}, {"first": "T", "middle": ["E"], "last": "Feasby", "suffix": ""}], "year": 1996, "venue": "Brain", "volume": "119", "issn": "", "pages": "1067--1077", "other_ids": {}}, "BIBREF356": {"ref_id": "b356", "title": "Intravenous immunoglobulin for myasthenia gravis", "authors": [{"first": "P", "middle": [], "last": "Gajdos", "suffix": ""}, {"first": "S", "middle": [], "last": "Chevret", "suffix": ""}, {"first": "K", "middle": [], "last": "Toyka", "suffix": ""}], "year": 2008, "venue": "Cochrane Database Syst Rev", "volume": "2", "issn": "", "pages": "", "other_ids": {}}, "BIBREF357": {"ref_id": "b357", "title": "IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial", "authors": [{"first": "L", "middle": [], "last": "Zinman", "suffix": ""}, {"first": "E", "middle": [], "last": "Ng", "suffix": ""}, {"first": "V", "middle": [], "last": "Bril", "suffix": ""}], "year": 2007, "venue": "Neurology", "volume": "68", "issn": "", "pages": "837--841", "other_ids": {}}, "BIBREF358": {"ref_id": "b358", "title": "Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis", "authors": [{"first": "G", "middle": ["I"], "last": "Wolfe", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Barohn", "suffix": ""}, {"first": "B", "middle": ["M"], "last": "Foster", "suffix": ""}, {"first": "C", "middle": ["E"], "last": "Jackson", "suffix": ""}, {"first": "J", "middle": ["T"], "last": "Kissel", "suffix": ""}, {"first": "J", "middle": ["W"], "last": "Day", "suffix": ""}, {"first": "C", "middle": ["A"], "last": "Thornton", "suffix": ""}, {"first": "S", "middle": ["P"], "last": "Nations", "suffix": ""}, {"first": "W", "middle": ["W"], "last": "Bryan", "suffix": ""}, {"first": "A", "middle": ["A"], "last": "Amato", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Freimer", "suffix": ""}, {"first": "G", "middle": ["J"], "last": "Parry", "suffix": ""}], "year": 2002, "venue": "Muscle Nerve", "volume": "26", "issn": "", "pages": "549--552", "other_ids": {}}, "BIBREF359": {"ref_id": "b359", "title": "Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis", "authors": [{"first": "J", "middle": [], "last": "Ronager", "suffix": ""}, {"first": "M", "middle": [], "last": "Ravnborg", "suffix": ""}, {"first": "I", "middle": [], "last": "Hermansen", "suffix": ""}, {"first": "S", "middle": [], "last": "Vorstrup", "suffix": ""}], "year": 2001, "venue": "Artif Organs", "volume": "25", "issn": "", "pages": "967--973", "other_ids": {}}, "BIBREF360": {"ref_id": "b360", "title": "Immunoglobulin treatment in refractory myasthenia gravis", "authors": [{"first": "A", "middle": [], "last": "Achiron", "suffix": ""}, {"first": "Y", "middle": [], "last": "Barak", "suffix": ""}, {"first": "S", "middle": [], "last": "Miron", "suffix": ""}, {"first": "I", "middle": [], "last": "Sarova-Pinhas", "suffix": ""}], "year": 2000, "venue": "Muscle Nerve", "volume": "23", "issn": "", "pages": "551--555", "other_ids": {}}, "BIBREF361": {"ref_id": "b361", "title": "High-dose, rapid-infusion IVIG in postvaccination acute disseminated encephalomyelitis", "authors": [{"first": "D", "middle": ["C"], "last": "Fu", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Montgomery", "suffix": ""}], "year": 2008, "venue": "Neurology", "volume": "71", "issn": "", "pages": "294--295", "other_ids": {}}, "BIBREF362": {"ref_id": "b362", "title": "Outcome of severe encephalomyelitis in children: effect of highdose methylprednisolone and immunoglobulins", "authors": [{"first": "E", "middle": [], "last": "Shahar", "suffix": ""}, {"first": "J", "middle": [], "last": "Andraus", "suffix": ""}, {"first": "D", "middle": [], "last": "Savitzki", "suffix": ""}, {"first": "G", "middle": [], "last": "Pilar", "suffix": ""}, {"first": "N", "middle": [], "last": "Zelnik", "suffix": ""}], "year": 2002, "venue": "J Child Neurol", "volume": "17", "issn": "", "pages": "810--814", "other_ids": {}}, "BIBREF363": {"ref_id": "b363", "title": "Effectiveness of intravenous immunoglobulin treatment in adult patients with steroid-resistant monophasic or recurrent acute disseminated encephalomyelitis", "authors": [{"first": "E", "middle": [], "last": "Marchioni", "suffix": ""}, {"first": "K", "middle": [], "last": "Marinou-Aktipi", "suffix": ""}, {"first": "C", "middle": [], "last": "Uggetti", "suffix": ""}, {"first": "M", "middle": [], "last": "Bottanelli", "suffix": ""}, {"first": "A", "middle": [], "last": "Pichiecchio", "suffix": ""}, {"first": "D", "middle": [], "last": "Soragna", "suffix": ""}, {"first": "I", "middle": ["F"], "last": "Piccolog", "suffix": ""}, {"first": "A", "middle": [], "last": "Romani", "suffix": ""}, {"first": "M", "middle": [], "last": "Ceroni", "suffix": ""}], "year": 2002, "venue": "J Neurol", "volume": "249", "issn": "", "pages": "100--104", "other_ids": {}}, "BIBREF364": {"ref_id": "b364", "title": "Improvement of atypical acute disseminated encephalomyelitis with steroids and intravenous immunoglobulins", "authors": [{"first": "R", "middle": [], "last": "Straussberg", "suffix": ""}, {"first": "T", "middle": [], "last": "Schonfeld", "suffix": ""}, {"first": "R", "middle": [], "last": "Weitz", "suffix": ""}, {"first": "B", "middle": [], "last": "Karmazyn", "suffix": ""}, {"first": "L", "middle": [], "last": "Harel", "suffix": ""}], "year": 2001, "venue": "Pediatr Neurol", "volume": "24", "issn": "", "pages": "139--143", "other_ids": {}}, "BIBREF365": {"ref_id": "b365", "title": "Dramatic improvement of severe acute disseminated encephalomyelitis after treatment with intravenous immunoglobulin in a three-year-old boy", "authors": [{"first": "J", "middle": ["B"], "last": "Andersen", "suffix": ""}, {"first": "L", "middle": ["H"], "last": "Rasmussen", "suffix": ""}, {"first": "M", "middle": [], "last": "Herning", "suffix": ""}, {"first": "A", "middle": [], "last": "Paerregaard", "suffix": ""}], "year": 2001, "venue": "Dev Med Child Neurol", "volume": "43", "issn": "", "pages": "136--138", "other_ids": {}}, "BIBREF366": {"ref_id": "b366", "title": "Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin", "authors": [{"first": "D", "middle": ["J"], "last": "Sahlas", "suffix": ""}, {"first": "S", "middle": ["P"], "last": "Miller", "suffix": ""}, {"first": "M", "middle": [], "last": "Guerin", "suffix": ""}, {"first": "M", "middle": [], "last": "Veilleux", "suffix": ""}, {"first": "G", "middle": [], "last": "Francis", "suffix": ""}], "year": 2000, "venue": "Neurology", "volume": "54", "issn": "", "pages": "1370--1372", "other_ids": {}}, "BIBREF367": {"ref_id": "b367", "title": "Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism", "authors": [{"first": "G", "middle": [], "last": "Delgiudice-Asch", "suffix": ""}, {"first": "L", "middle": [], "last": "Simon", "suffix": ""}, {"first": "J", "middle": [], "last": "Schmeidler", "suffix": ""}, {"first": "C", "middle": [], "last": "Cunningham-Rundles", "suffix": ""}, {"first": "E", "middle": [], "last": "Hollander", "suffix": ""}], "year": 1999, "venue": "J Autism Dev Disord", "volume": "29", "issn": "", "pages": "157--160", "other_ids": {}}, "BIBREF368": {"ref_id": "b368", "title": "Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients", "authors": [{"first": "P", "middle": [], "last": "Quartier", "suffix": ""}, {"first": "M", "middle": [], "last": "Debre", "suffix": ""}, {"first": "J", "middle": [], "last": "De Blic", "suffix": ""}], "year": 1999, "venue": "J Pediatr", "volume": "134", "issn": "", "pages": "589--596", "other_ids": {}}, "BIBREF369": {"ref_id": "b369", "title": "Highvs. low-dose immunoglobulin therapy in the long-term treatment of Xlinked agammaglobulinemia", "authors": [{"first": "J", "middle": ["G"], "last": "Liese", "suffix": ""}, {"first": "U", "middle": [], "last": "Wintergerst", "suffix": ""}, {"first": "K", "middle": ["D"], "last": "Tympner", "suffix": ""}, {"first": "B", "middle": ["H"], "last": "Belohradsky", "suffix": ""}], "year": 1992, "venue": "Am J Dis Child", "volume": "146", "issn": "", "pages": "335--339", "other_ids": {}}, "BIBREF370": {"ref_id": "b370", "title": "Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia", "authors": [{"first": "A", "middle": [], "last": "Aghamohammadi", "suffix": ""}, {"first": "M", "middle": [], "last": "Moin", "suffix": ""}, {"first": "A", "middle": [], "last": "Farhoudi", "suffix": ""}], "year": 2004, "venue": "FEMS Immunol Med Microbiol", "volume": "40", "issn": "", "pages": "113--118", "other_ids": {}}, "BIBREF371": {"ref_id": "b371", "title": "Intravenous immunoglobulin therapy for antibody deficiency", "authors": [{"first": "M", "middle": ["T"], "last": "Nolte", "suffix": ""}, {"first": "B", "middle": [], "last": "Pirofsky", "suffix": ""}, {"first": "G", "middle": ["A"], "last": "Gerritz", "suffix": ""}, {"first": "B", "middle": [], "last": "Golding", "suffix": ""}], "year": 1979, "venue": "Clin Exp Immunol", "volume": "36", "issn": "", "pages": "237--243", "other_ids": {}}, "BIBREF372": {"ref_id": "b372", "title": "The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia", "authors": [{"first": "H", "middle": ["W"], "last": "Eijkhout", "suffix": ""}, {"first": "Jwm", "middle": [], "last": "Van Der Meer", "suffix": ""}, {"first": "Cgm", "middle": [], "last": "Kallenberg", "suffix": ""}], "year": 2001, "venue": "Ann Int Med", "volume": "135", "issn": "", "pages": "165--174", "other_ids": {}}, "BIBREF373": {"ref_id": "b373", "title": "Intravenous immunoglobulin, splenectomy and antibiotic prophylaxis in Wiscott-Aldrich syndrome", "authors": [{"first": "J", "middle": [], "last": "Litzman", "suffix": ""}, {"first": "A", "middle": [], "last": "Jones", "suffix": ""}, {"first": "I", "middle": [], "last": "Hann", "suffix": ""}], "year": 1996, "venue": "Arch Dis Child", "volume": "75", "issn": "", "pages": "436--439", "other_ids": {}}, "BIBREF374": {"ref_id": "b374", "title": "New diagnostic and therapeutic aspects of hyper-IgE syndrome", "authors": [{"first": "Matamoros", "middle": [], "last": "Flori", "suffix": ""}, {"first": "N", "middle": [], "last": "", "suffix": ""}, {"first": "Mila", "middle": [], "last": "Llambi", "suffix": ""}, {"first": "J", "middle": [], "last": "", "suffix": ""}, {"first": "Hernandez", "middle": [], "last": "Gonzalez", "suffix": ""}, {"first": "M", "middle": [], "last": "", "suffix": ""}, {"first": "Julia", "middle": [], "last": "Benique", "suffix": ""}, {"first": "M", "middle": ["R"], "last": "", "suffix": ""}], "year": 1993, "venue": "Med Clin (Barc)", "volume": "101", "issn": "", "pages": "138--140", "other_ids": {}}, "BIBREF375": {"ref_id": "b375", "title": "Hyperimmunoglobulin E syndrome: two cases and a review of the literature", "authors": [{"first": "C", "middle": ["A"], "last": "Dewitt", "suffix": ""}, {"first": "A", "middle": ["B"], "last": "Bishop", "suffix": ""}, {"first": "L", "middle": ["S"], "last": "Buescher", "suffix": ""}, {"first": "S", "middle": ["P"], "last": "Stone", "suffix": ""}], "year": 2006, "venue": "J Am Acad Dermatol", "volume": "54", "issn": "", "pages": "855--865", "other_ids": {}}, "BIBREF376": {"ref_id": "b376", "title": "High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome", "authors": [{"first": "M", "middle": [], "last": "Wakim", "suffix": ""}, {"first": "M", "middle": [], "last": "Alazard", "suffix": ""}, {"first": "A", "middle": [], "last": "Yajima", "suffix": ""}, {"first": "D", "middle": [], "last": "Speights", "suffix": ""}, {"first": "A", "middle": [], "last": "Saxon", "suffix": ""}, {"first": "E", "middle": ["R"], "last": "Stiehm", "suffix": ""}], "year": 1998, "venue": "Ann Allergy Asthma Immunol", "volume": "81", "issn": "", "pages": "153--158", "other_ids": {}}, "BIBREF377": {"ref_id": "b377", "title": "Immunodeficiency presenting as hypergammaglobulinaemia with IgG2 subclass deficiency", "authors": [{"first": "J", "middle": ["P"], "last": "Shield", "suffix": ""}, {"first": "S", "middle": [], "last": "Strobel", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Levinsky", "suffix": ""}, {"first": "G", "middle": [], "last": "Morgan", "suffix": ""}], "year": 1992, "venue": "Lancet", "volume": "340", "issn": "", "pages": "448--450", "other_ids": {}}, "BIBREF378": {"ref_id": "b378", "title": "Deficiency in immunoglobulin subclasses as cause of increased infection susceptibility-a family study", "authors": [{"first": "M", "middle": [], "last": "Grob", "suffix": ""}, {"first": "H", "middle": ["I"], "last": "Joller-Jemelka", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Grob", "suffix": ""}], "year": 1991, "venue": "Schweiz Med Wochenschr", "volume": "121", "issn": "", "pages": "133--144", "other_ids": {}}, "BIBREF379": {"ref_id": "b379", "title": "Chronic rhinosinusitis and recurrent nasal polyps in two children with IgG subclass deficiency and review of the literature", "authors": [{"first": "S", "middle": [], "last": "Chinratanapisit", "suffix": ""}, {"first": "P", "middle": [], "last": "Tunsuriyawong", "suffix": ""}, {"first": "P", "middle": [], "last": "Vichyanond", "suffix": ""}, {"first": "N", "middle": [], "last": "Visitsunthorn", "suffix": ""}, {"first": "V", "middle": [], "last": "Luangwedchakarn", "suffix": ""}, {"first": "O", "middle": [], "last": "Jirapongsananuruk", "suffix": ""}], "year": 2005, "venue": "J Med Assoc Thai", "volume": "88", "issn": "8", "pages": "251--258", "other_ids": {}}, "BIBREF380": {"ref_id": "b380", "title": "A case of IgG subclass deficiency with the initial presentation of transient hypogamma immunoglobulinemia of infancy and a review of IgG subclass deficiencies", "authors": [{"first": "R", "middle": [], "last": "Nettagul", "suffix": ""}, {"first": "N", "middle": [], "last": "Visitsunthorn", "suffix": ""}, {"first": "P", "middle": [], "last": "Vichyanond", "suffix": ""}], "year": 2003, "venue": "J Med Assoc Thai", "volume": "86", "issn": "", "pages": "686--692", "other_ids": {}}, "BIBREF381": {"ref_id": "b381", "title": "Antibody response in patients with osteomyelitis of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod", "authors": [{"first": "U", "middle": [], "last": "Nordin", "suffix": ""}, {"first": "K", "middle": [], "last": "Wannfors", "suffix": ""}, {"first": "P", "middle": [], "last": "Colque-Navarro", "suffix": ""}, {"first": "R", "middle": [], "last": "Mollby", "suffix": ""}, {"first": "A", "middle": [], "last": "Heimdahl", "suffix": ""}], "year": 1995, "venue": "", "volume": "79", "issn": "", "pages": "429--435", "other_ids": {}}, "BIBREF382": {"ref_id": "b382", "title": "Clinical and laboratory characteristics of 75 patients with specific polysaccharide antibody deficiency syndrome", "authors": [{"first": "Y", "middle": ["K"], "last": "Cheng", "suffix": ""}, {"first": "P", "middle": ["A"], "last": "Decker", "suffix": ""}, {"first": "M", "middle": ["M"], "last": "O&apos;byrne", "suffix": ""}, {"first": "C", "middle": ["R"], "last": "Weiler", "suffix": ""}], "year": 2006, "venue": "Ann Allergy Asthma Immunol", "volume": "97", "issn": "", "pages": "306--311", "other_ids": {}}, "BIBREF383": {"ref_id": "b383", "title": "Selective antibody immune deficiency in a patient with Smith-Lemli-Opitz syndrome", "authors": [{"first": "D", "middle": [], "last": "Babovic-Vuksanovic", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "Jacobson", "suffix": ""}, {"first": "N", "middle": ["M"], "last": "Lindor", "suffix": ""}, {"first": "C", "middle": ["R"], "last": "Weiler", "suffix": ""}], "year": 2005, "venue": "J Inherit Metab Dis", "volume": "28", "issn": "", "pages": "181--186", "other_ids": {}}, "BIBREF384": {"ref_id": "b384", "title": "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to activation-induced cytidine deaminase deficiency", "authors": [{"first": "P", "middle": [], "last": "Quartier", "suffix": ""}, {"first": "J", "middle": [], "last": "Bustamante", "suffix": ""}, {"first": "O", "middle": [], "last": "Sanal", "suffix": ""}, {"first": "A", "middle": [], "last": "Plebani", "suffix": ""}, {"first": "M", "middle": [], "last": "Debre", "suffix": ""}, {"first": "A", "middle": [], "last": "Deville", "suffix": ""}, {"first": "J", "middle": [], "last": "Litzman", "suffix": ""}, {"first": "J", "middle": [], "last": "Levy", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Fermand", "suffix": ""}, {"first": "P", "middle": [], "last": "Lane", "suffix": ""}, {"first": "G", "middle": [], "last": "Horneff", "suffix": ""}, {"first": "G", "middle": [], "last": "Aksu", "suffix": ""}, {"first": "I", "middle": [], "last": "Yalcin", "suffix": ""}, {"first": "G", "middle": [], "last": "Davies", "suffix": ""}, {"first": "I", "middle": [], "last": "Tezcan", "suffix": ""}, {"first": "F", "middle": [], "last": "Ersoy", "suffix": ""}, {"first": "N", "middle": [], "last": "Catalan", "suffix": ""}, {"first": "K", "middle": [], "last": "Imai", "suffix": ""}, {"first": "A", "middle": [], "last": "Fischer", "suffix": ""}, {"first": "A", "middle": [], "last": "Durandy", "suffix": ""}], "year": 2004, "venue": "Clin Immunol", "volume": "110", "issn": "", "pages": "22--29", "other_ids": {}}, "BIBREF385": {"ref_id": "b385", "title": "The hyper-IgM syndrome: 13 observations", "authors": [{"first": "M", "middle": [], "last": "Bejaoui", "suffix": ""}, {"first": "F", "middle": [], "last": "Mellouli", "suffix": ""}, {"first": "R", "middle": [], "last": "Chouanine", "suffix": ""}, {"first": "K", "middle": [], "last": "Dellagi", "suffix": ""}, {"first": "M", "middle": ["R"], "last": "Barbouche", "suffix": ""}], "year": 2003, "venue": "Presse Med", "volume": "32", "issn": "", "pages": "544--549", "other_ids": {}}, "BIBREF386": {"ref_id": "b386", "title": "Effects of intravenous immunoglobulin on clinical and immunological findings of patients with humoral immunodeficiency diseases", "authors": [{"first": "F", "middle": [], "last": "Ersoy", "suffix": ""}, {"first": "I", "middle": [], "last": "Tezcan", "suffix": ""}, {"first": "O", "middle": [], "last": "Sanal", "suffix": ""}], "year": 1992, "venue": "Turk J Pediatr", "volume": "34", "issn": "", "pages": "203--209", "other_ids": {}}, "BIBREF387": {"ref_id": "b387", "title": "Non-X-linked hyperimmunoglobulin M syndrome with chronic interstitial pneumonitis", "authors": [{"first": "A", "middle": [], "last": "Quezada", "suffix": ""}, {"first": "X", "middle": [], "last": "Norambuena", "suffix": ""}, {"first": "R", "middle": [], "last": "Gonzalez", "suffix": ""}, {"first": "S", "middle": ["M"], "last": "Ramos", "suffix": ""}, {"first": "A", "middle": [], "last": "Chavez", "suffix": ""}, {"first": "S", "middle": [], "last": "Gonzalez", "suffix": ""}], "year": 2000, "venue": "J Investig Allergol Clin Immunol", "volume": "10", "issn": "", "pages": "375--379", "other_ids": {}}, "BIBREF388": {"ref_id": "b388", "title": "Successful management of neutropenia in a patient with CD40 ligand deficiency by immunoglobulin replacement therapy", "authors": [{"first": "L", "middle": [], "last": "Atarod", "suffix": ""}, {"first": "A", "middle": [], "last": "Aghamohammadi", "suffix": ""}, {"first": "M", "middle": [], "last": "Moin", "suffix": ""}, {"first": "H", "middle": [], "last": "Kanegane", "suffix": ""}, {"first": "N", "middle": [], "last": "Rezaei", "suffix": ""}, {"first": "Rezaei", "middle": [], "last": "Kalantari", "suffix": ""}, {"first": "K", "middle": [], "last": "Amirzagar", "suffix": ""}, {"first": "A", "middle": ["A"], "last": "Futatani", "suffix": ""}, {"first": "T", "middle": [], "last": "Miyawaki", "suffix": ""}, {"first": "M", "middle": [], "last": "", "suffix": ""}], "year": 2007, "venue": "Iran J Allergy Asthma Immunol", "volume": "6", "issn": "", "pages": "37--40", "other_ids": {}}, "BIBREF389": {"ref_id": "b389", "title": "Hyper-IgM syndrome: report of one case", "authors": [{"first": "Y", "middle": ["C"], "last": "Ma", "suffix": ""}, {"first": "S", "middle": ["D"], "last": "Shyur", "suffix": ""}, {"first": "L", "middle": ["H"], "last": "Huang", "suffix": ""}, {"first": "J", "middle": ["Y"], "last": "Wu", "suffix": ""}, {"first": "S", "middle": ["C"], "last": "Lin", "suffix": ""}], "year": 2004, "venue": "Acta Paediatr Taiwan", "volume": "45", "issn": "", "pages": "334--339", "other_ids": {}}, "BIBREF390": {"ref_id": "b390", "title": "Transient hypogammaglobulinemia of infancy presenting as Staphylococcus aureus sepsis with deep neck infection", "authors": [{"first": "K", "middle": ["C"], "last": "Hsueh", "suffix": ""}, {"first": "H", "middle": ["H"], "last": "Chiu", "suffix": ""}, {"first": "H", "middle": ["C"], "last": "Lin", "suffix": ""}, {"first": "C", "middle": ["H"], "last": "Hsu", "suffix": ""}, {"first": "F", "middle": ["J"], "last": "Tsai", "suffix": ""}], "year": 2005, "venue": "J Microbiol Immunol Infect", "volume": "38", "issn": "", "pages": "141--144", "other_ids": {}}, "BIBREF391": {"ref_id": "b391", "title": "Transient hypogammaglobulinemia of infancy with severe bacterial infections and persistent IgA deficiency", "authors": [{"first": "A", "middle": [], "last": "Benderly", "suffix": ""}, {"first": "S", "middle": [], "last": "Pollack", "suffix": ""}, {"first": "A", "middle": [], "last": "Etzioni", "suffix": ""}], "year": 1986, "venue": "Isr J Med Sci", "volume": "22", "issn": "", "pages": "393--396", "other_ids": {}}, "BIBREF392": {"ref_id": "b392", "title": "Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency", "authors": [{"first": "R", "middle": ["H"], "last": "Buckley", "suffix": ""}, {"first": "S", "middle": ["E"], "last": "Schiff", "suffix": ""}, {"first": "R", "middle": ["I"], "last": "Schiff", "suffix": ""}, {"first": "L", "middle": [], "last": "Markert", "suffix": ""}, {"first": "L", "middle": ["W"], "last": "Williams", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Roberts", "suffix": ""}, {"first": "L", "middle": ["A"], "last": "Myers", "suffix": ""}, {"first": "F", "middle": ["E"], "last": "Ward", "suffix": ""}], "year": 1999, "venue": "N Engl J Med", "volume": "340", "issn": "", "pages": "508--516", "other_ids": {}}, "BIBREF393": {"ref_id": "b393", "title": "Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency", "authors": [{"first": "P", "middle": ["J"], "last": "Busse", "suffix": ""}, {"first": "S", "middle": [], "last": "Razvi", "suffix": ""}, {"first": "C", "middle": [], "last": "Cunningham-Rundles", "suffix": ""}], "year": 2002, "venue": "J Allergy Clin Immunol", "volume": "109", "issn": "", "pages": "1001--1004", "other_ids": {}}}, "ref_entries": {"TABREF0": {"text": "Intravenous immunoglobulins . Intravenous gamma globulins . Autoimmunity . Evidence . IVIg . IgIV", "latex": null, "type": "table"}, "TABREF1": {"text": "The use of intravenous immunoglobulins in rheumatologic diseases", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>Systemic lupus erythematosus (SLE) systemic flare-up\n</td><td>[37] </td><td>Controlled trial\n</td><td>IVIg 0.4 g/kg for 5 days, between 1 and 8 monthly courses (mean 5; ISIVEN-Instituto Sierovaccinogeno, Italiano ISI SpA.)\n</td><td>20 patients with active SLE </td><td>Beneficial clinical response in 17 out of 20 pts (p&lt;0.0001); especially in arthritis, fever, thrombocytopenia, and CNS lupus\n</td></tr><tr><td>[38] </td><td>Uncontrolled multicenter\n</td><td>IVIg 0.4 g/kg for 5 days </td><td>13 females with acute exacerbation of SLE\n</td><td>After IVIg treatment, the modified European Consensus\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>trial\n</td><td>\u00a0</td><td>\u00a0</td><td>Lupus Activity Measurement\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>(mECLAM) declined in 12 out of 13 pts by \u22653 points (p=0.0002)\n</td></tr><tr><td>\u00a0</td><td>[39] </td><td>Uncontrolled trial\n</td><td>30 g of sulfonated IVIg preparation on days 1-4\n</td><td>12 patients with mild-to-moderate active SLE\n</td><td>Within 6 weeks, the mean Systemic Lupus Activity\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>and 21-24\n</td><td>\u00a0</td><td>Measure (SLAM) score declined from 7.3 to 5.25\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>(p&lt;0.01); in a minority, this effect lasted 5-12 months\n</td></tr><tr><td>\u00a0</td><td>[20] </td><td>Retrospective trial\n</td><td>Review of medical records of patients with SLE that were treated with low-dose IVIg (0.5 g/kg) for several courses\n</td><td>62 patients </td><td>Clinical improvement in most disease manifestations\nincluding pericarditis; not including thrombocytopenia and alopecia\n</td></tr><tr><td>Lupus myocarditis </td><td>[40] </td><td>Case series </td><td>IVIg 0.4 g/kg per day for 5 days, in addition to CP or\n</td><td>3 patients with lupus myocarditis and severe deterioration in contractile functions; high-dose CS had little effect\n</td><td>Marked clinical improvement; decreased need for CS\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>MMF (given to 2 patients)\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>[41] </td><td>Case report </td><td>IVIg 0.4 g/kg per day for 5 days\n</td><td>1 patient with lupus myocarditis refractory to CS\n</td><td>Marked improvement of severe cardiac dysfunction after one course of IVIg\n</td></tr><tr><td>SLE and thrombocytopenia\n</td><td>[42] </td><td>Retrospective trial\n</td><td>IVIg 2 g/kg for 2 to 5 days </td><td>31 patients with severe thrombocytopenia\nassociated with SLE refractory to PD treatment\n</td><td>A transient response was observed in 20 patients (65%); no sustained response was observed\n</td></tr><tr><td>Subacute cutaneous lupus erythematosus (SCLE)\n</td><td>[43] </td><td>Case series </td><td>IVIg with starting doses of 1 g/kg for 2 days, followed by 0.4 g/kg monthly, until disease resolution or for 6 months\n</td><td>12 patients with resistant SCLE\n</td><td>5 patients had complete or near-complete clearing of their skin disease; two had partial improvement and 3 had limited responses\n</td></tr><tr><td>[44] </td><td>Case series </td><td>IVIg 0.3 g/kg per day for 5 days each month for 12 months\n</td><td>7 patients with skin disease (5 had systemic LE; two had SCLE)\n</td><td>IVIg was unable to control cutaneous disease efficiently\n</td></tr><tr><td>\u00a0</td><td>[45] </td><td>Case series </td><td>IVIg </td><td>3 patients with SCLE resistant to topical and systemic therapy\n</td><td>Good response\n</td></tr><tr><td>\u00a0</td><td>[46] </td><td>Case report </td><td>IVIg 2 g/kg monthly </td><td>30-year-old woman with SCLE\n</td><td>Good response\n</td></tr><tr><td>Various manifestations of SLE\n</td><td>[47] </td><td>Various case reports\n</td><td>Different IVIg preparations and doses\n</td><td>26 patients with specific\n</td><td>Improvement of SLE-related condition\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>lupus manifestations refractory to standard Tx.: autoimmune hemolytic anemia (2), acquired factor VIII inhibitors (2), acquired von Willebrand disease (2), pure red cell aplasia(3), pancytopenia\n</td></tr></table></body></html>"}, "TABREF2": {"text": "", "latex": null, "type": "table"}, "TABREF3": {"text": "", "latex": null, "type": "table"}, "TABREF4": {"text": "", "latex": null, "type": "table"}, "TABREF5": {"text": "", "latex": null, "type": "table"}, "TABREF6": {"text": "The use of intravenous immunoglobulins in hematological diseases", "latex": null, "type": "table"}, "TABREF7": {"text": "The use of intravenous immunoglobulins in infectious diseases", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients. </td><td>Results/response\n</td></tr><tr><td>Cytomegalovirus (CMV)\n</td><td>[180] </td><td>Controlled trial\n</td><td>IVIg 0.25 g/kg weekly for 8 weeks, starting on the operative day\n</td><td>40 renal transplanted patients with negative serology for CMV\n</td><td>Effective prophylaxis, associated with excellent 1-year allograft survival\n</td></tr><tr><td>Human\n</td><td>[181] </td><td>RCT </td><td>IVIg 0.4 g/kg or placebo (0.1%\n</td><td>372 symptomatic children infected with HIV\n</td><td>Significant reduction in serious\n</td></tr><tr><td>immunodeficiency virus (HIV) child infection\n</td><td>\u00a0</td><td>\u00a0</td><td>albumin) every 28 days\n</td><td>infections (p=0.01) and hospitalizations (p=0.03), in the IVIg group only for those entering treatment with CD4+ lymphocyte \u2265200; no effect on mortality\n</td></tr><tr><td>[182] </td><td>Controlled\n</td><td>IVIg (Gamimune-N, Miles\n</td><td>135 symptomatic and asymptomatic children with perinatal HIV\n</td><td>Significant reduction in the frequency of bacterial infections in the symptomatic group\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>trial\n</td><td>Pharmaceutical Co.), 0.2 g/kg monthly for 1 year\nHIV-associated thrombocytopenia-see hematology section\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Malaria </td><td>[183] </td><td>RCT </td><td>All were treated with IV quinine dihydrochloride; in addition,\npatients were randomized to\n</td><td>31 children with\n</td><td>Of 16 patients receiving\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Plasmodium falciparum\nparasitemia and coma\n</td><td>immunoglobulin, 5 (31%) died, and 5 survivors had\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>receive either IVIg, 0.4 g/kg over 3 h, or placebo\n</td><td>\u00a0</td><td>neurological sequelae; of 15 patients receiving placebo, one (7%) died and 2 had sequelae (trial was stopped)\n</td></tr><tr><td>\u00a0</td><td>[184] </td><td>Controlled trial\n</td><td>IVIg was prepared from 180 donors after infection screening; 6\n</td><td>8 Thai patients with P. falciparum\nparasitemia\n</td><td>Clearance of parasites and symptoms was as fast as or faster than with drugs\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>patients were treated with a 0.1-g/ kg dose given over 3 days, one with a single 0.02-g/kg dose, and one with a single 0.02-g/kg dose\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Postpolio syndrome (PPS)\n</td><td>[185] </td><td>Multicentered RCT\n</td><td>90 g of IVIg during 3 days, repeated after 3 months\n</td><td>142 patients: 73 with IVIg and 69 placebos\n</td><td>Mild improvement in median muscle strength (p=0.03),\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>vitality (p=0.04), no change and quality of life (p=0.3)\n</td></tr><tr><td>\u00a0</td><td>[186] </td><td>RCT </td><td>Patients were randomized to\n</td><td>20 patients with PPS </td><td>No effect was seen with IVIg\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>IVIg, 2 g/kg, or placebo\n</td><td>\u00a0</td><td>treatment on muscle strength and fatigue; however, IVIg patients reported significantly less pain 3 months after treatment\n</td></tr><tr><td>\u00a0</td><td>[187] </td><td>Open clinical trial\n</td><td>90 g of IVIg (30 g daily for 3 days)\n</td><td>14 patients with PPS </td><td>Significant improvement in the quality of life, no change in muscle strength and physical performance\n</td></tr><tr><td>Sepsis </td><td>[188] </td><td>Meta analysis of RCT's from PubMed\n</td><td>Different preparations of relatively low doses of IVIg for severe sepsis, mostly surgical patients with gram-negative infections\n</td><td>14 RCTs published\n</td><td>Significant but heterogenic reduction in mortality\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>between 1988 and\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>2006 were included\n</td><td>associated with use of IVIg (p&lt;0.0005); this result was not confirmed when only high-quality studies were analyzed\n</td></tr><tr><td>West Nile Virus\n</td><td>[189] </td><td>Case report </td><td>0.4 g/kg IVIg preparation from\n</td><td>42-year-old male lung-transplant recipient with severe WNV encephalitis\n</td><td>Complete disappearance of signs\n</td></tr><tr><td>(WNV)\n</td><td>\u00a0</td><td>\u00a0</td><td>donors that contained a high titer of anti-WNV antibodies (1:1,600)\n</td><td>and symptoms within 48 h\n</td></tr><tr><td>[190] </td><td>Case report </td><td>IVIg 0.4 g/kg for 5 days (Omr-IgG-am, Omrix\n</td><td>70-year-old with chronic lymphatic leukemia and coma due to WNV\n</td><td>Level of consciousness returned to normal over 5 days\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Biopharmaceutical Ltd., Tel Hashomer, Israel)\n</td><td>\u00a0</td></tr><tr><td>Prophylaxis for infections (in intensive care units (ICU))\n</td><td>[191] </td><td>RCT </td><td>Patients received standard IVIg, 0.4 g/kg, hyperimmune globulin\n</td><td>329 postsurgical patients admitted to the surgical ICU\n</td><td>Significantly lower infections and hospital days in the IVIg group\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>(HG), 0.4 g/kg, or placebo, weekly, for amaximum of 4 doses\n</td><td>vs. placebo or HG (p=0.003); no lesser mortality/shock\n</td></tr></table></body></html>"}, "TABREF8": {"text": "", "latex": null, "type": "table"}, "TABREF9": {"text": "", "latex": null, "type": "table"}, "TABREF10": {"text": "The use of intravenous immunoglobulins in gyneco-obstetric diseases", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>Perinatal hemochromatosis\n</td><td>[212] </td><td>Case-control study; previous patients' pregnancies used as their own controls\n</td><td>IVIg 1 g/kg weekly since week 18\n</td><td>15 patients (16 pregnancies) with previous pregnancies resulting in perinatal hemochromatosis\n</td><td>Good outcome (survived with or without medical therapy) in 15 gestations treated with\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>IVIg; in historical controls\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>of the same mothers, 2 pregnancies had good\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>outcome and 13 had poor outcome (fetal or neonatal death, or liver failure\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>necessitating liver transplantation), p=0.0009\n</td></tr><tr><td>Recurrent pregnancy loss excluding antiphospholipid syndrome\n</td><td>[213] </td><td>Meta-analysis </td><td>IVIg </td><td>442 women with recurrent spontaneous miscarriages (at least 3) from eight RCTs; secondary recurrent miscarriages are defined as those in women that had at least a previous successful birth\n</td><td>No significant difference (p= 0.21) between women with primary recurrent miscarriages treated with IVIg or without; however, there was a significant improvement of live births when IVIg was given to women with secondary recurrent\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>miscarriages (p=0.03)\n</td></tr><tr><td>\u00a0</td><td>[214] </td><td>Meta-analysis </td><td>IVIg versus placebo or no treatment\n</td><td>303 women with idiopathic recurrent abortions from\n</td><td>No benefit of IVIg on recurrent pregnancy loss\n</td></tr><tr><td>\u00a0</td><td>[215] </td><td>Meta-analysis </td><td>IVIg </td><td>8 RCTs 246 women with recurrent spontaneous miscarriages (at least 2) from 5 RCTs; secondary recurrent miscarriages are defined as those in women that had at least a previous successful birth\n</td><td>No significant difference between women with primary recurrent miscarriages treated with IVIg or without; not enough patients to conclude something about women with secondary recurrent miscarriages but there was a trend towards improvement\n</td></tr><tr><td>\u00a0</td><td>[216] </td><td>RCT </td><td>29 women received IVIg, 29 placebos; IVIg was\nadministered from weeks 5-\n</td><td>58 women with recurrent spontaneous miscarriages (at least 4); secondary recurrent miscarriages are defined as those in women who had at least a previous pregnancy that progressed\n</td><td>No benefit in primary recurrent miscarriages but a trend towards improvement among women with secondary recurrent miscarriages\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>10 weekly at 0.8 g/kg every week, from weeks 10-20 at\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>0.8 g/kg every 2 weeks and from weeks 20-26 at 1 g/kg\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>every 2 weeks; no IVIg as given after week 26\n</td><td>to week 26 or more\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>[217] </td><td>Meta-analysis </td><td>IVIg in 125 patients, 115\n</td><td>240 women with recurrent\n</td><td>No benefit of IVIg\n</td></tr><tr><td>\u00a0</td><td>[217] </td><td>RCT </td><td>received placebo IVIg (Gammonativ) 20 g\n</td><td>spontaneous miscarriages 41 women with recurrent spontaneous miscarriages\n</td><td>No benefit of IVIg neither for women with primary or secondary recurrent miscarriage\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>every 3 weeks, 5 courses after confirmation of pregnancy\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>[218] </td><td>RCT </td><td>22 patients received IVIg (Sclavo) 50 g over 2 days\n</td><td>46 women with recurrent spontaneous miscarriages\n</td><td>No benefit of IVIg\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>RCT </td><td>upon confirmation of pregnancy (weeks 5-7) and again 25 g 3 weeks later\n</td><td>95 women with recurrent spontaneous miscarriages (2 or more)\n</td><td>More live births in women receiving placebo (p=0.04)\n</td></tr><tr><td>\u00a0</td><td>[219] </td><td>47 patients received IVIg 0.5 g/kg every month starting up to 4 months before pregnancy and until weeks 28-32 of pregnancy; 48 patients received placebo\n</td></tr></table></body></html>"}, "TABREF11": {"text": "", "latex": null, "type": "table"}, "TABREF12": {"text": "", "latex": null, "type": "table"}, "TABREF13": {"text": "The use of intravenous immunoglobulins in cardiac disease", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>Congestive heart failure (CHF)\n</td><td>[14] </td><td>RCT </td><td>Octagam (Octapharma)\n0.4 g/kg per day for 5 days followed by monthly dose of 0.4 mg/kg for 5 months, compared with placebo\n</td><td>40 patients with symptomatic CHF (NYHA II/III) and ejection fraction (EF) &lt;40% due to idiopathic dilated cardiomyopathy (42.5%) or secondary to ischemic heart disease; 20 patients (9 idiopathic DCM, 11 coronary artery disease) received IVIg; 20 patients\n</td><td>IVIg induced significant increase of EF by means of 5 EF units, regardless of the cause of CHF, compared to no significant change of EF in the placebo group; improved quality of life in 73% compared to 40% in placebo group; p value&lt; 0.05\n</td></tr><tr><td>Dilated cardiomyopathy (DCM)\n</td><td>[13] </td><td>RCT </td><td>Gamimune N, 10% (Bayer Corporation), 1 g/kg IV each day on 2 consecutive days, compared to placebo\n</td><td>received placebo 62 patients with new-onset DCM and EF \u226440% (with symptoms for less than\n6 months); both idiopathic DCM and myocarditis patients were included; 33 patients received IVIg, and 29 patients were treated with placebo\n</td><td>Mean EF improved from 0.25\u00b10.08 to 0.41\u00b10.17 following 6 months for all patients; there was no significant difference in EF improvement between IVIg and placebo group\n</td></tr><tr><td>Peripartum cardiomyopathy (PPCM)\n</td><td>[233] </td><td>Retrospective study, case series\n</td><td>2 g/kg of IVIg given as 1 g/kg q.d. on 2 consecutive days along with conventional therapy, compared to conventional therapy alone\n</td><td>17 patients with PPCM; 6 received IVIg; all with NYHA class II-IV and\n</td><td>In the control group, 1 patient died (9.09%), and others had a mean improvement of EF\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>EF&lt;40%, within 6 months from delivery\n</td><td>by 13\u00b113 EF units, compared to 26\u00b18 EF units in the IVIg group; p value 0.042\n</td></tr><tr><td>Myocarditis </td><td>[234] </td><td>Case series </td><td>Total dose of 1 to 2 g/kg IVIg\n</td><td>9 patients: 6 patients with acute myocarditis, 3 patients with acute dilated cardiomyopathy; NYHA III and IV\n</td><td>Mean EF improved significantly, from 19.0\u00b1 7.5% to 35.4\u00b19.1% following IVIg treatment;\nP value&lt;0.01\n</td></tr><tr><td>[235] </td><td>Prospective nonrandomized trial\n</td><td>over 48 h (Venilon,\nVenoglobulin-IH, and Polyglobin-N preparations were used); all patients received conventional therapy\nIVIg (Immuno AG, Vienna), total dose of 2 g/kg over a maximum of 24 h; some of the IVIg groups were treated with an additional dose of 1 g/kg a week later, compared with conventional therapy\n</td><td>46 patients with acute onset disease and severely depressed EF; 21 patients received IVIg; a control group of 25 patients was collected from retrospective files\n</td><td>There was no significant change of survival in the IVIg group compared to control; IVIg group had a higher fractional shortening than control during 3- to 6-month follow-up period; the control group failed to normalize EF; p value 0.033\n</td></tr><tr><td>Chronic idiopathic pericarditis (CIP)\n</td><td>[21] </td><td>Case series </td><td>Five monthly cycles of 0.4 g/kg per day for 5 consecutive days, followed by administration every 2 months\n</td><td>4 patients with CIP </td><td>Remarkable response in 3 patients, and a long-standing remission with no need for further steroid treatment; 1 patient with partial response\n</td></tr><tr><td>Pericardial diseases\n</td><td>[19] </td><td>Case report </td><td>Total dose of 2 g/kg of IVIg, and 100 mg/kg per day of acetylsalicylic acid for 14 days\n</td><td>1 patient with Kawasaki disease, left anterior descending artery aneurysm and septated pericardial effusion\n</td><td>2 weeks following treatment initiation, there was disappearance of the pericardial effusion and no change of the coronary aneurysm\n</td></tr><tr><td>[17] [20] </td><td>Case report Case series </td><td>IVIg treatment starting at the\n</td><td>1 patient with Kawasaki disease, complicated by cardiac tamponade\n62 lupus patients, of which several developed pericardial disease\n</td><td>Failure of treatment and need for salvage pericardiocentesis\n60% of affected patients had resolution of pericardial involvement\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>16th day following initial presentation, total of 2 g/kg, and 30 mg/kg per day of MP for 5 days Low-dose IVIg therapy-\napproximately 0.5 g/kg every 5\u00b12 weeks for 6\u00b16 courses\n</td></tr></table></body></html>"}, "TABREF14": {"text": "", "latex": null, "type": "table"}, "TABREF15": {"text": "", "latex": null, "type": "table"}, "TABREF16": {"text": "The use of intravenous immunoglobulins in ophthalmic disease", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>Ophthalmic IgA bullous disease\n</td><td>[248] </td><td>Case report </td><td>Monthly IVIg treatment, 4 g/kg per month, with graduate discontinuation following clinical improvement\n</td><td>1 patient with chronic cicatrizing conjunctivitis due to linear IgA bullous disease with poor response to topical or systemic CS\n</td><td>Improvement of clinical symptoms with maximal\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>effect 10-12 days following\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>infusion; decrease of circulating IgA anti-97-kDa epidermal protein\n</td></tr><tr><td>Mucous membrane pemphigoid\n</td><td>[28] </td><td>Nonrandomized controlled trial\n</td><td>IVIg, 2 g/kg per cycle, cycles were repeated every 2-\n4 weeks, compared to conventional immunosuppressive therapy\n</td><td>16 patients that were equally divided to control and IVIg group\n</td><td>Remission was achieved after 4 months in IVIg group vs 8.5 months in control\n</td></tr><tr><td>(MMP)\n</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>group; IVIg had less recurrence and decreased progression; p value&lt;0.05\n</td></tr><tr><td>Ocular Behcet's disease\n</td><td>[91] </td><td>Case series </td><td>IVIg 0.4 g/kg per day: 5 times in first week, 3 more in the\n</td><td>4 patients refractory to CS and cyclosporine A\n</td><td>Control of acute inflammation and preservation of\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>next months and once every 20 days for total of 3 months\n</td><td>\u00a0</td><td>remission for 1 year; marked improvement of visual acuity\n</td></tr><tr><td>Optic neuritis </td><td>[249] </td><td>RCT </td><td>27 patients were treated with\n</td><td>55 patients with multiple sclerosis and visual loss due to optic neuritis\n</td><td>No difference between treatment groups was observed; there was no absolute reversal of persistent visual loss; the trial was terminated by the National Eye Institute\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>IVIg (Gamimune N; Bayer\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Pharmaceutical Division,\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>West Haven, CT, USA)\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>0.4 g/kg per day for 5 days\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>followed by 3 monthly single cycles vs placebo (n=28)\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>[250] </td><td>RCT </td><td>IVIg 0.4 g/kg per day (Immunoglobulin SSI liquid;\nStatens Serum Institute, Copenhagen, Denmark), infused on days 0-2, and 1 to 2 months later (n=34) vs placebo (n=34)\n</td><td>68 patients with recent visual accuracy loss; 34 patients received IVIg (of which 15 had multiple sclerosis), compared with 34 patients who received placebo (of which 8 patients had multiple sclerosis)\n</td><td>No immediate or delayed effects were observed; there was no change in visual acuity, MRI findings and visual evoked potential results\n</td></tr><tr><td>Inflammatory pseudotumor of orbit\n</td><td>[251] </td><td>Case report </td><td>IVIg 2 g/kg divided over\n</td><td>1 patient with inflammatory pseudotumor of the orbit, resistant to systemic CS, and radiation therapy\n</td><td>Both clinical and radiographic improvement within days\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>4 days\n</td><td>\u00a0</td></tr><tr><td>Birdshot retinochoroiditis\n</td><td>[252] </td><td>Case series </td><td>IVIg 0.4 g/kg per day for 4 days; then 0.6 g/kg per day\n</td><td>37, of which 18 were followed up\n</td><td>Visual acuity of 53% of patients' eyes has increased\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>for 2 days, every 4 weeks\n</td><td>\u00a0</td><td>by 2.6\u00b11.5; in 29% of patients, visual acuity remained stable, and in 18% of eyes VA have decrease\n</td></tr><tr><td>\u00a0</td><td>[30] </td><td>Case series </td><td>IVIg 1.6 g/kg every month for 6 months, followed by\n</td><td>18 patients </td><td>In patients with visual acuity of 20/30, there was increase\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>1.2-1.6 g/kg every 6-\n8 weeks\n</td><td>in visual acuity in 53.8% of eyes and decrease of acuity in 7.7% while there was no change in the remaining eyes\n</td></tr><tr><td>Orbital myositis </td><td>[253] </td><td>Case report </td><td>IVIg (Venimmun) 0.3 g/kg per day for 3 days\n</td><td>1 patient intolerant to CS treatment and poor clinical response\n</td><td>Both clinical and tomographic resolution within 2 weeks\n</td></tr><tr><td>Refractory uveitis\n</td><td>[254] </td><td>Case series </td><td>IVIg (Baxter Healthcare, Glendale, CA, USA),\n0.5 g/kg per day for 3 days each month; median of 7.5 cycles\n</td><td>10 patients with poor response to immunosuppression (some cases were idiopathic, others were secondary to sarcoidosis, Behcet, inflammatory bowel disease, and birdshot retinochoroiditis)\n</td><td>50% sustained improvement of visual acuity, 20% have required a reduced doses of immunosuppressive therapy without disease progression; the patient with sarcoidosis had improved vision and reduced need for immunosuppression,\n</td></tr></table></body></html>"}, "TABREF17": {"text": "", "latex": null, "type": "table"}, "TABREF18": {"text": "The use of intravenous immunoglobulins in kidney diseases", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>Membranous nephropathy\n</td><td>[260] </td><td>Retrospective uncontrolled trial\n</td><td>IVIg 0.4 g/kg every 21 days (mean duration of treatment was 15 months equal to 21 cycles)\n</td><td>13 adult patients (8 males, 5 females) with primary membranous glomerulonephritis\n</td><td>5 patients had complete\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>remission\n5 patients had partial remission\n3 patients no clinical remission but presented marked reduction in proteinuria\n</td></tr><tr><td>\u00a0</td><td>[261] </td><td>Case series </td><td>IVIg 0.4 g/kg per day for 3 days every 21 days (3\n</td><td>9 patients with biopsy-confirmed idiopathic membranous nephropathy\n</td><td>5 patients with normal renal function: 4 had complete\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>courses), then once every 3 weeks for 10 months\n</td><td>\u00a0</td><td>remission, 1 had partial remission\n4 patients with moderate renal insufficiency: 1 had complete remission, 2 had partial remission, 1 had no response\n</td></tr><tr><td>\u00a0</td><td>[262] </td><td>Retrospective analysis\n</td><td>IVIg 0.1-0.15 g/kg per day for 6 days, 1-3 courses\n</td><td>86 with primary membranous glomerulonephritis\n</td><td>30 patients were treated with IVIg: 13 patients had complete remission; 11 patients had partial remission; 3 patients had continued nephrotic state with renal dysfunction; 3 patients reached end-stage renal disease\n</td></tr><tr><td>IgA nephropathy </td><td>[263] </td><td>Single-arm, nonrandomized study\n</td><td>IVIg 2 g/kg monthly for 6 months\n</td><td>14 patients with progressive IgA nephropathy\n</td><td>6 patients received IVIg; the mean loss of renal function and proteinuria were significantly reduced in the IVIg group (p=0.024, p= 0.015, respectively)\n</td></tr><tr><td>[63] </td><td>Open prospective cohort study\n</td><td>IVIg 2 g/kg per month for 3 months followed by IMIg for another 6 months\n</td><td>11 patients with moderate IgA nephropathy\n</td><td>Proteinuria, glomerular filtration rate, and histologic index of activity were significantly decreased\n</td></tr><tr><td>BK-virus-associated nephropathy in renal allograft recipients\n</td><td>[264] </td><td>Case series </td><td>IVIg 2 g/kg over 2-5 days + immunosuppression\n</td><td>8 renal allograft recipients with BK-virus-associated nephropathy\n</td><td>88% of the patients were dialysis free and had stable renal function after follow-up of 15 months\n</td></tr><tr><td>[265] </td><td>Case report </td><td>IVIg 0.6 g/kg, 5 doses repeated every 4-6 weeks\n</td><td>A pediatric renal transplant patient recipients with BK-virus-associated nephropathy\n</td><td>Stabilized renal function, reduced viral load, and resolved histological findings were noted after IVIg treatment\n</td></tr><tr><td>ANCA-associated rapidly progressive\n</td><td>[266] </td><td>Case series </td><td>IVIg 0.4 g/kg per day for 5 days + CS \u00b1 CP after IVIg\n</td><td>Twelve patients with MPO-ANCA-associated RPGN (7\n</td><td>After IVIg treatment, a significant reduction was noted in white blood cell\n</td></tr><tr><td>glomerulonephritis (RPGN)\n</td><td>[58] </td><td>Case series </td><td>IVIg 0.4 g/kg per day for\n</td><td>men, 5 women)\n30 patients with MPO-\n</td><td>count (p&lt;0.05), in C-reactive protein values (p&lt;0.001), in Birmingham vasculitis; Activity Score (p&lt;0.001) and in the rate of change in 1/Cre (p&lt;0.05)\nAfter IVIg, significant\n</td></tr><tr><td>[267] </td><td>Case report </td><td>5 days +\nimmunosuppressive therapy\nIVIg (Omr-IgG-am5%IV)\n</td><td>ANCA-associated RPGN (male 17, female 13)\n</td><td>reduction in CRP (p&lt;0.001), improvement in serum creatinine in 63% of patients; at 3 months, disease activity was completely reduced; at 6 months, renal survival rate was 92% and life survival was 93%\nSignificant improvement in renal function after IVIg treatment\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>0.5 g/kg per day for 4 days after immunosuppressive therapy\n</td><td>A 68 year-old woman with RPGN\n</td></tr></table></body></html>"}, "TABREF19": {"text": "", "latex": null, "type": "table"}, "TABREF20": {"text": "The use of intravenous immunoglobulins in dermatologic diseases", "latex": null, "type": "table"}, "TABREF21": {"text": "", "latex": null, "type": "table"}, "TABREF22": {"text": "", "latex": null, "type": "table"}, "TABREF23": {"text": "", "latex": null, "type": "table"}, "TABREF25": {"text": "The use of intravenous immunoglobulins in endocrine disorders", "latex": null, "type": "table"}, "TABREF26": {"text": "", "latex": null, "type": "table"}, "TABREF27": {"text": "", "latex": null, "type": "table"}, "TABREF28": {"text": "", "latex": null, "type": "table"}, "TABREF29": {"text": "", "latex": null, "type": "table"}, "TABREF30": {"text": "", "latex": null, "type": "table"}, "TABREF31": {"text": "Level of evidence C There is weak evidence indicating significant benefit of IVIg in Rasmussen's encephalitis either used as monotherapy or combined with other therapies. It should be considered as one of the treatment options in this disease (strength of recommendation I).", "latex": null, "type": "table"}, "TABREF32": {"text": "PANDAS pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections", "latex": null, "type": "table"}, "TABREF33": {"text": "The use of intravenous immunoglobulins in immunodeficiencies", "latex": null, "type": "table"}, "TABREF34": {"text": "", "latex": null, "type": "table"}, "TABREF35": {"text": "", "latex": null, "type": "table"}, "TABREF36": {"text": "Common variable immune deficiencyLevel of evidence C Common variable immune deficiency (CVID) is an idiopathic hypoimmunoglobulinemia. World Health Organization diagnostic criteria are well established[32]. Both B and T cells dysfunction have been observed[33]. There are both theoretical logic and experimental evidences that support IVIg administration in CVID (strength of recommendation IIb).", "latex": null, "type": "table"}, "TABREF37": {"text": "myocarditis: a case of acute parvovirus myocarditis treated with intravenous immunoglobulin. Am J Med Sci 326:369-374 17. Ozdogu H, Boga C (2005) Fatal cardiac tamponade in a patient with Kawasaki disease. Heart Lung 34:257-259 18. Hunsaker DM, Hunsaker JC 3rd, Adams KC, Noonan JA, Ackermann DM (2003) Fatal Kawasaki disease due to coronary aneurysm rupture with massive cardiac tamponade. J Ky Med Assoc 101:233-238 19. Soncagi A, Devrim I, Karagoz T, Dilber E, Celiker A, Ozen S, Secmeer G (2007) Septated pericarditis associated with Kawasaki disease: a brief case report. Turk J Pediatr 49:312-314 20. Sherer Y, Kuechler S, Jose Scali J, Rovensky J, Levy Y, Zandman-Goddard G, Shoenfeld Y (2008) Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J 10:55-57 21. Peterlana D, Puccetti A, Simeoni S, Tinazzi E, Corrocher R, Lunardi C (2005) Efficacy of intravenous immunoglobulin in chronic idiopathic pericarditis: report of four cases. Clin Rheumatol 24:18-21 22. Shapiro S, Shoenfeld Y, Gilburd B, Sobel E, Lahat N (2002) Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer 95:2032-2037 23. Matsuura E, Kobayashi K, Inoue K, Shoenfeld Y (2005) Intravenous immunoglobulin and atherosclerosis. Clin Rev Allergy Immunol 29:311-319 24. Williams RV, Minich LL, Tani LY (2001) Pharmacological therapy for patients with Kawasaki disease. Paediatr Drugs 3:649-660 25. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 114:1708-1733 26. Nussinovitch U, Shoenfeld Y (2007) Neonatal lupus erythematosus-cardiac manifestations and atrio-ventricular conduction block. Harefuah 146(940-944):998 27. Kaaja R, Julkunen H (2003) Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon et al. Arthritis Rheum 48:280-281 author reply 281-282 28. Letko E, Miserocchi E, Daoud YJ, Christen W, Foster CS, Ahmed AR (2004) A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol 111:303-310 29. Sami N, Letko E, Androudi S, Daoud Y, Foster CS, Ahmed AR (2004) Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology 111:1380-1382 30. LeHoang P, Cassoux N, George F, Kullmann N, Kazatchkine MD (2000) Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul Immunol Inflamm 8:49-57 31. Hamill RJ, Musher DM, Groover JE, Zavell PJ, Watson DA (1992) IgG antibody reactive with five serotypes of Streptococcus pneumoniae in commercial intravenous immunoglobulin preparations. J Infect Dis 166:38-42 32. Pourpak Z, Aghamohammadi A, Sedighipour L, Farhoudi A, Movahedi M, Gharagozlou M, Chavoshzadeh Z, Jadid L, Rezaei N, Moin M (2006) Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect 39:114-120 33. Favre O, Leimgruber A, Nicole A, Spertini F (2005) Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and nonrespiratory infections in common variable immune deficiency. Allergy 60:385-390 34. Lekstrom-Himes JA, Gallin JI (2000) Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med 343:1703-1714 35. Katz U, Achiron A, Sherer Y, Shoenfeld Y (2007) Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 6:257-259 36. Misbah S (1996) Intravenous immunoglobulin in the Guillain-Barr\u00e9 syndrome. Products with low IgA content may be used in patients with total IgA deficiency. BMJ 313:1400 37. Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, Terryberry J, Meissner M, Lorber M, Peter JB, Shoenfeld Y (1999) A study of 20 SLE patients with intravenous immunoglobulin-clinical and serologic response. Lupus 8:705-712 38. Hundt M, Manger K, Dorner T, Grimbacher B, Kalden P, Rascu A, Weber D, Burmester GR, Peter HH, Kalden JR, Schmidt RE (2000) Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. Rheumatology (Oxford) 39:1301-1302 39. Schroeder JO, Zeuner RA, Euler HH, Loffler H (1996) High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 23:71-75 40. Micheloud D, Calderon M, Caparrros M, D'Cruz DP (2007) Intravenous immunoglobulin therapy in severe lupus myocarditis: good outcome in three patients. Ann Rheum Dis 66:986-987 41. Sherer Y, Levy Y, Shoenfeld Y (1999) Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 18:238-240 42. Arnal C, Piette JC, Leone J, Taillan B, Hachulla E, Roudot-Thoraval F, Papo T, Schaeffer A, Bierling P, Godeau B (2002) Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 29:75-83 43. Goodfield M, Davison K, Bowden K (2004) Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat 15:46-50 44. De Pita O, Bellucci AM, Ruffelli M, Girardelli CR, Puddu P (1997) Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus 6:415-417 45. Lampropoulos CE, Hughes GR, DC DP (2007) Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative. Clin Rheumatol 26:981-983 46. Genereau T, Chosidow O, Danel C, Cherin P, Herson S (1999) High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol 135:1124-1125 47. Zandman-Goddard G, Levy Y, Shoenfeld Y (2005) Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 29:219-228 48. Noursadeghi M, Aqel N, Gibson P, Pasvol G (2006) Successful treatment of severe Kikuchi's disease with intravenous immunoglobulin. Rheumatology (Oxford) 45:235-237 49. Chen JS, Chang KC, Cheng CN, Tsai WH, Su IJ (2000) Childhood hemophagocytic syndrome associated with Kikuchi's disease. Haematologica 85:998-1000 50. Vignes S, Wechsler B (1999) Still's disease in adults: treatment with intravenous immunoglobulins. Rev Med Interne 20(Suppl 4):419s-422s 51. Permal S, Wechsler B, Cabane J, Perrot S, Blum L, Imbert JC (1995) Treatment of Still disease in adults with intravenous immunoglobulins. Rev Med Interne 16:250-254", "latex": null, "type": "table"}, "TABREF38": {"text": "Table 2 (continued)", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>lupus (6), peripheral neuropathy (1), polyradiculoneuropathy (1)\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>For lupus nephritis, see kidney section\nFor Kawasaki disease, see cardiology section\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Kikuchi Disease </td><td>[48] </td><td>Case report </td><td>IVIg 0.4 g/kg per day for 3 days\n</td><td>A 35-year-old patient with Kikuchi, refractory to steroids and thalidomide\n</td><td>Adefinite improvement in her facial swelling occurred within\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>4 days, followed by gradual but complete resolution of lymphadenopathy over the subsequent 8 weeks, despite stopping steroid medication\n</td></tr><tr><td>\u00a0</td><td>[49] </td><td>Case report </td><td>IVIg 1 g/kg per day for 2 days, plus PD (2 mg/kg per day)\n</td><td>2 children who had Kikuchi complicated with hemophagocytic syndrome\n</td><td>One responded dramatically; second case responded partially to IVIg and fully after PD was added\n</td></tr><tr><td>Still's disease </td><td>[50] </td><td>Uncontrolled trial\n</td><td>Patients received monthly IVIg\n</td><td>7 patients unresponsive or poorly responsive to nonsteroidal anti-inflammatory drugs\n</td><td>5 patients responded after 4-6\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>treatments; 2 failed to respond\n</td></tr><tr><td>\u00a0</td><td>[51] </td><td>Uncontrolled trial\n</td><td>Between 1 and 8 IVIg monthly infusions with a dose of 1 g/kg per day for 2 days\n</td><td>7 patients suffering from adult Still's disease\n</td><td>All patients improved but relapsed after 3-24 months\n</td></tr><tr><td>\u00a0</td><td>[52] </td><td>Case report </td><td>2 courses of IVIg 1 g/kg for 2 days\n</td><td>23-year-old patient with\n</td><td>Significant clinical and laboratory improvement\n</td></tr><tr><td>Granulomatous arteritis (GA, Wegener's granulomatosis)\n</td><td>[53] </td><td>Multicentered RCT\n</td><td>14 patients received IVIg 2 g/kg in 5 days (sandoglobulin Novartis)\nvs. 14 placebo\n</td><td>flare-up of disease while taking salicylates at gestational week 22\n34 patients with ANCA-associated vasculitis (GA or MPA), refractory to CS or CP\n</td><td>Reduction in Birmingham Vasculitis Activity Score of 50% in 14/17 and 6/17 of the IVIg and placebo groups, respectively\n</td></tr><tr><td>[54] </td><td>Uncontrolled trial\n</td><td>Patients received IVIg (Sandoglobulin)\n</td><td>14 patients with GA who responded poorly to standard therapy\n</td><td>All patients were in full and partial remission after 8 weeks; clinical benefit was maintained a year later\n</td></tr><tr><td>\u00a0</td><td>[55] </td><td>Uncontrolled trial\n</td><td>Single or multiple courses\n</td><td>15 patients with GA who responded poorly to standard therapy\n</td><td>40% of patients benefited from IVIg treatment but without complete remission\n</td></tr><tr><td>\u00a0</td><td>[56] </td><td>Uncontrolled trial\n</td><td>of IVIg, 30 g/day, over 5 days\nMonthly IVIg, 0.4 g/kg for 5 days, 1-6 cycles (Isiven\n</td><td>10 patients with GA, CSS, or undifferentiated vasculitis which were refractory to standard treatment\n</td><td>IVIg treatment was found beneficial in 6 out of the 10 patients\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Instituto Sierovaccinogeno, Italiano ISI SpA.)\n</td></tr><tr><td>\u00a0</td><td>[57] </td><td>Uncontrolled trial\n</td><td>IVIg 0.5 g/kg per day for 4 days; Sandoglobulin (Sandoz, Basel, Switzerland)\n</td><td>3 patients with GA not treated with immunosuppressants before\n</td><td>One patient had full remission; one had transitional response; one had no response\n</td></tr><tr><td>Microscopic polyangitis (MPA)\n</td><td>[58] </td><td>Uncontrolled\n</td><td>IVIg 0.4 g/kg per day for\n</td><td>30 patients with MPA plus rapidly progressive glomerulonephritis\n</td><td>At 6 months, renal and general\n</td></tr><tr><td>\u00a0</td><td>trial\n</td><td>5 days, before or along with CS or CP (kenketsu velilon-I,\n</td><td>survival were 92% and 93%, respectively, compared to 70%\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Teijin Co., Ltd., Tokyo or kenketsu Glovenon-I, Nihon pharmaceutical Co., Ltd., Tokyo, Japan)\n</td><td>and 74% with conventional therapy in other studies\n</td></tr><tr><td>\u00a0</td><td>[57] </td><td>Uncontrolled\n</td><td>IVIg 0.5 g/kg per day for\n</td><td>3 patients with MPA not treated with immunosuppressants before\n</td><td>One patient had full remission; one had transitional response; one had no response\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>trial\n</td><td>4 days (Sandoglobulin, Sandoz, Basel, Switzerland)\n</td></tr></table></body></html>"}, "TABREF39": {"text": "Table 2 (continued)", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>[54] </td><td>Uncontrolled trial\n</td><td>Patients received IVIg (Sandoglobulin)\n</td><td>11 patients with MPA who responded poorly to standard therapy\n</td><td>8 weeks after IVIg, all patients were in full and partial remission, clinical benefit was maintained 12 months later in most patients\n</td></tr><tr><td>Churg-Strauss syndrome (CSS)\n</td><td>[59] </td><td>Controlled\n</td><td>All patients received PS and\n</td><td>18 patients with CSS </td><td>After 12 months, all patients in\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>trial\n</td><td>CP in severe cases; 9\n</td><td>\u00a0</td><td>the IVIg group and 4 (44%) in the control group were in remission; a significant\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>received monthly PP, followed by IVIg 1 g/kg\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>for 2 days (Ig vena N IVH; Sclavo, Siena, Italy)\n</td><td>\u00a0</td><td>favorable outcome was kept after 3 years (p&lt;0.01)\n</td></tr><tr><td>\u00a0</td><td>[60] </td><td>Case series </td><td>Daily IVIg 0.4 g/kg for 5 days\n</td><td>5 patients with cardiac CSS\n</td><td>Neuropathy improved; EF of\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>who showed poor response to PS \u00b1 CP patients improved from 35.2%\nto 61% (p&lt;0.02)\n</td></tr><tr><td>\u00a0</td><td>[56] </td><td>Case report </td><td>5-6 courses of monthly IVIg, each course 0.4 g/kg for 5 days (Isiven Instituto Sierovaccinogeno, Italiano ISI SpA.)\n</td><td>2 patients with CSS, nonresponsive to standard treatment\n</td><td>First patient had no improvement; second patient had clinical and laboratory improvement and was steroid-spared\n</td></tr><tr><td>Autoimmune hepatitis (AIH)\n</td><td>[61] </td><td>Case report </td><td>IVIg was initiated because of adverse affects of long-term steroid therapy\n</td><td>A patient with chronic AIH </td><td>Immediate clinical, serological, and histological improvement\n</td></tr><tr><td>Autoimmune features in hepatitis C virus (HCV) infection\n</td><td>[62] </td><td>RCT </td><td>IVIg 0.4 g/kg for 5 days, and then IFN alpha 3 times a week, compared to treatment with IFN alpha alone\n</td><td>42 patients with HCV and autoimmune phenomena\n</td><td>A higher percentage of patients who received IFN alpha plus\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>IVIg showed complete virological and histological responses\n</td></tr><tr><td>Henoch-\nSch\u00f6nlein purpura (HSP)\n</td><td>[63] </td><td>Cohort study </td><td>IVIg 1 g/kg for 2 days, every month for 3 months (Biotransfusion, Roissy, France)\n</td><td>11 adult patients with severe IgA nephropathy (9\n</td><td>Substantial improvement in glomerular filtration rate and\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>idiopathic, 2 with HSP)\n</td><td>kidney functions; 2 patients with HSP had resolution of other systemic symptoms\n</td></tr><tr><td>\u00a0</td><td>[64] </td><td>Case report </td><td>IVIg (Tegelines) 1 g/kg per day for 2 days\n</td><td>A 10-year-old boy with HSP and severe abdominal manifestations refractory to treatment with CS\n</td><td>Digestive symptoms disappeared within 3 days\n</td></tr><tr><td>\u00a0</td><td>[65] </td><td>Case report </td><td>Patient was treated with IVIg\n</td><td>A 26-year-old woman with HSP with nephrotic syndrome refractory to CS\n</td><td>Dramatic resolution\n</td></tr><tr><td>\u00a0</td><td>[66] </td><td>Case report </td><td>IVIg (polyglobulin N containing maltose) 0.4 g/ kg, for 2 days\n</td><td>46-year-old man with HSP and MPGN\n</td><td>Developed hemolysis and rapid deterioration renal function\n</td></tr><tr><td>\u00a0</td><td>[67] </td><td>Case report </td><td>IVIg 1 g/kg for 2 days </td><td>56-year-old man with HSP and severe digestive manifestations\n</td><td>The patient's purpura and abdominal syndrome improved dramatically\n</td></tr><tr><td>Mixed connective tissue disease\n</td><td>[68] </td><td>Case report </td><td>IVIg 0.4 g/kg for 5 days </td><td>A woman with MCTD and fasciitis\n</td><td>Quick improvement of her symptoms and decreased CRP\n</td></tr><tr><td>(MCTD)\n</td><td>[69] </td><td>Case report </td><td>Patient was treated with IVIg\n</td><td>A 69-year-old man with MCTD and nonresponsive skin eruptions\n</td><td>Successful control of disease\n</td></tr><tr><td>Systemic sclerosis (SSc)\n</td><td>[70] </td><td>Controlled trial\n</td><td>IVIg 0.4 g/kg daily for 5 days, monthly for 3-6 cycles\n</td><td>15 patients with SSc </td><td>Treatment resulted in significant improvement in quality of life (p=0.03) and a decrease in Rodnan skin score (p&lt;0.001)\n</td></tr><tr><td>[71] </td><td>Case series </td><td>IVIg 0.4 g/kg daily for 5 days\n</td><td>5 patients with diffuse SSc </td><td>Marked long-term improvement in skin thickness from 2 weeks of treatment (p&lt;0.01)\n</td></tr><tr><td>\u00a0</td><td>[72] </td><td>Controlled trial\n</td><td>Monthly IVIg 0.4 g/kg for 4 days, for 6 months\n</td><td>7 female patients with SSc (5 limited, 2 diffuse), with\n</td><td>Significant improvement in joint swelling and pain (p&lt;0.03), as\n</td></tr></table></body></html>"}, "TABREF40": {"text": "Table 2 (continued)", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients a severe refractory joint involvement\n</td><td>Results/response\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>well as skin score (p&lt;0.003), after 6 months of therapy\n</td></tr><tr><td>\u00a0</td><td>[73] </td><td>Case report </td><td>3-6 cycles of IVIg 0.4 g/kg for 5 days; ISIVEN\n(Instituto Sierovaccinogeno, Italiano ISI SpA, Italy)\n</td><td>3 patients with rapid deteriorating SSc refractory to treatment\n</td><td>All patients had a significant decrease in their skin score\n</td></tr><tr><td>\u00a0</td><td>For scleromyxedema, see dermatology section\nFor Evan's syndrome, see hematology section\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Juvenile rheumatoid arthritis (JRA)\n</td><td>[74] </td><td>Multicentered\n</td><td>Bimonthly IVIg 1.5-2.0 g/\n</td><td>25 patients with resistant\n</td><td>19 (76%) had moderate to large improvement; the group which switched to placebo showed rapid loss of this effect\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>RCT\n</td><td>kg for the first 2 months, then monthly for up to 6 months (Iveegam, Immuno AG, Vienna) after 3 and a half months was switched to placebo\n</td><td>JRA\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>[75] </td><td>RCT </td><td>Patients were additionally treated with high-dose\nIVIg or MP\n</td><td>20 patients with JRA treated with MTX and CS\n</td><td>Clinical effects were rapid in both groups\n</td></tr><tr><td>\u00a0</td><td>[76] </td><td>Retrospective cohort\n</td><td>IVIg monthly for 3-\n54 months\n</td><td>27 patients with systemic JRA\n</td><td>20 patients responded after\n6 months, especially systemic features and CS dependence\n</td></tr><tr><td>\u00a0</td><td>[77] </td><td>Controlled trial\n</td><td>High-dose IVIg </td><td>16 children with severe juvenile chronic arthritis\n</td><td>Mild-moderate systemic, articular and laboratory improvement in most patients\n</td></tr><tr><td>Rheumatoid arthritis (RA)\n</td><td>[78] </td><td>RCT </td><td>IVIg 5 g/kg every 3 weeks for 6 courses vs albumin\n</td><td>20 patients with refractory RA\n</td><td>No significant differences between treatment groups were noted during the 18-week trial\n</td></tr><tr><td>[79] </td><td>Controlled trial\n</td><td>Patients were treated with IVIg\n</td><td>11 patients with refractory RA\n</td><td>In 6 patients, clinical results were impressive; lasting responses could be achieved in 3 patients only\n</td></tr><tr><td>\u00a0</td><td>[80] </td><td>Case report </td><td>IVIg 1 g per day for 2 days, monthly for 3 months\n</td><td>4 patients with severe refractory RA who have failed at least 4 second-line drugs\n</td><td>None of the patients improved or worsened\n</td></tr><tr><td>\u00a0</td><td>[81] </td><td>Case report </td><td>IVIg 0.4 g/kg for 5 days </td><td>A 50-year-old woman with acute systemic RA\nrefractory to treatment with CS, CP, or PP\n</td><td>Clinical improvement 3 days after IVIg treatment\n</td></tr><tr><td>Sj\u00f6gren's disease </td><td>[82] </td><td>Case series </td><td>3 monthly courses of IVIg\n</td><td>5 Sj\u00f6gren patients complicated with ataxic sensory neuropathy, refractory to CS or PP\n</td><td>4 patients showed remarkable\n</td></tr><tr><td>\u00a0</td><td>0.4 g/kg body for 5 days\n</td><td>improvement, 2 of whom responded after the first course\n</td></tr><tr><td>\u00a0</td><td>[83] </td><td>Case report </td><td>IVIg 0.4 g/kg for 5 days </td><td>A patient with long-standing Sj\u00f6gren's that developed a painful sensory neuropathy\n</td><td>Remarkable clinical improvement and reduction of pain\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Case report </td><td>[84] IVIg 0.4 g/kg for 5 days every 3 weeks\nFor antiphospholipid syndrome, see gyneco-obstetric section\n</td><td>A patient with Sj\u00f6gren syndrome complicated with ataxic sensory neuropathy\n</td><td>Remarkable improvement that subsided after switching to CS but regained after reintroduction to IVIg despite withdrawal of CS\n</td></tr><tr><td>Polymyositis (PM) and dermatomyositis\n(DM)\n</td><td>[85] </td><td>RCT </td><td>Received PD 25 mg plus\n</td><td>15 patients with treatment-resistant DM\n</td><td>Significant improvement of muscle strength (p&lt;0.018) and\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>IVIg 2 g/kg or placebo every month for 3 months\n</td><td>neuromuscular symptoms (p&lt; 0.035), with IVIg treatment compared to placebo\n</td></tr><tr><td>\u00a0</td><td>[86] </td><td>Controlled trial\n</td><td>IVIg or standard therapy </td><td>16 patients with PM or DM </td><td>Clinical and functional remission in a higher percentage (81%) that\n</td></tr></table></body></html>"}, "TABREF41": {"text": "Table 2 (continued)", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>was maintained after a mean 5-year follow-up period, as\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Controlled trial\n</td><td>IVIg 0.4 g/kg per day for\n</td><td>15 patients with Dm (7) or\n</td><td>compared to control group (p&lt;0.001)\n</td></tr><tr><td>\u00a0</td><td>[87] </td><td>Significant improvement in muscle strength, daily activity scores with no severe adverse reactions\n</td></tr><tr><td>Inclusion Body myositis (IBM)\n</td><td>[88] </td><td>RCT </td><td>5 days in addition to CS (Benesis Corporation, Osaka, Japan). Randomized to receive IVIg\n</td><td>PM (8), who were refractory to traditional CS therapy\n</td><td>No clinical significant difference\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>or placebo monthly for 3 months\n</td><td>36 patients with IBM, treated with high dose PD\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>[89] </td><td>RCT </td><td>IVIg 2 g/kg Vs placebo </td><td>22 patients with sporadic inclusion body myositis\n</td><td>No significant changes between groups according to modified Medical Research Council (MRC) score; mild improvement with IVIg according to Neuromuscular Symptom Score (NSS)\n</td></tr><tr><td>\u00a0</td><td>[90] </td><td>RCT </td><td>IVIg 2 g/kg vs placebo monthly for 3 months\n</td><td>19 patients with IBM </td><td>No significant changes between the groups according to MRC score; significant improvement in swallowing with IVIg (p&lt;0.05)\n</td></tr><tr><td>Behcet's disease\n(BD)\n</td><td>[91] </td><td>Case series </td><td>0.4 g/kg daily of IVIg (Omr-\nIgG-am, a 5% solution of human normal immunoglobulin G; Omrix Biopharmaceuticals Ltd, Nes-Ziona, Israel) 5 times in the first week, an additional 3 applications in the first month, once every 20 days for the next 3 months, then\n</td><td>6 eyes of 4 patients with ocular BD refractory to CS and cyclosporin A\n</td><td>All 6 eyes of all 4 patients showed good response to IVIg therapy\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>every 6 weeks for 1 year\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>[92] </td><td>Case report </td><td>IVIg was started with 5\n</td><td>A 28-year-old man with BD suffering from severe leg, mouth, and scrotal ulcers and phlebitis resistant to immunosuppressants\n</td><td>After 4 days, the ulcers started to\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>daily doses of 0.4 g/kg\n</td><td>heal; 2 months later, the patient became totally pain free and walked without limping\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>followed by reinforcement doses of 0.4 g/kg at 2-week intervals\n</td></tr></table></body></html>"}, "TABREF42": {"text": "Table 4 (continued)", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients. </td><td>Results/response\n</td></tr><tr><td>[192] </td><td>RCT </td><td>Patients received IVIg (36 g) versus 0.03% albumin\n</td><td>150 trauma patients in ICU ventilated for &gt;24 h\n</td><td>Decreased overall incidence of infection (p=0.02) and antibiotic need in IVIg group\n</td></tr><tr><td>\u00a0</td><td>[193] </td><td>RCT </td><td>Ten patients received IVIg and ten albumin\n</td><td>20 patients with extensive thermal injury\n</td><td>No statistically significant difference was found between mortality rates of the groups\n</td></tr><tr><td>\u00a0</td><td>[194] </td><td>RCT </td><td>18 received IVIg, 0.4 g/kg, and 14 placebo within 48 h of admission\n</td><td>33 children (mean age, 6.67 years) with severe head injuries\n</td><td>No effect on the incidence of secondary infections\n</td></tr><tr><td>\u00a0</td><td>[195] </td><td>RCT </td><td>Within 12 h of ICU admission, 1 g/kg of IVIg or human albumin divided over 4 days\n</td><td>39 trauma patients in an ICU\n</td><td>No difference in overall infection rates, but fewer\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>pneumonias (p=0.003) and non-catheter-related infections\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>(p=0.04); no difference in ICU length of stay or antibiotic use\n</td></tr><tr><td>\u00a0</td><td>[196] </td><td>RCT </td><td>Patients were randomly assigned to either 20 g IVIg or saline\n</td><td>40 postoperative open-heart surgery patients with cutaneous anergy preoperatively\n</td><td>Infection incidence 5% in IVIg versus 43% placebo (p=0.007)\n</td></tr><tr><td>Prophylaxis for infections (in immune-compromised patients)\n</td><td>[143] </td><td>RCT </td><td>82 received IVIg weekly,\n0.5 g/kg, from the initiation of cytotoxic therapy to the\n</td><td>170 neutropenic patients undergoing BMT or severe myelosuppressive therapy\n</td><td>The use of IVIg did not prevent infection; fewer deaths occurred among controls due to a higher incidence of fatal hepatic veno-occlusive disease in patients receiving IVIg\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>resolution of neutropenia and 88 were untreated controls\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>[197] </td><td>RCT </td><td>Monthly IVIg 0.4 g/kg or placebo for 1 year\n</td><td>82 patients with stable multiple myeloma\n</td><td>Less infection sepsis in the IVIg group (p=0.002)\n</td></tr><tr><td>Necrotizing fasciitis (NF)\n</td><td>[198] </td><td>Controlled trial\n</td><td>16 were treated with \u22651 mg/kg of IVIg; all were treated with antibiotics and debridement\n</td><td>20 patients with NF </td><td>No difference in case fatality\n</td></tr><tr><td>[199] </td><td>Controlled\n</td><td>Patients were treated with effective antimicrobials, high-dose IVIg; surgery was either not performed or only limited exploration was carried out\n</td><td>7 patients with severe\n</td><td>All patients survived\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>trial\n</td><td>NF\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>[200] </td><td>Controlled trial\n</td><td>Patients that had hypotension and multiorgan failure were treated with a single dose of IVIg 50 g in addition to antibiotics\n</td><td>11 patients with toxic shock syndrome with or without NF\n</td><td>Ten patients were fully recovered\n</td></tr><tr><td>\u00a0</td><td>[201] </td><td>Case report </td><td>Patient declined on antibiotic therapy and was treated with IVIg, 0.4 g/kg (Omr-IgG-am 5% IV, Omrix, Israel)\n</td><td>A renal transplant lupus patient with NF\n</td><td>A marked improvement in patient's condition on the next day\n</td></tr><tr><td>Recurrent otitis media (OM)\n</td><td>[202] </td><td>RCT </td><td>IVIg or placebo </td><td>22 otitis-prone children, 1-4 years old\n</td><td>No significant difference in the frequency ofOMattacks or other respiratory tract IVIg group\n</td></tr><tr><td>[203] </td><td>Controlled\n</td><td>IVIg </td><td>9 children with recurrent sinopulmonary\ninfections which failed to improve after antibiotic Tx\n</td><td>Significant decrease in the episodes of sinusitis and OM\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>trial\n</td><td>\u00a0</td></tr><tr><td>Varicella (transmission prevention)\n</td><td>[204] </td><td>Controlled trial\n</td><td>IVIg prophylaxis (single-dose 0.5 g/kg) administered soon after birth or postnatal contact, either alone or with IV acyclovir\n</td><td>24 newborns whose mother had a varicella\n</td><td>Treatment with IVIg + acyclovir effectively prevented perinatal varicella\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>rash within 14 days before and after delivery\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>[205] </td><td>Controlled\n</td><td>IVIg 0.04 to 0.045 g/kg per day\n</td><td>5 infants whose mothers had varicella\n</td><td>Some had a mild-moderate transient rash but none had constitutional symptoms\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>trial\n</td><td>for 5 to 9 days was given soon after birth, along with acyclovir\n</td></tr></table></body></html>"}, "TABREF43": {"text": "Table 4 (continued)", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients. </td><td>Results/response\n</td></tr><tr><td>Varicella (pulmonary disease)\n</td><td>[206] </td><td>Case report </td><td>IVIg and IV acyclovir </td><td>2 cases of varicella infection complicated by severe pulmonary involvement previously healthy adults\n</td><td>Gradual clinical improvement after administration\n</td></tr><tr><td>[207] </td><td>Case report </td><td>IVIg, 2.5 g every 12 h, with IV acyclovir and ABx\n</td><td>A healthy adult with severe respiratory failure due to varicella pneumonia\n</td><td>Gradual clinical improvement after administration\n</td></tr><tr><td>\u00a0</td><td>[208] </td><td>Case report </td><td>IVIg and IV acyclovir </td><td>32-year-old patient with varicella and ARDS\n</td><td>Quick improvement\n</td></tr><tr><td>\u00a0</td><td>[209] </td><td>Case report </td><td>Patient was mechanically ventilated and treated with\n</td><td>26-year-old with\n</td><td>Quick improvement\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>ARDS secondary to varicella pneumonia\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>IVIg and acyclovir\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Varicella (complicated with ITP)\n</td><td>[210] </td><td>Case report </td><td>IVIg </td><td>ITP in a 3-year-old girl with an active\nvaricella infection\n</td><td>Drastically improved bleeding and active varicella infection\n</td></tr><tr><td>[211] </td><td>Case report </td><td>IVIg, 0.4 g/kg per day for\n</td><td>40-year-old with bleeding due to varicella-related ITP\n</td><td>The platelet counts increased to\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>3 days, and acyclovir\n</td><td>254,000 per microliter over the next 5 days, and the skin rashes associated with varicella\n</td></tr></table></body></html>"}, "TABREF44": {"text": "Table 5 (continued)", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>[220] </td><td>RCT </td><td>IVIg (Nordimmun, Novo-Nordisk, Gentofte,\nDenmark) 25-40 g per dose according to patient weight every 2 weeks until week 34 of pregnancy or placebo\n</td><td>34 women with secondary recurrent spontaneous abortion (subsequent to a birth or including at least one second trimester miscarriage)\n</td><td>More live births but not statistically significant in the IVIg group (52.9% against 29.4%)\n</td></tr><tr><td>[221] </td><td>RCT </td><td>IVIg initial dose 30 g, then 20 g every 3 weeks until week 25 (Verum, Immuno GmbH, Heidelberg, Germany) or placebo\n</td><td>64 women with primary recurrent spontaneous abortion\n</td><td>No benefit of IVIg\n</td></tr><tr><td>Recurrent pregnancy loss in antiphospholipid syndrome\n[222] </td><td>Meta-analysis </td><td>IVIg given in addition to heparin and aspirin\n</td><td>58 women with recurrent miscarriages due to\n</td><td>Increased risk of pregnancy loss or premature birth in the group receiving IVIg\n</td></tr><tr><td>\u00a0</td><td>antiphospholipid syndrome in 2 RCTs\n</td></tr><tr><td>[223] </td><td>Randomized trial\n</td><td>21 women received IVIg (IgVENA N; Sclavo, Siena, Italy) at the dose of 0.8 g/kg\n</td><td>40 women with at least 3 abortions due to antiphospholipid syndrome were treated since conception with IVIg or heparin + aspirin\n</td><td>More live births (84% against 57%, not significant difference) in\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>over 2 consecutive days as initial dose followed by 0.4 g/kg each month up to week 31; 19 women received aspirin 75 mg/day up to week 34 + heparin 5,700 IU/day up to week 37\n</td><td>the aspirin + heparin group (p=0.06)\n</td></tr><tr><td>[224] </td><td>RCT </td><td>IVIg 2 g/kg (Gamimune-N, Bayer Corporation, West\n</td><td>16 pregnant women (no more than 12 weeks'\n</td><td>No benefit of IVIg\n</td></tr><tr><td>[225] </td><td>Prospective two-center trial study\nCase series </td><td>Haven, CT, USA) over 2 days every 4 weeks through 36 weeks' gestation\n29 were treated with PD and\n</td><td>gestation) with recurrent miscarriages due to antiphospholipid syndrome received low-dose aspirin and heparin and received random IVIg or placebo 82 pregnant women with a\n</td><td>Live-birth rates were\n</td></tr><tr><td>[226] </td><td>LDA; 53 received IVIg 0.5 g/kg (Alphaglobin, Grifols International, Pisa, Italy) for 2 consecutive days, once a month from the 5th to the 32nd week of pregnancy Patients were treated with\n</td><td>history of recurrent fetal loss and APS\n19 pregnancies of 15 women with APS and recurrent fetal loss\n</td><td>equivalent between groups (78% vs 76%), mean birth weight was higher in the IVIg group gestational hypertension and diabetes were found significantly more often in the PD group (14% vs 5%), respectively (p&lt;0.05)\nThe live-birth rate was 84%;\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>heparin (15), LDA (18), and\nCS (6); additionally, they received IVIg 0.4 g/kg for 5 days monthly from the first or early second trimester In phase III, they received heparin + LDA with or without IVIg\n</td><td>compared to approximately 70% described in literature without IVIg\n</td></tr><tr><td>\u00a0</td><td>[227] </td><td>Controlled trial </td><td>121 women with APS, who failed to achieve live births after 2 IVF attempts with heparin + LDA\n</td><td>The birth rate was 41% when IVIg was added and anti-PS or anti-PE involving IgG or IgM isotypes were present, as compared with 17% when\n</td></tr></table></body></html>"}, "TABREF45": {"text": "Table 5 (continued)", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>[228] </td><td>Controlled trial </td><td>IVIg 0.3 g/kg every 3 weeks until the 16th to 17th week of pregnancy\n</td><td>38 women after 3 or more consecutive first trimester spontaneous abortions and APS\n</td><td>Pregnancy proceeded beyond the first trimester in 34 of the patients (89.4%), and 31 patients (81.4%) gave birth to healthy infants at 37 to 42 weeks' gestation\n</td></tr><tr><td>[229] </td><td>Case control </td><td>IVIg 0.5 g/kg for 2 days from the fifth week of pregnancy and repeated\n</td><td>14 women with a history of recurrent spontaneous abortion and APLA\n</td><td>No significant biometrical differences between the groups were seen; no fetal or neonatal growth retardation was seen\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>every 4 weeks until the\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>33rd week of gestation\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Data were compared to 70 matched uneventful pregnancies\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Premature rupture of membranes\n[230] </td><td>RCT </td><td>IVIg (Pentaglobin, Biotest, Frankfurt/Main, Germany) 20 g, 24-48 h after premature rupture of membranes; thereafter, 10 g was administered in weekly intervals\n</td><td>18 women with premature rupture of membranes\n</td><td>Infants in treated group showed less laboratory and clinical signs compatible with prenatally acquired infection (p&lt;0.002); less chorioamnionitis in treatment group (p&lt;0.036)\n</td></tr><tr><td>Failure of in vitro\nfertilization\n[231] </td><td>Meta-analysis </td><td>IVF along with or without\n</td><td>Women with IVF failure </td><td>Improvement in live-birth\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>IVIg\n</td><td>\u00a0</td><td>rate (p=0.012)\n</td></tr><tr><td>[232] </td><td>RCT </td><td>IVIg (Gamimune 5%, Bayer Canada Inc., Etobicoke,\n</td><td>51 women after IVF failure </td><td>No significant improvement in implantation, pregnancy, or live birth rate\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Canada) 0.5 g/kg or placebo (saline), first infusion on the day of embryo transfer or\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>during preceding 72 h,\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>second infusion 4 weeks later upon evidence of embryonic heart activity\n</td></tr></table></body></html>"}, "TABREF46": {"text": "Table 6 (continued)", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>[243] </td><td>Multicenter RCT\n</td><td>Single infusion of 2 or 0.4 g/kg for 4 days; both received\n</td><td>549 children with KD </td><td>Single-dose patients had less fever (p=0.001),\ninflammatory markers, and\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>aspirin (100 mg/kg per day\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>through the 14th day of illness,\n</td><td>\u00a0</td><td>CAA (p=0.004)\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>then 3 to 5 mg/kg per day)\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Rheumatic fever\n</td><td>[244] </td><td>RCT </td><td>IVIg (Intragam, from\n</td><td>59 patients with RF, diagnosed according to\n</td><td>IVIg did not affect the natural history of RF during\n</td></tr><tr><td>(RF)\n</td><td>\u00a0</td><td>\u00a0</td><td>Common wealth Serum\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Laboratories) 1 g/kg on days\n</td><td>Jones criteria; 27 patients\n</td><td>52 weeks of follow-up\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>1 and 2 and 0.4 g/kg on days 14 and 28\n</td><td>received IVIg and 32 patients received placebo\n</td><td>\u00a0</td></tr><tr><td>Congenital heart block\n</td><td>[27] </td><td>Case series </td><td>1 gm/kg IVIg (Sandoglobulin; Novartis, Bern,\n</td><td>8 pregnant women with past history of an affected child with neonatal lupus\n</td><td>1 child was born with erythematosus skin rash,\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Switzerland), at 14th and\n</td><td>and 1 child had congenital heart block-interestingly, his mother was the only patient that refused PD intake\n</td></tr><tr><td>Awaiting for cardiac transplantation\n</td><td>[245] </td><td>Controlled trial </td><td>18th weeks of gestation; PD (40 mg/day) from the 14th week, which was tapered down to 10 mg/day 1 to 3 monthly courses of IVIg 2 g/kg administered in 4 divided daily doses or high-dose IVIg therapy (3 g/kg) in poorly responsive patients; all patients received monthly 0.5-1.0 g/m2 cyclosporine\n</td><td>16 sensitized patients with left ventricular assist device (LVAD) awaiting cardiac transplantation; results were compared to plasmapheresis (n=4) and to cyclosporine alone (n=28)\n</td><td>Within 1 week of infusion of IVIg, the reactivity of IgG antibodies for allogeneic HLA class I molecules was reduced by a mean of 33%; high-dose IVIg for unresponsive patients resulted in a mean reduction of 20%; IVIg has earlier onset of action and greater efficacy than plasmapheresis; waiting time for donation was significantly reduced\n</td></tr></table></body></html>"}, "TABREF47": {"text": "Table 7 (continued)", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\ntreatment discontinuation; the Behcet patient showed marked improvement\n</td></tr><tr><td>[255] </td><td>Case series </td><td>IVIg, 1-2.5 g/kg per cycle over 3 days; cycles were\n</td><td>5 patients unresponsive to conventional therapy, of\n</td><td>In 60% (2 idiopathic cases, 1 patient with vasculitis and\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>repeated every 2-4 weeks\n</td><td>which 1 patient had juvenile\n</td><td>APLA), treatment was effective in controlling inflammation, and visual acuity remained stable or improved\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>initially and every 5 to\n</td><td>idiopathic arthritis and 1 patient had psoriatic arthritis;\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>6 weeks after effect was observed; treatment time\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>1 patient had retinal\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>averaged at 16.8 months\n</td><td>vasculitis and APLA; the other 2 cases were idiopathic\n</td></tr><tr><td>Graves'\nophthalmopathy\n[256] </td><td>Prospective nonrandomized\n</td><td>35 patients were treated with IVIg and 27 with CS\n</td><td>62 patients with Graves'\nophthalmopathy\n</td><td>76% response in IVIg-treated patients compared to 66% in CS group, in a manner that was statistically insignificant; side effects were more common in patients receiving CS therapy\n</td></tr><tr><td>[257] </td><td>RCT </td><td>21 patients were treated with 6 cycles of 1 g/kg IVIg for 2 days every 3 weeks; 19 patients were treated with oral prednisolone (starting dose 100 mg/day)\n</td><td>40 patients </td><td>No marked difference\n</td></tr><tr><td>Paraneoplastic visual loss\n[258] </td><td>Case series </td><td>2 patients were treated with IVIg 0.4 mg/kg per day for 5 days; 1 patient received single-dose d/t treatment intolerance\n</td><td>3 patients </td><td>between IVIg (62% response) and prednisolone (63% response); both groups had significantly improved proptosis, visual acuity, decrease of intraocular pressure, and decrease of eye muscle area 1st patient improved from distinguishing hand\nmovement to 20/40 and 20/ 50OS; improved visual fields\n2nd patient, no improvement\n3rd patient, improved visual field without change in visual acuity\n</td></tr><tr><td>[259] </td><td>Case report </td><td>IVIg, as well as radiotherapy and surgical resection\n</td><td>1 patient with melanoma-associated retinopathy\n</td><td>Improvement in visual fields over 1 year of follow-up\n</td></tr></table></body></html>"}, "TABREF48": {"text": "Table 12 The use of intravenous immunoglobulins in neurological diseases", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>Opsoclonus myoclonus [344] </td><td>Case reports </td><td>IVIg 3 doses of 0.3 g/kg\n</td><td>2 patients with postinfectious opsoclonus myoclonus syndrome\n</td><td>Significant clinical improvement without relapses\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>over 4 months + rituximab\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>[345] </td><td>Case report </td><td>IVIg 0.4 g/kg per day for 5 days + prednisolone + clonazepam\n</td><td>A 41-year-old woman with idiopathic opsoclonus myoclonus syndrome\n</td><td>Complete recovery\n</td></tr><tr><td>[346] </td><td>Case report </td><td>IVIg 30 g/day for 5 days with 5 repeated doses after 2 months + CS\n</td><td>A 36 year-old man with parainfectious opsoclonus myoclonus syndrome\n</td><td>Accelerated recovery\n</td></tr><tr><td>[347] </td><td>Case report </td><td>IVIg + ACTH + CS </td><td>A patient with childhood-onset opsoclonus\nmyoclonus\n</td><td>Partial recovery\n</td></tr><tr><td>[348] </td><td>Case report </td><td>IVIg initially 5.5 g and 6 additional courses at a\n</td><td>A 22-month-old girl with neuroblastoma-associated opsoclonus myoclonus\n</td><td>Partial recovery\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>dosage of 2.5 g and 7 courses at a dosage of 5 g every 2 to 3 weeks + ACTH\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>[349] </td><td>Case report </td><td>IVIg + ACTH </td><td>A 27-year-old woman with severe opsoclonus\nmyoclonus\n</td><td>Complete recovery\n</td></tr><tr><td>[350] </td><td>Case report </td><td>IVIg 1 g/kg for 2 days with 12 additional doses given every 4-6 weeks\n</td><td>An 18-month-old black girl with neuroblastoma-associated opsoclonus myoclonus\n</td><td>Complete recovery\n</td></tr><tr><td>[351] </td><td>Case report </td><td>High-dose IVIg </td><td>A 14-month-old male with infantile opsoclonus myoclonus\n</td><td>Complete recovery\n</td></tr><tr><td>[352] </td><td>Retrospective study\n</td><td>IVIg + CS </td><td>9 patients with idiopathic and paraneoplastic\nopsoclonus myoclonus\n</td><td>Idiopathic opsoclonus myoclonus: 2/9 complete recovery, 1/9 partial recovery, 2/9 remission\nParaneoplastic opsoclonus\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>myoclonus: 3/9 no response,\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>1/9 partial recovery\n</td></tr><tr><td>PANDAS [353] </td><td>RCT </td><td>IVIg I g/kg per day for\n</td><td>29 children with severe infection-triggered exacerbations of obsessive-compulsive disorder (OCD) or tic disorders, including\n</td><td>At 1 month, significant improvement in global\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>2 days vs PP vs placebo\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>impairment (p=0.0009), obsessive- compulsive\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>symptoms (p=0.006),\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>anxiety (p=0.001),\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Tourette syndrome\n</td><td>depression (0.002); at\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>1 year, more than 80% of patients receiving IVIg or\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>PP remained improved\n</td></tr><tr><td>Multiple sclerosis (MS) [354] </td><td>RCT </td><td>IVIg 0.2 g/kg-0.4 g/kg\n</td><td>127 patients with relapsing-\nremitting multiple sclerosis (RRMS)\n</td><td>At 1 year, there was no significant difference in the proportion of relapse-free patients among treated groups\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>every 4 weeks for 48 weeks vs placebo\n</td><td>\u00a0</td></tr><tr><td>[355] </td><td>RCT (primary and secondary chronic progressive\n</td><td>IVIg 0.4 g/kg per month for 24 months vs placebo\n</td><td>231 patients with primary (PPMS) and secondary (SPMS) chronic progressive MS\n</td><td>IVIg can delay progression of disease in primary chronic progressive MS; no significant difference in progression was noted for secondary chronic progressive MS; no\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>MS)\n</td></tr></table></body></html>"}, "TABREF49": {"text": "Table 12 (continued)", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>[356] </td><td>RCT\n</td><td>Monthly IVIg 1 g/kg for\n</td><td>34 patients with secondary progressive (SP) MS\n</td><td>No reduction in the relapse rate or the progression of disability\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>(secondary progressive\n</td><td>27 months vs placebo\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>MS)\n</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>[357] </td><td>Retrospective\n</td><td>IVIg treatment at a mean\n</td><td>308 patients with RRMS </td><td>69% reduction of mean annual relapse rate was observed after IVIg treatment initiation\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>study\n</td><td>time of 3.4\u00b11.8 years at a\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>(relapsing-\nremitting MS)\n</td><td>mean dose of 15.5\u00b1\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>8.3 g/month\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>[358] </td><td>RCT\n</td><td>IVIg 1 g/kg per month for\n</td><td>318 patients with secondary progressive multiple sclerosis\n</td><td>No effect on the time to confirmed progression on\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>(secondary progressive MS)\n</td><td>27 months vs placebo\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>the EDSS, annual relapse rate, and the change in T2 lesion load on MRI\n</td></tr><tr><td>\u00a0</td><td>[359] </td><td>Meta-\n</td><td>IVIg 0.15-2 g/kg for 12-\n</td><td>4 RCT (265 patients with\n</td><td>Significant beneficial effect:\n</td></tr><tr><td>\u00a0</td><td>[360] </td><td>analysis RCT </td><td>24 months vs placebo IVIg 0.15-0.2 g/kg per\n</td><td>RRMS)\n148 patients with RRMS </td><td>on the annual relapse rate (p=0.00003), on the proportion of relapse-free patients (p=2.1\u00d710\u22128) Progression of disability\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>month for 2 years vs placebo\n</td><td>\u00a0</td><td>was reduced in 24% of the patients with therapeutic efficacy to be noted in the\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>first 6 months of the treatment\n</td></tr><tr><td>\u00a0</td><td>[361] </td><td>RCT\n</td><td>IVIg 0.4 g/kg for 5 days followed by once every\n</td><td>40 patients with RRMS </td><td>Reduction in yearly exacerbation rate (p=\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>(relapsing remitting MS)\n</td><td>2 months for 2 years vs placebo\n</td><td>\u00a0</td><td>0.0006 (overall))\n</td></tr><tr><td>\u00a0</td><td>[362] </td><td>RCT\n</td><td>IVIg 1 g/kg for 2 days every\n</td><td>17 patients with relapsing-\nremitting or relapsing progressive multiple sclerosis\n</td><td>11 had no exacerbations during IVIg treatment\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>(relapsing remitting\n</td><td>4 weeks for 24 weeks vs placebo\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>compared with only 6 on\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>MS)\n</td><td>\u00a0</td><td>\u00a0</td><td>placebo (p=0.05)\n</td></tr><tr><td>Guillain-Barr\u00e9 syndrome (GBS)\n</td><td>[363] </td><td>Systematic reviewmeta-analysis\n</td><td>IVIg 0.2-1 g/kg per day for\n</td><td>11 RCT (913 patients) </td><td>Improvement on the disability grade scale with intravenous immunoglobulin (IVIg),\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>2-6 days vs PP vs immunoabsorption vs supportive care\n</td></tr></table></body></html>"}, "TABREF50": {"text": "Table 12 (continued)", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>\u00a0</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>RCT (IgG\n</td><td>Intervention including dose and IVIg preparation used\n</td><td>24 patients with Guillain-\n</td><td>to assisted walking in ventilated patients in the 6-day group (p=0.04) IVIg-treated patients had:\n</td></tr><tr><td>\u00a0</td><td>[366] </td><td>IVIg vs plasmapheresis </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>anti-GM1-\n</td><td>\u00a0</td><td>Barr\u00e9 syndrome\n</td><td>significantly lower Hughes\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>grade scores 1, 3, and\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>positive subgroup)\n</td><td>\u00a0</td><td>\u00a0</td><td>6 months after onset (p= 0.03); higher probability to regain independent locomotion at 6 months (p=0.044); more frequent rapid recovery within 4 weeks (p=0.03)\n</td></tr><tr><td>\u00a0</td><td>[367] </td><td>RCT </td><td>IVIg 0.4 g/kg per day for\n</td><td>379 adult patients with\n</td><td>IVIg is equivalent to\n</td></tr><tr><td>\u00a0</td><td>[368] </td><td>RCT </td><td>5 days vs plasma exchange IVIg 0.4 g/kg per day for\n</td><td>Guillain-Barr\u00e9 syndrome\n150 patients with Guillain-\n</td><td>plasmapheresis in reducing the amount of disability at 4 weeks after treatment\n53% of patients treated with\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>5 days vs plasma exchange\n</td><td>Barr\u00e9 syndrome\n</td><td>IVIg improved compared\n</td></tr><tr><td>Paraproteinemic neuropathy (IgM)\n</td><td>[369] </td><td>\u00a0</td><td>\u00a0</td><td>5 trials (97 patients with\n</td><td>to 34% in the PP group (p=0.024)\n2 trials with 33 patients\n</td></tr><tr><td>\u00a0</td><td>Systematic review\n</td><td>IVIg or interferon alpha or plasma exchange\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>Crossover\n</td><td>IVIg 2 g/kg over 1 to 2 days\n</td><td>IgM antimyelin-associated glycoprotein paraproteinemic\n</td><td>suggest that IVIg may sometimes produce short-term benefit (in terms of\n</td></tr><tr><td>\u00a0</td><td>[370] </td><td>neuropathy)\n22 patients with\n</td><td>improvement in Modified Rankin Scale at 2 weeks and\n10-m walk time at 4 weeks) and is relatively safe\nAfter 4 weeks, the overall\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>RCT\n</td><td>vs placebo\n</td><td>\u00a0</td><td>disability significantly\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>paraproteinemic demyelinating neuropathy\n</td><td>decreased during the IVIg period (p=0.001)\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>compared to the placebo period where it was unchanged; the mean difference between the treatment effects was\n</td></tr><tr><td>\u00a0</td><td>[371] </td><td>Crossover\n</td><td>IVIg vs placebo given\n</td><td>11 patients with\n</td><td>significant (p = 0.05)\nModest benefit with IVIg\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>RCT\n</td><td>monthly for 3 months\n</td><td>demyelinating\n</td><td>\u00a0</td></tr><tr><td>Amyotrophic lateral\n</td><td>[372] </td><td>Case series </td><td>IVIg 0.4 g/kg per day for\n</td><td>polyneuropathy associated with monoclonal IgM antibodies 7 patients with amyotrophic\n</td><td>All patients worsened according to MRC and/or bulbar and/or Rankin scores\nAll patients worsened after\n</td></tr><tr><td>sclerosis\n</td><td>[373] </td><td>Case series </td><td>5 days followed by monthly 2-day infusions + CP IVIg monthly for 3 months </td><td>lateral sclerosis 9 patients with rapidly\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>progressive amyotrophic\nlateral sclerosis\n</td><td>3 months with decrease in mean total muscle scores\n</td></tr><tr><td>Lambert-Eaton myasthenic syndrome\n</td><td>[374] </td><td>Crossover\n</td><td>IVIg 1 g/kg per day for\n</td><td>9 with Lambert-Eaton\n</td><td>(megascores)\nIVIg showed significant improvements in limb, respiratory, and bulbar muscle strength measures\n</td></tr><tr><td>\u00a0</td><td>RCT\n</td><td>2 days vs placebo\n</td><td>myasthenic syndrome\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr></table></body></html>"}, "TABREF51": {"text": "Table 12 (continued)", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>Stiff person syndrome </td><td>[375] </td><td>Case series </td><td>IVIg </td><td>3 patients with active disease and/or disease refractory to treatment with diazepam and/or CS\n</td><td>Improvement after treatment\n</td></tr><tr><td>[376] </td><td>Uncontrolled pilot study\n</td><td>IVIg </td><td>3 patients with stiff-man syndrome\n</td><td>Improvement after treatment\n</td></tr><tr><td>\u00a0</td><td>[377] </td><td>Case report </td><td>IVIg </td><td>A patient with refractory stiff-man syndrome\n</td><td>Long-term remission after treatment\n</td></tr><tr><td>\u00a0</td><td>[378] </td><td>Crossover RCT\n</td><td>IVIg 2 g/kg once a month for 3 months vs placebo\n</td><td>14 patients with stiff-person syndrome and anti-GAD65 antibodies\n</td><td>According to stiffness scores, IVIg was superior compared to placebo in direct treatment effect (p= 0.01) and in first-order carryover effect (p=0.001)\n</td></tr><tr><td>Adrenoleukodystrophy </td><td>[379] </td><td>RCT </td><td>IVIg 1 g/kg per day every\n</td><td>12 X-linked adrenoleukodystrophy\n</td><td>No significant differences in deterioration of\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>15 days for 3 months and\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>every month for 1 year + VLCFA-restricted diet + GTOE vs VLCFA-restricted diet + GTOE\n</td><td>\u00a0</td><td>neurological symptoms in the 2 groups according to EDSS score\n</td></tr><tr><td>Intractable childhood epilepsy\n</td><td>[380] </td><td>RCT </td><td>IVIg 0.1-0.4 g/kg (7 infusions in 6 weeks total time) vs placebo\n</td><td>61 patients with refractory\n</td><td>No significant difference between the groups studied; no relationship between IVIg dose and efficacy\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>epilepsy (46 with partial epilepsy)\n</td></tr><tr><td>\u00a0</td><td>[381] </td><td>Crossover RCT\n</td><td>IVIg 0.4 g/kg (Sandoglobulin) 2\n</td><td>10 patients aged 4-14 years with Lennox-Gastaut syndrome\n</td><td>2/10: immediate reduction in their high-frequency and\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>infusions each with an interval of 2 weeks vs placebo\n</td><td>\u00a0</td><td>invariable seizure activity from 42% to 100% and a less abnormal EEG\n</td></tr><tr><td>Critical illness polyneuropathy\n</td><td>[382] </td><td>Retrospective chart analysis\n</td><td>IVIg 0.3 g/kg per day for 3 days\n</td><td>16 patients with critical illness polyneuropathy following multiple-organ failure and gram-negative sepsis\n</td><td>8/10: unchanged general condition, no EEG changes\n8/16 patients of multi-organ failure with sepsis without the development of critical illness polyneuropathy had been treated with IVIg immediately after the\n</td></tr></table></body></html>"}, "TABREF52": {"text": "Table 13 (continued)", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>high-dose IVIg (adults 0.6 g/kg and children\n</td><td>\u00a0</td><td>subgroup) and duration (median, 33 vs. 21 days\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>0.8 g/kg every 4 weeks) or vice versa (Immunoglobuline IV,\n</td><td>\u00a0</td><td>(p=0.015), in XLA\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>subgroup 28.5 vs. 19 days) of infections\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Sanquin Blood Supply\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Foundation, the Netherlands)\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Wiscott-Aldrich syndrome (WAS)\n</td><td>[409] </td><td>Retrospective trial\n</td><td>IVIg 0.18-0.58 g/kg every 2-4 weeks and antibiotic prophylaxis with acyclovir and/or fluconazole in some cases\n</td><td>21 patients with WAS </td><td>Only 4 episodes of sever acute bacterial infection in\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>451 patient months after splenectomy\n</td></tr><tr><td>Hyper-IgE syndrome (Job syndrome)\n</td><td>[410] </td><td>Case series </td><td>IVIg </td><td>3 adult patients with hyper-IgE syndrome\n</td><td>Marked improvement in tendency to infections\n</td></tr><tr><td>[411] </td><td>Case report </td><td>Monthly IVIg and interferon\n</td><td>15-year-old boy with hyper-IgE syndrome\n</td><td>Good control of disease\n</td></tr><tr><td>\u00a0</td><td>[412] </td><td>Case report </td><td>gamma three times a week since age 3; he received also prophylaxis with antibiotic and fluconazole IVIg 2 g/kg (Venoglobulin I-Alpha Therapeutic\nCorporation, Los Angeles, CA, USA) monthly for 7 courses\n</td><td>Patient with hyper-IgE syndrome\n</td><td>No improvement\n</td></tr><tr><td>\u00a0</td><td>[413] </td><td>Case series </td><td>IVIg </td><td>8 children with recurrent infections, failure to thrive, hypergammaglobulinemia and IgG2 subclass deficiency\n</td><td>Clinical resolution\n</td></tr><tr><td>\u00a0</td><td>[414] </td><td>Case series </td><td>IVIg (Sandoglobulin) 6-12 g monthly\n</td><td>3 members of a family (2 children, 1 adult) with recurrent severe respiratory\n</td><td>Clinical resolution\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>infections and IgG2 subclass deficiency\n</td><td>\u00a0</td></tr><tr><td>IgG subclass deficiencies\n</td><td>[415] </td><td>Case report </td><td>IVIg monthly 7 courses </td><td>A-6-year old child with chronic rhinosinusitis, nasal\n</td><td>Clinical improvement\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>polyps and IgG3 deficiency\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>[416] </td><td>Case report </td><td>IVIg monthly </td><td>A 2-year-old child with recurrent sinopulmonary\n</td><td>Clinical improvement\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>infections and IgG2 deficiency\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>[417] </td><td>Cases report </td><td>IVIg 10-15 g every 3 weeks for 6 months\n</td><td>2 patients with treatment-resistant osteomyelitis of the jaw, one with IgG2 deficiency, and the other with IgG3 deficiency\n</td><td>Clinical improvement in both patients\n</td></tr><tr><td>Specific antibody deficiency\n</td><td>[418] </td><td>Retrospective study\n</td><td>Part of this patients received IVIg\n</td><td>75 patients with recurrent infections and low response to pneumococcal polyvalent vaccine\n</td><td>Reduction in number of infections\n</td></tr><tr><td>[203] </td><td>Series report </td><td>IVIg </td><td>9 children with recurrent sinopulmonary infections\nand poor response to\n</td><td>Reduction of infections upon start of IVIg treatment and recurrence after discontinuation\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Haemophilus influenzae type b capsular polysaccharide\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>[419] </td><td>Case report </td><td>IVIg </td><td>Patient with Smith-Lemli-\nOpitz syndrome, frequent\ninfections and absent response to Pneumovax\n</td><td>Same frequency of infections, less severity\n</td></tr></table></body></html>"}, "TABREF53": {"text": "Table 13 (continued)", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Disease </td><td>Ref. </td><td>Study design </td><td>Intervention including dose and IVIg preparation used\n</td><td>Number of patients </td><td>Results/response\n</td></tr><tr><td>Hyper-IgM syndrome (HIGM)\n</td><td>[420] </td><td>Case control study\n</td><td>IVIg was administered every 4 weeks and serum IgG\n</td><td>29 patients with HIGM due to activation-induced cytidine deaminase deficiency, suffering from recurrent infections\n</td><td>After IVIg therapy was initiated, frequency of infections markedly decreased\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>levels were consistently maintained above 4 or 5 g/l in most patients\n</td></tr><tr><td>\u00a0</td><td>[421] </td><td>Case control </td><td>IVIg </td><td>9 patients with HIGM and recurrent infections\n</td><td>Regression in the manifestations of infection\n</td></tr><tr><td>\u00a0</td><td>[422] </td><td>Case control </td><td>IVIg, 0.25-0.3 g/kg every 4 weeks for 1 year\n</td><td>6 patients with HIGM and recurrent infections\n</td><td>Severity and frequency of infections decreased significantly\n</td></tr><tr><td>\u00a0</td><td>[423] </td><td>Case report </td><td>IVIg with antibiotics, chloroquine, and PD\n</td><td>A 6-year-old with HIGM and severe recurrent respiratory infections\n</td><td>Mild improvement with a decrease in the inflammatory infiltrate in thoracoscopic biopsy\n</td></tr><tr><td>\u00a0</td><td>[424] </td><td>Case report </td><td>IVIg and prophylactic antibiotic therapy\n</td><td>A 6 years old with CD40 ligand deficiency, chronic neutropenia, and HIGM\n</td><td>Management of neutropenia, better quality of life with decreasing occurrence of infection\n</td></tr><tr><td>\u00a0</td><td>[425] </td><td>Case report </td><td>IVIg </td><td>A 5-month-old boy with HIGM and severe pneumonia refractory to antibiotics\n</td><td>His pneumonia improved; after that, he had no recurrent infections\n</td></tr><tr><td>Transient hypogamma of infancy (THI)\n</td><td>[426] </td><td>Case report </td><td>IVIg every 4 weeks </td><td>1-year-old girl with THI and\n</td><td>Gradual improvement\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Staphylococcus aureus\nsepsis refractory to antibiotics\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>[427] </td><td>Case report </td><td>Treated with antibiotics and IVIg\n</td><td>1-year-old boy with THI and recurrent sepsis\n</td><td>Fewer infections\n</td></tr><tr><td>Severe combined immunodeficiency (SCID)\n</td><td>[428] </td><td>Case control </td><td>Monthly IVIg </td><td>45 children surviving BMT for SCID\n</td><td>Effective as adjuvant for BMT\n</td></tr><tr><td>Common Variable Immune Deficiency (CVID)\n</td><td>[429] </td><td>Case series </td><td>The number of pneumonia episodes was compared prior to and after initiation of IVIg maintenance therapy for 6.6\u00b15.2 years (0.3-0.4 g/kg every 3 to 4 weeks)\n</td><td>50 patients with confirmed CVID\n</td><td>Prior to IVIg therapy, 84% of patients had an episode of pneumonia, and 22% had recurrent pneumonias; following IVIg administration, 22% of the patients have acquired pneumonia; this change was found to be statistically significant (p&lt;0.001)\n</td></tr><tr><td>[33] </td><td>Case series </td><td>Data were collected retrospectively; all the\n</td><td>7 patients diagnosed with\n</td><td>Number of infections per\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>CVID\n</td><td>patient-year was 5 in the no-\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>patients were treated by 3 modalities: no IVIg, low-\n</td><td>\u00a0</td><td>IVIg period, 2.79 in the low-\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>dose period (p=0.002), and\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>dose IVIg (0.2 g/kg every\n</td><td>\u00a0</td><td>1.53 in the standard-dose\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>3 weeks), and standard-dose IVIg (0.4 g/kg every 3 weeks)\n</td><td>\u00a0</td><td>period (p=0.02); lower respiratory tract infections were markedly decreased due to IVIg therapy\n</td></tr><tr><td>\u00a0</td><td>[32] </td><td>Case series </td><td>IVIg (Sandoglobulin and/or Nordimmune), 0.4 g/kg every 3 to 4 weeks; the follow-up period was 41.5\u00b1 35.4 months\n</td><td>26 patients diagnosed with CVID\n</td><td>IVIg therapy was associated with significant decrease of annual hospitalization due to pneumonia: from 88.5% to 46% (p=0.0025); a significant decrease of total hospital admissions was also observed (from 3.4 to 0.7 per year, p&lt;0.0005)\n</td></tr></table></body></html>"}}, "back_matter": []}